

Tight blood pressure control and risk of macrovascular in type 2 diabetes: UKPDS 38

BMJ: British Medical Journal

317, 703-713

DOI: [10.1136/bmj.317.7160.703](https://doi.org/10.1136/bmj.317.7160.703)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Preexisting hypertension in pregnancy. , 0, , 63-78.		0
2	Treatment of Diabetic Nephropathy in its Early Stages. , 1997, 13, 51-61.		17
3	Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. American Journal of Cardiology, 1998, 82, 4-8.	0.7	17
4	The UK Prospective Diabetes study. Lancet, The, 1998, 352, 1934.	6.3	71
5	Impact of new criteria for diabetes on pattern of disease. Lancet, The, 1998, 352, 1000-1001.	6.3	22
6	Some answers, more controversy, from UKPDS. Lancet, The, 1998, 352, 832-833.	6.3	167
7	Reducing mortality and increasing awareness. Lancet, The, 1998, 352, S20.	6.3	1
8	Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ: British Medical Journal, 1998, 317, 713-720.	2.4	1,293
9	Diabetes: a time for excitement--and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.4	19
10	Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ: British Medical Journal, 1998, 317, 720-726.	2.4	260
11	Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.4	72
12	United Kingdom Prospective Diabetes Study: the end of the beginning?. Medical Journal of Australia, 1998, 169, 511-512.	0.8	0
13	Update in General Internal Medicine. Annals of Internal Medicine, 1999, 131, 199.	2.0	6
14	Pronounced Diastolic Blood Pressure Day- and Nighttime Difference: An Indicator for Longevity?. Gerontology, 1999, 45, 298-299.	1.4	0
15	The progression of chronic renal failure: a harmful quartet. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 421-424.	0.2	5
16	The 1999 WHO "ISH Guidelines for the Management of Hypertension. Medical Journal of Australia, 1999, 171, 458-459.	0.8	59
17	Treatment of hypertension. Practice Nursing, 1999, 10, 29-30.	0.1	0
18	Blood pressure control in type 2 diabetes--what does the United Kingdom prospective diabetes study (UKPDS) tell us?. Nephrology Dialysis Transplantation, 1999, 14, 2562-2564.	0.4	12

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Hospitalization in People With Diabetes. Archives of Internal Medicine, 1999, 159, 2053.	4.3	70
20	Anti-oxidant therapy for the treatment of coronary artery disease. Expert Opinion on Investigational Drugs, 1999, 8, 1763-1784.	1.9	10
21	Diabetic retinopathy: Some cellular, molecular and therapeutic considerations. Eye, 1999, 13, 497-523.	1.1	61
22	Diabetic retinopathy: An end of the century perspective. Eye, 1999, 13, 133-135.	1.1	4
23	Progression from Hypertension to Heart Failure. Cardiology, 1999, 92, 10-19.	0.6	20
24	A New Pressure Attenuation Index to Evaluate Retinal Circulation. JAMA Ophthalmology, 1999, 117, 84.	2.6	65
25	Management of retinopathy in type 2 diabetes. Eye, 1999, 13, 131-132.	1.1	1
26	The Importance of a Name. New England Journal of Medicine, 1999, 340, 1418-1421.	13.9	40
27	Loss of the female advantage with cardiovascular disease for women with diabetes. Lupus, 1999, 8, 351-355.	0.8	7
28	Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vascular Medicine, 1999, 4, 67-75.	0.8	43
29	Assessment of glycaemic control in stable type 2 black South African diabetics attending a peri-urban clinic. Postgraduate Medical Journal, 1999, 75, 603-606.	0.9	37
30	A Napoleonic future for cardiology?. Heart, 1999, 81, 455-455.	1.2	2
31	The patient's role in the improvement of care. Multiple Sclerosis Journal, 1999, 5, 302-305.	1.4	0
32	Diabetes and Cardiovascular Events in Hypertensive Patients. Hypertension, 1999, 33, 1130-1134.	1.3	138
33	Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes. Circulation, 1999, 99, 461-462.	1.6	59
34	Type 2 Diabetes Mellitus. Archives of Internal Medicine, 1999, 159, 1033.	4.3	58
35	Hypertension and diabetic retinopathy--what's the story?. British Journal of Ophthalmology, 1999, 83, 1083-1087.	2.1	53
36	Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabetic Medicine, 1999, 16, 358-372.	1.2	23

#	ARTICLE	IF	CITATIONS
37	Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999, 16, 388-394.	1.2	16
38	Public Health Diabetes Surveillance in Managed Healthcare Systems. <i>Disease Management: DM</i> , 1999, 2, 3-6.	1.0	0
39	A Tool for Diabetes Disease Management and Quality Assurance: The ADA/NCQA Provider Recognition Program. <i>Disease Management: DM</i> , 1999, 2, 7-12.	1.0	0
40	Diabetic Nephropathy. <i>Diabetes Technology and Therapeutics</i> , 1999, 1, 489-496.	2.4	7
41	Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1165-1171.	1.8	131
42	Glimepiride. Review of the first available 3rd generation sulphonylurea. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1999, 16, S1-S3.	0.2	1
43	Screening for diabetic retinopathy. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1999, 16, 51-55.	0.2	1
45	Reasons for non-urgent referral to a hospital diabetic clinic and the potential unmet need. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1999, 16, 167-169.	0.2	0
46	Blood pressure measurement in diabetes: Lack of effect from stress factors in the clinic. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1999, 16, 215-216.	0.2	0
47	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 643-648.	1.1	436
48	UKPDS and beyond: into the next millennium. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 13-22.	2.2	17
49	Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 67-74.	2.2	36
50	Dyslipidaemia and cardiovascular risk in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 189-198.	2.2	27
51	Clinical management of diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 307-315.	2.2	5
52	The natural history of diabetes-related complications: the UKPDS experience. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 7-13.	2.2	29
53	Cardiovascular risk in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 24-36.	2.2	15
54	Editorial: a new beginning?. <i>Diabetic Medicine</i> , 1999, 16, 1-1.	1.2	26
55	Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 1999, 16, 522-526.	1.2	41

#	ARTICLE	IF	CITATIONS
56	A five-year evaluation of intervention in diabetes care in Trinidad and Tobago. <i>Diabetic Medicine</i> , 1999, 16, 939-945.	1.2	24
57	Small is beautiful - but too cheap. <i>Diabetic Medicine</i> , 1999, 16, 445-445.	1.2	0
58	Is there a role for glycosuria testing in sub-Saharan Africa?. <i>Tropical Medicine and International Health</i> , 1999, 4, 506-513.	1.0	12
59	Diabetic retinopathy: classification, description and optometric management. <i>Australasian journal of optometry, The</i> , 1999, 82, 59-71.	0.6	3
60	A review of current research on the effect of diabetes mellitus on the eye. <i>Australasian journal of optometry, The</i> , 1999, 82, 84-97.	0.6	1
61	Treatment of diabetic retinopathy. <i>Australasian journal of optometry, The</i> , 1999, 82, 98-101.	0.6	4
62	Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. <i>Diabetologia</i> , 1999, 42, 263-285.	2.9	253
63	Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. <i>Diabetologia</i> , 1999, 42, 793-801.	2.9	334
64	Treatment of diabetic patients with hypertension. <i>Current Hypertension Reports</i> , 1999, 1, 225-231.	1.5	10
65	Diabetes epidemiology as a tool to trigger diabetes research and care. <i>Diabetologia</i> , 1999, 42, 499-518.	2.9	234
66	Does social medicine still matter in an era of molecular medicine?. <i>Journal of Urban Health</i> , 1999, 76, 164-175.	1.8	23
67	Controversies surrounding the treatment of the hypertensive patient with diabetes. <i>Current Hypertension Reports</i> , 1999, 1, 512-520.	1.5	9
68	Obesity, hypertension, and vascular disease. <i>Current Hypertension Reports</i> , 1999, 1, 140-144.	1.5	8
69	Antihypertensive drugs and diabetic nephropathy. <i>Current Hypertension Reports</i> , 1999, 1, 170-177.	1.5	0
70	Current Trials. <i>Current Hypertension Reports</i> , 1999, 1, 201-203.	1.5	0
71	Recent outcome trials of newer antihypertensives. <i>Current Hypertension Reports</i> , 1999, 1, 238-240.	1.5	0
72	Recent clinical trials: A critical appraisal. <i>Current Hypertension Reports</i> , 1999, 1, 333-336.	1.5	4
73	The world health organization's International society of hypertension blood pressure lowering treatment trialists'™ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. <i>Current Hypertension Reports</i> , 1999, 1, 346-356.	1.5	19

#	ARTICLE	IF	CITATIONS
74	Three recently published trials in hypertension. Current Hypertension Reports, 1999, 1, 377-378.	1.5	0
75	Good news for the older patient with diabetes: added cardiovascular risk reduction. Current Hypertension Reports, 1999, 1, 379-380.	1.5	1
76	Optimal blood pressure on antihypertensive medication. Current Hypertension Reports, 1999, 1, 381-386.	1.5	1
77	Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports, 1999, 1, 411-413.	1.5	0
78	Is normotension good enough for the patient with type 2 diabetes?. Current Hypertension Reports, 1999, 1, 414-416.	1.5	0
79	Antihypertensive therapy and progression of chronic renal disease. Current Hypertension Reports, 1999, 1, 417-422.	1.5	1
80	Importance of blood pressure reduction for prevention of progression of renal disease. Current Hypertension Reports, 1999, 1, 423-430.	1.5	1
81	Calcium-channel blockers and the progression of renal disease. Current Hypertension Reports, 1999, 1, 436-445.	1.5	16
82	The case for combining angiotensinconverting enzyme inhibitors and calcium-channel blockers. Current Hypertension Reports, 1999, 1, 446-453.	1.5	13
83	The diabetic patient as paradigm for selective antihypertensive therapy. Clinical Cornerstone, 1999, 2, 1-12.	1.0	10
84	United Kingdom Prospective Diabetes Study (UKPDS): what now or so what?. Diabetes/Metabolism Research and Reviews, 1999, 15, 65-71.	1.7	35
85	Reducing the burden of diabetes: managing cardiovascular disease. Diabetes/Metabolism Research and Reviews, 1999, 15, 186-196.	1.7	37
86	Glycemic control and cardiovascular disease in Type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews, 1999, 15, 197-204.	1.7	23
87	Treatment of severe proliferative retinopathy and diabetic maculopathy. Diabetes/Metabolism Research and Reviews, 1999, 15, 373-377.	1.7	3
88	Pharmacologic Therapy for Type 2 Diabetes Mellitus. Annals of Internal Medicine, 1999, 131, 281.	2.0	974
89	Disease Management by Prevention. Disease Management and Health Outcomes, 1999, 6, 279-290.	0.3	1
90	Clinical Efficacy of Metformin against Insulin Resistance Parameters. Drugs, 1999, 58, 21-28.	4.9	19
91	Concluding Remarks. Clinical Pharmacokinetics, 1999, 37, 33-38.	1.6	4

#	ARTICLE	IF	CITATIONS
92	THE TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN DIABETES MELLITUS. Primary Care - Clinics in Office Practice, 1999, 26, 951-964.	0.7	5
93	Treatment of Diabetic Retinopathy. New England Journal of Medicine, 1999, 341, 667-678.	13.9	160
94	Nephropathy in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 1999, 341, 1127-1133.	13.9	685
95	The challenge of European guidelines for prevention. European Journal of General Practice, 1999, 5, 134-134.	0.9	0
96	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1009-1060.	0.5	471
97	An Overview of 37 Randomised Trials of Blood Pressure Lowering Agents Among 270,000 Individuals. Clinical and Experimental Hypertension, 1999, 21, 517-529.	0.5	14
98	Drug Treatment for Hypertensive Patients in Special Situations: Diabetes and Hypertension. Clinical and Experimental Hypertension, 1999, 21, 895-906.	0.5	22
99	No additional benefit seen with lower target DBP. Evidence-based Cardiovascular Medicine, 1999, 3, 29-30.	0.0	0
100	Detection, treatment, and control of adult hypertension in Northwest Indiana. American Journal of Hypertension, 1999, 12, 830-834.	1.0	7
101	Benefits of combination angiotensin- converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. American Journal of Hypertension, 1999, 12, 80-85.	1.0	31
102	Current antihypertensive treatment: can we do better?. American Journal of Hypertension, 1999, 12, 131-138.	1.0	8
103	End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases, 1999, 34, 795-808.	2.1	703
104	Risk for posttransplant diabetes mellitus with current immunosuppressive medications. American Journal of Kidney Diseases, 1999, 34, 1-13.	2.1	363
105	Trandolapril and human diabetic neuropathy. Lancet, The, 1999, 353, 927.	6.3	0
106	Preventive medicine in a diabetes clinic: an opportunity to make a difference. Lancet, The, 1999, 353, 606-608.	6.3	9
107	Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet, The, 1999, 353, 617-622.	6.3	911
108	HYPERGLYCEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES. Primary Care - Clinics in Office Practice, 1999, 26, 829-839.	0.7	49
109	PREVENTION AND TREATMENT OF MICROVASCULAR AND NEUROPATHIC COMPLICATIONS OF DIABETES. Primary Care - Clinics in Office Practice, 1999, 26, 791-807.	0.7	5

#	ARTICLE	IF	CITATIONS
110	IMPLICATIONS OF THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY. Primary Care - Clinics in Office Practice, 1999, 26, 809-827.	0.7	12
112	HYPERTENSION IN THE ELDERLY. Cardiology Clinics, 1999, 17, 79-92.	0.9	13
113	Renal Protection and Antihypertensive Drugs. Drugs, 1999, 57, 665-693.	4.9	46
114	Antihypertensive Therapy in the Prevention of Stroke. Drugs, 1999, 58, 663-674.	4.9	26
115	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina11This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999. When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, The necessity for recognition and treatment of patients with a cerebral hypertension. This manuscript was written during Dr. Frohlich's tenure representing the American College of Cardiology on the Joint National Committee of the National High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute.. Journal of the American College of Cardiology, 1999, 34, 1369-1377.	1.2	608
116	The necessity for recognition and treatment of patients with a cerebral hypertension. This manuscript was written during Dr. Frohlich's tenure representing the American College of Cardiology on the Joint National Committee of the National High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute.. Journal of the American College of Cardiology, 1999, 34, 1369-1377.	1.2	5
117	The epidemiology of Type 2 diabetes and its current measurement. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 197-220.	2.2	16
118	Diabetic nephropathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 239-264.	2.2	26
119	Diabetes and myocardial infarction. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 331-343.	2.2	8
121	Erectile dysfunction in patients with diabetes. British Journal of Hospital Medicine, 1999, 60, 638-644.	0.3	35
122	Discussion and Debate. Cardiology, 1999, 92, 7-9.	0.6	0
123	Diabetes and the heart. British Journal of Hospital Medicine, 1999, 60, 90-94.	0.3	0
124	Drug Therapy for Type 2 Diabetes. Journal of Pharmacy Practice, 1999, 12, 84-97.	0.5	0
125	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension, 1999, 17, 151-183.	0.3	1,232
126	Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial. Journal of Hypertension, 1999, 17, 1917-1923.	0.3	14
127	Detection of non-dipper hypertensives in clinical practice: does it really matter?. Nephrology Dialysis Transplantation, 1999, 14, 2969-2970.	0.4	5
128	Supplement to the Guidelines for the Management of Transient Ischemic Attacks. Stroke, 1999, 30, 2502-2511.	1.0	156
129	Effects of intensified antihypertensive treatment in diabetic nephropathy. Journal of Hypertension, 1999, 17, 1497-1503.	0.3	38

#	ARTICLE	IF	CITATIONS
130	Cardiac and Arterial Target Organ Damage in Adults with Elevated Ambulatory and Normal Office Blood Pressure. <i>Annals of Internal Medicine</i> , 1999, 131, 564.	2.0	301
131	British Hypertension Society guidelines for hypertension management 1999: summary. <i>BMJ: British Medical Journal</i> , 1999, 319, 630-635.	2.4	324
132	Hypertension in patients with diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 47-60.	0.9	25
133	Towards Remote Glucose Control in Diabetes. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2000, 33, 245-248.	0.4	0
134	Diabetes in the Elderly Population. <i>Advances in Chronic Kidney Disease</i> , 2000, 7, 32-51.	2.2	14
135	The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. <i>International Journal of Obesity</i> , 2000, 24, S6-S11.	1.6	218
136	Combating Sloth as Well as Gluttony: The Role of Physical Fitness in Mortality among Men with Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2000, 132, 669.	2.0	8
137	That Was the Year That Was: An Evidence-Based Clinical Geriatrics Update 1998-1999. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 1717-1725.	1.3	1
138	Risk of Stroke in Relation to Level of Blood Pressure and Other Risk Factors in Treated Hypertensive Patients. <i>Stroke</i> , 2000, 31, 48-52.	1.0	21
139	Outcomes of Atherosclerotic Renal Artery Stenosis Managed Without Revascularization. <i>Mayo Clinic Proceedings</i> , 2000, 75, 437-444.	1.4	99
140	Diabetes Mellitus in Older Adults: Underdiagnosis and Undertreatment. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 340-341.	1.3	12
141	European Society of Hypertension Scientific Newsletter, Update on Hypertension Management. <i>Journal of Hypertension</i> , 2000, 18, 1345-1346.	0.3	5
142	Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 173-179.	1.0	6
143	Large multicentre hypertension trials. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 285-292.	1.0	0
144	Diabetic nephropathy—where next?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 643-646.	0.2	3
145	Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients. <i>European Heart Journal</i> , 2000, 21, 2-7.	1.0	10
146	The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 487-497.	0.4	117
147	Difficult therapeutic decisions in the management of diabetic retinopathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2000, 16, 133-137.	1.7	2

#	ARTICLE	IF	CITATIONS
148	Reducing the risk and impact of retinopathy: new screening and treatment strategies. Proceedings of a Round Table Meeting, 27 September 1999, Brussels. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, S1-S6.	0.2	0
149	Managing blood pressure in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 35-35.	0.2	0
150	Pattern of hospital mortality among diabetic patients in Sudan. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 41-43.	0.2	10
151	Managing blood pressure in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 49-53.	0.2	3
152	Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 54-59.	0.2	4
153	Genes and diabetic nephropathy: what have we learnt so far?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 84-90.	0.2	4
154	Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. , 2000, 18, 23-28.		25
155	Use of calcium channel blockers and beta blockers as antihypertensives in relation to mortality in type 2 diabetes patients: a population-based observational study. , 2000, 9, 127-131.		1
156	UKPDS and the old. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 101-101.	0.2	0
157	Cardiovascular disease risk reduction in patients with diabetes - is clinical practice effective?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 155-158.	0.2	3
158	MANAGING DYSLIPIDAEMIA IN TYPE 2 DIABETES IN PRIMARY CARE. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, S1-S8.	0.2	1
159	Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes/Metabolism Research and Reviews, 2000, 16, 230-236.	1.7	229
160	Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice. Diabetes/Metabolism Research and Reviews, 2000, 16, 164-171.	1.7	308
161	Effect of insulin and heparin on glucose-induced vascular damage in cell culture. Kidney International, 2000, 57, 2492-2501.	2.6	14
162	Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney International, 2000, 57, 590-600.	2.6	158
163	Epidemiology and Clinical Presentation of Type 2 Diabetes. Value in Health, 2000, 3, S3-S6.	0.1	13
164	Perceived access problems among patients with diabetes in two public systems of care. Journal of General Internal Medicine, 2000, 15, 797-804.	1.3	19
165	Risk factors for vascular disease in patients with diabetes. Diabetes, Obesity and Metabolism, 2000, 2, 11-18.	2.2	10

#	ARTICLE	IF	CITATIONS
166	Vascular disease prevention in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 25-36.	2.2	5
167	Postprandial hyperglycaemia: potential relationship to the development and progression of diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S13-S20.	2.2	5
168	The impact of antihypertensive therapy in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S37-S41.	2.2	1
169	Case presentations - challenging problems in the management of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S49-S55.	2.2	0
170	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 263-270.	2.2	4
171	The prevalence of multiple diabetes-related complications. <i>Diabetic Medicine</i> , 2000, 17, 146-151.	1.2	116
172	Screening for Type 2 diabetes mellitus: a decision analytic approach. <i>Diabetic Medicine</i> , 2000, 17, 469-477.	1.2	19
173	Evidence-based patient information in diabetes. <i>Diabetic Medicine</i> , 2000, 17, 823-829.	1.2	54
174	Redefining Type 2 diabetes: 'Diabesity' or 'Obesity Dependent Diabetes Mellitus'?. <i>Obesity Reviews</i> , 2000, 1, 57-59.	3.1	348
175	Towards an optimal model for community-based diabetes care: design and baseline data from the Mayo Health System Diabetes Translation Project. <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 421-429.	0.9	18
176	Direct medical costs for patients with type 2 diabetes in Sweden. <i>Journal of Internal Medicine</i> , 2000, 248, 387-396.	2.7	123
177	Microvascular complications of diabetes: the role of angiotensin converting enzyme inhibitors. Proceedings of a Round Table Meeting, June 1999, San Diego, USA. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2000, 17, S1-S12.	0.2	0
178	The effect of introducing prompted, systematic, protocol-based diabetic care in a practice: 18 months of improvement. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2000, 17, 255-260.	0.2	1
179	Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin. <i>Archives of Gerontology and Geriatrics</i> , 2000, 31, 27-34.	1.4	5
180	Cerebral complications of hypertension. <i>Journal of Human Hypertension</i> , 2000, 14, 605-616.	1.0	53
181	The pattern of diabetes care in New South Wales: a five-year analysis using Medicare occasions of service data. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 391-395.	0.8	18
182	Diabetes mellitus and coronary heart disease –from prevention to intervention: Part I. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 351-359.	0.5	8
183	Fasting plasma glucose in non-diabetic elderly women predicts increased all-cause mortality and coronary heart disease risk. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 41-47.	0.5	31

#	ARTICLE	IF	CITATIONS
184	Clinical trials and clinical practice –bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes. Australian and New Zealand Journal of Medicine, 2000, 30, 483-491.	0.5	3
185	Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. Journal of General Internal Medicine, 2000, 15, 220-228.	1.3	55
186	The Role of Nutrition Therapy in the Management of Diabetes Mellitus. Nutrition in Clinical Care: an Official Publication of Tufts University, 2000, 3, 334-348.	0.2	0
187	Cardiovascular risk in diabetes. Journal of Diabetes and Its Complications, 2000, 14, 108-115.	1.2	86
188	Therapeutic objectives and their practical achievement in type 2 diabetes. Journal of Diabetes and Its Complications, 2000, 14, 180-184.	1.2	7
189	Slightly elevated blood pressure as well as poor metabolic control are risk factors for the progression of retinopathy in early-onset Japanese Type 2 diabetes. Journal of Diabetes and Its Complications, 2000, 14, 281-287.	1.2	34
190	The prognosis for Type 2 diabetic patients with heart disease. Journal of Diabetes and Its Complications, 2000, 14, 301-306.	1.2	12
191	Using semi-automated oscillometric blood pressure measurement in diabetic patients and their offspring. Journal of Diabetes and Its Complications, 2000, 14, 288-293.	1.2	11
192	Reflections on Diabetes, Clinical Trials, and Cardiovascular Morbidity and Mortality. Congestive Heart Failure, 2000, 6, 110-115.	2.0	0
193	The prevalence and prognostic significance of electrocardiographic abnormalities. Current Problems in Cardiology, 2000, 25, 1-72.	1.1	87
194	Northwest Herts diabetic management system. Computer Methods and Programs in Biomedicine, 2000, 62, 177-189.	2.6	4
195	Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. American Journal of Cardiology, 2000, 86, 897-902.	0.7	120
196	Different risk factors of microangiopathy in patients with Type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia, 2000, 43, 348-355.	2.9	69
198	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports, 2000, 2, 243-246.	1.5	3
199	Treatment of hypertension in diabetes mellitus. Current Hypertension Reports, 2000, 2, 335-342.	1.5	8
200	Protection from vascular risk in diabetic hypertension. Current Hypertension Reports, 2000, 2, 154-159.	1.5	25
201	Diabetes care needs evidence based interventions to reduce risk of vascular disease. BMJ: British Medical Journal, 2000, 320, 1554-1555.	2.4	5
202	Antihypertensive Therapy: Beta-Blockers and Diuretics –Why Do Physicians Not Always Follow Guidelines?. Baylor University Medical Center Proceedings, 2000, 13, 128-134.	0.2	10

#	ARTICLE	IF	CITATIONS
203	Other Views (Commentary on "Antihypertensive Therapy: Beta-Blockers and Diuretics"). Baylor University Medical Center Proceedings, 2000, 13, 131-136.	0.2	0
204	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 53-64.	0.9	16
205	Therapeutic Strategies of Coronary Artery Disease in Diabetic Patients. Sunhwan'gi, 2000, 30, 1184.	0.3	0
206	Management of gestational diabetes with a conservative insulin protocol. Medical Journal of Australia, 2000, 172, 537-540.	0.8	10
207	Who looks after people with diabetes: Primary or secondary care?. Journal of the Royal Society of Medicine, 2000, 93, 183-186.	1.1	60
208	Excess Costs of Diabetes in the Aboriginal Population of Manitoba, Canada. Canadian Journal of Public Health, 2000, 91, 298-301.	1.1	16
209	Stroke Risk Factors. CNS Spectrums, 2000, 5, 70-74.	0.7	10
210	The renin angiotensin system and cardiovascular disease: hope or hype?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 142-146.	1.0	22
211	The HOPE Study (Heart Outcomes Prevention Evaluation). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 18-20.	1.0	111
212	ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 234-239.	1.0	5
213	Prevalence and characteristics of diabetic patients with no ongoing care in South Auckland. Diabetes Care, 2000, 23, 1791-1793.	4.3	20
214	Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes, 2000, 49, 1049-1056.	0.3	80
215	Anaesthetic management of patients with diabetes mellitus. British Journal of Anaesthesia, 2000, 85, 80-90.	1.5	91
216	Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. British Heart Journal, 2000, 84, 357-360.	2.2	38
217	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.4	1,737
218	Hyperhomocysteinemia Is Associated With the Presence of Retinopathy in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2000, 160, 2984.	4.3	64
219	Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 823-829.	1.1	167
220	Beta-blockers continue to surprise us. European Heart Journal, 2000, 21, 354-364.	1.0	60

#	ARTICLE	IF	CITATIONS
221	Preventing cardiovascular disease in hypertensive patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2000, 18, 1553-1556.	0.3	1
222	Pharmacological interventions in type 2 diabetes: the role of nurses. <i>British Journal of Nursing</i> , 2000, 9, 866-870.	0.3	5
223	Evidence-based therapy for type 2 diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 27-47.	0.9	6
224	Glycated haemoglobin in the year 2000. <i>Journal of Clinical Pathology</i> , 2000, 53, 335-339.	1.0	55
225	Modern management of hypertension and heart failure: evidence and practice. <i>British Heart Journal</i> , 2000, 84, 35i-38.	2.2	5
226	Blood Pressure and the Risk of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2000, 342, 50-52.	13.9	73
227	The Treatment of Hypertension in Patients with Erectile Dysfunction. <i>Current Medical Research and Opinion</i> , 2000, 16, s31-s36.	0.9	25
228	Management of the older person with diabetes in the community. <i>British Journal of Community Nursing</i> , 2000, 5, 448-453.	0.2	1
229	Management of Type 2 Diabetes in the Geriatric Patient. <i>Journal of Pharmacy Practice</i> , 2000, 13, 263-276.	0.5	1
230	The Management of Chronic Ischemic Heart Disease in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2000, 9, 145-151.	0.7	0
231	Relation of high blood pressure to glucose intolerance, plasma lipids and educational status in an Arabian Gulf population. <i>International Journal of Epidemiology</i> , 2000, 29, 71-76.	0.9	39
232	RAS blockade: new possibilities in the treatment of complications of diabetes. <i>British Heart Journal</i> , 2000, 84, 32i-34.	2.2	5
233	Inequalities in access to diabetes care: evidence from a historical cohort study. <i>Quality in Health Care: QHC</i> , 2000, 9, 85-89.	1.2	25
234	Development and Testing of Culturally Sensitive Instruments for African American Women With Type 2 Diabetes. <i>The Diabetes Educator</i> , 2000, 26, 769-777.	2.6	20
235	Complications of diabetes: renal disease and promotion of self-management. <i>Quality in Health Care: QHC</i> , 2000, 9, 257-263.	1.2	5
236	Long-Term Absolute Benefit of Lowering Blood Pressure in Hypertensive Patients According to the JNC VI Risk Stratification. <i>Hypertension</i> , 2000, 35, 539-543.	1.3	262
237	Essential Hypertension. <i>Circulation</i> , 2000, 101, 446-453.	1.6	66
238	An Integrative Literature Review of Cardiac Risk Factor Management in Diabetes Education Interventions. <i>The Diabetes Educator</i> , 2000, 26, 812-820.	2.6	14

#	ARTICLE	IF	CITATIONS
239	Variations in the Care of Elderly Persons With Diabetes Among Endocrinologists, General Internists, and Geriatricians. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2000, 55, M601-M606.	1.7	32
240	The losartan renal protection study â€” rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 328-335.	1.0	118
241	Clinical governance in primary care groups: the feasibility of deriving evidence-based performance indicators. <i>Quality in Health Care: QHC</i> , 2000, 9, 90-97.	1.2	29
242	Cardiac, renal and vascular complications in the diabetic patient. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 21-24.	1.0	0
243	Macular circulation in patients with diabetes mellitus with and without arterial hypertension. <i>British Journal of Ophthalmology</i> , 2000, 84, 1392-1396.	2.1	10
244	Pathophysiology and Pharmacological Treatment of Insulin Resistance*. <i>Endocrine Reviews</i> , 2000, 21, 585-618.	8.9	263
245	Hypertension and its management: A problem in need of new treatment strategies. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 10-13.	1.0	2
246	Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. <i>American Journal of Medicine</i> , 2000, 108, 238-245.	0.6	31
247	The HOPE study and diabetes. <i>Lancet, The</i> , 2000, 355, 1181-1182.	6.3	1
248	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. <i>Lancet, The</i> , 2000, 355, 253-259.	6.3	3,134
249	Phacoemulsification versus extracapsular cataract extraction in patients with diabetes ¹¹ The authors have no financial interest in any of the materials used in this study.. <i>Ophthalmology</i> , 2000, 107, 457-462.	2.5	90
250	Potential new treatments for type 2 diabetes. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 259-265.	4.0	69
251	Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. <i>Diabetes Research and Clinical Practice</i> , 2000, 49, 187-194.	1.1	73
252	Epidemiology of diabetes mellitus in Western Pacific region: focus on Philippines. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S29-S34.	1.1	13
253	Diabetes â€” a common, growing, serious, costly, and potentially preventable public health problem. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S77-S84.	1.1	227
254	Life-expectancy projection by modelling and computer simulation (UKPDS 46). <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S5-S13.	1.1	22
255	The global diabetes model: user friendly version 3.0. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S15-S46.	1.1	76
256	The Mt. Hood challenge: cross-testing two diabetes simulation models. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, S57-S64.	1.1	54

#	ARTICLE	IF	CITATIONS
257	Limitations of glycosylated haemoglobin as an index of glucose intolerance. <i>Diabetes Research and Clinical Practice</i> , 2000, 47, 129-133.	1.1	18
258	Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. <i>Diabetes Research and Clinical Practice</i> , 2000, 47, 97-104.	1.1	18
259	The role of platelets in diabetes-related vascular complications. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, 1-16.	1.1	111
260	Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. <i>American Journal of Hypertension</i> , 2000, 13, 899-906.	1.0	54
261	TGF- β^2 in diabetic kidney disease: role of novel signaling pathways. <i>Cytokine and Growth Factor Reviews</i> , 2000, 11, 115-123.	3.2	84
262	Preserving renal function in adults with hypertension and diabetes: A consensus approach. <i>American Journal of Kidney Diseases</i> , 2000, 36, 646-661.	2.1	1,314
263	Chronic renal insufficiency: Current understandings and their implications. <i>American Journal of Kidney Diseases</i> , 2000, 36, S4-S12.	2.1	23
264	Complications of chronic renal insufficiency: Beyond cardiovascular disease. <i>American Journal of Kidney Diseases</i> , 2000, 36, S31-S38.	2.1	21
265	Treating high-risk diabetic hypertensive patients with comorbid conditions. <i>American Journal of Kidney Diseases</i> , 2000, 36, S10-S17.	2.1	17
266	Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. <i>American Journal of Kidney Diseases</i> , 2000, 36, S24-S30.	2.1	64
267	Treatment of diabetes in patients with severe obesity. <i>Biomedicine and Pharmacotherapy</i> , 2000, 54, 74-79.	2.5	20
268	Oxidative stress: Introduction. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1-2.	1.5	1
269	Part III. Patient compliance. <i>Disease-a-Month</i> , 2000, 46, 811-822.	0.4	3
270	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. <i>Lancet, The</i> , 2000, 356, 1955-1964.	6.3	1,559
271	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 405-412.	2.4	7,060
272	Control metabólico de la diabetes y complicaciones crónicas. <i>Medicine</i> , 2000, 8, 1064-1070.	0.0	0
273	Management of Hypertension in Patients with Diabetes Mellitus. <i>Disease Management and Health Outcomes</i> , 2000, 7, 267-288.	0.3	2
274	Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 463-476.	1.3	12

#	ARTICLE	IF	CITATIONS
275	Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 283-294.	1.3	8
276	Implications of the UK Prospective Diabetes Study. <i>Drugs and Aging</i> , 2000, 16, 159-164.	1.3	18
277	Risks of Coronary Heart Disease in Women: Current Understanding and Evolving Concepts. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1289-1303.	1.4	37
279	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1875.	3.8	68
280	Valsartan: a novel angiotensin Type 1 receptor antagonist. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 337-350.	0.9	32
281	Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2601-2617.	1.9	7
282	The fixed combination of verapamil SR/trandolapril. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 515-535.	0.9	3
283	ACE Gene Polymorphism and Diabetic Complications. <i>BioDrugs</i> , 2000, 14, 73-81.	2.2	4
284	The Outcome of STOP-Hypertension-2 in Relation to the 1999 WHO/ISH Hypertension Guidelines. <i>Blood Pressure</i> , 2000, 9, 21-24.	0.7	6
285	Renal arterial intervention and angiotensin blockade in atherosclerotic nephropathy. <i>American Journal of Kidney Diseases</i> , 2000, 36, 837-843.	2.1	20
287	DANGEROUS AND COMMON DRUG INTERACTIONS IN PATIENTS WITH DIABETES MELLITUS. <i>Endocrinology and Metabolism Clinics of North America</i> , 2000, 29, 789-801.	1.2	31
288	STROKE PREVENTION. <i>Neurologic Clinics</i> , 2000, 18, 309-319.	0.8	42
290	MANAGEMENT OF ELDERLY DIABETIC PATIENTS IN THE SUBACUTE CARE SETTING. <i>Clinics in Geriatric Medicine</i> , 2000, 16, 833-852.	1.0	3
293	Nefropatía diabética. <i>Medicine</i> , 2000, 8, 1001-1008.	0.0	0
294	Pharmacotherapy of Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2000, 34, 878-895.	0.9	24
296	Tratamiento de la diabetes tipo 2. Fármacos insulinosensibilizadores e inhibidores de las glucosidasas intestinales. <i>Medicine</i> , 2000, 8, 1054-1063.	0.0	0
297	La hipertensión arterial en la diabetes mellitus tipo 2. <i>Hipertension Y Riesgo Vascular</i> , 2000, 17, 272-283.	0.3	2
298	Outcomes of Atherosclerotic Renal Artery Stenosis Managed Without Revascularization. <i>Mayo Clinic Proceedings</i> , 2000, 75, 437-444.	1.4	117

#	ARTICLE	IF	CITATIONS
299	Irbesartan. <i>Drugs</i> , 2000, 59, 1187-1206.	4.9	39
300	Eprosartan. <i>Drugs</i> , 2000, 60, 177-201.	4.9	26
301	Management of coronary artery disease: therapeutic options in patients with diabetes. <i>Journal of the American College of Cardiology</i> , 2000, 36, 355-365.	1.2	229
302	ACC/AHA guidelines for the management of patients with unstable angina and non- σ st-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 36, 970-1062.	1.2	882
303	Diabetes mellitus: the disease. , 2000, , 1-24.		0
304	Epidemiology of diabetic eye disease. , 2000, , 44-51.		0
305	The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 7-12.	2.4	26
306	PATHOPHYSIOLOGY OF HYPERTENSION AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH DIABETES MELLITUS. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001, 30, 983-997.	1.2	57
307	??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 429-435.	4.9	7
308	Hypertension in Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1531-1533.	4.9	4
309	Hypertension in Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1531-1533.	4.9	0
310	Role of ACE Inhibitors in Patients with Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1883-1892.	4.9	19
311	New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1543-1550.	1.2	167
312	Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1628-1632.	1.2	62
314	Management of Type 2 Diabetes Mellitus in the Elderly. <i>Drugs and Aging</i> , 2001, 18, 31-44.	1.3	88
315	Optimizing the Delivery of Effective Diabetes Care. <i>Disease Management and Health Outcomes</i> , 2001, 9, 683-690.	0.3	0
316	Management of Diabetes Mellitus. <i>Disease Management and Health Outcomes</i> , 2001, 9, 711-730.	0.3	2
317	Diabetes, Hypertension, and Cardiovascular Disease. <i>Hypertension</i> , 2001, 37, 1053-1059.	1.3	1,076

#	ARTICLE	IF	CITATIONS
318	The β Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. Journal of Clinical Hypertension, 2001, 3, 236-243.	1.0	8
319	Diuretics Revisited?Again. Journal of Clinical Hypertension, 2001, 3, 136-138.	1.0	7
320	Management of High-Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists. Journal of Clinical Hypertension, 2001, 3, 225-235.	1.0	3
321	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Medicine, 2001, 111, 633-642.	0.6	159
322	Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?. American Heart Journal, 2001, 142, 857-863.	1.2	43
323	Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ: British Medical Journal, 2001, 323, 970-970.	2.4	252
324	Developing a Prediction Rule From Automated Clinical Databases to Identify High-Risk Patients in a Large Population With Diabetes. Diabetes Care, 2001, 24, 1547-1555.	4.3	89
326	Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Research and Clinical Practice, 2001, 51, 195-203.	1.1	41
327	Heart rate elevation and diabetic retinopathy in patients with type 2 diabetes mellitus and normoalbuminuria. Diabetes Research and Clinical Practice, 2001, 52, 185-191.	1.1	16
328	Screening for people with diabetes mellitus for poor blood glucose control in an ophthalmological laser clinic. Diabetes Research and Clinical Practice, 2001, 53, 173-179.	1.1	3
329	The Poole Diabetes Study: how many cases of Type 2 diabetes are diagnosed each year during normal health care in a defined community?. Diabetes Research and Clinical Practice, 2001, 53, 107-112.	1.1	34
330	Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Research and Clinical Practice, 2001, 54, 191-201.	1.1	89
331	An initial assessment of the feasibility and effectiveness of implementing diabetes shared care system in Taiwan—some experiences from I-Lan County. Diabetes Research and Clinical Practice, 2001, 54, 67-73.	1.1	34
332	Use of diabetes preventive care and complications risk in two African-American communities. American Journal of Preventive Medicine, 2001, 21, 197-202.	1.6	42
333	Adjusting for multiple testing—when and how?. Journal of Clinical Epidemiology, 2001, 54, 343-349.	2.4	2,133
334	Antihypertensive Therapy in Diabetic Hypertensive Patients. American Journal of Hypertension, 2001, 14, S12-S16.	1.0	27
335	Diabetic nephropathy in African Americans. American Journal of Hypertension, 2001, 14, S132-S138.	1.0	8
336	Clinical overview of hypertension and emerging treatment considerations. American Journal of Hypertension, 2001, 14, S226-S230.	1.0	3

#	ARTICLE	IF	CITATIONS
337	Renal implications of angiotensin receptor blockers. American Journal of Hypertension, 2001, 14, S237-S241.	1.0	20
338	Retinopathy and microalbuminuria in type 2 diabetes: determinants and time-dependency of the association. European Journal of Internal Medicine, 2001, 12, 28-34.	1.0	3
339	Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension. Current Therapeutic Research, 2001, 62, 79-91.	0.5	14
340	Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstetrics and Gynecology, 2001, 98, 427-433.	1.2	48
341	Diabetes mellitus: a major challenge in transplantation. Transplantation Proceedings, 2001, 33, S3-S7.	0.3	10
342	Drug therapy for management of obesity. Lancet, The, 2001, 357, 1287.	6.3	3
343	Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, The, 2001, 358, 1305-1315.	6.3	892
345	Riesgo cardiovascular asociado a la insuficiencia renal. Hipertension Y Riesgo Vascular, 2001, 18, 285-290.	0.3	1
346	DIABETES MELLITUS AND CORONARY HEART DISEASE. Endocrinology and Metabolism Clinics of North America, 2001, 30, 857-881.	1.2	45
349	¿Controlamos correctamente la presión arterial en nuestros pacientes diabéticos? (Evolución) Tj ETQq1 1 0.784314 rgBT /Overload	0.3	3
353	Criterios y pautas de terapia combinada en la diabetes tipo 2. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2001, 48, 82-97.	0.8	9
354	Step Care Therapy for Hypertension in Diabetic Patients. Mayo Clinic Proceedings, 2001, 76, 1266-1274.	1.4	9
355	Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. Semergen, 2001, 27, 132-145.	0.2	6
359	MICROVASCULAR COMPLICATIONS. Endocrinology and Metabolism Clinics of North America, 2001, 30, 833-856.	1.2	51
360	Tratamiento de la insuficiencia cardíaca. Medidas preventivas. Factores de riesgo asociados. Medicine, 2001, 8, 1994-2000.	0.0	0
361	Beta-Adrenergic Blocking Drugs in the Treatment of Hypertension. Blood Pressure, 2001, 10, 366-386.	0.7	61
362	Preventive measures help patients with diabetes see into the future. Drugs and Therapy Perspectives, 2001, 17, 12-15.	0.3	0
363	Management of type 2 diabetes: finding a sensible pathway through the maze of available agents. Drugs and Therapy Perspectives, 2001, 17, 4-8.	0.3	1

#	ARTICLE	IF	CITATIONS
364	What is the Optimal Blood Pressure in Patients with Diabetes Mellitus?. American Journal of Cardiovascular Drugs, 2001, 1, 173-177.	1.0	3
365	Treatment of Obesity Hypertension and Diabetes Syndrome. Hypertension, 2001, 38, 705-708.	1.3	102
366	SYMPATHETIC NERVOUS SYSTEM, DIABETES, AND HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 45-55.	0.5	134
367	Racial and Ethnic Differences in Health Care Access and Health Outcomes for Adults With Type 2 Diabetes. Diabetes Care, 2001, 24, 454-459.	4.3	346
368	A Model Educational Program for People With Type 2 Diabetes: A cooperative Latin American implementation study (PEDNID-LA). Diabetes Care, 2001, 24, 1001-1007.	4.3	119
369	Improved Hypertension Management and Control. Hypertension, 2001, 38, 827-832.	1.3	232
370	Management of Diabetic Nephropathy. Journal of the Royal Society of Medicine, 2001, 94, 210-217.	1.1	21
371	The management of diabetes in adults. Nursing and Residential Care, 2001, 3, 308-310.	0.1	0
373	Clinic Diabetes. Practice Nursing, 2001, 12, 337-338.	0.1	0
374	Comparison Of Effects Of Thiazolidinediones On Cardiovascular Risk Factors: Observations From A Clinical Practice. Endocrine Practice, 2001, 7, 162-169.	1.1	77
375	Should Angiotensin-Converting Enzyme Inhibitors Be Added To The Water Supply Of Patients With Diabetes?. Endocrine Practice, 2001, 7, 59-63.	1.1	2
377	Recent developments in the management of type 2 diabetes. British Journal of Community Nursing, 2001, 6, 572-580.	0.2	0
378	Enfoque multidisciplinar ao paciente diabético: avaliação do impacto do "staged diabetes management" em um sistema de saúde privado. Arquivos Brasileiros De Endocrinologia E Metabologia, 2001, 45, 481-486.	1.3	4
379	Clinic Diabetes. Practice Nursing, 2001, 12, 517-518.	0.1	1
380	Hypertension in four African-origin populations: current 'Rule of Halves', quality of blood pressure control and attributable risk of cardiovascular disease. Journal of Hypertension, 2001, 19, 41-46.	0.3	106
381	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 257-264.	1.5	5
382	Treatment of Hypertension in Patients with Diabetes: Lessons from Recent Trials. Cardiology in Review, 2001, 9, 36-44.	0.6	9
383	Cataract surgery in diabetes. Current Opinion in Ophthalmology, 2001, 12, 175-178.	1.3	19

#	ARTICLE	IF	CITATIONS
384	Antihypertensive drug therapy in older patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 263-269.	1.0	5
385	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 73-79.	1.5	12
386	The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women. <i>Archives of Internal Medicine</i> , 2001, 161, 1717.	4.3	451
387	EVIDENCE-BASED TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES. <i>Acta Clinica Belgica</i> , 2001, 56, 96-102.	0.5	0
388	A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients. <i>Archives of Internal Medicine</i> , 2001, 161, 2661.	4.3	82
389	The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. <i>Annals of Internal Medicine</i> , 2001, 134, 663.	2.0	3,157
390	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). <i>Clinical Science</i> , 2001, 101, 671.	1.8	695
394	Update on screening for type 2 diabetes. <i>Postgraduate Medicine</i> , 2001, 109, 27-34.	0.9	9
395	Maternally Inherited Diabetes and Deafness: A Multicenter Study. <i>Annals of Internal Medicine</i> , 2001, 134, 721.	2.0	251
396	"Normal" blood glucose and coronary risk. <i>BMJ: British Medical Journal</i> , 2001, 322, 5-6.	2.4	28
397	Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence. <i>Annals of Internal Medicine</i> , 2001, 135, 1079.	2.0	58
398	Impaired Renal Autoregulation: Implications for the Genesis of Hypertension and Hypertension-Induced Renal Injury. <i>American Journal of the Medical Sciences</i> , 2001, 321, 388-400.	0.4	51
399	Perspectives on Vascular Biology and Diabetes. <i>Journal of Investigative Medicine</i> , 2001, 49, 100-103.	0.7	4
401	Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. <i>BMJ: British Medical Journal</i> , 2001, 322, 986-988.	2.4	120
402	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. , 2001, 11, 474-490.		7
403	Lercanidipine. <i>Heart Disease (Hagerstown, Md)</i> , 2001, 3, 398-407.	1.3	34
404	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. <i>Journal of Hypertension</i> , 2001, 19, 1139-1147.	0.3	234
405	Vascular complications in diabetes and their prevention. <i>Vascular Medicine</i> , 2001, 6, 249-255.	0.8	34

#	ARTICLE	IF	CITATIONS
406	Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 2001, 32, 280-299.	1.0	512
407	Actos (pioglitazone): a new treatment for type 2 diabetes. <i>British Journal of Hospital Medicine</i> , 2001, 62, 411-416.	0.3	2
408	Diabetes Mellitus in Tassin, France: Remarkable Transformation in Incidence and Outcome of ESRD in Diabetes. <i>Advances in Chronic Kidney Disease</i> , 2001, 8, 42-56.	2.2	20
409	Reducing cardiovascular risk in diabetes. <i>Postgraduate Medicine</i> , 2001, 109, 26-36.	0.9	15
410	Autonomic Neuropathy in Nondiabetic Offspring of Type 2 Diabetic Subjects Is Associated With Urinary Albumin Excretion Rate and 24-h Ambulatory Blood Pressure: The Fredericia Study. <i>Diabetes</i> , 2001, 50, 630-636.	0.3	27
411	Choice of drug treatment for obesity-related hypertension: where is the evidence?. <i>Journal of Hypertension</i> , 2001, 19, 667-674.	0.3	78
412	Population-based estimates of mortality associated with diabetes: use of a death certificate check box in North Dakota. <i>American Journal of Public Health</i> , 2001, 91, 84-92.	1.5	59
413	Diabetes: Statins, fibrates, or both?. <i>Current Atherosclerosis Reports</i> , 2001, 3, 19-28.	2.0	19
414	Prevention of strokes. <i>Current Atherosclerosis Reports</i> , 2001, 3, 321-327.	2.0	5
415	Type 2 diabetes in children. <i>Current Diabetes Reports</i> , 2001, 1, 19-27.	1.7	43
416	Drugs for cardiovascular risk reduction in the diabetic patient. <i>Current Diabetes Reports</i> , 2001, 1, 133-139.	1.7	5
417	Combating diabetic nephropathy with drug therapy. <i>Current Diabetes Reports</i> , 2001, 1, 148-156.	1.7	12
418	Treatment of hypertension in diabetic patients with nephropathy. <i>Current Diabetes Reports</i> , 2001, 1, 251-260.	1.7	6
419	Angiotensin receptor blockers in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2001, 1, 267-274.	1.7	2
420	Choices and goals in the treatment of the diabetic hypertensive patient. <i>Current Hypertension Reports</i> , 2001, 3, 387-391.	1.5	2
421	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. <i>Current Hypertension Reports</i> , 2001, 3, 422-428.	1.5	11
422	Systolic hypertension and cardiovascular risk reduction: A clinical review. <i>Current Hypertension Reports</i> , 2001, 3, S11-S15.	1.5	4
424	Implementing a psychological intervention to improve lifestyle self-management in patients with Type 2 diabetes. <i>Patient Education and Counseling</i> , 2001, 42, 247-256.	1.0	79

#	ARTICLE	IF	CITATIONS
425	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 8.	1.5	6
426	Impact of Long-Term Complications on Quality of Life in Patients with Type 2 Diabetes not Using Insulin. Value in Health, 2001, 4, 392-400.	0.1	173
427	PPAR α agonists in type 2 diabetes: how far have we come in "preventing the inevitable"? A review of the metabolic effects of rosiglitazone. Diabetes, Obesity and Metabolism, 2001, 3, 34-43.	2.2	31
428	Treating type 2 diabetes - today's targets, tomorrow's goals. Diabetes, Obesity and Metabolism, 2001, 3, 3-10.	2.2	15
429	The NEPI Antidiabetes Study (NANSY). 1: Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose*. Diabetes, Obesity and Metabolism, 2001, 3, 443-451.	2.2	11
430	A case for lipid lowering? Response to Dr Paul Durrington. Diabetic Medicine, 2001, 18, 11-12.	1.2	0
431	Microalbuminuria in patients with Type 2 diabetes mellitus from general practice: course and predictive value. Diabetic Medicine, 2001, 18, 139-143.	1.2	8
432	Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. Diabetic Medicine, 2001, 18, 288-294.	1.2	54
433	Limited impact of lifestyle education in patients with Type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. Diabetic Medicine, 2001, 18, 104-108.	1.2	36
434	Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabetic Medicine, 2001, 18, 178-184.	1.2	99
435	An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic Medicine, 2001, 18, 438-444.	1.2	18
436	Assessment of blood pressure in patients with Type 2 diabetes: comparison between home blood pressure monitoring, clinic blood pressure measurement and 24-h ambulatory blood pressure monitoring. Diabetic Medicine, 2001, 18, 431-437.	1.2	43
437	The ADKnowl: identifying knowledge deficits in diabetes care. Diabetic Medicine, 2001, 18, 626-633.	1.2	95
438	Blood Pressure Lowering In Diabetes: A Brief Review Of The Current Evidence And Description Of A New Trial. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1108-1111.	0.9	6
439	Expanding the enablement framework and testing an evaluative instrument for diabetes patient education. Journal of Advanced Nursing, 2001, 35, 365-372.	1.5	14
440	Betablocker treatment in diabetes mellitus. Journal of Internal Medicine, 2001, 250, 11-17.	2.7	48
441	Diabetes mellitus - a more solid ground for treatment. Journal of Internal Medicine, 2001, 249, 391-393.	2.7	2
442	Baseline clinical profile and rapid progression to insulin treatment in newly diagnosed diabetic patients over 50 years of age. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 99-101.	0.2	1

#	ARTICLE	IF	CITATIONS
443	Reducing the risk of type 2 diabetes - covering all bases. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, S13-S15.	0.2	0
444	The national service framework for diabetes and deficiencies in specialist care - putting the cart before the horse?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 113-114.	0.2	3
445	CODE-2 UK: our contribution to a European study of the costs of type 2 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 235-238.	0.2	17
446	Attaining UKPDS management targets in type 2 diabetes: failures and difficulties. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 307-310.	0.2	8
447	The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. Pharmacoepidemiology and Drug Safety, 2001, 10, 497-508.	0.9	38
448	Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes/Metabolism Research and Reviews, 2001, 17, 124-130.	1.7	17
449	Random fasting hyperglycemia as cardiovascular risk factor in the elderly: A 6-year longitudinal study. Clinical Cardiology, 2001, 24, 341-344.	0.7	9
450	Diabetic complications are associated with high blood pressure for type-2 diabetes patients. Evidence-Based Healthcare and Public Health, 2001, 5, 16.	0.0	2
451	Glycaemia and high blood pressure are associated with type 2 diabetes complications over time. Evidence-Based Healthcare and Public Health, 2001, 5, 47-48.	0.0	0
452	Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT. Journal of Human Hypertension, 2001, 15, S79-S80.	1.0	0
453	First-line treatment of hypertension: from monotherapy to fixed low-dose combination therapy. Journal of Human Hypertension, 2001, 15, 443-446.	1.0	4
454	Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. Journal of Human Hypertension, 2001, 15, 841-848.	1.0	29
455	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. American Journal of Cardiology, 2001, 88, 1-20.	0.7	202
456	Insulin resistance syndrome and type 2 diabetes mellitus. American Journal of Cardiology, 2001, 88, 38-42.	0.7	49
457	Calculating Confidence Intervals for the Number Needed to Treat. Contemporary Clinical Trials, 2001, 22, 102-110.	2.0	187
458	Manipulating the vascular biology of coronary atherosclerosis in diabetes: New opportunities. Translational Research, 2001, 137, 82-92.	2.4	1
459	Diabetic retinopathy, visual acuity, and medical risk indicators. A continuous 10-year follow-up study in Type 1 diabetic patients under routine care. Journal of Diabetes and Its Complications, 2001, 15, 287-294.	1.2	37
460	The impact of metabolic and blood pressure control on incidence and progression of nephropathy. Journal of Diabetes and Its Complications, 2001, 15, 307-313.	1.2	36

#	ARTICLE	IF	CITATIONS
461	A clinical trial in type 2 diabetic nephropathy. American Journal of Kidney Diseases, 2001, 38, S191-S194.	2.1	21
462	Diagnosis and management of carotid artery disease: The role of carotid artery stenting. Current Problems in Cardiology, 2001, 26, 493-555.	1.1	2
463	Glycemic control in the prevention of diabetic complications. Clinical Cornerstone, 2001, 4, 24-37.	1.0	20
464	Current therapeutic algorithms for type 2 diabetes. Clinical Cornerstone, 2001, 4, 38-49.	1.0	4
465	Diabetic nephropathy in type 2 diabetes mellitus: prevention and treatment. Hong Kong Journal of Nephrology, 2001, 3, 3-6.	0.0	0
466	Diabetes. British Medical Bulletin, 2001, 59, 159-172.	2.7	4
467	"Seeing" Between the Lines. Clinical Diabetes, 2001, 19, 28-28.	1.2	0
469	Slowing the Progression of Renal Disease in Diabetic Patients. Annals of Pharmacotherapy, 2001, 35, 452-463.	0.9	15
470	Perceived Difficulty of Diabetes Treatment in Primary Care: Does it Differ by Patient Ethnicity?. The Diabetes Educator, 2001, 27, 678-684.	2.6	10
471	Diabetes, Hypertension, and Cardiovascular Disease: An Update. Hypertension, 2001, 38, E11.	1.3	7
472	Comprehensive Evaluation of Community-Based Diabetic Patients: Effect of feedback to patients and their physicians: a randomized controlled trial. Diabetes Care, 2001, 24, 690-694.	4.3	42
473	A Diabetes-Specific Measure of Patient Desire to Participate in Medical Decision Making. The Diabetes Educator, 2001, 27, 875-886.	2.6	29
475	Prevention of Stroke. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 257-264.	3.1	4
476	Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria. Nephrology Dialysis Transplantation, 2001, 16, 529-536.	0.4	26
477	Treatment of Hypertension in Pregnancy. Obstetrics and Gynecology, 2001, 98, 427-433.	1.2	36
478	Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes?. European Heart Journal, 2001, 22, 1102-1110.	1.0	81
479	Treatment of Hypertension in Type 2 Diabetes. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 897-905.	1.7	2
480	Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ: British Medical Journal, 2001, 322, 15-15.	2.4	832

#	ARTICLE	IF	CITATIONS
482	Cardiovascular Drug Use and Hospitalizations Attributable to Type 2 Diabetes. <i>Diabetes Care</i> , 2001, 24, 1428-1432.	4.3	11
483	Glucose Control and Cardiovascular Complications: The VA Diabetes Trial. <i>Diabetes Care</i> , 2001, 24, 942-945.	4.3	94
484	Diabetes Screening in Canada (DIASCAN) Study: Prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. <i>Diabetes Care</i> , 2001, 24, 1038-1043.	4.3	77
485	Fasting Versus Postload Glucose Levels: Why the controversy?. <i>Diabetes Care</i> , 2001, 24, 1855-1857.	4.3	31
486	Risk of Developing Retinopathy in Diabetes Control and Complications Trial Type 1 Diabetic Patients With Good or Poor Metabolic Control. <i>Diabetes Care</i> , 2001, 24, 1275-1279.	4.3	217
487	Review: UKPDS odyssey 2001. <i>British Journal of Diabetes and Vascular Disease</i> , 2001, 1, 14-21.	0.6	2
488	Review: Promise of prevention and reversal of target organ involvement in hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, S4-S9.	1.0	6
489	Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 170-173.	1.0	1
490	Improvement in Hypertension in Patients With Diabetes Mellitus After Kidney/Pancreas Transplantation. <i>Circulation</i> , 2001, 104, 563-569.	1.6	31
493	Congestive Heart Failure in Type 2 Diabetes: Prevalence, incidence, and risk factors. <i>Diabetes Care</i> , 2001, 24, 1614-1619.	4.3	521
494	Potential for the prevention of type 2 diabetes. <i>British Medical Bulletin</i> , 2001, 60, 183-199.	2.7	41
495	Applying the Diabetes Quality Improvement Project Indicators in the Indian Health Service Primary Care Setting. <i>Diabetes Care</i> , 2001, 24, 22-26.	4.3	51
496	Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/Â-Blocker-Based Treatment Regimen: A subanalysis of the Captopril Prevention Project. <i>Diabetes Care</i> , 2001, 24, 2091-2096.	4.3	230
497	Evidence based management of hypertension: What to do when blood pressure is difficult to control. <i>BMJ: British Medical Journal</i> , 2001, 322, 1229-1232.	2.4	31
498	Lowering blood pressure in particular patient groups. <i>Drug and Therapeutics Bulletin</i> , 2001, 39, 37-40.	0.3	3
499	External Barriers to Diabetes Care: Addressing Personal and Health Systems Issues. <i>Diabetes Spectrum</i> , 2001, 14, 23-28.	0.4	89
500	GENERAL CARDIOLOGY: Diabetic heart disease: clinical considerations. <i>British Heart Journal</i> , 2001, 85, 463-469.	2.2	29
501	Incorporating the Results of Diabetes Research Into Clinical Practice: Celebrating 25 years of Diabetes Research and Training Center translation research. <i>Diabetes Care</i> , 2001, 24, 2134-2142.	4.3	7

#	ARTICLE	IF	CITATIONS
502	The Diabetes Quality Improvement Project: Moving science into health policy to gain an edge on the diabetes epidemic. <i>Diabetes Care</i> , 2001, 24, 1815-1820.	4.3	245
503	Cyclic Stretch and Hypertension Induce Retinal Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2: Potential Mechanisms for Exacerbation of Diabetic Retinopathy by Hypertension. <i>Diabetes</i> , 2001, 50, 444-454.	0.3	128
504	Primary Prevention of Ischemic Stroke. <i>Circulation</i> , 2001, 103, 163-182.	1.6	340
505	Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 31-36.	1.0	51
507	A Systematic Approach to Risk Stratification and Intervention Within a Managed Care Environment Improves Diabetes Outcomes and Patient Satisfaction. <i>Diabetes Care</i> , 2001, 24, 1079-1086.	4.3	96
508	Interventions to Improve the Management of Diabetes in Primary Care, Outpatient, and Community Settings: A systematic review. <i>Diabetes Care</i> , 2001, 24, 1821-1833.	4.3	722
509	The National Diabetes Education Program, Changing the Way Diabetes Is Treated: Comprehensive diabetes care. <i>Diabetes Care</i> , 2001, 24, 617-618.	4.3	41
510	Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention. <i>Postgraduate Medical Journal</i> , 2001, 77, 68-74.	0.9	15
511	Review: Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 146-152.	1.0	8
512	Markers of Insulin Resistance Are Strong Risk Factors for Retinopathy Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study. <i>Diabetes Care</i> , 2001, 24, 284-289.	4.3	192
513	Local Hemodynamic Changes in Hypertension. <i>Hypertension</i> , 2001, 38, 1388-1394.	1.3	33
514	Prescribing Patterns and Therapeutic Implications for Diabetic Hypertension in Bahrain. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1350-1359.	0.9	22
515	Review: intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus. <i>Evidence-Based Medicine</i> , 2001, 6, 44-44.	0.6	3
517	Unchanged Incidence of Lower-Limb Amputations in a German City, 1990-1998. <i>Diabetes Care</i> , 2001, 24, 855-859.	4.3	122
518	Who's on First?. <i>Circulation</i> , 2001, 104, 508-510.	1.6	6
519	Short-term mortality among middle-aged cataract surgery patients. <i>Eye</i> , 2001, 15, 209-212.	1.1	22
520	Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects. <i>Circulation</i> , 2001, 103, 102-107.	1.6	285
521	Increased numbers of caveolae in retinal endothelium and pericytes in hypertensive diabetic rats. <i>Eye</i> , 2001, 15, 319-325.	1.1	12

#	ARTICLE	IF	CITATIONS
522	Konjac-Mannan and American Ginseng: Emerging Alternative Therapies for Type 2 Diabetes Mellitus. <i>Journal of the American College of Nutrition</i> , 2001, 20, 370S-380S.	1.1	121
523	Retinal microvascular abnormalities and blood pressure in older people: the Cardiovascular Health Study. <i>British Journal of Ophthalmology</i> , 2002, 86, 1007-1013.	2.1	235
524	Halting the Progression of Chronic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S190-S195.	3.0	43
525	Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in diabetic renal disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 81-84.	0.6	0
526	Prevention of Diabetic Nephropathy in Rats by Prostaglandin E Receptor EP1-Selective Antagonist. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1757-1765.	3.0	105
527	Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. <i>Diabetes Care</i> , 2002, 25, 512-516.	4.3	1,095
528	Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. <i>Vascular Medicine</i> , 2002, 7, 35-43.	0.8	244
530	The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 255-261.	1.0	50
531	Therapeutic approaches to the management of dysmetabolic cardiovascular disease. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 615-620.	2.4	2
532	Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk: The Framingham Offspring Study. <i>Diabetes Care</i> , 2002, 25, 1845-1850.	4.3	474
533	Diabetic Patients Detected by Population-Based Stepwise Screening Already Have a Diabetic Cardiovascular Risk Profile. <i>Diabetes Care</i> , 2002, 25, 1784-1789.	4.3	98
534	Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. <i>BMJ: British Medical Journal</i> , 2002, 324, 459-464.	2.4	58
535	Blood pressure control and diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2002, 86, 365-367.	2.1	51
536	Inside Guidelines: Comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. <i>Diabetes Care</i> , 2002, 25, 1933-1939.	4.3	184
537	Stretch-induced Retinal Vascular Endothelial Growth Factor Expression Is Mediated by Phosphatidylinositol 3-Kinase and Protein Kinase C (PKC)- η but Not by Stretch-induced ERK1/2, Akt, Ras, or Classical/Novel PKC Pathways. <i>Journal of Biological Chemistry</i> , 2002, 277, 1047-1057.	1.6	69
538	Macular Edema Reflects Generalized Vascular Hyperpermeability in Type 2 Diabetic Patients With Retinopathy. <i>Diabetes Care</i> , 2002, 25, 2328-2334.	4.3	89
539	Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics?. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S202-S207.	3.0	14
542	Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance. <i>Circulation</i> , 2002, 106, 2085-2090.	1.6	1,387

#	ARTICLE	IF	CITATIONS
543	Culturally Competent Dietary Education for Southern Rural African Americans With Diabetes. <i>The Diabetes Educator</i> , 2002, 28, 245-257.	2.6	36
544	Protecting the kidneys and cardiovascular system in type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 77-79.	0.6	1
546	Review: Thirty-seven years with diabetic retinopathy. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 452-456.	0.6	0
547	Review: Diabetes nursing: a personal perspective of the last 50 years. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, 464-467.	0.6	0
548	Adherence to American Diabetes Association Standards of Care by Rural Health Care Providers. <i>Diabetes Care</i> , 2002, 25, 2224-2229.	4.3	85
549	A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2002, 25, 303-308.	4.3	54
551	Blood Pressure, Lipids, and Obesity Are Associated With Retinopathy: The Hoorn Study. <i>Diabetes Care</i> , 2002, 25, 1320-1325.	4.3	363
552	Review: Rationale for combination therapy in the treatment of hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 63-65.	1.0	4
553	Laparoscopic Adjustable Gastric Banding for the Treatment of Morbid (Grade 3) Obesity and its Metabolic Complications: A Three-Year Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3555-3561.	1.8	160
554	What should cardiologists be telling general practitioners/family physicians?. <i>European Heart Journal Supplements</i> , 2002, 4, F54-F59.	0.0	0
555	Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 241-246.	0.2	93
556	Diabetic nephropathy: how effective is treatment in clinical practice?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 41-49.	0.2	39
557	Sources of misunderstanding numbers needed to treat. <i>European Journal of General Practice</i> , 2002, 8, 101-103.	0.9	1
558	Trough-to-Peak Ratio, Smoothness Index, and Circadian Blood Pressure Profile After Treatment With Once-Daily Fixed Combination of Losartan 100 and Hydrochlorothiazide 25 in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 824-833.	0.8	18
559	Successful Blood Pressure Control in the African American Study of Kidney Disease and Hypertension. <i>Archives of Internal Medicine</i> , 2002, 162, 1636.	4.3	122
560	Self-monitoring of glucose levels for people with type 2 diabetes. <i>British Journal of Community Nursing</i> , 2002, 7, 41-46.	0.2	17
561	Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. <i>New England Journal of Medicine</i> , 2002, 346, 705-707.	13.9	18
562	New strategies for blood pressure control. <i>Journal of Human Hypertension</i> , 2002, 16, S124-S127.	1.0	2

#	ARTICLE	IF	CITATIONS
563	UKPDS 60. Stroke, 2002, 33, 1776-1781.	1.0	391
564	Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study. Diabetes Care, 2002, 25, 95-100.	4.3	200
565	Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes. Medical Decision Making, 2002, 22, 80-91.	1.2	37
566	Review: Managing the diabetic patient with angina. British Journal of Diabetes and Vascular Disease, 2002, 2, 169-175.	0.6	0
568	ACE Inhibitor as One of Several Possible First-Line Agents Is Reasonable for Diabetic Patients With Hypertension. Diabetes Care, 2002, 25, 1488-1489.	4.3	2
569	Transfer of knowledge from the specialist to the generalist by videoconferencing: effect on diabetes care. Journal of Telemedicine and Telecare, 2002, 8, 350-355.	1.4	32
571	Review: Type 2 diabetes: how far have we come?. British Journal of Diabetes and Vascular Disease, 2002, 2, 446-449.	0.6	3
572	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease <SUBTITLE>Results From the AASK Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 288, 2421.	3.8	1,792
574	Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers. Journal of the American Society of Nephrology: JASN, 2002, 13, S224-S229.	3.0	47
575	Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 79-89.	1.0	9
577	The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. British Journal of Ophthalmology, 2002, 86, 84-90.	2.1	117
578	Is It the Agent or the Blood Pressure Level that Matters for Renal Protection in Chronic Nephropathies?. Journal of the American Society of Nephrology: JASN, 2002, 13, S196-S201.	3.0	18
580	Review: Overview of diabetic eye disease. British Journal of Diabetes and Vascular Disease, 2002, 2, 14-17.	0.6	0
581	A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus Hydrochlorothiazide. Journal of International Medical Research, 2002, 30, 366-379.	0.4	17
582	Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Diabetes Care, 2002, 25, 542-549.	4.3	189
583	Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers. Diabetes Care, 2002, 25, 718-723.	4.3	211
586	Atherosclerotic cardiovascular disease and diabetic retinopathy. British Journal of Ophthalmology, 2002, 86, 3-4.	2.1	4
587	Review: The renin-angiotensin-aldosterone system and the eye in diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 243-246.	1.0	41

#	ARTICLE	IF	CITATIONS
588	Obesity, Hypertension, and Insulin Resistance. <i>Diabetes Care</i> , 2002, 25, 2088-2097.	4.3	53
589	Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding. <i>Diabetes Care</i> , 2002, 25, 358-363.	4.3	298
591	Critical Pathways. <i>Critical Pathways in Cardiology</i> , 2002, 1, 184-193.	0.2	0
592	The Translating Research Into Action for Diabetes (TRIAD) Study: A multicenter study of diabetes in managed care. <i>Diabetes Care</i> , 2002, 25, 386-389.	4.3	107
593	Standards of Medical Care for Patients With Diabetes Mellitus. <i>Diabetes Care</i> , 2002, 25, 213-229.	4.3	201
595	Modifiable Cardiovascular Risk Factors in Adults With Diabetes. <i>Archives of Internal Medicine</i> , 2002, 162, 427.	4.3	108
596	Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. <i>Journal of Human Hypertension</i> , 2002, 16, S17-S23.	1.0	14
597	Research Opportunities in Diabetes. <i>Journal of Cardiovascular Nursing</i> , 2002, 16, 86-94.	0.6	2
598	Long-term renal consequences of hypertension for normal and diseased kidneys. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 73-80.	1.0	96
599	Clinical Trial Evidence for Cardiovascular Risk Reduction in Type 2 Diabetes. <i>Journal of Cardiovascular Nursing</i> , 2002, 16, 24-43.	0.6	6
600	Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.3	56
601	Critical Pathways. <i>Critical Pathways in Cardiology</i> , 2002, 1, 184-193.	0.2	1
602	Diabetes and Cardiovascular Diseases. <i>American Journal of Therapeutics</i> , 2002, 9, 510-515.	0.5	48
603	Hypertension and diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 221-228.	1.0	64
604	Losartan titration versus diuretic combination in type 2 diabetic patients. <i>Journal of Hypertension</i> , 2002, 20, 715-719.	0.3	11
605	Antihypertensive treatment in patients with type-2 diabetes mellitus. <i>Journal of Hypertension</i> , 2002, 20, 2099-2110.	0.3	121
606	Treating Hypertension in Patients with Diabetes. <i>Nurse Practitioner</i> , 2002, 27, 11-15.	0.2	1
607	MANAGEMENT OF THE PATIENT WITH CHRONIC RENAL FAILURE IN THE EVIDENCE BASED ERA. <i>Acta Clinica Belgica</i> , 2002, 57, 257-265.	0.5	0

#	ARTICLE	IF	CITATIONS
608	Diabetes and behavioral medicine: The second decade.. Journal of Consulting and Clinical Psychology, 2002, 70, 611-625.	1.6	151
610	A Diabetes Report Card for the United States: Quality of Care in the 1990s. Annals of Internal Medicine, 2002, 136, 565.	2.0	505
611	Quality of Care in Diabetes: Understanding the Guidelines. American Journal of the Medical Sciences, 2002, 324, 196-206.	0.4	14
612	The Epidemiology of End-Stage Renal Disease among African Americans. American Journal of the Medical Sciences, 2002, 323, 65-71.	0.4	78
613	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ: British Medical Journal, 2002, 325, 860-860.	2.4	72
614	Mechanisms in the Development of Type 2 Diabetes Mellitus. Journal of Cardiovascular Nursing, 2002, 16, 1-16.	0.6	22
615	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 147-152.	1.5	11
616	Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design. Journal of the American Medical Informatics Association: JAMIA, 2002, 9, 49-62.	2.2	162
617	The Treatment of Hypertension in Adult Patients With Diabetes. Diabetes Care, 2002, 25, 134-147.	4.3	280
618	Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. American Journal of Medicine, 2002, 112, 603-609.	0.6	93
619	Effectiveness of diabetes management: is improvement feasible?. American Journal of Medicine, 2002, 112, 670-672.	0.6	8
620	Diabetes management in the primary care setting: summary. American Journal of Medicine, 2002, 113, 36-40.	0.6	14
621	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. American Journal of Ophthalmology, 2002, 133, 693-698.	1.7	106
622	Should β Blockers Be Used in the Treatment of Hypertension in the Elderly?. Journal of Clinical Hypertension, 2002, 4, 286-294.	1.0	7
623	Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?. Journal of Clinical Hypertension, 2002, 4, 20-31.	1.0	8
624	Update on the Management of Diabetes and Hypertension. Journal of Clinical Hypertension, 2002, 4, 3-10.	1.0	9
625	Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology, 2002, 40, 652-661.	1.2	26
626	Initial Management of Glycemia in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2002, 347, 1342-1349.	13.9	309

#	ARTICLE	IF	CITATIONS
627	Prevention of heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 333-346.	0.7	84
628	Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. <i>Current Problems in Cardiology</i> , 2002, 27, 6-36.	1.1	12
629	A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. <i>Drug Safety</i> , 2002, 25, 943-963.	1.4	8
630	Treatment of Heart Failure in Patients with Diabetes Mellitus. <i>Drugs</i> , 2002, 62, 285-307.	4.9	7
631	Rationale for Fixed-Dose Combinations in the Treatment of Hypertension. <i>Drugs</i> , 2002, 62, 443-462.	4.9	263
632	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. <i>Drugs</i> , 2002, 62, 2007-2012.	4.9	13
633	Fixed Combination Trandolapril/Verapamil Sustained-Release. <i>Drugs</i> , 2002, 62, 2541-2569.	4.9	11
634	Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and Hypertension. <i>Clinical Drug Investigation</i> , 2002, 22, 541-546.	1.1	12
635	Pathophysiology of Type 2 Diabetes Mellitus in Children and Adolescents. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002, 1, 359-371.	1.8	24
636	Treatment of Microalbuminuria in Patients with Type 2 Diabetes Mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002, 1, 163-173.	1.8	33
637	Improved Diabetes Control Through a Provider-Based Disease Management Program. <i>Disease Management and Health Outcomes</i> , 2002, 10, 1-8.	0.3	11
640	El control de la presi3n arterial del paciente diab3tico hipertenso. <i>Hipertension Y Riesgo Vascular</i> , 2002, 19, 335-337.	0.3	2
641	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2002, 31, 537-551.	1.2	8
642	Antihipertensivos cl3sicos o modernos en el tratamiento de la hipertensi3n arterial: ¿debe seguir existiendo controversia en su elecci3n?. <i>Semergen</i> , 2002, 28, 560-572.	0.2	1
643	Ascorbic Acid Reduces Blood Pressure and Arterial Stiffness in Type 2 Diabetes. <i>Hypertension</i> , 2002, 40, 804-809.	1.3	176
644	Hypertension and Diabetes. <i>Current Medical Research and Opinion</i> , 2002, 18, s48-s57.	0.9	15
645	ACE inhibitors prove beneficial for an increasing range of complications of diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2002, 18, 11-13.	0.3	0
646	Effects of Combined Treatment with Simvastatin and L-Carnitine on Triglyceride Levels in Diabetic Patients with Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 2002, 22, 23-28.	1.1	12

#	ARTICLE	IF	CITATIONS
647	Increasing Incidence of Type 2 Diabetes in Children and Adolescents. Paediatric Drugs, 2002, 4, 209-221.	1.3	55
648	Calcium Channel Antagonists in the Treatment of Hypertension. American Journal of Cardiovascular Drugs, 2002, 2, 415-431.	1.0	18
649	Mechanisms for Monitoring Changes in Retinal Status Following Therapeutic Intervention in Diabetic Retinopathy. Survey of Ophthalmology, 2002, 47, S270-S277.	1.7	24
650	Prevention of Visual Loss From Diabetic Retinopathy. Survey of Ophthalmology, 2002, 47, S246-S252.	1.7	25
652	Changing Times for the Management of Diabetic Retinopathy. Survey of Ophthalmology, 2002, 47, S238-S245.	1.7	19
653	Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. American Heart Journal, 2002, 144, 726-732.	1.2	11
654	Clinical implications of aldosterone blockade. American Heart Journal, 2002, 144, S12-S18.	1.2	28
655	Acute myocardial infarction in the elderly with diabetes. Heart and Lung: Journal of Acute and Critical Care, 2002, 31, 327-339.	0.8	11
656	Cardiovascular risk factors, change in risk factors over 7 years, and the risk of clinical diabetes mellitus type 2. Journal of Clinical Epidemiology, 2002, 55, 647-653.	2.4	21
657	Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial. American Journal of Hypertension, 2002, 15, 193-198.	1.0	24
658	Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. American Journal of Hypertension, 2002, 15, 244-250.	1.0	91
659	American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. American Journal of Hypertension, 2002, 15, 372-379.	1.0	23
660	Ace inhibition and cardiovascular mortality and morbidity in essential hypertension: The end of the search or a need for further investigations?. American Journal of Hypertension, 2002, 15, 367-371.	1.0	20
661	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. American Journal of Hypertension, 2002, 15, 550-556.	1.0	46
662	Recent landmark clinical trials: how do they modify the therapeutic paradigm?. American Journal of Hypertension, 2002, 15, S82-S84.	1.0	9
663	Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. American Journal of Hypertension, 2002, 15, S85-S93.	1.0	31
664	Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. American Journal of Hypertension, 2002, 15, 108S-114S.	1.0	16
665	Elevated blood pressure among U.S. adults with diabetes, 1988-1994 1The full text of this article is available via AJPM Online at http://www.elsevier.com/locate/ajpmonline.. American Journal of Preventive Medicine, 2002, 22, 42-48.	1.6	112

#	ARTICLE	IF	CITATIONS
666	The effectiveness of disease and case management for people with diabetesA systematic review. American Journal of Preventive Medicine, 2002, 22, 15-38.	1.6	438
667	Increasing diabetes self-management education in community settingsA systematic review. American Journal of Preventive Medicine, 2002, 22, 39-66.	1.6	274
668	Diabetes modulates the expression of glomerular kinin receptors. International Immunopharmacology, 2002, 2, 1771-1779.	1.7	23
669	Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Research and Clinical Practice, 2002, 55, 113-121.	1.1	50
670	Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Research and Clinical Practice, 2002, 56, 1-11.	1.1	154
671	Process measures and outcome research as tools for future improvement of diabetes treatment quality. Diabetes Research and Clinical Practice, 2002, 56, 207-211.	1.1	7
672	The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clinical Therapeutics, 2002, 24, 1019-1034.	1.1	30
673	Pharmacologic management of diabetic nephropathy. Clinical Therapeutics, 2002, 24, 1741-1756.	1.1	25
675	The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes. Ophthalmology, 2002, 109, 1225-1234.	2.5	264
676	Hypertension in the elderly: evidence-based management. International Congress Series, 2002, 1237, 75-85.	0.2	1
680	Modificaci3n de los factores de riesgo en el paciente arterioscler3tico joven: mecanismos implicados. Angiologia, 2002, 54, 174-181.	0.0	0
682	Morbimortalidad cardiovascular en la diabetes mellitus tipo 2. Hipertension Y Riesgo Vascular, 2002, 19, 193-196.	0.3	0
683	Aspirin in diabetic retinopathy. Endocrinology and Metabolism Clinics of North America, 2002, 31, 779-793.	1.2	37
687	Diabetes mellitus. Clinics in Podiatric Medicine and Surgery, 2002, 19, 79-107.	0.2	48
688	Morbimortalidad en diab3ticos tipo 2 seguidos durante 5 a±os. Hipertension Y Riesgo Vascular, 2002, 19, 200-205.	0.3	0
689	Evoluci3n del control de la hipertensi3n arterial en Espa±a. Resultados del estudio Controlpres 2001. Hipertension Y Riesgo Vascular, 2002, 19, 390-399.	0.3	89
691	A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes: Impact on physical activity. Diabetes Care, 2002, 25, 1576-1583.	4.3	228
692	Renoprotective Effects of Blockade of Angiotensin II AT1 Receptors in an Animal Model of Type 2 Diabetes. Hypertension Research, 2002, 25, 271-278.	1.5	73

#	ARTICLE	IF	CITATIONS
693	Targeting the Renin-Angiotensin System in Patients with Renal Disease. <i>Journal of the Royal Society of Medicine</i> , 2002, 95, 391-397.	1.1	3
694	Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive. <i>Hypertension</i> , 2002, 40, 781-788.	1.3	95
695	Selection of the Dose of Angiotensin Converting Enzyme Inhibitor for Patients with Diabetic Nephropathy Depends on the Presence or Absence of Left Ventricular Hypertrophy.. <i>Hypertension Research</i> , 2002, 25, 865-873.	1.5	11
696	The Relationship of Coronary Arterial Lesion with Clinical Factors in Type II Diabetes. <i>Sunhwan'gi</i> , 2002, 32, 106.	0.3	2
697	A New Paradigm for Control of Diabetes. <i>Endocrine Practice</i> , 2002, 8, 65-67.	1.1	1
698	Nutrition and diabetes control: advice for non-dietitians. <i>British Journal of Community Nursing</i> , 2002, 7, 414-419.	0.2	3
699	Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension,,. <i>American Journal of Clinical Nutrition</i> , 2002, 76, 1007-1015.	2.2	296
700	National Pharmacy Cardiovascular Council Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists. <i>Pharmacotherapy</i> , 2002, 22, 436-444.	1.2	28
701	The Use of Combination Drug Therapy in the Treatment of Hypertension. <i>Progress in Cardiovascular Nursing</i> , 2002, 17, 81-95.	0.5	17
702	Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2002, 90, 42-50.	0.7	148
703	Involving users in the design and usability evaluation of a clinical decision support system. <i>Computer Methods and Programs in Biomedicine</i> , 2002, 69, 123-135.	2.6	49
704	Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1173-1197.	6.6	60
705	Epidemiology of diabetes. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1165-1172.	6.6	52
706	Delivery of photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital: comparisons with national clinical practice guidelines. <i>Clinical and Experimental Ophthalmology</i> , 2002, 30, 115-119.	1.3	5
707	Addressing the Insulin Resistance Syndrome A Role for the Thiazolidinediones. <i>Trends in Cardiovascular Medicine</i> , 2002, 12, 354-362.	2.3	42
708	Risk of macrovascular and microvascular complications in Type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 271-276.	1.2	74
709	Clinical implication of multiple risk factor control in the management of diabetic macrovascular complications. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 115-118.	1.2	1
710	The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 123-132.	1.2	51

#	ARTICLE	IF	CITATIONS
711	An introduction to new advances in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S1-S6.	1.7	4
713	Considerations for treating dyslipidemia in special diabetic populations. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 88-95.	1.7	1
714	Diabetes trends in Europe. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S3-S8.	1.7	95
715	Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S32-S35.	1.7	13
716	Diagnosing coronary artery disease in diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 201-208.	1.7	14
719	Prevention of heart failure. <i>Current Cardiology Reports</i> , 2002, 4, 194-199.	1.3	7
720	Patient-centered diabetes self-management education. <i>Current Diabetes Reports</i> , 2002, 2, 145-152.	1.7	23
721	Is hepatic glucose production increased in type 2 diabetes mellitus?. <i>Current Diabetes Reports</i> , 2002, 2, 231-236.	1.7	32
722	Role of ACE Inhibitors in treating hypertensive diabetic patients. <i>Current Diabetes Reports</i> , 2002, 2, 251-257.	1.7	9
723	Cardiovascular risk factors in diabetic patients with hypertension. <i>Current Diabetes Reports</i> , 2002, 2, 263-266.	1.7	2
724	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. <i>Current Diabetes Reports</i> , 2002, 2, 423-430.	1.7	0
725	Blood pressure control—Effects on diabetic nephropathy progression: How low does blood pressure have to be?. <i>Current Diabetes Reports</i> , 2002, 2, 530-538.	1.7	5
726	Appropriate drug therapy for improving outcomes in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2002, 2, 545-552.	1.7	3
727	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. <i>Current Hypertension Reports</i> , 2002, 4, 290-297.	1.5	1
728	A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2002, 80, 310-315.	0.4	17
729	Vascular reactivity in diabetic rats: effect of melatonin. <i>Journal of Pineal Research</i> , 2002, 33, 81-86.	3.4	27
730	The cardioprotective role of beta-blockers in patients with diabetes mellitus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 233-242.	0.7	14
731	Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care. <i>Journal of Evaluation in Clinical Practice</i> , 2002, 8, 19-30.	0.9	22

#	ARTICLE	IF	CITATIONS
732	Costs for screening, intervention and hospital treatment generated by the Malmo Preventive Project: a large-scale community screening programme. <i>Journal of Internal Medicine</i> , 2002, 251, 44-52.	2.7	7
733	Body position and blood pressure measurement in patients with diabetes mellitus. <i>Journal of Internal Medicine</i> , 2002, 251, 393-399.	2.7	32
734	Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. <i>Kidney International</i> , 2002, 61, 1086-1097.	2.6	727
735	Screening for diabetes in an outpatient clinic population. <i>Journal of General Internal Medicine</i> , 2002, 17, 23-28.	1.3	38
736	The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. <i>Journal of General Internal Medicine</i> , 2002, 17, 243-252.	1.3	564
737	Savings in Dialysis Treatment?. <i>Artificial Organs</i> , 2002, 26, 49-54.	1.0	5
738	What should we measure in the diabetic patient and how does this respond to therapy?. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 81-86.	1.1	0
739	Reducing the risk of stroke in diabetes: what have we learned that is new?. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 27-34.	2.2	24
740	What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 19-25.	2.2	11
741	Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 13-18.	2.2	83
742	Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 5-12.	2.2	42
743	Vasopeptidase inhibitors and their potential role in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 89-95.	2.2	1
744	Blood pressure control in patients with type 2 diabetes and hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 81-88.	2.2	4
745	Improvements in the provision of hospital diabetes services in an English region 1988-98. <i>Diabetic Medicine</i> , 2002, 19, 79-82.	1.2	1
746	Diabetic nephropathy is associated with the 5'Â¢-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 113-118.	1.2	21
747	Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus-a randomized prospective study. <i>Diabetic Medicine</i> , 2002, 19, 385-392.	1.2	102
748	Cardiovascular risk profile assessment in glucose-intolerant Asian individuals-an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 T International Diabetes Epidemiology Group*. <i>Diabetic Medicine</i> , 2002, 19, 549-557.	1.2	49
749	Mistaken priorities in diabetes research. <i>Diabetic Medicine</i> , 2002, 19, 263-264.	1.2	9

#	ARTICLE	IF	CITATIONS
750	Ambulatory blood pressure monitoring: is it necessary for the routine assessment of hypertension in people with diabetes?. Diabetic Medicine, 2002, 19, 787-789.	1.2	23
751	The evaluation of screening policies for diabetic retinopathy using simulation. Diabetic Medicine, 2002, 19, 762-770.	1.2	47
752	Perceptions of diabetic retinopathy and screening procedures among diabetic people. Diabetic Medicine, 2002, 19, 810-813.	1.2	31
753	The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabetic Medicine, 2002, 19, 889-894.	1.2	16
754	Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabetic Medicine, 2002, 19, 1014-1021.	1.2	63
755	Visual outcome after laser treatment for diabetic retinopathy. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 6-9.	0.2	2
756	Characteristics of those registered blind as a result of diabetes in Fife over a ten year period. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 40-42.	0.2	0
757	An evaluation of diabetic care in registered nursing homes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 146-148.	0.2	2
758	The prevalence of diabetes related complications amongst the Turkish diabetes population attending a south London hospital. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 251-254.	0.2	1
759	The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?. Eye, 2002, 16, 689-693.	1.1	90
760	The problem of uncontrolled hypertension. Journal of Human Hypertension, 2002, 16, S3-S8.	1.0	34
761	The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. Journal of Human Hypertension, 2002, 16, S42-S46.	1.0	53
762	The reno-protective role of AT1-receptor blockers. Journal of Human Hypertension, 2002, 16, S52-S58.	1.0	22
763	Hypertension and the eye: changing perspectives. Journal of Human Hypertension, 2002, 16, 667-675.	1.0	77
764	Type 2 Diabetes Outcomes. Obesity, 2002, 10, 22S-26S.	4.0	8
765	Age structured models for diabetes in East Morocco. Mathematics and Computers in Simulation, 2002, 58, 215-229.	2.4	18
766	The effect of physical exercise on the dynamics of glucose and insulin. Journal of Biomechanics, 2002, 35, 911-917.	0.9	111
767	Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology, 2002, 25, 205-212.	0.7	23

#	ARTICLE	IF	CITATIONS
768	The Cost of Diabetes Type II in Europe The CODE-2 Study. <i>Diabetologia</i> , 2002, 45, S1-S4.	2.9	97
769	Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. <i>Diabetologia</i> , 2002, 45, 1004-1010.	2.9	124
770	Evaluation of risk factors for development of complications in Type II diabetes in Europe. <i>Diabetologia</i> , 2002, 45, S23-S28.	2.9	182
771	Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. <i>Diabetologia</i> , 2002, 45, 1231-1239.	2.9	191
772	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. <i>Diabetologia</i> , 2002, 45, 1362-1371.	2.9	33
773	Structured personal programme in primary care does not improve mortality and morbidity for type 2 diabetes. <i>Evidence-Based Healthcare and Public Health</i> , 2002, 6, 66-67.	0.0	0
774	Angiotensin II blockade: A therapeutic strategy with wide applications. <i>Clinical Cardiology</i> , 2003, 26, 500-502.	0.7	4
775	Translating worldwide calcium-channel blocker experience into clinical practice. <i>Clinical Cardiology</i> , 2003, 26, 1-2.	0.7	0
776	Getting to goal in complex patients. <i>Clinical Cardiology</i> , 2003, 26, 3-6.	0.7	1
777	Evolution of calcium antagonists: Past, present, and future. <i>Clinical Cardiology</i> , 2003, 26, 12-16.	0.7	24
780	Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. <i>Irish Journal of Medical Science</i> , 2003, 172, 168-170.	0.8	4
781	Clinical trials report. <i>Current Atherosclerosis Reports</i> , 2003, 5, 339-340.	2.0	1
782	Microalbuminuria and diabetic cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2003, 5, 350-357.	2.0	9
783	Heart disease in diabetic patients. <i>Current Diabetes Reports</i> , 2003, 3, 223-229.	1.7	71
784	Prevention of type 2 diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 235-241.	1.7	32
785	Are low target blood pressure goals justified in persons with diabetes mellitus?. <i>Current Hypertension Reports</i> , 2003, 5, 231-238.	1.5	3
786	Management of diabetic and hypertensive cardiovascular disease. <i>Current Hypertension Reports</i> , 2003, 5, 309-315.	1.5	3
787	Lessons from trials in hypertensive type 2 diabetic patients. <i>Current Hypertension Reports</i> , 2003, 5, 322-328.	1.5	1

#	ARTICLE	IF	CITATIONS
789	Treatment of diabetic nephropathy with angiotensin II receptor antagonist. <i>Clinical and Experimental Nephrology</i> , 2003, 7, 1-8.	0.7	45
790	Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2. <i>Journal of Diabetes and Its Complications</i> , 2003, 17, 314-322.	1.2	148
791	Clinical outcomes following laser photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 305-309.	1.3	5
792	Clinical Research. Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 397-402.	1.3	52
793	Diabetic retinopathy. <i>Clinical Cornerstone</i> , 2003, 5, 12-21.	1.0	65
794	Cardiovascular complications of diabetes: Prevention and management. <i>Clinical Cornerstone</i> , 2003, 5, 22-37.	1.0	6
795	Management of neuropathy and foot problems in diabetic patients. <i>Clinical Cornerstone</i> , 2003, 5, 38-55.	1.0	21
796	Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. <i>American Journal of Kidney Diseases</i> , 2003, 41, 903-924.	2.1	69
797	Compliance with Clinical Practice Guidelines for Type 2 Diabetes in Rural Patients: Treatment Gaps and Opportunities for Improvement. <i>Pharmacotherapy</i> , 2003, 23, 659-665.	1.2	64
798	Assessment of Factors Influencing Blood Pressure Control in a Managed Care Population. <i>Pharmacotherapy</i> , 2003, 23, 1060-1070.	1.2	13
799	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , 2003, 91, 10-17.	0.7	20
800	Treatment for patients with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2003, 91, 29-39.	0.7	81
801	Trials on blood pressureâ€“lowering and secondary stroke prevention. <i>American Journal of Cardiology</i> , 2003, 91, 3-8.	0.7	14
802	Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockersâ€“a gap in evidence-based medicine. <i>American Journal of Cardiology</i> , 2003, 91, 15-21.	0.7	108
803	Comparison of patients with acute coronary syndrome with and without systemic hypertension. <i>American Journal of Cardiology</i> , 2003, 92, 258-263.	0.7	31
804	Missing.... presumed at random: cost-analysis of incomplete data. <i>Health Economics (United Kingdom)</i> , 2003, 12, 377-392.	0.8	280
805	Treatment of diabetic nephropathy in its early stages. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 101-114.	1.7	19
806	Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 442-455.	1.7	253

#	ARTICLE	IF	CITATIONS
807	Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. <i>Journal of Internal Medicine</i> , 2003, 254, 147-158.	2.7	27
808	Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. <i>Journal of Internal Medicine</i> , 2003, 254, 455-463.	2.7	197
809	Reduction of risk factors following lifestyle modification programme in subjects with type 2 (non-insulin dependent) diabetes mellitus. <i>Clinical Physiology and Functional Imaging</i> , 2003, 23, 21-30.	0.5	41
810	Pathogenesis of diabetic retinopathy and the renin-angiotensin system. <i>Ophthalmic and Physiological Optics</i> , 2003, 23, 495-501.	1.0	38
811	Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). <i>Kidney International</i> , 2003, 63, 225-232.	2.6	1,429
812	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Applying Multiple Interventions in Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2003, 16, 157-164.	0.7	16
813	Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 265-280.	1.3	625
814	Facilitating best practice - cardiovascular risk management for patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s29-s34.	2.2	1
815	Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s19-s27.	2.2	162
816	Diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, s11-s18.	2.2	14
817	Evidence-based treatment of hypertension in patients with diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 13-26.	2.2	15
818	Metabolic syndrome - a new risk factor of coronary heart disease?. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 359-370.	2.2	29
819	Screening for Type 2 diabetes-should it be now?. <i>Diabetic Medicine</i> , 2003, 20, 175-181.	1.2	51
820	Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. <i>Diabetic Medicine</i> , 2003, 20, 127-134.	1.2	130
821	Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year. <i>Diabetic Medicine</i> , 2003, 20, 319-324.	1.2	56
822	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. <i>Diabetic Medicine</i> , 2003, 20, 607-621.	1.2	75
823	Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. <i>Diabetic Medicine</i> , 2003, 20, 580-585.	1.2	35
824	Quality of care for patients with Type 2 diabetes mellitus-a long-term comparison of two quality improvement programmes in the Netherlands. <i>Diabetic Medicine</i> , 2003, 20, 846-852.	1.2	49

#	ARTICLE	IF	CITATIONS
825	Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. <i>Diabetic Medicine</i> , 2003, 20, 972-987.	1.2	44
826	Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. <i>Diabetic Medicine</i> , 2003, 20, 708-712.	1.2	17
827	Screening for diabetic retinopathy: a cause for concern in people who drive. <i>Diabetic Medicine</i> , 2003, 20, 812-815.	1.2	5
828	Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. <i>Diabetic Medicine</i> , 2003, 20, 921-929.	1.2	156
829	A qualitative investigation of the views and health beliefs of patients with Type 2 diabetes following the introduction of a diabetes shared care service. <i>Diabetic Medicine</i> , 2003, 20, 853-857.	1.2	28
830	A countywide primary care annual audit fails to demonstrate an improvement in diabetes care between 1996 and 2001. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 129-134.	0.2	4
831	Ensuring the quality of diabetes care: Use of the QUAD-CAT model and Alphabet Strategy in clinical practice. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 171-177.	0.2	2
832	Hypertension in diabetes: what's new, what's true, what's next?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 247-254.	0.2	3
833	Implementing evidence-based practice. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 269-270.	0.2	1
834	Rosiglitazone reduces urinary albumin excretion in type II diabetes. <i>Journal of Human Hypertension</i> , 2003, 17, 7-12.	1.0	237
835	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. <i>Journal of Human Hypertension</i> , 2003, 17, 37-44.	1.0	48
836	Better blood pressure control: how to combine drugs. <i>Journal of Human Hypertension</i> , 2003, 17, 81-86.	1.0	135
837	How well are hypertension and albuminuria treated in type II diabetic patients?. <i>Journal of Human Hypertension</i> , 2003, 17, 413-418.	1.0	15
838	Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. <i>Journal of Human Hypertension</i> , 2003, 17, 425-432.	1.0	78
839	Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study. <i>Journal of Human Hypertension</i> , 2003, 17, 569-575.	1.0	23
840	Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached?. <i>Journal of Human Hypertension</i> , 2003, 17, 767-773.	1.0	15
841	Impact of an integrated approach to diabetes care at the Rumbalara Aboriginal Health Service. <i>Internal Medicine Journal</i> , 2003, 33, 581-585.	0.5	35
842	Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. <i>Bipolar Disorders</i> , 2003, 5, 62-79.	1.1	41

#	ARTICLE	IF	CITATIONS
843	Tratamiento farmacológico de la hipertensión arterial. <i>Medicine</i> , 2003, 8, 6357-6372.	0.0	0
844	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. <i>Primary Care - Clinics in Office Practice</i> , 2003, 30, 569-592.	0.7	17
845	Protección del riesgo vascular del paciente diabético hipertenso. <i>Hipertension Y Riesgo Vascular</i> , 2003, 20, 127-135.	0.3	0
846	Treating Type 2 Diabetes Mellitus: A Growing Epidemic. <i>Mayo Clinic Proceedings</i> , 2003, 78, 411-413.	1.4	16
849	Diabetes mellitus en el anciano. <i>Medicine</i> , 2003, 8, 5834-5840.	0.0	0
850	A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. <i>Diabetes Care</i> , 2003, 26, 125-131.	4.3	182
851	Prevención primaria del ictus. <i>Gaceta Medica De Bilbao</i> , 2003, 100, 99-104.	0.0	1
854	Heart Failure. <i>New England Journal of Medicine</i> , 2003, 348, 2007-2018.	13.9	1,692
855	The Heavy Burden of Cardiovascular Disease in Type 2 Diabetes. , 2003, , 1-10.		0
856	The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 51-63.	0.6	45
857	Echocardiographic detection of early diabetic myocardial disease. <i>Journal of the American College of Cardiology</i> , 2003, 41, 611-617.	1.2	322
858	Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2003, 348, 383-393.	13.9	3,894
859	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. <i>Drugs</i> , 2003, 63, 1165-1184.	4.9	76
860	Current Treatment of Patients with Hypertension. <i>Drugs</i> , 2003, 63, 1435-1444.	4.9	7
861	Dual ACE and Neutral Endopeptidase Inhibitors. <i>Drugs</i> , 2003, 63, 2185-2202.	4.9	29
862	Low-Glycemic Index Diets in the Management of Diabetes: A meta-analysis of randomized controlled trials. <i>Diabetes Care</i> , 2003, 26, 2261-2267.	4.3	826
863	Tolerability and treatment compliance with angiotensin II receptor antagonists. <i>American Journal of Hypertension</i> , 2003, 16, 1066-1073.	1.0	49
864	Hypertension and nephropathy. <i>American Journal of Medicine</i> , 2003, 115, 49-54.	0.6	20

#	ARTICLE	IF	CITATIONS
865	Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes. American Journal of Medicine, 2003, 114, 377-382.	0.6	17
866	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. American Journal of Medicine, 2003, 115, 122-128.	0.6	7
867	Perspectives on diabetic retinopathy. American Journal of Ophthalmology, 2003, 136, 122-135.	1.7	251
868	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. American Journal of Pathology, 2003, 162, 151-160.	1.9	100
869	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. Journal of Clinical Hypertension, 2003, 5, 202-209.	1.0	82
870	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	1.0	26
871	Evaluation of Angiotensin II Receptor Blockers for 24-Hour Blood Pressure Control: Meta-Analysis of a Clinical Database. Journal of Clinical Hypertension, 2003, 5, 58-63.	1.0	63
872	Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. Journal of Clinical Hypertension, 2003, 5, 393-401.	1.0	17
873	Blockade of the Renin-Angiotensin System in African Americans With Hypertension and Cardiovascular Disease. Journal of Clinical Hypertension, 2003, 5, 12-17.	1.0	13
874	The Economic Impact of Hypertension. Journal of Clinical Hypertension, 2003, 5, 3-13.	1.0	86
875	Rationale for Combination Therapy as Initial Treatment for Hypertension. Journal of Clinical Hypertension, 2003, 5, 4-11.	1.0	16
876	Creating a Combination Antihypertensive Regimen: What Does the Research Show?. Journal of Clinical Hypertension, 2003, 5, 12-20.	1.0	20
877	Who Should Be Treated With Combination Therapy as Initial Treatment for Hypertension?. Journal of Clinical Hypertension, 2003, 5, 21-28.	1.0	4
878	Randomized controlled trial of the effects of nurse case manager and community health worker interventions on risk factors for diabetes-related complications in urban African Americans. Preventive Medicine, 2003, 37, 23-32.	1.6	190
879	Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet, The, 2003, 361, 195-200.	6.3	261
880	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, The, 2003, 361, 2005-2016.	6.3	2,587
881	Demographics and concomitant disorders in heart failure. Lancet, The, 2003, 362, 147-158.	6.3	127
882	Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism: Clinical and Experimental, 2003, 52, 1147-1152.	1.5	22

#	ARTICLE	IF	CITATIONS
883	Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 19-23.	1.5	65
884	How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 24-28.	1.5	9
885	Ischemic heart disease in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 6-12.	1.5	15
886	Kidney function in older people: pathology, assessment and management. <i>Clinica Chimica Acta</i> , 2003, 334, 25-40.	0.5	87
887	Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. <i>Current Therapeutic Research</i> , 2003, 64, 422-433.	0.5	5
888	Temporal visual filtering in diabetes mellitus. <i>Vision Research</i> , 2003, 43, 2377-2385.	0.7	4
889	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. <i>Lancet, The</i> , 2003, 362, 1527-1535.	6.3	2,300
890	Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. <i>Clinical Therapeutics</i> , 2003, 25, 1872-1887.	1.1	13
891	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2003, 25, 2006-2021.	1.1	30
892	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. <i>Clinical Therapeutics</i> , 2003, 25, B4-B31.	1.1	54
893	Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis. <i>Clinical Therapeutics</i> , 2003, 25, 2754-2764.	1.1	22
894	Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. <i>Clinical Therapeutics</i> , 2003, 25, 2849-2864.	1.1	29
895	Guest editorial: a simplified diabetic retinopathy scale. <i>Ophthalmology</i> , 2003, 110, 1675-1676.	2.5	21
896	Current concepts of cardiovascular diseases in diabetes mellitus. <i>International Journal of Cardiology</i> , 2003, 89, 123-134.	0.8	48
897	Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 372-378.	1.5	173
898	Don't miss this opportunity: Diagnosing diabetes. <i>American Heart Journal</i> , 2003, 145, 195-197.	1.2	6
899	Screening for high blood pressure. <i>American Journal of Preventive Medicine</i> , 2003, 25, 159-164.	1.6	22
900	Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. <i>American Journal of Hypertension</i> , 2003, 16, 381-386.	1.0	60

#	ARTICLE	IF	CITATIONS
901	Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?. American Journal of Hypertension, 2003, 16, 689-697.	1.0	44
902	Do effects on blood pressure contribute to improved clinical outcomes with metformin?. Diabetes and Metabolism, 2003, 29, 6S62-6S70.	1.4	12
903	Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France 2001). Diabetes and Metabolism, 2003, 29, 58-64.	1.4	25
904	Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes and Metabolism, 2003, 29, 152-158.	1.4	71
905	Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes and Metabolism, 2003, 29, 505-508.	1.4	14
906	Tratamiento de la hipertensi3n arterial. Medicina Cl3nica, 2003, 120, 108-116.	0.3	1
908	Peripheral Arterial Disease in People With Diabetes. Diabetes Care, 2003, 26, 3333-3341.	4.3	928
910	Initial Treatment of Hypertension. New England Journal of Medicine, 2003, 348, 610-617.	13.9	102
911	Diabetes Self-Management Education Research. Disease Management and Health Outcomes, 2003, 11, 415-428.	0.3	37
912	Treatment of Hypertension in Bahrain. Annals of Pharmacotherapy, 2003, 37, 1511-1517.	0.9	10
913	News in Brief. Expert Review of Cardiovascular Therapy, 2003, 1, 5-9.	0.6	0
914	Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies. Diabetes Care, 2003, 26, 2653-2664.	4.3	695
915	Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom. Pharmacoeconomics, 2003, 21, 33-41.	1.7	30
916	Transient Ischaemic Attacks. CNS Drugs, 2003, 17, 293-305.	2.7	0
917	Inhibition of the renin-angiotensin system provides renoprotective effects for patients with type 2 diabetes mellitus. Drugs and Therapy Perspectives, 2003, 19, 18-21.	0.3	0
918	Prevention Strategies for Type 1 Diabetes Mellitus. BioDrugs, 2003, 17, 39-64.	2.2	23
919	Preventing Renal Dysfunction in Patients with Hypertension. American Journal of Cardiovascular Drugs, 2003, 3, 193-200.	1.0	1
920	Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2003, 3, 283-297.	1.0	18

#	ARTICLE	IF	CITATIONS
921	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42, 1206-1252.	1.3	11,852
923	Capillary Pressure in Subjects With Type 2 Diabetes and Hypertension and the Effect of Antihypertensive Therapy. Hypertension, 2003, 41, 1111-1117.	1.3	22
924	Screening for Type 2 Diabetes. Diabetes Care, 2003, 26, S21-S24.	4.3	138
927	Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment. Journal of the American Society of Nephrology: JASN, 2003, 14, S92-S98.	3.0	70
928	Review: The management of stable angina in diabetes. British Journal of Diabetes and Vascular Disease, 2003, 3, 18-25.	0.6	3
929	Diabetic Retinopathy: Contemporary prevalence in a well-controlled population. Diabetes Care, 2003, 26, 2637-2642.	4.3	49
930	International Comparison of Health Resource Utilization in Subjects With Diabetes: An analysis of Canadian and American national health surveys. Diabetes Care, 2003, 26, 1116-1122.	4.3	19
932	Control of Hypertension in Diabetes. Diabetes Care, 2003, 26, 534-535.	4.3	4
933	National Surveillance for Type 2 Diabetes Mellitus in Taiwanese Children. JAMA - Journal of the American Medical Association, 2003, 290, 1345.	3.8	195
934	Pediatricians' Perceptions and Practices Regarding Prevention and Treatment of Type 2 Diabetes Mellitus in Children and Adolescents. JAMA Pediatrics, 2003, 157, 913.	3.6	18
935	Critical Issues in Peripheral Arterial Disease Detection and Management<subtitle>A Call to Action</subtitle>. Archives of Internal Medicine, 2003, 163, 884.	4.3	486
936	Review: Early renal involvement in Type 1 diabetes mellitus â€” Part 2: ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 17-26.	1.0	4
937	Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1174-81.	1.4	46
938	Diabetic Nephropathy. Diabetes Care, 2003, 26, S94-S98.	4.3	209
941	Identification and Management of Diabetic Nephropathy in the Diabetes Clinic. Diabetes Care, 2003, 26, 1806-1811.	4.3	38
943	Commentary: Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy?. British Journal of Diabetes and Vascular Disease, 2003, 3, 282-284.	0.6	0
944	Did Publication of a Clinical Practice Guideline Recommendation to Screen for Type 2 Diabetes in Women With Gestational Diabetes Change Practice?. Diabetes Care, 2003, 26, 265-268.	4.3	60
945	Signs of Nephropathy May Occur Early in Young Adults With Diabetes Despite Modern Diabetes Management: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care, 2003, 26, 2903-2909.	4.3	98

#	ARTICLE	IF	CITATIONS
946	Diabetes and Vascular Disease: A New International Trial. Asian Cardiovascular and Thoracic Annals, 2003, 11, 180-184.	0.2	0
947	Management of peripheral arterial disease in primary care. BMJ: British Medical Journal, 2003, 326, 584-588.	2.4	139
948	Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 62-73.	1.0	9
949	Quality of Care for Patients Diagnosed With Diabetes at Screening. Diabetes Care, 2003, 26, 367-371.	4.3	11
950	Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2003, 26, S33-S50.	4.3	613
951	Quality of Care for Diabetic Patients in a Large Urban Public Hospital. Diabetes Care, 2003, 26, 563-568.	4.3	45
952	The Prevalence of and Factors Associated With Diabetic Retinopathy in the Australian Population. Diabetes Care, 2003, 26, 1731-1737.	4.3	347
954	Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 74-79.	1.0	5
955	Biochemical Pathways for Microvascular Complications of Diabetes Mellitus. Annals of Pharmacotherapy, 2003, 37, 1858-1866.	0.9	59
956	Diabetes and obesity in Northern Sweden: occurrence and risk factors for stroke and myocardial infarction. Scandinavian Journal of Public Health, 2003, 31, 70-77.	1.2	31
957	The Diabetes Prevention Program and Its Global Implications. Journal of the American Society of Nephrology: JASN, 2003, 14, S103-S107.	3.0	46
958	Addressing the Burden of Diabetes in the 21st Century: Better Care and Primary Prevention. Journal of the American Society of Nephrology: JASN, 2003, 14, S88-S91.	3.0	49
959	Association of Solute Carrier Family 12 (Sodium/Chloride) Member 3 With Diabetic Nephropathy, Identified by Genome-Wide Analyses of Single Nucleotide Polymorphisms. Diabetes, 2003, 52, 2848-2853.	0.3	107
960	Implications of the Diabetes Control and Complications Trial. Diabetes Care, 2003, 26, S25-S27.	4.3	88
961	Integrating Medical Management With Diabetes Self-Management Training: A randomized control trial of the Diabetes Outpatient Intensive Treatment program. Diabetes Care, 2003, 26, 3048-3053.	4.3	126
962	Quality of recording of data from patients with type 2 diabetes is not a valid indicator of quality of care. A cross-sectional study. Family Practice, 2003, 20, 173-177.	0.8	52
963	Management of High Blood Pressure in African Americans <subtitle>Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks</subtitle>. Archives of Internal Medicine, 2003, 163, 525.	4.3	393
964	Review: Hypertension in diabetes: a perspective from clinical pharmacology. British Journal of Diabetes and Vascular Disease, 2003, 3, 252-256.	0.6	0

#	ARTICLE	IF	CITATIONS
965	The relationship between primary care physicians's adherence to guidelines for the treatment of diabetes and patient satisfaction: findings from a pilot study. <i>Family Practice</i> , 2003, 20, 563-569.	0.8	42
966	Diabetic Retinopathy. <i>Diabetes Care</i> , 2003, 26, S99-S102.	4.3	200
967	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy<subtitle>Results From the RENAAL Study</subtitle>. <i>Archives of Internal Medicine</i> , 2003, 163, 1555.	4.3	399
969	Haemoglobin A1c â€“ A Marker for Complications of Type 2 Diabetes: The Experience from the UK Prospective Diabetes Study (UKPDS). <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1182-90.	1.4	84
970	Clinical Impact of the New Criteria for the Diagnosis of Diabetes Mellitus. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1239-45.	1.4	11
971	Death, Taxes, Public Opinion, and the Midas Touch of Mary Tyler Moore: Accounting for Promises by Politicians to Help Avert and Control Diabetes. <i>Medical Anthropology Quarterly</i> , 2003, 17, 200-232.	0.7	11
972	A Systematic Review of Diabetes Self-Care Interventions for Older, African American, or Latino Adults. <i>The Diabetes Educator</i> , 2003, 29, 467-479.	2.6	104
973	Effect of Pharmacological Treatments for Diabetes on Homocysteine. <i>Metabolic Syndrome and Related Disorders</i> , 2003, 1, 149-158.	0.5	1
974	Diabetic macular edema: classification, medical and laser therapy. <i>Seminars in Ophthalmology</i> , 2003, 18, 251-258.	0.8	37
975	Cataract surgery and diabetic retinopathy. <i>Seminars in Ophthalmology</i> , 2003, 18, 103-108.	0.8	26
976	Evaluation of Equity in Diabetes Health Care in Relation to African and Caribbean Ethnicity. <i>Ethnicity and Health</i> , 2003, 8, 121-133.	1.5	18
977	Prospective Analysis of Mortality, Morbidity, and Risk Factors in Elderly Diabetic Subjects: Nagano Study. <i>Diabetes Care</i> , 2003, 26, 638-644.	4.3	53
978	Controlled Trial of a Multifaceted Intervention for Improving Quality of Care for Rural Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 3061-3066.	4.3	85
979	Hypertension Management in Patients With Diabetes: The need for more aggressive therapy. <i>Diabetes Care</i> , 2003, 26, 355-359.	4.3	132
981	Diabetic Retinopathy. <i>Diabetes Care</i> , 2003, 26, 226-229.	4.3	255
982	Implications of the United Kingdom Prospective Diabetes Study. <i>Diabetes Care</i> , 2003, 26, S28-S32.	4.3	184
984	Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT): A randomized controlled trial. <i>Diabetes Care</i> , 2003, 26, 2250-2255.	4.3	154
985	Microvascular Complications at Time of Diagnosis of Type 2 Diabetes Are Similar Among Diabetic Patients Detected by Targeted Screening and Patients Newly Diagnosed in General Practice: The Hoorn Screening Study. <i>Diabetes Care</i> , 2003, 26, 2604-2608.	4.3	188

#	ARTICLE	IF	CITATIONS
986	Prevalences of Diabetes and Impaired Glucose Regulation in a Danish Population: The Inter99 study. <i>Diabetes Care</i> , 2003, 26, 2335-2340.	4.3	250
987	Diabetes Mellitus and Heart Failure. <i>The American Heart Hospital Journal</i> , 2003, 1, 273-280.	0.2	14
988	Increasing Physical Activity in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 1186-1192.	4.3	167
989	Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. <i>Hypertension</i> , 2003, 41, 1063-1071.	1.3	142
990	Genomic Strategies for Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S271-S278.	3.0	46
991	Review: Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 245-251.	0.6	2
992	Coronary Heart Disease in Women With Diabetes. <i>Diabetes Spectrum</i> , 2003, 16, 148-153.	0.4	18
993	Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. <i>Diabetes</i> , 2003, 52, 1215-1221.	0.3	68
994	Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, 253-260.	1.0	50
995	Obesity, Glucose Intolerance and Diabetes and Their Links to Cardiovascular Disease. Implications for Laboratory Medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1266-78.	1.4	34
996	Insulin resistance: a global epidemic in need of effective therapies. <i>European Heart Journal Supplements</i> , 2003, 5, C13-C18.	0.0	17
997	Intensified treatment of type 2 diabetes—positive effects on blood pressure, but not glycaemic control. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 833-836.	0.2	27
998	Pulse pressure and arterial stiffness in type 1 diabetic patients. <i>Journal of Hypertension</i> , 2003, 21, 2005-2007.	0.3	23
999	What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2003, 327, 266-0.	2.4	63
1000	Prospective Evaluation of Carotid Bruit as a Predictor of First Stroke in Type 2 Diabetes. <i>Stroke</i> , 2003, 34, 2145-2151.	1.0	36
1001	Is Diabetes Mellitus a Cardiovascular Disease Risk Equivalent for Fatal Stroke in Women?. <i>Stroke</i> , 2003, 34, 2812-2816.	1.0	88
1002	The ALLHAT trial. <i>Journal of Hypertension</i> , 2003, 21, 229-232.	0.3	16
1003	Pharmacologic therapy for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 239-250.	1.0	21

#	ARTICLE	IF	CITATIONS
1004	TREATMENT OF TYPE 2 DIABETES. Acta Clinica Belgica, 2003, 58, 318-324.	0.5	18
1006	Microalbuminuria testing in diabetes: is a dipstick as effective as laboratory tests?. British Journal of Community Nursing, 2003, 8, 267-273.	0.2	7
1007	Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 516-523.	1.8	66
1008	Multifactorial Intervention and Cardiovascular Disease in Type 2 Diabetes. New England Journal of Medicine, 2003, 348, 1925-1927.	13.9	7
1009	Association Between Diabetes and Stroke Subtype on Survival and Functional Outcome 3 Months After Stroke. Stroke, 2003, 34, 688-694.	1.0	321
1010	Evaluation of methods for interval estimation of model outputs, with application to survival models. Journal of Applied Statistics, 2003, 30, 967-981.	0.6	2
1011	Outcome beyond blood pressure control?. European Heart Journal, 2003, 24, 504-514.	1.0	40
1012	Diabetology for cardiologists. European Heart Journal Supplements, 2003, 5, B5-B13.	0.0	13
1013	Renal involvement in hypertensive cardiovascular disease. European Heart Journal Supplements, 2003, 5, F12-F18.	0.0	2
1014	PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme. European Heart Journal Supplements, 2003, 5, F40-F47.	0.0	1
1015	Prevention of macrovascular complications. European Heart Journal Supplements, 2003, 5, B21-B26.	0.0	3
1016	Use of Beta Blockers in the Patient With Diabetes. , 2003, 13, 116-123.		17
1017	Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. Heart Disease (Hagerstown, Md), 2003, 5, 18-33.	1.3	7
1018	Cardiovascular prevention and blood pressure reduction. Journal of Hypertension, 2003, 21, 1055-1076.	0.3	427
1019	Early and More Vigorous Detection of Diabetes. Journal of Cardiovascular Nursing, 2003, 18, 103-107.	0.6	7
1020	Evaluation and medical treatment of peripheral arterial disease. Current Opinion in Cardiology, 2003, 18, 436-443.	0.8	17
1021	Self-Monitoring of Blood Glucose. Point of Care, 2003, 2, 62-68.	0.5	3
1022	Trends in Management of Type 2 Diabetes. , 2003, 13, S1-S21.		2

#	ARTICLE	IF	CITATIONS
1023	Diabetes Mellitus and Hypertension: A Mandate for Intense Treatment According to New Guidelines. American Journal of Therapeutics, 2003, 10, 363-369.	0.5	6
1024	Prevention of type 2 diabetes and its macrovascular complications: whom, when, and how should we treat?. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 229-236.	0.6	6
1025	Diabetic Retinopathy in African Americans: Vision Impairment, Prevalence, Incidence, and Risk Factors. International Ophthalmology Clinics, 2003, 43, 105-122.	0.3	5
1026	Influence of body and arm position on blood pressure readings. Journal of Hypertension, 2003, 21, 237-241.	0.3	63
1027	Preventing diabetic retinopathy through control of systemic factors. Current Opinion in Ophthalmology, 2003, 14, 389-394.	1.3	20
1028	Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles. Journal of Hypertension, 2003, 21, 797-804.	0.3	111
1029	Intensive blood pressure treatment. Journal of Hypertension, 2003, 21, 697-700.	0.3	5
1030	Metabolic effects of antihypertensive treatment. Journal of Hypertension, 2003, 21, 1459-1462.	0.3	9
1031	The Emerging Role of Electronic Diaries in the Management of Diabetes Mellitus. AACN Advanced Critical Care, 2003, 14, 371-378.	1.9	23
1032	Benefits of blood pressure reduction in diabetic patients. Journal of Hypertension, 2003, 21, S31-S36.	0.3	11
1033	2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension, 2003, 21, 1983-1992.	0.3	2,162
1034	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 97-102.	1.5	56
1035	New Evidence-Based Diabetes Nutrition Recommendations. Home Healthcare Nurse, 2003, 21, 249-257.	0.4	3
1036	International Society of Hypertension (ISH). Journal of Hypertension, 2003, 21, 651-663.	0.3	45
1037	The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease, 2003, 14, 335-348.	0.3	50
1038	Diabetes and Heart Disease. Cardiology in Review, 2003, 11, 262-274.	0.6	28
1040	Emerging drugs in the management of hypertension. Expert Opinion on Emerging Drugs, 2003, 8, 377-388.	1.0	15
1041	Involvement of transforming growth factor- β 2 in regulation of calcium transients in diabetic vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2003, 285, F1258-F1270.	1.3	47

#	ARTICLE	IF	CITATIONS
1042	Hypertension Control. Archives of Internal Medicine, 2003, 163, 2705.	4.3	104
1043	The evolution of treatment guidelines for diabetic nephropathy. Postgraduate Medicine, 2003, 113, 35-50.	0.9	4
1044	Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy. Annals of Internal Medicine, 2003, 138, 542.	2.0	345
1046	Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care. Annals of Internal Medicine, 2003, 138, 593.	2.0	207
1047	The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2003, 138, 587.	2.0	107
1048	Diabetic retinopathy: medical management and assessment. British Journal of Hospital Medicine, 2003, 64, 400-403.	0.3	3
1049	Epidemiology of diabetic retinopathy. British Journal of Hospital Medicine, 2003, 64, 396-399.	0.3	13
1050	A Practical Scheme for the Initial Out-Patient Management of Type-2 Diabetes Mellitus. Tropical Doctor, 2003, 33, 14-18.	0.2	0
1051	Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ: British Medical Journal, 2003, 326, 251-252.	2.4	74
1052	Type 2 Diabetes is Cardiovascular Disease. Journal of the Royal Society of Medicine, 2003, 96, 371-372.	1.1	1
1055	Prescribing options for treating people with diabetes mellitus. NursePrescribing, 2003, 1, 15-20.	0.1	0
1056	The eye in cardiac and cardiovascular disease. British Journal of Hospital Medicine, 2003, 64, 299-301.	0.3	5
1057	Vitreous haemorrhage in the diabetic eye. British Journal of Hospital Medicine, 2003, 64, 391-395.	0.3	0
1058	Mortality From Cerebrovascular Disease in a Cohort of 23 000 Patients With Insulin-Treated Diabetes. Stroke, 2003, 34, 418-421.	1.0	119
1059	Captopril Inhibits Glucose Accumulation in Retinal Cells in Diabetes. , 2003, 44, 4001.		52
1060	An update on cardiovascular risk of metabolic syndrome. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 220-227.	1.3	16
1061	Prevention and Health Services Delivery. Stroke, 2003, 34, 367-369.	1.0	6
1062	Diabetic nephropathy in type 2 diabetes mellitus: risk factors and prevention. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 207-219.	1.3	17

#	ARTICLE	IF	CITATIONS
1063	Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 2593-2596.	0.5	30
1064	Longitudinal Assessment of a Diabetes Care Management System in an Integrated Health Network. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 552-558.	2.2	37
1065	Brachial-Ankle Pulse Wave Velocity Is Useful for Evaluation of Complications in Type 2 Diabetic Patients. <i>Hypertension Research</i> , 2003, 26, 807-813.	1.5	70
1066	Retinopathy in Monkeys with Spontaneous Type 2 Diabetes. , 2004, 45, 4543.		51
1067	Impact of Improved Glycemic Control on Quality of Life in Patients with Diabetes. <i>Endocrine Practice</i> , 2004, 10, 502-508.	1.1	52
1068	Lying awake worrying about asteroids. <i>Medical Journal of Australia</i> , 2004, 181, 417-418.	0.8	1
1069	The continuing legacy of the United Kingdom Prospective Diabetes Study. <i>Medical Journal of Australia</i> , 2004, 180, 104-105.	0.8	8
1070	Diabetes and Renal Failure. , 0, , 122-133.		0
1072	Inpatient to Outpatient Transfer of Care in Urban Patients With Diabetes. <i>Archives of Internal Medicine</i> , 2004, 164, 447.	4.3	22
1073	Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertensive, Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled 12-Month Study. <i>Hypertension Research</i> , 2004, 27, 457-464.	1.5	148
1074	Stage 1: The Normal Foot. , 0, , 17-34.		0
1075	A Systematic Approach to Managing Hypertension and the Metabolic Syndrome in Primary Care. <i>Southern Medical Journal</i> , 2004, 97, 932-938.	0.3	11
1076	Ambulatory Blood Pressure Level Rather than Dipper/Nondipper Status Predicts Vascular Events in Type 2 Diabetic Subjects. <i>Hypertension Research</i> , 2004, 27, 647-656.	1.5	56
1077	Monitoring skills: diabetes. <i>Nurse Prescriber</i> , 2004, 1, 1-6.	0.2	0
1078	Epidemiology of Diabetes. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 397-405.	1.0	182
1079	Telehealth Practice Recommendations for Diabetic Retinopathy. <i>Telemedicine Journal and E-Health</i> , 2004, 10, 469-482.	1.6	62
1080	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
1081	Impact of Appropriate Pharmaceutical Therapy for Chronic Conditions on Direct Medical Costs and Workplace Productivity: A Review of the Literature. <i>Disease Management: DM</i> , 2004, 7, 61-75.	1.0	19

#	ARTICLE	IF	CITATIONS
1082	Glycosylated Hemoglobin, Cardiovascular, and Renal Outcomes in a Pharmacist-Managed Clinic. <i>Annals of Pharmacotherapy</i> , 2004, 38, 771-775.	0.9	56
1083	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2004, 44, 637-642.	1.3	114
1087	Concentration of Circulating Rhodopsin mRNA in Diabetic Retinopathy. <i>Clinical Chemistry</i> , 2004, 50, 2152-2155.	1.5	35
1088	Nurse led clinics controlled hypertension and hyperlipidaemia better than usual care in diabetes. <i>Evidence-based Nursing</i> , 2004, 7, 48-48.	0.1	3
1090	Primary prevention of cardiovascular disease: managing hypertension and hyperlipidaemia. <i>British Heart Journal</i> , 2004, 90, iv22-iv25.	2.2	7
1091	Standards of Medical Care in Diabetes. <i>Diabetes Care</i> , 2004, 27, S15-S35.	4.3	607
1092	Women and Heart Disease. <i>Archives of Internal Medicine</i> , 2004, 164, 934.	4.3	144
1093	Expert consensus document on β -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	1.0	465
1094	Cardiovascular Risk Factor Control Among Veterans With Diabetes: The Ambulatory Care Quality Improvement Project. <i>Diabetes Care</i> , 2004, 27, B33-B38.	4.3	11
1095	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. <i>Blue Books of Practical Neurology</i> , 2004, 29, 5-54.	0.1	0
1096	Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. <i>Journal of Clinical Investigation</i> , 2004, 114, 877-883.	3.9	142
1097	Sex Differences in Age-Related Stiffening of the Aorta in Subjects With Type 2 Diabetes. <i>Hypertension</i> , 2004, 44, 67-71.	1.3	97
1098	Hypertensive Therapy: Part I. <i>Circulation</i> , 2004, 109, 2953-2958.	1.6	33
1099	Recent advances in diabetic nephropathy. <i>Postgraduate Medical Journal</i> , 2004, 80, 624-633.	0.9	60
1100	Enhanced left ventricular systolic function early in type 2 diabetic mice: clinical implications. <i>Diabetes and Vascular Disease Research</i> , 2004, 1, 89-94.	0.9	5
1101	Increasing Severity of Cardiovascular Risk Factors With Increasing Middle Cerebral Artery Stenotic Involvement in Type 2 Diabetic Chinese Patients With Asymptomatic Cerebrovascular Disease. <i>Diabetes Care</i> , 2004, 27, 1121-1126.	4.3	28
1102	Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 6S-11.	3.0	21
1104	Comment: renal protective effects of angiotensin receptor blockers. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2176-2176.	0.9	0

#	ARTICLE	IF	CITATIONS
1105	Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. <i>British Heart Journal</i> , 2004, 90, 732-738.	2.2	58
1106	Altered Age-Related Blood Pressure Pattern in Type 1 Diabetes. <i>Circulation</i> , 2004, 110, 1076-1082.	1.6	110
1107	Impact of Changes in HbA1c, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model. <i>Current Medical Research and Opinion</i> , 2004, 20, S53-S58.	0.9	30
1108	Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1278-1282.	0.9	10
1109	Cardiac Abnormalities in Diabetic Patients With Neuropathy: Effects of aldose reductase inhibitor administration. <i>Diabetes Care</i> , 2004, 27, 448-454.	4.3	84
1110	Screening for Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, S11-S14.	4.3	393
1111	Retinopathy in Diabetes. <i>Diabetes Care</i> , 2004, 27, S84-S87.	4.3	853
1112	Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes. <i>Diabetes Care</i> , 2004, 27, 699-703.	4.3	488
1113	Improvements in Patient-Reported Outcomes Associated With an Intervention to Enhance Quality of Care for Rural Patients With Type 2 Diabetes: Results of a controlled trial. <i>Diabetes Care</i> , 2004, 27, 1306-1312.	4.3	46
1114	Diabetes Process and Outcome Measures in the Department of Veterans Affairs. <i>Diabetes Care</i> , 2004, 27, B90-B94.	4.3	39
1115	Adiponectin may play a part in the pathogenesis of diabetic retinopathy. <i>European Journal of Endocrinology</i> , 2004, 151, 135-140.	1.9	61
1116	Overview. <i>British Journal of Ophthalmology</i> , 2004, 88, 436-437.	2.1	0
1117	INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. <i>FASEB Journal</i> , 2004, 18, 1767-1769.	0.2	39
1118	Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment. <i>Hypertension</i> , 2004, 43, 399-404.	1.3	107
1119	The Complex World of Prescribing Behavior. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 104.	3.8	24
1120	Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker: A Role for Combination in Diabetic Nephropathy? <i>Canadian Pharmacists Journal</i> , 2004, 137, 35-39.	0.4	0
1122	The Burden of Diabetes-Associated Cardiovascular Hospitalizations in Veterans Administration (VA) and Non-VA Medical Facilities. <i>Diabetes Care</i> , 2004, 27, B27-B32.	4.3	13
1123	Medical Treatment of Retinopathy of Type-2 Diabetes. <i>Ophthalmologica</i> , 2004, 218, 291-296.	1.0	5

#	ARTICLE	IF	CITATIONS
1124	Statins for the prevention of cerebrovascular disease: the rationale for robust intervention. <i>European Heart Journal Supplements</i> , 2004, 6, C34-C42.	0.0	4
1125	Hypertension in diabetes: is there a place for age-adjusted centile cut-offs in those aged <50 years?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2004, 97, 747-753.	0.2	9
1126	Blowing the whistle on review articles. <i>BMJ: British Medical Journal</i> , 2004, 328, E280-E282.	2.4	2
1127	Protective Role of Imatinib in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 801-803.	1.1	13
1128	Prevention and Health Services Delivery. <i>Stroke</i> , 2004, 35, 401-403.	1.0	1
1129	A Hospital-Based Survey of Risk Factors for Diabetic Foot Ulceration in Northern Thailand. <i>International Journal of Lower Extremity Wounds</i> , 2004, 3, 220-222.	0.6	1
1130	Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1881-1885.	0.4	31
1131	The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2519-2525.	0.4	17
1132	The growing volume of diabetes-related dialysis: a population based study. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3098-3103.	0.4	88
1133	Magnetic Resonance Imaging of the Brain in Diabetes: The Cardiovascular Determinants of Dementia (CASCADE) Study. <i>Diabetes</i> , 2004, 53, 687-692.	0.3	237
1134	Predictors of Heart Failure Among Women With Coronary Disease. <i>Circulation</i> , 2004, 110, 1424-1430.	1.6	147
1135	Diabetic Retinopathy. <i>Diabetes Care</i> , 2004, 27, 2540-2553.	4.3	575
1136	Birth Weight Is Inversely Correlated to Adult Systolic Blood Pressure and Pulse Pressure in Type 1 Diabetes. <i>Hypertension</i> , 2004, 44, 832-837.	1.3	17
1137	Plasma Vascular Endothelial Growth Factor, Angiotensin-1, and Angiotensin-2 in Diabetes: Implications for cardiovascular risk and effects of multifactorial intervention. <i>Diabetes Care</i> , 2004, 27, 2918-2924.	4.3	135
1138	Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis. <i>Diabetes</i> , 2004, 53, S39-S47.	0.3	91
1139	Development of Evidence-Based Clinical Practice Guidelines for Diabetes: The Department of Veterans Affairs/Department of Defense Guidelines Initiative. <i>Diabetes Care</i> , 2004, 27, B82-B89.	4.3	70
1140	Blood Glucose and Risk of Cardiovascular Disease in the Asia Pacific Region. <i>Diabetes Care</i> , 2004, 27, 2836-2842.	4.3	269
1141	Importance of Achieving Lower Blood Pressure in Hypertensive Patients With Diabetes. <i>Hypertension</i> , 2004, 44, 614-615.	1.3	4

#	ARTICLE	IF	CITATIONS
1142	Development and evaluation of a point-of-care interactive patient education kiosk. <i>Journal of Telemedicine and Telecare</i> , 2004, 10, 30-32.	1.4	19
1143	Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 251-262.	0.5	3
1144	The Impact of Vitamins and/or Mineral Supplementation on Blood Pressure in Type 2 Diabetes. <i>Journal of the American College of Nutrition</i> , 2004, 23, 272-279.	1.1	35
1145	The Renal Protective Effects of Angiotensin II Receptor Blockers in Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1731-1738.	0.9	20
1146	Blood Pressure and Stroke. <i>Stroke</i> , 2004, 35, 1024-1033.	1.0	238
1147	Preventing Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2004, 351, 1941-1951.	13.9	952
1148	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. <i>Clinical Trials</i> , 2004, 1, 532-544.	0.7	54
1149	Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). <i>Current Medical Research and Opinion</i> , 2004, 20, 765-772.	0.9	13
1150	Effects of Health Maintenance Organization Coverage of Self-monitoring Devices on Diabetes Self-care and Glycemic Control. <i>Archives of Internal Medicine</i> , 2004, 164, 645.	4.3	62
1151	Health promotion and health education about diabetes mellitus. <i>Perspectives in Public Health</i> , 2004, 124, 70-73.	0.5	10
1152	Epidemiology of Stroke. , 2004, , 13-34.		76
1153	Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 335.	3.8	1,182
1155	What is the impact of PRIME on real-life diabetic nephropathy?. <i>International Journal of Clinical Practice</i> , 2004, 58, 268-276.	0.8	2
1156	Trends in diabetes management practices of patients from an Australian insulin-treated diabetes register. <i>Diabetic Medicine</i> , 2004, 21, 165-170.	1.2	9
1157	Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. <i>Diabetic Medicine</i> , 2004, 21, 18-25.	1.2	23
1158	Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme. <i>Diabetic Medicine</i> , 2004, 21, 592-598.	1.2	34
1159	Medical management of diabetic retinopathy. <i>Diabetic Medicine</i> , 2004, 21, 666-672.	1.2	14
1160	Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial. <i>Diabetic Medicine</i> , 2004, 21, 599-603.	1.2	34

#	ARTICLE	IF	CITATIONS
1161	Trends in mortality rates for death-certificate-coded diabetes mellitus in an English population 1979-99. <i>Diabetic Medicine</i> , 2004, 21, 936-939.	1.2	13
1162	Sustainability and effectiveness of comprehensive diabetes care to a district population. <i>Diabetic Medicine</i> , 2004, 21, 1221-1228.	1.2	20
1163	Evaluation of delivery of enhanced diabetes care to patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS). <i>Diabetic Medicine</i> , 2004, 21, 1357-1365.	1.2	85
1164	Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2004, 21, 901-905.	1.2	22
1165	The association of coronary calcium score and conventional cardiovascular risk factors in Type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study). <i>Diabetic Medicine</i> , 2004, 21, 1129-1134.	1.2	48
1166	Effects of calcium antagonists in hypertensive patients with renal dysfunction: A prospective, randomized, parallel trial comparing benidipine and nifedipine. <i>Nephrology</i> , 2004, 9, 265-271.	0.7	9
1167	Analysis of factors that influence body mass index from ages 3 to 6 years: A study based on the Toyama cohort study. <i>Pediatrics International</i> , 2004, 46, 302-310.	0.2	105
1168	Evidence-based guide to slowing the progression of early renal insufficiency. <i>Internal Medicine Journal</i> , 2004, 34, 50-57.	0.5	59
1169	Evaluating the treatment of hypertension in diabetes mellitus: a need for better control?. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 107-116.	0.9	17
1170	Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat. <i>Kidney International</i> , 2004, 65, 209-218.	2.6	48
1171	An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. <i>Kidney International</i> , 2004, 66, S18-S21.	2.6	155
1172	Strategies to curb the epidemic of diabetes and obesity in primary care settings. <i>Journal of General Internal Medicine</i> , 2004, 19, 1242-1243.	1.3	4
1173	The case for blood pressure control in risk groups. <i>International Journal of Clinical Practice</i> , 2004, 58, 844-849.	0.8	4
1174	Stroke recurrence within the first year following cerebral infarction - Tottori University Lacunar Infarction Prognosis Study (TULIPS)*. <i>Acta Neurologica Scandinavica</i> , 2004, 110, 343-349.	1.0	44
1175	The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. <i>Acta Ophthalmologica</i> , 2004, 82, 443-448.	0.4	77
1176	The occurrence and causes of registered blindness in diabetes patients in Århus County, Denmark. <i>Acta Ophthalmologica</i> , 2004, 82, 526-530.	0.4	48
1177	Cardiovascular Disease: Application of a Composite Risk Index from the Telehealth System in a District Community. <i>Public Health Nursing</i> , 2004, 21, 524-532.	0.7	3
1178	Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy. <i>Eye</i> , 2004, 18, 117-125.	1.1	19

#	ARTICLE	IF	CITATIONS
1179	Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. <i>Eye</i> , 2004, 18, 460-465.	1.1	44
1180	Diabetic retinopathy progression and visual outcome after phacoemulsification in South-Asian and Afro-Caribbean patients with diabetes. <i>Eye</i> , 2004, 18, 575-579.	1.1	8
1181	Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?. <i>Eye</i> , 2004, 18, 821-825.	1.1	14
1182	Risk factors for uncontrolled hypertension in Italy. <i>Journal of Human Hypertension</i> , 2004, 18, 207-213.	1.0	56
1183	Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. <i>Journal of Human Hypertension</i> , 2004, 18, 273-278.	1.0	20
1184	Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. <i>Journal of Human Hypertension</i> , 2004, 18, 669-675.	1.0	50
1185	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004â€”BHS IV. <i>Journal of Human Hypertension</i> , 2004, 18, 139-185.	1.0	1,072
1186	Effect of delaprilâ€“manidipine combination vs irbesartanâ€“hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. <i>Journal of Human Hypertension</i> , 2004, 18, 687-691.	1.0	27
1187	Pathophysiology and Longâ€“Term Management of the Metabolic Syndrome. <i>Obesity</i> , 2004, 12, 174S-80S.	4.0	20
1188	Current approaches and perspectives in the medical treatment of diabetic retinopathy. , 2004, 103, 167-177.		41
1189	Effects of diabetes on the vascular system: current research evidence and best practice recommendations. <i>Journal of Vascular Nursing</i> , 2004, 22, 2-11.	0.2	10
1190	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. <i>American Journal of Kidney Diseases</i> , 2004, 43, 782-795.	2.1	91
1191	Awareness of hypertension and diabetes in the Hispanic community. <i>Clinical Cornerstone</i> , 2004, 6, 7-15.	1.0	17
1192	Educating Patients With Diabetes About Cardiovascular Disease Risk. <i>Progress in Cardiovascular Nursing</i> , 2004, 19, 107-113.	0.5	2
1193	Angiotensin-Converting Enzyme Inhibitors and Stroke Risk: Benefit Beyond Blood Pressure Reduction?. <i>Pharmacotherapy</i> , 2004, 24, 1064-1076.	1.2	16
1194	Focusing on Patient-Oriented Evidence that Matters in the Care of Patients with Diabetes Mellitus. <i>Pharmacotherapy</i> , 2004, 24, 295-297.	1.2	2
1195	A systematic critique of diabetes on the world wide web for patients and their physicians. <i>International Journal of Medical Informatics</i> , 2004, 73, 687-694.	1.6	51
1196	Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. <i>Journal of the American Dietetic Association</i> , 2004, 104, 1805-1815.	1.3	65

#	ARTICLE	IF	CITATIONS
1197	Does the Modern Concept of "Best Medical Therapy" Render Carotid Surgery Obsolete?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2004, 28, 457-461.	0.8	17
1198	Strategies for managing the diabetic patient. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2004, 18, 631-643.	1.7	23
1200	Chemistry and Biochemistry of Type 2 Diabetes. <i>Chemical Reviews</i> , 2004, 104, 1255-1282.	23.0	303
1201	RAAS Inhibitors in the Cardiovascular Continuum: What is Still Missing?. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 311-320.	1.3	2
1202	Evolving targets for risk reduction in diabetes. <i>Clinical Cardiology</i> , 2004, 27, 125-128.	0.7	1
1205	Hypertension therapy: Mixing, matching, and meeting targets. <i>Advances in Therapy</i> , 2004, 21, 107-122.	1.3	5
1207	Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in Type 2 diabetic Chinese patients. <i>Diabetologia</i> , 2004, 47, 1528-1534.	2.9	23
1209	Antihypertensive drugs and the kidney. <i>Current Cardiology Reports</i> , 2004, 6, 403-408.	1.3	4
1210	Heart protection study: A focus on diabetic patients. <i>Current Diabetes Reports</i> , 2004, 4, 185-186.	1.7	1
1211	Management of hypertension in the cardiometabolic syndrome and diabetes. <i>Current Diabetes Reports</i> , 2004, 4, 199-205.	1.7	2
1212	Hypertension management in patients with diabetic nephropathy. <i>Current Hypertension Reports</i> , 2004, 6, 272-279.	1.5	2
1213	Clinical importance of microalbuminuria in diabetes and hypertension. <i>Current Hypertension Reports</i> , 2004, 6, 352-356.	1.5	43
1214	Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. <i>Current Hypertension Reports</i> , 2004, 6, 215-223.	1.5	99
1215	Hypertensive renal damage: Insights from animal models and clinical relevance. <i>Current Hypertension Reports</i> , 2004, 6, 145-153.	1.5	41
1216	Behavioral counseling interventions for primary prevention of coronary heart disease in individuals with type-2 diabetes. <i>Comprehensive Therapy</i> , 2004, 30, 141-147.	0.2	2
1217	Management of Geriatric endocrine disorders. <i>Comprehensive Therapy</i> , 2004, 30, 10-17.	0.2	1
1218	When there is too much to do. <i>Journal of General Internal Medicine</i> , 2004, 19, 646-653.	1.3	56
1220	Primary diabetes care: yesterday, today and tomorrow. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2004, 21, 65-68.	0.2	4

#	ARTICLE	IF	CITATIONS
1221	Ethnicity and prevalence of diabetic complications in elderly patients. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2004, 21, 139-142.	0.2	3
1222	One way to reduce ophthalmology clinic waiting times for patients with diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2004, 21, 183-186.	0.2	3
1223	Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 139-146.	0.9	35
1224	A novel approach to treatment of hypertension in diabetic patients at a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2004, 5, 9.	1.5	6
1225	The association of patient trust and self-care among patients with diabetes mellitus. <i>BMC Family Practice</i> , 2004, 5, 26.	2.9	106
1226	Diabetes-related inequalities in health status and financial barriers to health care access in a population-based study. <i>Diabetic Medicine</i> , 2004, 21, 45-51.	1.2	23
1227	The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. <i>Diabetic Medicine</i> , 2004, 21, 52-58.	1.2	248
1228	A pilot study comparing a type 1 nurse-led diabetes clinic with a conventional doctor-led diabetes clinic. <i>European Diabetes Nursing</i> , 2004, 1, 18-21.	0.2	4
1229	A utility-theoretic approach to the aggregation of willingness to pay measured in decomposed scenarios: development and empirical test. <i>Health Economics (United Kingdom)</i> , 2004, 13, 345-361.	0.8	8
1230	Pharmacological approach to diabetic retinopathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 91-113.	1.7	76
1231	Stroke in patients with diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 268-287.	1.7	93
1232	Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, S13-S23.	1.7	16
1233	An age structured model for complications of diabetes mellitus in Morocco. <i>Simulation Modelling Practice and Theory</i> , 2004, 12, 77-87.	2.2	16
1234	Artropatie diabetiche dei membri inferiori. <i>EMC - Endocrinologie</i> , 2004, 1, 117-132.	0.0	3
1235	Nephropathy in Diabetes. <i>Diabetes Care</i> , 2004, 27, S79-S83.	4.3	842
1236	Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. <i>Pharmacoeconomics Italian Research Articles</i> , 2004, 6, 81-93.	0.2	15
1238	Nebivolol: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 893-899.	0.9	37
1239	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	1.7	25

#	ARTICLE	IF	CITATIONS
1240	Efficacy and Tolerability of Long-Term Rilmenidine Treatment in Hypertensive Diabetic Patients. American Journal of Cardiovascular Drugs, 2004, 4, 195-200.	1.0	8
1241	Impaired Glucose Metabolism in Patients with Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 269-280.	1.0	32
1242	Renal protection. American Journal of Cardiovascular Drugs, 2004, 4, 31-36.	1.0	2
1243	Blood Pressure and Stroke. Stroke, 2004, 35, 776-785.	1.0	535
1244	Quality Improvement Initiatives: Issues in moving from diabetes guidelines to policy. Diabetes Care, 2004, 27, B54-B60.	4.3	39
1245	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. Circulation, 2004, 110, 921-927.	1.6	679
1246	The Incidence of Congestive Heart Failure in Type 2 Diabetes: An update. Diabetes Care, 2004, 27, 1879-1884.	4.3	685
1247	Continued importance of diuretics and β -adrenergic blockers in the management of hypertension. Medical Clinics of North America, 2004, 88, 167-187.	1.1	15
1248	La protecci3n card3aca es la estrategia prioritaria de prevenci3n cardiovascular en hipertensi3n arterial. Hipertension Y Riesgo Vascular, 2004, 21, 187-196.	0.3	1
1249	Aterosclerosis: 2mantequilla en las arterias?. EMC - Tratado De Medicina, 2004, 8, 1-6.	0.0	0
1250	Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiology Clinics, 2004, 22, 553-568.	0.9	40
1255	Diabetic nephropathy and retinopathy. Medical Clinics of North America, 2004, 88, 1001-1036.	1.1	111
1256	Endothelial dysfunction and hypertension in diabetes mellitus. Medical Clinics of North America, 2004, 88, 911-931.	1.1	35
1257	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	0.6	8
1259	Target organ involvement in hypertension: a realistic promise of prevention and reversal. Medical Clinics of North America, 2004, 88, 209-221.	1.1	20
1260	Impact of kidney transplantation on the progression of cardiovascular disease. Advances in Chronic Kidney Disease, 2004, 11, 274-293.	0.6	8
1261	Diabetic neuropathies. Medical Clinics of North America, 2004, 88, 947-999.	1.1	204
1262	Microvascular complications of diabetes. Endocrinology and Metabolism Clinics of North America, 2004, 33, 215-238.	1.2	132

#	ARTICLE	IF	CITATIONS
1265	Diabetic Retinopathy. New England Journal of Medicine, 2004, 350, 48-58.	13.9	974
1266	Irbesartan. Drugs, 2004, 64, 999-1028.	4.9	70
1267	Regression of Microalbuminuria in Type 2 Diabetics after Switch to Irbesartan Treatment. Clinical Drug Investigation, 2004, 24, 217-225.	1.1	8
1268	Quality of Care and Attributable Healthcare Costs in Diabetic Hypertensive Patients Initiated on Calcium Antagonist Therapy. Clinical Drug Investigation, 2004, 24, 641-649.	1.1	2
1269	A mathematical model for the burden of diabetes and its complications. BioMedical Engineering OnLine, 2004, 3, 20.	1.3	60
1270	National Performance Measures for Diabetes Mellitus Care. Disease Management and Health Outcomes, 2004, 12, 285-298.	0.3	4
1271	Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons. Drugs and Aging, 2004, 21, 19-41.	1.3	60
1272	Cardiovascular disease: different strategies for primary and secondary prevention?. Heart, 2004, 90, 1217-1223.	1.2	73
1273	Diabetes in the elderly and in women: cardiovascular risks. Cardiology Clinics, 2004, 22, 541-551.	0.9	21
1274	The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Current Medical Research and Opinion, 2004, 20, S5-S26.	0.9	453
1275	Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Research and Clinical Practice, 2004, 64, 59-70.	1.1	58
1276	Hospitalization and re-hospitalization of people with and without diabetes in La Plata, Argentina: comparison of their clinical characteristics and costs. Diabetes Research and Clinical Practice, 2004, 65, 51-59.	1.1	17
1277	Cardiovascular risk factors in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2004, 65, 125-133.	1.1	37
1278	Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Research and Clinical Practice, 2004, 66, 87-95.	1.1	23
1279	Quantitative measurement of retinal thickness in patients with diabetic macular edema is useful for evaluation of therapeutic agents. Diabetes Research and Clinical Practice, 2004, 66, 219-227.	1.1	7
1280	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 119-120.	0.0	0
1281	Are persons with diabetes practicing healthier behaviors in the year 2001? Results from the Behavioral Risk Factor Surveillance System. Preventive Medicine, 2004, 38, 203-208.	1.6	19
1282	Single-field fundus photography for diabetic retinopathy screening. Ophthalmology, 2004, 111, 1055-1062.	2.5	232

#	ARTICLE	IF	CITATIONS
1287	Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1473-1479.	1.5	60
1288	High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. <i>American Heart Journal</i> , 2004, 147, 239-245.	1.2	50
1289	Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension*1. <i>American Journal of Hypertension</i> , 2004, 17, 495-501.	1.0	97
1290	Beyond hypertension toward guidelines for cardiovascular risk reduction. <i>American Journal of Hypertension</i> , 2004, 17, 1068-1074.	1.0	48
1291	Are calcium antagonists beneficial in diabetic patients with hypertension?. <i>American Journal of Medicine</i> , 2004, 116, 44-49.	0.6	28
1292	Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. <i>American Journal of Medicine</i> , 2004, 116, 236-240.	0.6	117
1293	The importance of blood pressure control in the patient with diabetes. <i>American Journal of Medicine</i> , 2004, 116, 30-38.	0.6	89
1294	Managing the patient with diabetes mellitus and heart failure: issues and considerations. <i>American Journal of Medicine</i> , 2004, 116, 76-88.	0.6	23
1295	Case management for patients with poorly controlled diabetes: a randomized trial. <i>American Journal of Medicine</i> , 2004, 116, 732-739.	0.6	116
1296	A Statewide Primary Care Approach to Cardiovascular Risk Factor Control in High-Risk Diabetic and Nondiabetic Patients With Hypertension. <i>Journal of Clinical Hypertension</i> , 2004, 6, 18-25.	1.0	21
1297	Hypertension and the Elderly: More Than Just Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2004, 6, 249-255.	1.0	15
1298	The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double-Blind Trial of Initial Monotherapy vs. Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2004, 6, 437-442.	1.0	12
1299	Managing High-Risk Patients With Hypertension: Focus on the Renin-Angiotensin System. <i>Journal of Clinical Hypertension</i> , 2004, 6, 501-508.	1.0	5
1300	Metabolic Properties of Vasodilating \hat{I}^2 Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2004, 6, 690-696.	1.0	20
1301	Blood Pressure Goal Attainment: Meeting the Challenge of the JNC 7's Blood Pressure Goals and the Role of Renin-Angiotensin-Aldosterone System Blockade. <i>Journal of Clinical Hypertension</i> , 2004, 6, 699-705.	1.0	4
1302	Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7. <i>Journal of Clinical Hypertension</i> , 2004, 6, 4-13.	1.0	30
1303	Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. <i>Journal of Clinical Hypertension</i> , 2004, 6, 168-399.	1.0	42
1304	Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. <i>Diabetes and Metabolism</i> , 2004, 30, 2S2-2S8.	1.4	18

#	ARTICLE	IF	CITATIONS
1306	Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations. <i>Diabetes and Metabolism</i> , 2004, 30, 3S3-3S18.	1.4	53
1307	Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. <i>Diabetes and Metabolism</i> , 2004, 30, 327-333.	1.4	11
1308	Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study)*1. <i>Current Therapeutic Research</i> , 2004, 65, 138-148.	0.5	0
1309	The Prevalence of Diabetic Retinopathy Among Adults in the United States. <i>JAMA Ophthalmology</i> , 2004, 122, 552.	2.6	992
1310	Stroke and neurodegenerative disorders. 1. acute stroke evaluation, management, risks, prevention, and prognosis11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.. <i>Archives of Physical Medicine and Rehabilitation</i> , 2004, 85, 3-10.	0.5	40
1311	Impact of age on cardiovascular risk: implications for cardiovascular disease management. <i>Atherosclerosis Supplements</i> , 2004, 5, 9-17.	1.2	29
1313	Association of dyslipidemia and effects of statins on nonmacrovascular diseases. <i>Clinical Therapeutics</i> , 2004, 26, 337-351.	1.1	21
1314	Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. <i>Clinical Therapeutics</i> , 2004, 26, 855-865.	1.1	64
1315	How important is optimal blood pressure control?. <i>Clinical Therapeutics</i> , 2004, 26, A3-A11.	1.1	23
1316	Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 1159S-1163S.	2.2	39
1317	Modification of Insulin, Glucose and Cholesterol Levels in Nonobese Women Undergoing Liposuction. <i>Annals of Plastic Surgery</i> , 2004, 52, 64-67.	0.5	37
1318	Use of Arterial Transfer Functions for the Derivation of Central Aortic Waveform Characteristics in Subjects With Type 2 Diabetes and Cardiovascular Disease. <i>Diabetes Care</i> , 2004, 27, 746-751.	4.3	87
1319	Physician Process and Patient Outcome Measures for Diabetes Care. <i>Medical Care</i> , 2004, 42, 840-850.	1.1	45
1320	Perioperative diabetic and hyperglycemic management issues. <i>Critical Care Medicine</i> , 2004, 32, S116-S125.	0.4	94
1322	Review: Aldosterone - the future challenge in cardiovascular disease?. <i>British Journal of Diabetes and Vascular Disease</i> , 2004, 4, 370-376.	0.6	2
1323	Register-Recall Systems: Tools for Chronic Disease Management in General Practice. <i>Health Information Management Journal</i> , 2004, 33, 31-35.	0.9	3
1324	Pharmacotherapy for diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2004, 15, 508-518.	1.3	56
1328	Clinical relevance of glucose metabolism disturbances induced by antihypertensive drugs. <i>European Heart Journal Supplements</i> , 2004, 6, h31-h35.	0.0	1

#	ARTICLE	IF	CITATIONS
1329	Testing for microalbuminuria and albuminuria in diabetes should be as important as checking blood pressure. <i>Blood Pressure</i> , 2004, 13, 326-329.	0.7	1
1330	The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes. <i>European Heart Journal Supplements</i> , 2004, 6, G3-G7.	0.0	3
1331	Screening for High Blood Pressure: Recommendations and Rationale. <i>American Journal of Nursing</i> , 2004, 104, 82-87.	0.2	0
1332	Screening for Type 2 Diabetes Mellitus in Adults: Recommendations and Rationale. <i>American Journal of Nursing</i> , 2004, 104, 83-90.	0.2	7
1333	Surgical and Other Treatments of Diabetic Macular Edema: An Update. <i>International Ophthalmology Clinics</i> , 2004, 44, 139-160.	0.3	28
1334	Low-renin status in therapy-resistant hypertension. <i>Journal of Hypertension</i> , 2004, 22, 2217-2226.	0.3	229
1335	The role of calcium antagonists in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 155-161.	1.0	23
1336	CARDIOVASCULAR PREVENTION IN TYPE 2 DIABETIC PATIENTS: REVIEW OF EFFICACIOUS TREATMENTS. <i>Acta Clinica Belgica</i> , 2004, 59, 329-339.	0.5	3
1337	ALLHAT and its implications in the diabetic population. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 43-47.	0.2	0
1338	Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2004, 140, 689.	2.0	140
1339	Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: The TRIAD Study. <i>Annals of Internal Medicine</i> , 2004, 141, 272.	2.0	254
1340	Association of Hemoglobin A_{1c} with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk. <i>Annals of Internal Medicine</i> , 2004, 141, 413.	2.0	847
1341	Regular screening in type 2 diabetes. <i>Postgraduate Medicine</i> , 2004, 115, 19-27.	0.9	7
1342	As campanhas nacionais para detecÃ§Ã£o das doenÃ§as crÃ³nicas nÃ£o-transmissÃveis: diabetes e hipertensÃ£o arterial. <i>Ciencia E Saude Coletiva</i> , 2004, 9, 885-895.	0.1	51
1343	Adapting Root Cause Analysis to Chronic Medical Conditions. <i>Joint Commission Journal on Quality and Safety</i> , 2004, 30, 175-186.	1.3	12
1344	Implementation and Evaluation of Australian Pharmacistsâ€™ Diabetes Care Services. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 455-466.	0.7	62
1346	Diabetes Outcomes in the Indian Health System During the Era of the Special Diabetes Program for Indians and the Government Performance and Results Act. <i>American Journal of Public Health</i> , 2005, 95, 1518-1522.	1.5	44
1348	Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. <i>Journal of Hypertension</i> , 2005, 23, 905-911.	0.3	17

#	ARTICLE	IF	CITATIONS
1349	Strategies for the prevention of type 2 diabetes and cardiovascular disease. Country Review Ukraine, 2005, 7, D18-D22.	0.8	6
1350	Treating Hypertension With Cardioprotective Therapies. Journal of Cardiovascular Nursing, 2005, 20, 354-364.	0.6	25
1351	Recent advances in hypertension, stroke, and cardiorenal disease. Current Opinion in Cardiology, 2005, 20, 258-263.	0.8	8
1352	Lowering blood pressure for cardiovascular risk reduction. Journal of Hypertension, 2005, 23, S3-S8.	0.3	68
1353	Predictors of successful long-term blood pressure control in type 2 diabetic patients: data from the Swedish National Diabetes Register (NDR). Journal of Hypertension, 2005, 23, 2305-2311.	0.3	16
1354	Microvascular and Macrovascular Complications of Diabetes Mellitus. American Journal of Pharmaceutical Education, 2005, 69, 87.	0.7	24
1355	Hypertensive retinopathy: there's more than meets the eye. Journal of Hypertension, 2005, 23, 683-696.	0.3	36
1356	Does the metabolic syndrome make blood pressure control more difficult in diabetes?. Journal of Hypertension, 2005, 23, 2155-2156.	0.3	2
1357	Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost. Medical Care, 2005, 43, 521-530.	1.1	1,429
1358	Diabetic Retinopathy: Epidemiology and Risk Factors. , 0, , 129-138.		0
1359	Bioavailability of Amlodipine Besylate Following Oral Administration as a Tablet Dispersed in Applesauce. Journal of Clinical Pharmacology, 2005, 45, 695-698.	1.0	5
1360	Glycemic index, postprandial glycemia and cardiovascular disease. Current Opinion in Lipidology, 2005, 16, 69-75.	1.2	75
1361	Prevention. Journal of Cardiovascular Nursing, 2005, 20, 433-441.	0.6	4
1362	Diabetic eye disease. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 670-675.	0.2	1
1364	Serial Angiographic Follow-up Beyond 10 Years After Coronary Artery Bypass Grafting. Circulation Journal, 2005, 69, 896-902.	0.7	26
1365	Relationships between Echocardiographic Findings, Pulse Wave Velocity, and Carotid Atherosclerosis in Type 2 Diabetic Patients. Hypertension Research, 2005, 28, 965-971.	1.5	35
1366	Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ACC Current Journal Review, 2005, 14, 24.	0.1	0
1367	The management of systemic hypertension in optometric practice. Ophthalmic and Physiological Optics, 2005, 25, 523-533.	1.0	5

#	ARTICLE	IF	CITATIONS
1368	Patterns of antihypertensive therapy among patients with diabetes. <i>Journal of General Internal Medicine</i> , 2005, 20, 842-846.	1.3	32
1369	Self-Reported Goals of Older Patients with Type 2 Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 306-311.	1.3	119
1370	A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 285-292.	2.6	63
1371	Targets to retard the progression of diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 1439-1445.	2.6	30
1372	Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. <i>Kidney International</i> , 2005, 67, S15-S19.	2.6	6
1373	Cardiovascular risk factors in type 2 diabetic patients: Multifactorial intervention in primary care. <i>Kidney International</i> , 2005, 67, S55-S62.	2.6	18
1374	What have we learned from clinical trials on prevention?. <i>Kidney International</i> , 2005, 67, S101-S106.	2.6	2
1375	Prevention of chronic kidney disease: A global challenge. <i>Kidney International</i> , 2005, 68, S11-S17.	2.6	139
1376	Epidemiology of diabetic nephropathy in Spain. <i>Kidney International</i> , 2005, 68, S20-S24.	2.6	16
1377	An algorithm for the treatment of type 2 diabetes in Latin America. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 148-160.	2.2	10
1378	Controlling the diabetes epidemic: how should we screen for undiagnosed diabetes and dysglycaemia?. <i>Diabetic Medicine</i> , 2005, 22, 207-212.	1.2	19
1379	The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease. <i>Diabetic Medicine</i> , 2005, 22, 249-255.	1.2	20
1380	Cardiovascular therapies and their role in diabetic eye disease. <i>Diabetic Medicine</i> , 2005, 22, 665-666.	1.2	4
1381	The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of Type 2 diabetes: a population-based screening study. <i>Diabetic Medicine</i> , 2005, 22, 1173-1177.	1.2	34
1382	Setting and negotiating targets in people with Type 2 diabetes in primary care J. Stewart & D. Kendrick. <i>Diabetic Medicine</i> , 2005, 22, 683-687.	1.2	19
1383	Dissemination of 'patient-oriented evidence that matters' on the Internet: the case of Type 2 diabetes treatment. <i>Diabetic Medicine</i> , 2005, 22, 688-692.	1.2	13
1384	Improved glycaemic control-an unintended benefit of a nurse-led cardiovascular risk reduction clinic. <i>Diabetic Medicine</i> , 2005, 22, 1272-1274.	1.2	23
1385	ADVANCE-Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. <i>Diabetic Medicine</i> , 2005, 22, 882-888.	1.2	56

#	ARTICLE	IF	CITATIONS
1386	Comparison of processes and intermediate outcomes between South Asian and European patients with diabetes in Blackburn, north-west England. <i>Diabetic Medicine</i> , 2005, 22, 1226-1233.	1.2	29
1387	The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. <i>Diabetic Medicine</i> , 2005, 22, 1420-1426.	1.2	114
1388	Type 2 diabetes mellitus: a cardiovascular perspective. <i>International Journal of Clinical Practice</i> , 2005, 59, 798-816.	0.8	44
1389	Impact of a two-arm educational program for improving diabetes care in primary care centres. <i>International Journal of Clinical Practice</i> , 2005, 59, 1126-1130.	0.8	15
1390	Diabetes mellitus and stroke. <i>International Journal of Clinical Practice</i> , 2005, 60, 48-56.	0.8	94
1391	Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency. <i>Nephrology</i> , 2005, 10, 40-47.	0.7	15
1392	Assessing genetic susceptibility to diabetic nephropathy. <i>Nephrology</i> , 2005, 10, S17-S21.	0.7	13
1393	Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain*. <i>Journal of Evaluation in Clinical Practice</i> , 2005, 11, 121-131.	0.9	8
1394	Pulse pressure is independently associated with sensorimotor peripheral neuropathy in patients with type 2 diabetes. <i>Journal of Internal Medicine</i> , 2005, 258, 38-44.	2.7	12
1395	Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989-2000. <i>Journal of Internal Medicine</i> , 2005, 258, 369-377.	2.7	26
1396	Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996-2004. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 90-97.	1.1	14
1397	Changes in the usage of antihypertensive drugs: implications and prospects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 231-234.	1.1	5
1398	Queen Mary Utilization of Antihypertensive Drugs Study: side-effects of antihypertensive drugs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 391-399.	0.7	16
1399	Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. <i>European Journal of Clinical Nutrition</i> , 2005, 59, 456-458.	1.3	101
1400	Is measurement of blood pressure worthwhile in the diabetic eye clinic?. <i>Eye</i> , 2005, 19, 312-316.	1.1	10
1401	Progressive changes in diabetics and their management. <i>Eye</i> , 2005, 19, 1115-1118.	1.1	41
1402	Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. <i>International Journal of Obesity</i> , 2005, 29, 1115-1120.	1.6	95
1403	Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets. <i>International Journal of Obesity</i> , 2005, 29, 1445-1451.	1.6	75

#	ARTICLE	IF	CITATIONS
1404	Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?. <i>Journal of Human Hypertension</i> , 2005, 19, 111-117.	1.0	21
1405	Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. <i>Journal of Human Hypertension</i> , 2005, 19, 429-437.	1.0	47
1406	Hypertension " still an important cause of heart failure?. <i>Journal of Human Hypertension</i> , 2005, 19, 267-275.	1.0	19
1407	Transiently elevated diastolic blood pressure is associated with a gender-dependent effect on cardiovascular risk. <i>Journal of Human Hypertension</i> , 2005, 19, 347-354.	1.0	9
1408	ADVANCE: action in diabetes and vascular disease. <i>Journal of Human Hypertension</i> , 2005, 19, S27-S32.	1.0	32
1409	Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists'™ Collaboration meta-analysis. <i>Journal of Human Hypertension</i> , 2005, 19, 851-853.	1.0	19
1410	Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. <i>International Journal of Clinical Practice</i> , 2005, 59, 1345-1355.	0.8	123
1411	Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control. <i>International Journal of Clinical Practice</i> , 2005, 59, 1309-1316.	0.8	40
1412	Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. <i>European Journal of Pharmacology</i> , 2005, 512, 239-246.	1.7	24
1413	Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. <i>European Journal of Pharmacology</i> , 2005, 519, 267-276.	1.7	24
1414	An Approach to Heart Failure and Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2005, 96, 47-52.	0.7	26
1415	Association of heart disease with diabetes and hypertension in patients with ESRD. <i>American Journal of Kidney Diseases</i> , 2005, 45, 316-323.	2.1	32
1416	Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT). <i>American Journal of Transplantation</i> , 2005, 5, 1120-1129.	2.6	142
1417	ORIGINAL RESEARCH"PSYCHOLOGY: Relationships between Erectile Dysfunction, Depression, and Anxiety in Japanese Subjects. <i>Journal of Sexual Medicine</i> , 2005, 2, 390-396.	0.3	65
1418	Thiazolidinediones" Benefits on microvascular complications of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 168-177.	1.2	33
1419	Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D). <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 80-87.	1.2	28
1420	Risk factors for heart disease and stroke among diabetic persons, by disability status. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 201-206.	1.2	9
1421	Long-term outcomes after a structured hypertension education programme for patients with diabetes and hypertension. <i>European Diabetes Nursing</i> , 2005, 2, 51-57.	0.2	0

#	ARTICLE	IF	CITATIONS
1422	Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 483-490.	0.8	44
1425	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. <i>Diabetologia</i> , 2005, 48, 282-289.	2.9	322
1426	Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). <i>Diabetologia</i> , 2005, 48, 868-877.	2.9	147
1427	Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. <i>Diabetologia</i> , 2005, 48, 856-861.	2.9	142
1428	Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?. <i>Diabetologia</i> , 2005, 48, 1445-1453.	2.9	115
1429	Differences in the association between type 2 diabetes and impaired microvascular function among Europeans and African Caribbeans. <i>Diabetologia</i> , 2005, 48, 2269-2277.	2.9	24
1430	Prevention of type 2 diabetes: what challenges do we have to address?. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2005, 13, 303-308.	0.8	10
1432	Risk and potential risk reduction in diabetes type 2 patients in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 152-158.	1.4	6
1433	Do angiotensin II antagonists provide benefits beyond blood pressure reduction?. <i>Advances in Therapy</i> , 2005, 22, 117-136.	1.3	6
1434	Advantages of blood pressure optimization. <i>Advances in Therapy</i> , 2005, 22, 285-296.	1.3	2
1436	Prevention of coronary heart disease in diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 259-271.	0.4	3
1437	Hypertrophy in the female heart. <i>Current Cardiology Reports</i> , 2005, 7, 173-177.	1.3	1
1438	Stroke prevention in diabetic and other high cardiovascular risk patients. <i>Current Diabetes Reports</i> , 2005, 5, 200-207.	1.7	7
1439	Statins and the prevention of stroke in diabetes. <i>Current Diabetes Reports</i> , 2005, 5, 1-3.	1.7	1
1440	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. <i>Current Hypertension Reports</i> , 2005, 7, 439-449.	1.5	8
1441	Does ALLHAT change the management of hypertension in chronic kidney disease?. <i>Current Hypertension Reports</i> , 2005, 7, 474-483.	1.5	5
1442	Cardiorenal Disease: A Clinical Intersection. <i>International Urology and Nephrology</i> , 2005, 37, 175-184.	0.6	4
1443	A community-based follow-up study on diabetic retinopathy among type 2 diabetics in Kinmen. <i>European Journal of Epidemiology</i> , 2005, 20, 317-323.	2.5	20

#	ARTICLE	IF	CITATIONS
1444	Implementation of a Pharmacist-Led Clinic for Hypertensive Patients in Primary Care – A Pilot Study. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 202-207.	1.4	40
1445	Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I). <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 6.	1.5	29
1446	GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. <i>BMC Family Practice</i> , 2005, 6, 20.	2.9	137
1447	Progression of kidney disease in type 2 diabetes – beyond blood pressure control: an observational study. <i>BMC Nephrology</i> , 2005, 6, 8.	0.8	43
1448	Hypertension control: results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines. <i>Cardiovascular Diabetology</i> , 2005, 4, 11.	2.7	3
1449	Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. <i>Pediatric Pulmonology</i> , 2005, 39, 103-107.	1.0	22
1450	Inadequate use of evidence-based doses of ramipril in type 2 diabetic patients with hypertension: HOPE for better results. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 161-163.	0.2	2
1451	Strokes and diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 215-221.	0.2	4
1452	Improving diabetes care in general practice using a nurse-led, GP supported clinic: a cohort study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 295-301.	0.2	10
1454	Zerebrale Durchblutungsstörungen. , 2005, , 1347-1361.		0
1455	Diabetiker und akutes Koronarsyndrom. , 2005, , 255-271.		0
1456	Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S17-S23.	0.6	0
1458	Prevalence of retinopathy in Caucasian type 2 diabetic patients from the South of Brazil and relationship with clinical and metabolic factors. <i>Brazilian Journal of Medical and Biological Research</i> , 2005, 38, 221-225.	0.7	14
1459	Macrovascular Risk Factors in Patients With Diabetes: Physician Treatment Strategies and Extent of Control. <i>Endocrine Practice</i> , 2005, 11, 172-179.	1.1	8
1460	PPAR β agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F1153-F1158.	1.3	84
1461	The Impact of History of Hypertension and Type 2 Diabetes at Baseline on the Incidence of Stroke and Stroke Mortality. <i>Stroke</i> , 2005, 36, 2538-2543.	1.0	142
1462	Case-Based Study: From Prediabetes to Complications – Opportunities for Prevention. <i>PLoS Medicine</i> , 2005, 2, e40.	3.9	1
1463	Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. <i>Cmaj</i> , 2005, 173, 1457-1466.	0.9	54

#	ARTICLE	IF	CITATIONS
1464	Angiotensinâ€‘receptor blockers and diureticsâ€‘ Advantages of combination. Blood Pressure, 2005, 14, 6-11.	0.7	14
1465	Antihypertensive Treatment and Multifactorial Approach for Renal Protection in Diabetes. Journal of the American Society of Nephrology: JASN, 2005, 16, S18-S21.	3.0	27
1466	Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation. Journal of the American Society of Nephrology: JASN, 2005, 16, S48-S52.	3.0	30
1468	The Diabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 25-32.	1.0	59
1469	Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control. British Journal of Diabetes and Vascular Disease, 2005, 5, 303-304.	0.6	0
1470	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart, 2005, 91, 451-455.	1.2	14
1471	Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome. Hypertension, 2005, 45, 907-913.	1.3	253
1472	Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients. Diabetes Care, 2005, 28, 1649-1655.	4.3	109
1473	Hypertension in type 2 diabetes - targeting angiotensin. Drug and Therapeutics Bulletin, 2005, 43, 41-45.	0.3	1
1474	Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes. Diabetes Care, 2005, 28, 1611-1617.	4.3	47
1475	Increased Utilization of Primary Care 5 Years Before Diagnosis of Type 2 Diabetes: A matched cohort study. Diabetes Care, 2005, 28, 47-52.	4.3	24
1477	Glucose, Lipid, and Blood Pressure Control in Australian Adults With Type 2 Diabetes: The 1999-2000 AusDiab. Diabetes Care, 2005, 28, 1490-1492.	4.3	89
1479	Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology, 2005, 44, 1473-1482.	0.9	69
1480	Effect of Ruboxistaurin on Bloodâ€‘Retinal Barrier Permeability in Relation to Severity of Leakage in Diabetic Macular Edema. , 2005, 46, 3855.		63
1481	Retinal Artery and Vein Diameters during Pregnancy in Diabetic Women. , 2005, 46, 709.		34
1482	Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial. Journal of the American Society of Nephrology: JASN, 2005, 16, 2170-2179.	3.0	297
1483	Reconstituting populations through evidence-based medicine: an ethnographic account of recommending procedures for diagnosing type 2 diabetes in clinical practice guidelines. Health (United Kingdom), 2005, 9, 241-266.	0.9	4
1484	The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology, 2005, 44, 781-788.	0.9	44

#	ARTICLE	IF	CITATIONS
1485	Primary Care Physical Therapy Practice Models. <i>Journal of Orthopaedic and Sports Physical Therapy</i> , 2005, 35, 699-707.	1.7	42
1486	Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus. <i>Cmaj</i> , 2005, 173, 1154-1157.	0.9	0
1487	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. <i>Cmaj</i> , 2005, 172, 177-180.	0.9	34
1488	Cardiovascular risk in patients with type 2 diabetes. <i>Cmaj</i> , 2005, 172, 1160-1160.	0.9	0
1489	Cost implications of new evidence on prevention of cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 183-192.	0.7	1
1490	CARDS on the table: should everybody with type 2 diabetes take a statin?. <i>Current Medical Research and Opinion</i> , 2005, 21, 357-361.	0.9	10
1491	Data for Management of Diabetes in Primary Care—Master or Minion?. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 209-212.	2.4	0
1492	Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. <i>Neurology</i> , 2005, 65, 835-842.	1.5	156
1493	Challenges in preventing cardiovascular complications in type 2 diabetes in primary care. <i>European Journal of General Practice</i> , 2005, 11, 11-16.	0.9	6
1494	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. <i>Circulation</i> , 2005, 112, 1825-1852.	1.6	402
1495	Cyclic Relationships Between Diabetic Nephropathy and Cardiovascular Risk Factors. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 203-212.	0.5	0
1496	Antidiabetic Effect of <i>Anacardium occidentale</i> . Stem-Bark in Fructose-Diabetic Rats. <i>Pharmaceutical Biology</i> , 2005, 43, 589-593.	1.3	32
1497	Improving Quality of Care Using a Diabetes Registry and Disease Management Services in an Integrated Delivery Network. <i>Disease Management: DM</i> , 2005, 8, 245-252.	1.0	8
1498	Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?. <i>Diabetes Care</i> , 2005, 28, 101-107.	4.3	141
1499	The Role of the Family in Adult Chronic Illness: A Review of the Literature on Type 2 Diabetes. <i>Irish Journal of Psychology</i> , 2005, 26, 9-15.	0.2	13
1500	Major Clinical Trials of Hypertension. <i>Hypertension</i> , 2005, 46, 1-6.	1.3	102
1501	Tranilast Prevents the Progression of Experimental Diabetic Nephropathy through Suppression of Enhanced Extracellular Matrix Gene Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 514-521.	1.3	21
1502	Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. <i>Diabetes Care</i> , 2005, 28, 337-442.	4.3	289

#	ARTICLE	IF	CITATIONS
1503	Association Among Individual Deprivation, Glycemic Control, and Diabetes Complications: The EPICES score. <i>Diabetes Care</i> , 2005, 28, 2680-2685.	4.3	142
1504	Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic analysis of the SPLINT trial. <i>Diabetes Care</i> , 2005, 28, 40-46.	4.3	59
1505	Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study. <i>Diabetes Care</i> , 2005, 28, 2106-2112.	4.3	266
1506	Blood Pressure as a Risk Factor for Stroke and the Impact of Antihypertensive Treatment. <i>Cerebrovascular Diseases</i> , 2005, 20, 40-52.	0.8	23
1507	Surgery as an Effective Early Intervention for Diabetes: Why the reluctance?. <i>Diabetes Care</i> , 2005, 28, 472-474.	4.3	55
1508	Generalizability and Persistence of a Multifaceted Intervention for Improving Quality of Care for Rural Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 783-788.	4.3	19
1509	End-Stage Renal Disease due to Diabetes Among Southwestern American Indians, 1990-2001. <i>Diabetes Care</i> , 2005, 28, 1041-1044.	4.3	30
1510	Female Advantage in AMI Mortality Is Reversed in Patients With Type 2 Diabetes in the Skaraborg Project. <i>Diabetes Care</i> , 2005, 28, 2246-2248.	4.3	14
1511	Ambulatory Blood Pressure Comparison of the Anti-hypertensive Efficacy of Fixed Combinations of Irbesartan/hydrochlorothiazide and Losartan/hydrochlorothiazide in Patients with Mild-to-moderate Hypertension. <i>Journal of International Medical Research</i> , 2005, 33, 620-631.	0.4	22
1512	Treatment of Type 2 Diabetes in Primary Health Care: A Drug Utilization Study. <i>Annals of Pharmacotherapy</i> , 2005, 39, 441-445.	0.9	13
1513	Early Diabetes-Related Complications in Adolescents. <i>Hormone Research in Paediatrics</i> , 2005, 63, 75-85.	0.8	22
1514	Secondary Prevention of Stroke with Antiplatelet Agents in Patients with Diabetes mellitus. <i>Cerebrovascular Diseases</i> , 2005, 20, 15-23.	0.8	8
1515	The RAGE Axis in Early Diabetic Retinopathy. , 2005, 46, 2916.		189
1516	QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. <i>Heart</i> , 2005, 91, 44-50.	1.2	71
1517	A Community-Based Program to Encourage Patients's Attention to Their Own Diabetes Care. <i>The Diabetes Educator</i> , 2005, 31, 691-699.	2.6	16
1518	Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. <i>Archives of Internal Medicine</i> , 2005, 165, 1401.	4.3	256
1519	Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). <i>Diabetes Care</i> , 2005, 28, 1151-1157.	4.3	377
1520	Pro-Active Call Center Treatment Support (PACCTS) to Improve Glucose Control in Type 2 Diabetes: A randomized controlled trial. <i>Diabetes Care</i> , 2005, 28, 278-282.	4.3	93

#	ARTICLE	IF	CITATIONS
1521	Review: Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 320-324.	0.6	2
1522	Ethnicity, Race, and Baseline Retinopathy Correlates in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2005, 28, 1954-1958.	4.3	120
1523	Insulin Detemirâ€”A New Basal Insulin Analog. <i>Annals of Pharmacotherapy</i> , 2005, 39, 502-507.	0.9	39
1524	Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes: A meta-analysis of clinical studies. <i>Diabetes Care</i> , 2005, 28, 942-949.	4.3	114
1525	Current and future pharmacological intervention for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 441-455.	1.0	16
1526	Cardiovascular Mortality in Overweight Subjects. <i>Hypertension</i> , 2005, 46, 654-659.	1.3	140
1527	Evaluation of the UCL Diabetes Self-management Programme (UCL-DSMP): A Randomized Controlled Trial. <i>Journal of Health Psychology</i> , 2005, 10, 261-276.	1.3	54
1528	Review: Dual blockade of the renin angiotensin system in diabetes â€” rationale and risks. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 266-271.	0.6	4
1529	THE TREAT-TO-TARGET PARADIGM: A CROSS-SECTIONAL SURVEY OF CURRENT THERAPIES AND ACHIEVED METABOLIC CONTROL IN 800 TYPE 2 DIABETIC PATIENTS. <i>Acta Clinica Belgica</i> , 2005, 60, 79-85.	0.5	5
1530	Visual impairment in the elderly. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 662-663.	0.2	1
1531	Hypertension-based clinical risk strategies for detecting microalbuminuria in diabetes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 427-433.	0.2	3
1532	The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 599-614.	0.2	44
1533	Chronic kidney disease: the global challenge. <i>Lancet, The</i> , 2005, 365, 331-340.	6.3	878
1538	Metformin monotherapy for type 2 diabetes mellitus. , 2005, , CD002966.		203
1539	Vascular risk factors in patients with type 1 diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 81-85.	0.2	6
1541	Cross-sectional study of care, socio-economic status and complications in young French patients with type 1 diabetes mellitus. <i>Diabetes and Metabolism</i> , 2005, 31, 41-46.	1.4	27
1542	Evaluation of a screening program for diabetic retinopathy in a primary care setting Dodia (DÃ©pistage) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	35
1543	Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). <i>Diabetes and Metabolism</i> , 2005, 31, 479-485.	1.4	29

#	ARTICLE	IF	CITATIONS
1544	Cardiovascular risks in type 2 diabetes and secondary cardiovascular prevention. <i>Diabetes and Metabolism</i> , 2005, 31, 503-506.	1.4	2
1547	Strategies to reduce length of stay and costs associated with decompensated heart failure. <i>Current Heart Failure Reports</i> , 2005, 2, 140-147.	1.3	3
1548	Carotid artery intimal medial thickness, brachial artery flow-mediated vasodilation and cardiovascular risk factors in diabetic and non-diabetic indigenous Australians. <i>Atherosclerosis</i> , 2005, 180, 319-326.	0.4	16
1549	The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. <i>Atherosclerosis</i> , 2005, 182, 367-374.	0.4	96
1550	Integrated Management of Patients with Diabetes Mellitus and Ischemic Heart Disease: PCI, CABG, and Medical Therapy. <i>Current Problems in Cardiology</i> , 2005, 30, 583-617.	1.1	4
1551	Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. <i>Journal of Clinical Hypertension</i> , 2005, 7, 96-101.	1.0	17
1553	Plasma glucose goals and therapeutic management in elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2005, 31, 5S58-5S61.	1.4	18
1556	R�cepteurs PPAR et insulinosensibilit� : nouveaux agonistes en d�veloppement. <i>Annales D'Endocrinologie</i> , 2005, 66, 10-17.	0.6	8
1558	Evoluci�n del control de la hipertensi�n arterial en Atenci�n Primaria en Espa�a. Resultados del estudio Controlpres 2003. <i>Hipertension Y Riesgo Vascular</i> , 2005, 22, 5-14.	0.3	80
1559	Heart Disease in Diabetic Patients. <i>Seminars in Nephrology</i> , 2005, 25, 372-378.	0.6	15
1560	Therapeutic Controversies in Hypertension. <i>Seminars in Nephrology</i> , 2005, 25, 227-235.	0.6	7
1561	Hypertension Treatment Guidelines: Practical Implications. <i>Seminars in Nephrology</i> , 2005, 25, 198-209.	0.6	9
1562	�valuation de l'impact budg�taire de l'application des recommandations de bonne pratique dans le diab�te de type II en France. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2005, 53, 67-78.	0.3	6
1563	Hypertension and the Kidney. <i>Seminars in Nephrology</i> , 2005, 25, 236-245.	0.6	22
1564	Hypertension in Special Populations. <i>Seminars in Nephrology</i> , 2005, 25, 210-214.	0.6	3
1565	Multiple Risk Factor Intervention in Chronic Kidney Disease: Management of Cardiac Disease in Chronic Kidney Disease Patients. <i>Medical Clinics of North America</i> , 2005, 89, 511-523.	1.1	10
1566	Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. <i>Cardiology Clinics</i> , 2005, 23, 139-152.	0.9	33
1567	Effects of nifedipine GITS 20�mg or enalapril 20�mg on blood pressure and inflammatory markers in patients with mild�moderate hypertension. <i>Blood Pressure</i> , 2005, 14, 14-22.	0.7	22

#	ARTICLE	IF	CITATIONS
1568	Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opinion on Pharmacotherapy, 2005, 6, 643-651.	0.9	44
1569	Hypertensive retinopathy revisited: some answers, more questions. British Journal of Ophthalmology, 2005, 89, 1646-1654.	2.1	101
1570	Place of Drug Therapy in the Treatment of Carotid Stenosis. CNS Drugs, 2005, 19, 597-622.	2.7	5
1571	Eplerenone. American Journal of Cardiovascular Drugs, 2005, 5, 51-69.	1.0	34
1572	Cardiovascular Risk Factors Associated with Insulin Resistance. American Journal of Cardiovascular Drugs, 2005, 5, 201-209.	1.0	38
1573	Pharmacoeconomic Study of First-Line Perindopril/Indapamide Combination in Lowering Blood Pressure and Reducing Albuminuria. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 203-213.	1.0	0
1574	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 2005, 91, v1-v52.	1.2	731
1575	Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study. Journal of the American Society of Nephrology: JASN, 2005, 16, S22-S26.	3.0	49
1576	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112, e154-235.	1.6	2,179
1577	The Efficacy and Safety of Low- and High- Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. Journal of Clinical Hypertension, 2005, 7, 578-586.	1.0	75
1578	Control of Blood Pressure and Other Cardiovascular Risk Factors at Different Practice Settings: Outcomes of Care Provided to Diabetic Women Compared to Men. Journal of Clinical Hypertension, 2005, 7, 73-80.	1.0	49
1579	Is There More to Life Than Blood Pressure?. Journal of Clinical Hypertension, 2005, 7, 149-151.	1.0	1
1580	Stroke in Patients With Diabetes and Hypertension. Journal of Clinical Hypertension, 2005, 7, 286-294.	1.0	32
1581	Treating Stage 2 Hypertension. Journal of Clinical Hypertension, 2005, 7, 464-470.	1.0	6
1582	Ethnic Differences in the Treatment and Control of Hypertension in Patients With Diabetes. Journal of Clinical Hypertension, 2005, 7, 445-454.	1.0	15
1583	Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome. Journal of Clinical Hypertension, 2005, 7, 669-678.	1.0	15
1584	Albuminuria and hypertension are independently associated with circulating antipericyte autoantibodies in type 2 diabetic patients. Metabolism: Clinical and Experimental, 2005, 54, 188-193.	1.5	3
1585	Preventive effects of a soy-based diet supplemented with stevioside on the development of the metabolic syndrome and type 2 diabetes in Zucker diabetic fatty rats. Metabolism: Clinical and Experimental, 2005, 54, 1181-1188.	1.5	59

#	ARTICLE	IF	CITATIONS
1586	Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 1158-1164.	2.4	22
1587	Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. <i>Clinical Therapeutics</i> , 2005, 27, 1658-1668.	1.1	2
1588	Role of transforming growth factor- β 2 in, and possible transforming growth factor- β 2 gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients. <i>Current Therapeutic Research</i> , 2005, 66, 266-278.	0.5	1
1589	Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2005, 67, 258-266.	1.1	55
1590	Arterial stiffness is associated with diabetic retinopathy in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, 162-166.	1.1	31
1591	Diabetes worsens the outcome of acute ischemic stroke. <i>Diabetes Research and Clinical Practice</i> , 2005, 69, 293-298.	1.1	82
1592	Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 13-19.	1.1	18
1593	Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S2-S9.	1.1	41
1594	Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S43-S47.	1.1	21
1595	Can the atherosclerosis prevention targets be achieved in type 2 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S48-S51.	1.1	8
1596	The prevention of diabetic microvascular complications of diabetes: Is there a role for lipid lowering?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S3-S14.	1.1	85
1597	Comparison of the quality of diabetes care in primary care diabetic clinics and general practice clinics. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 174-182.	1.1	21
1598	Hypertension: A Review and Rationale of Treatment. <i>Disease-a-Month</i> , 2005, 51, 548-614.	0.4	9
1599	Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. <i>European Journal of Internal Medicine</i> , 2005, 16, 154-159.	1.0	11
1600	Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. <i>FEBS Letters</i> , 2005, 579, 4265-4270.	1.3	66
1601	Symptom-focused management for African American women with Type 2 diabetes: a pilot study. <i>Applied Nursing Research</i> , 2005, 18, 213-220.	1.0	36
1602	Barriers to hypertension control. <i>American Heart Journal</i> , 2005, 149, 785-794.	1.2	100
1603	Pulse Pressure Predicts Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Hypertension</i> , 2005, 18, 1463-1467.	1.0	85

#	ARTICLE	IF	CITATIONS
1604	A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. American Journal of Medicine, 2005, 118, 276-284.	0.6	236
1605	Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy. American Journal of Medicine, 2005, 118, 1414.e21-1414.e27.	0.6	64
1606	The importance of tight glyceimic control. American Journal of Medicine, 2005, 118, 7-11.	0.6	78
1607	The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. American Journal of Medicine, 2005, 118, 1-6.	0.6	121
1615	Pioglitazone Lowers Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2005, 25, 337-340.	1.1	7
1617	Grado de control de la presi3n arterial en un grupo de pacientes con diabetes mellitus tipo 2. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2005, 52, 493-497.	0.8	0
1618	The Gender-Specific Impact of Diabetes and Myocardial Infarction at Baseline and During Follow-Up on Mortality From All Causes and Coronary Heart Disease. Journal of the American College of Cardiology, 2005, 45, 1413-1418.	1.2	68
1619	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology, 2005, 46, e1-e82.	1.2	1,860
1620	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Summary Article. Journal of the American College of Cardiology, 2005, 46, 1116-1143.	1.2	373
1621	Épidémiologie de l'infarctus du myocarde. EMC - Cardiologie-Angéiologie, 2005, 2, 375-387.	0.9	5
1622	Néphropathie diabétique et traitement antihypertenseur: quelles sont les leçons des essais cliniques? EMC - Néphrologie, 2005, 2, 182-193.	0.0	0
1623	Œdème maculaire. EMC - Ophtalmologie, 2005, 2, 35-75.	0.0	1
1624	Blood pressure control in an African American sample with diabetes mellitus in an urban eye clinic. Optometry - Journal of the American Optometric Association, 2005, 76, 653-656.	0.6	3
1625	Increased Urinary TGF-β1 and Cortical Renal GLUT1 and GLUT2 Levels: Additive Effects of Hypertension and Diabetes. Nephron Physiology, 2005, 100, p43-p50.	1.5	17
1626	Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. The Cochrane Library, 2005, , CD003638.	1.5	175
1628	Treatment of Hypertension in Chronic Kidney Disease. Seminars in Nephrology, 2005, 25, 435-439.	0.6	83
1629	Congestive Heart Failure in Chronic Kidney Disease: Disease-specific Mechanisms of Systolic and Diastolic Heart Failure and Management. Cardiology Clinics, 2005, 23, 275-284.	0.9	52
1630	Hypertension. Primary Care - Clinics in Office Practice, 2005, 32, 1011-1025.	0.7	3

#	ARTICLE	IF	CITATIONS
1631	Rein et glitazones. Annales D'Endocrinologie, 2005, 66, 81-90.	0.6	3
1632	Hypertension Management in Type 2 Diabetes Mellitus: Recommendations of the Joint National Committee VII. Endocrinology and Metabolism Clinics of North America, 2005, 34, 63-75.	1.2	22
1633	Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. Cardiology Clinics, 2005, 23, 193-210.	0.9	11
1634	Is Increasing Urinary Albumin a Better Marker for Microvascular than for Macrovascular Complication of Type 2 Diabetes mellitus?. Nephron Clinical Practice, 2005, 101, c116-c121.	2.3	10
1635	Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care, 2005, 28, 164-176.	4.3	1,347
1636	Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 771-776.	4.3	156
1637	Hypertension in the Elderly. Drugs and Aging, 2005, 22, 297-314.	1.3	11
1638	Oxidative Stress in Insulin-Resistant Conditions. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 343-351.	1.8	28
1639	Calcium Dobesilate in the Treatment of Diabetic Retinopathy. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 221-232.	1.8	37
1640	Cardiovascular Disease Morbidity and Mortality in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 75-86.	1.8	9
1641	Diabetic neuropathies: clinical manifestations and current treatment options. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 269-281.	2.9	123
1642	The Treatment of Type 2 Diabetes Mellitus in Youth. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 201-210.	1.8	11
1643	Type 2 Diabetes Mellitus Treatment Patterns and Healthcare Costs in the Elderly Population. Disease Management and Health Outcomes, 2006, 14, 75-83.	0.3	4
1644	The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. Drugs and Aging, 2006, 23, 131-155.	1.3	32
1645	Beta Blockade in Diabetic Heart Failure. Heart Failure Clinics, 2006, 2, 89-99.	1.0	2
1646	Factors Influencing the Management of Hypertension in Type 2 Diabetes. Canadian Journal of Diabetes, 2006, 30, 38-45.	0.4	6
1647	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	1.0	1,617
1648	Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Review of Cardiovascular Therapy, 2006, 4, 319-333.	0.6	6

#	ARTICLE	IF	CITATIONS
1649	Stroke prevention in diabetes and obesity. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 487-502.	0.6	20
1650	Hypertension and Diabetes: Role of the Renin-Angiotensin System. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 469-490.	1.2	43
1652	A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies. <i>Pharmacoeconomics</i> , 2006, 24, 5-19.	1.7	15
1653	Disease Management Programmes in Germany. <i>Pharmacoeconomics</i> , 2006, 24, 55-57.	1.7	4
1654	Diabetes Mellitus-Associated Atherosclerosis. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 15-40.	1.0	26
1655	Left Ventricular Diastolic Dysfunction in Diabetic Patients. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 219-230.	1.0	31
1656	Treatment of High-Risk Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 13-19.	1.0	0
1657	Lens Fluorescence in Relation to Glucose Tolerance and Genetic Predisposition to Type 2 Diabetes Mellitus in a Population-Based Study. <i>Current Eye Research</i> , 2006, 31, 733-738.	0.7	8
1658	Prevention of Cardiovascular Complications of the Metabolic Syndrome: Focus on Pharmacotherapy. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 328-341.	0.5	4
1659	Management issues in hypertensive diabetics. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2006, 48, 38-40.	0.2	2
1660	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 577-617.	1.0	1,510
1661	An Extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) System for Grading of Diabetic Macular Edema in the Astemizole Retinopathy Trial. <i>Current Eye Research</i> , 2006, 31, 535-547.	0.7	24
1662	Introduction: beyond glycemic control in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2006, 22, S1-S4.	0.9	1
1663	Pharmacotherapies for Diabetes Management: An Update for the Practicing Clinician. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2006, 18, 379-389.	0.4	3
1664	Hypertension in type 2 diabetes mellitus. <i>Insulin</i> , 2006, 1, 22-37.	0.2	13
1665	Clinical and metabolic characteristics of newly diagnosed diabetes patients. <i>Diabetes and Metabolism</i> , 2006, 32, 632-635.	1.4	29
1666	Treatment of Type 2 Diabetes Mellitus in a Primary Care Setting in Taiwan: Comparison with Secondary/Tertiary Care. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 105-117.	0.8	26
1669	Treatment and blood pressure control in 47,964 people with diabetes and hypertension: A systematic review of observational studies. <i>Canadian Journal of Cardiology</i> , 2006, 22, 855-860.	0.8	47

#	ARTICLE	IF	CITATIONS
1670	Metabolic syndrome: A marker of patients at high cardiovascular risk. Canadian Journal of Cardiology, 2006, 22, 85B-90B.	0.8	41
1672	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 897-898.	6.3	11
1673	Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet, The, 2006, 368, 1651-1659.	6.3	339
1674	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabetic Medicine, 2006, 23, 780-787.	1.2	35
1675	Management of Global Risk Across the Continuum of Hypertensive Heart Disease. Journal of Clinical Hypertension, 2006, 8, 21-30.	1.0	2
1676	Diabetes and hypertension. Medicine, 2006, 34, 76-79.	0.2	0
1677	Decrease Heart Rate Variability But Preserve Postural Blood Pressure Change in Type 2 Diabetes with Microalbuminuria. Journal of the Chinese Medical Association, 2006, 69, 254-258.	0.6	6
1679	Optimal care of cardiovascular disease and type 2 diabetes patients: Shared responsibilities between the cardiologist and diabetologist. Atherosclerosis Supplements, 2006, 7, 37-42.	1.2	9
1680	Diabetic Hypertension. Heart Failure Clinics, 2006, 2, 25-36.	1.0	4
1681	Diabetic Cardiomyopathy. Endocrinology and Metabolism Clinics of North America, 2006, 35, 575-599.	1.2	49
1682	Manitoba Diabetes Care Project: Examining Trends in Diabetes Therapy Prescribing Patterns in Manitoba. Canadian Journal of Diabetes, 2006, 30, 248-255.	0.4	1
1683	Epidemiologic Perspectives of Risk for Developing Diabetes and Diabetes Complications. Nursing Clinics of North America, 2006, 41, 487-498.	0.7	2
1684	Economics of Diabetes Mellitus. Nursing Clinics of North America, 2006, 41, 499-511.	0.7	10
1686	Manitoba Diabetes Care Project: A1C and Microalbumin Testing. Canadian Journal of Diabetes, 2006, 30, 1-7.	0.4	2
1688	Diabetes Mellitus and Cardiovascular Disease. Nursing Clinics of North America, 2006, 41, 681-695.	0.7	10
1689	Microalbuminuria. Clinics in Laboratory Medicine, 2006, 26, 635-653.	0.7	56
1690	Impact of Type 2 Diabetes Mellitus on Aortic Elastic Properties in Normotensive Diabetes: Doppler Tissue Imaging Study. Journal of the American Society of Echocardiography, 2006, 19, 1471-1481.	1.2	29
1691	Management of hypertension. Medicine, 2006, 34, 290-295.	0.2	1

#	ARTICLE	IF	CITATIONS
1692	Evaluaci3n de los objetivos de Saint Vincent en Catalu±a. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2006, 53, 93-98.	0.8	3
1693	Concentraciones de hemoglobina glucosilada A1c, lipoprote±nas de baja densidad y valores de presi3n arterial en adultos diagnosticados previamente de diabetes mellitus tipo 2. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2006, 53, 246-251.	0.8	2
1694	Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease. <i>Drugs</i> , 2006, 66, 2213-2234.	4.9	36
1695	Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals. <i>Clinical Drug Investigation</i> , 2006, 26, 185-193.	1.1	39
1701	Pinitol from Soybeans Reduces Postprandial Blood Glucose in Patients with Type 2 Diabetes Mellitus. <i>Journal of Medicinal Food</i> , 2006, 9, 182-186.	0.8	78
1702	Diabetic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2006, 2, 71-80.	1.0	2
1703	Microvascular Complications of Diabetes. <i>Nursing Clinics of North America</i> , 2006, 41, 719-736.	0.7	4
1704	Peripheral Arterial Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2006, 47, 921-929.	1.2	430
1705	Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1053-1059.	1.5	107
1706	Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KK _{Ay} /Ta mice: involvement of anti-inflammation and antioxidative stress. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1590-1598.	1.5	33
1707	Metformin extended release for the treatment of Type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 803-809.	0.9	12
1708	Preventing Cardiovascular Disease in the 21st Century. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 87-101.	1.0	65
1709	Ability to manage diabetesâ€”community health workers' knowledge, attitudes and beliefs. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2006, 11, 10-14.	0.4	9
1710	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
1711	Comparison of two low-calorie diets: A prospective study of effectiveness and safety. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 633-640.	1.8	11
1712	Diabetic Retinopathy in a Multi-ethnic Cohort in the United States. <i>American Journal of Ophthalmology</i> , 2006, 141, 446-455.e1.	1.7	548
1713	The effects of home monitoring by public health nurse on individuals' diabetes control. <i>Applied Nursing Research</i> , 2006, 19, 134-143.	1.0	18
1714	Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. <i>American Heart Journal</i> , 2006, 152, 27-38.	1.2	413

#	ARTICLE	IF	CITATIONS
1715	Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study. <i>Current Therapeutic Research</i> , 2006, 67, 81-102.	0.5	6
1716	Walking for exercise“ does three times per week influence risk factors in type 2 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 21-27.	1.1	48
1717	The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 290-298.	1.1	51
1718	Evaluation of diabetes care in the Otago region using a diabetes register, 1998“2003. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 345-352.	1.1	14
1719	The ROC analysis for different time points during oral glucose tolerance test. <i>Diabetes Research and Clinical Practice</i> , 2006, 72, 88-92.	1.1	6
1720	Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. <i>Diabetes Research and Clinical Practice</i> , 2006, 72, 135-141.	1.1	7
1721	The current status of home and office blood pressure control among hypertensive patients with diabetes mellitus: The Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) study. <i>Diabetes Research and Clinical Practice</i> , 2006, 73, 276-283.	1.1	21
1722	Six year incidence and progression of diabetic retinopathy: Results from the Mauritius diabetes complication study. <i>Diabetes Research and Clinical Practice</i> , 2006, 73, 298-303.	1.1	39
1723	The relationship between genetic and haemodynamic factors in diabetic nephropathy (DN): Case“control study in type 1 diabetes mellitus (T1DM). <i>Diabetes Research and Clinical Practice</i> , 2006, 74, S41-S50.	1.1	14
1724	Management Strategies for Patients With Hypertension and Diabetes: Why Combination Therapy Is Critical. <i>Journal of Clinical Hypertension</i> , 2006, 8, 108-113.	1.0	13
1725	Is New“Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?“Con. <i>Journal of Clinical Hypertension</i> , 2006, 8, 126-132.	1.0	8
1726	More Confusing Messages From the Hypertension Treatment Trials. <i>Journal of Clinical Hypertension</i> , 2006, 8, 8-11.	1.0	1
1727	Dispelling the Myth of “Aggressive“Antihypertensive Therapy. <i>Journal of Clinical Hypertension</i> , 2006, 8, 4-11.	1.0	23
1728	Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. <i>Journal of Clinical Hypertension</i> , 2006, 8, 31-39.	1.0	1
1729	Is the Development of Diabetes With Antihypertensive Therapy a Problem?“Pro. <i>Journal of Clinical Hypertension</i> , 2006, 8, 120-126.	1.0	7
1730	Impact of Blood Pressure vs. Glycemic Factors on Target Organ Damage in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2006, 8, 404-410.	1.0	8
1731	Attempted Forced Titration of Blood Pressure to <130/85 mm Hg in Type 2 Diabetic Hypertensive Patients in Clinical Practice: The Diastolic Cost. <i>Journal of Clinical Hypertension</i> , 2006, 8, 29-34.	1.0	8
1732	Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001“2002. <i>Journal of Clinical Hypertension</i> , 2006, 8, 93-98.	1.0	82

#	ARTICLE	IF	CITATIONS
1733	Physician Familiarity With Diagnosis and Management of Hypertension According to JNC 7 Guidelines. <i>Journal of Clinical Hypertension</i> , 2006, 8, 344-350.	1.0	19
1734	Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. <i>Journal of Clinical Hypertension</i> , 2006, 8, 470-480.	1.0	39
1735	Achieving Blood Pressure Goals: Why Aren't We?. <i>Journal of Clinical Hypertension</i> , 2006, 8, 865-871.	1.0	41
1736	Assessment of Global Risk: A Foundation for a New, Better Definition of Hypertension. <i>Journal of Clinical Hypertension</i> , 2006, 8, 5-14.	1.0	21
1737	Managing Multiple Cardiovascular Risk Factors: State of the Science. <i>Journal of Clinical Hypertension</i> , 2006, 8, 12-24.	1.0	17
1738	Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus. <i>Life Sciences</i> , 2006, 79, 2135-2143.	2.0	7
1739	Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control. <i>International Journal of Cardiology</i> , 2006, 110, 137-145.	0.8	16
1740	Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. <i>International Immunopharmacology</i> , 2006, 6, 445-453.	1.7	37
1741	Disease-specific medical records improve the recording of processes of care in the management of type 2 diabetes mellitus. <i>Public Health</i> , 2006, 120, 650-653.	1.4	5
1742	Understanding the Development and Prevention of Type 2 Diabetes in Youth (Part 1). <i>Journal of Pediatric Health Care</i> , 2006, 20, 3-10.	0.6	20
1743	Management of Type 2 Diabetes in Youth (Part 2). <i>Journal of Pediatric Health Care</i> , 2006, 20, 88-97.	0.6	11
1744	Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 137-147.	1.1	39
1745	Interobserver Agreement in the Interpretation of Single-Field Digital Fundus Images for Diabetic Retinopathy Screening. <i>Ophthalmology</i> , 2006, 113, 826-832.	2.5	56
1746	The Relation of Ambulatory Blood Pressure and Pulse Rate to Retinopathy in Type 1 Diabetes Mellitus The Renin-Angiotensin System Study. <i>Ophthalmology</i> , 2006, 113, 2231-2236.	2.5	23
1747	Retinal vascular manifestations of metabolic disorders. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 262-268.	3.1	154
1748	Urinary Albumin Excretion in Patients With Diabetes After Renal Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 2879-2882.	0.3	1
1750	Current Status of Diabetic End-Stage Renal Disease Using Korean Health Insurance Database. <i>The Journal of Korean Diabetes Association</i> , 2006, 30, 355.	0.1	7
1751	Effects of Type 2 Diabetes Mellitus on Risk Factors of Acute Coronary Syndrome. <i>The Journal of Korean Diabetes Association</i> , 2006, 30, 435.	0.1	1

#	ARTICLE	IF	CITATIONS
1752	Residual cardiovascular risk and practical management of type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, S17-S23.	0.6	0
1753	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2006, 113, .	1.6	416
1754	Peripheral Arterial Disease in Patients with Diabetes Mellitus. <i>Southern Medical Journal</i> , 2006, 99, 707-708.	0.3	1
1756	OTC Product: SideKick Blood Glucose Testing System. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 416.	0.7	0
1757	Medical Management of Diabetic Vascular Disease. <i>Journal for Vascular Ultrasound</i> , 2006, 30, 199-201.	0.2	0
1758	Recognition and management of cardiovascular risk factors in type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, S2-S6.	0.6	0
1759	A Case Presentation. <i>The Diabetes Educator</i> , 2006, 32, 137S-145S.	2.6	0
1760	Diabetes guidelines: easier to preach than to practise?. <i>Medical Journal of Australia</i> , 2006, 185, 305-309.	0.8	76
1762	Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988â€“2002. <i>Annals of Internal Medicine</i> , 2006, 144, 465.	2.0	486
1764	Diabetes as a cardiovascular disease: Addressing the risk. <i>British Journal of Cardiac Nursing</i> , 2006, 1, 117-125.	0.0	4
1765	Prevention of Progression in Diabetic Nephropathy. <i>Diabetes Spectrum</i> , 2006, 19, 18-24.	0.4	29
1769	Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 23-28.	0.6	4
1770	Pioglitazone for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2006, , CD006060.	1.5	49
1771	Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. <i>Journal of Hypertension</i> , 2006, 24, S19-S27.	0.3	11
1772	Total cardiovascular risk: a new treatment concept. <i>Journal of Hypertension</i> , 2006, 24, S17-S24.	0.3	23
1773	Effects of angiotensin II receptor antagonist on impaired endothelium-dependent and endothelium-independent relaxations in type II diabetic rats. <i>Journal of Hypertension</i> , 2006, 24, 331-338.	0.3	19
1774	Antihypertensive therapy and cerebrovascular protection. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 498-504.	1.0	9
1775	Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2133-2143.	0.4	132

#	ARTICLE	IF	CITATIONS
1776	Therapy Insight: neurological complications of prediabetes. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 276-282.	2.7	28
1777	Metabolic Syndrome in the Acute Care Setting. <i>AACN Advanced Critical Care</i> , 2006, 17, 79-85.	1.9	6
1782	25 Years of Progress in the Treatment of Retinal Diseases: Where We Have Been, Where We Are Now, and Where We Will Be. <i>Retina</i> , 2006, 26, S1-S6.	1.0	2
1783	DIABETIC RETINOPATHY: THE LATEST IN CURRENT MANAGEMENT. <i>Retina</i> , 2006, 26, S71-S79.	1.0	12
1784	ADVANCE: breaking new ground in type 2 diabetes. <i>Journal of Hypertension</i> , 2006, 24, S22-S28.	0.3	18
1785	Working on the positive emotional attractor through training in health care. <i>Journal of Management Development</i> , 2006, 25, 671-688.	1.1	10
1786	Glycated hemoglobin as a marker of cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2006, 17, 637-643.	1.2	74
1787	DIABETIC RETINOPATHY: THE LATEST IN CURRENT MANAGEMENT. <i>Retina</i> , 2006, 26, S71-S79.	1.0	46
1788	Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. <i>Journal of Hypertension</i> , 2006, 24, S73-S80.	0.3	37
1789	Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. <i>Journal of Hypertension</i> , 2006, 24, 1655-1661.	0.3	59
1790	Diabetes and cardiovascular disease: does sugar matter?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006, 13, 99-102.	0.6	0
1791	25 Years of Progress in the Treatment of Retinal Diseases: Where We Have Been, Where We Are Now, and Where We Will Be. <i>Retina</i> , 2006, 26, S1-S6.	1.0	11
1792	Update on Hypertension Management: Treatment of hypertension in patients with type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2006, 24, 208-210.	0.3	8
1793	Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2006, 24, 185-192.	0.3	47
1794	Implementing Diabetes Self-Management Training Programs: Breaking Through the Barriers in Primary Care. <i>Endocrine Practice</i> , 2006, 12, 124-130.	1.1	15
1796	Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. <i>Cardiovascular Diabetology</i> , 2006, 5, 15.	2.7	62
1797	Quality of diabetes care in England: results of the Quality and Outcomes Framework for primary care. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2006, 23, 379-380.	0.2	1
1798	General medical practitioners in Pakistan fail to educate patients adequately about complications of diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2006, 23, 57-61.	0.2	4

#	ARTICLE	IF	CITATIONS
1799	The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 365-380.	2.2	9
1800	Treatment of isolated systolic hypertension in diabetes mellitus type 2. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 381-387.	2.2	23
1801	Residual risk for acute stroke in patients with type 2 diabetes and hypertension in primary care: Skaraborg Hypertension and Diabetes Project. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 492-500.	2.2	8
1802	Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2006, 23, 265-270.	1.2	111
1803	Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. <i>Diabetic Medicine</i> , 2006, 23, 803-807.	1.2	13
1804	Relationship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance. <i>Diabetic Medicine</i> , 2006, 23, 887-893.	1.2	10
1805	Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. <i>Diabetic Medicine</i> , 2006, 23, 1069-1078.	1.2	34
1806	Use of vascular risk-modifying medications for diabetic patients differs between physician specialties. <i>Diabetic Medicine</i> , 2006, 23, 1117-1123.	1.2	11
1807	Mortality in individuals with Type 2 diabetes and heart disease in a unique New Zealand population. <i>Diabetic Medicine</i> , 2006, 23, 1313-1318.	1.2	8
1808	Glomerular changes in the KK-Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy. <i>Nephrology</i> , 2006, 11, 29-35.	0.7	61
1809	Calcium Antagonists in Patients with Type 2 Diabetes and Hypertension. <i>Cardiovascular Drug Reviews</i> , 2003, 21, 105-118.	4.4	16
1810	The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. <i>Acta Ophthalmologica</i> , 2006, 84, 619-623.	0.4	38
1811	Diabetic microvascular complications: can patients at risk be identified? A review. <i>International Journal of Clinical Practice</i> , 2006, 60, 1471-1483.	0.8	132
1812	Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 409-419.	0.7	104
1813	An educational programme for peer review groups to improve treatment of chronic heart failure and diabetes mellitus type 2 in general practice. <i>Journal of Evaluation in Clinical Practice</i> , 2006, 12, 613-621.	0.9	26
1814	Sharing specialist skills for diabetes in an inner city: A comparison of two primary care organisations over 4 years. <i>Journal of Evaluation in Clinical Practice</i> , 2006, 12, 583-590.	0.9	12
1815	Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. <i>Journal of Internal Medicine</i> , 2006, 259, 314-322.	2.7	82
1816	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 295-309.	21.5	230

#	ARTICLE	IF	CITATIONS
1817	Japanese Society of Hypertension. Hypertension Research, 2006, 29, S1-S105.	1.5	32
1818	Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations. Eye, 2006, 20, 674-680.	1.1	32
1819	Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye, 2006, 20, 861-862.	1.1	1
1820	Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. Journal of Human Hypertension, 2006, 20, 239-253.	1.0	51
1821	Blood pressure control in a diabetic population assessed by computer review. Journal of Human Hypertension, 2006, 20, 540-542.	1.0	5
1822	Blood pressure control in the setting of diabetes mellitus: new targets, new hope for improvement?. Journal of Human Hypertension, 2006, 20, 635-637.	1.0	27
1823	Influence of antihypertensive therapy and blood pressure control on left ventricular geometry and function in subjects with type II diabetes: The Augsburg Diabetes Family Study. Journal of Human Hypertension, 2006, 20, 757-764.	1.0	4
1824	Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney International, 2006, 70, 471-476.	2.6	33
1825	Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney International, 2006, 70, 1223-1233.	2.6	194
1826	Time to abandon microalbuminuria?. Kidney International, 2006, 70, 1214-1222.	2.6	182
1828	Circulating Nucleic Acids and Diabetic Complications. Annals of the New York Academy of Sciences, 2006, 1075, 258-270.	1.8	20
1829	Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners, 2006, 18, 524-533.	1.4	9
1830	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus. Journal of the American Medical Informatics Association: JAMIA, 2006, 13, 40-51.	2.2	278
1831	Blood pressure as an example of a biomarker that functions as a surrogate. AAPS Journal, 2006, 8, E146-E152.	2.2	51
1832	Population-Based Study of Nonproliferative Diabetic Retinopathy Among Type 2 Diabetic Patients in Kinmen, Taiwan. Japanese Journal of Ophthalmology, 2006, 50, 44-52.	0.9	14
1833	Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflammation Research, 2006, 55, 192-199.	1.6	24
1834	ESH-ESC Guidelines for the Management of Hypertension. Herz, 2006, 31, 331-338.	0.4	52
1836	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia, 2006, 49, 1761-1769.	2.9	303

#	ARTICLE	IF	CITATIONS
1837	Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. <i>Diabetologia</i> , 2006, 49, 2514-2524.	2.9	43
1838	The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. <i>Diabetologia</i> , 2006, 49, 2309-2316.	2.9	30
1841	Diabetes, aging and physical activity. <i>European Review of Aging and Physical Activity</i> , 2006, 3, 63-73.	1.3	7
1843	The diabetic myocardium. <i>Current Diabetes Reports</i> , 2006, 6, 36-41.	1.7	10
1844	Metabolic syndrome in the elderly. <i>Current Diabetes Reports</i> , 2006, 6, 64-71.	1.7	46
1845	Central nervous system involvement in diabetes mellitus. <i>Current Diabetes Reports</i> , 2006, 6, 431-438.	1.7	34
1846	Clinic versus home blood pressure measurements in patients with CKD. <i>Current Diabetes Reports</i> , 2006, 6, 453-454.	1.7	0
1847	Metabolic safety of antihypertensive drugs: Myth versus reality. <i>Current Hypertension Reports</i> , 2006, 8, 403-408.	1.5	16
1848	Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. <i>Advances in Therapy</i> , 2006, 23, 680-695.	1.3	19
1850	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. <i>Irish Journal of Medical Science</i> , 2006, 175, 36-41.	0.8	1
1851	Structuring diabetes care in general practices: Many improvements, remaining challenges. <i>Irish Journal of Medical Science</i> , 2006, 175, 42-47.	0.8	11
1852	Diagnosis and Management of Stage A Heart Failure. <i>Congestive Heart Failure</i> , 2006, 12, 146-152.	2.0	2
1853	Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus as a Component of the Cardiometabolic Syndrome. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 133-140.	1.7	10
1854	Treatment and Control of Diabetes Mellitus in the United States National Health and Nutrition Examination Survey, 1999-2002. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 301-307.	1.7	13
1855	The Editor's Roundtable: Diabetes Mellitus and Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 842-856.	0.7	4
1856	Controlled-Release Carvedilol in the Treatment of Essential Hypertension. <i>American Journal of Cardiology</i> , 2006, 98, 32-38.	0.7	30
1857	Early intervention to achieve optimal outcomes in type 2 diabetes: A case presentation. <i>Clinical Cornerstone</i> , 2006, 8, S6-S18.	1.0	4
1858	Urinary creatinine concentration is inversely related to glycaemic control and the presence of some diabetic complications in patients with newly diagnosed Type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 45-50.	1.2	9

#	ARTICLE	IF	CITATIONS
1859	Falls as a complication of diabetes mellitus in older people. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 158-162.	1.2	158
1860	The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: The VA Cooperative Study in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 75-80.	1.2	52
1861	Factors influencing the cost of hospital care for people with diabetes in Australia. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 349-355.	1.2	27
1862	Diabetes Nutrition and Complications Trial: adherence to the ADA nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multicenter study. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 361-366.	1.2	39
1863	Diabetic microvascular complications—can the presence of one predict the development of another?. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 228-237.	1.2	101
1864	Poststroke Complications and Risk Factors: Implications for Primary Care Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2006, 2, 533-546.	0.4	0
1865	Long-term safety of antihypertensive therapy. <i>Progress in Cardiovascular Diseases</i> , 2006, 49, 16-25.	1.6	25
1866	A multifocal electroretinogram model predicting the development of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2006, 25, 425-448.	7.3	211
1867	Prevalence of self-reported hypertension and its relation to dietary habits, in adults; a nutrition & health survey in Greece. <i>BMC Public Health</i> , 2006, 6, 206.	1.2	30
1868	Primary prevention of ischaemic heart disease. <i>Medicine</i> , 2006, 34, 178-180.	0.2	0
1869	Carvedilol versus Cardioselective β_2 -Blockers for the Treatment of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2006, 26, 1491-1500.	1.2	8
1870	Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2006, 26, 168-181.	1.2	32
1871	Introduction: Addressing Cardiometabolic Risk. <i>Pharmacotherapy</i> , 2006, 26, 1S-2S.	1.2	0
1872	The Metabolic Syndrome and Cardiometabolic Risk: Scope of the Problem and Current Standard of Care. <i>Pharmacotherapy</i> , 2006, 26, 3S-12S.	1.2	16
1873	Outcome research in diabetes: from theory to practice. Results of the QuED study. <i>Drug Development Research</i> , 2006, 67, 280-286.	1.4	0
1874	Treatment of hypertension in patients with type-2 diabetes mellitus. <i>Blood Pressure</i> , 2006, 15, 62-63.	0.7	0
1875	METABOLIC (GLYCAEMIC, LIPIDIC) AND BLOOD PRESSURE CONTROL IN 101 TYPE 2 DIABETIC PATIENTS ON FIRST ADMISSION TO DIABETES CENTRES. <i>Acta Clinica Belgica</i> , 2006, 61, 127-133.	0.5	1
1876	What is the impact of blood-pressure control on cardiovascular events in patients with diabetic nephropathy?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 132-133.	2.0	0

#	ARTICLE	IF	CITATIONS
1877	A Community-Based Epidemiologic Study of Gender Differences in the Relationship between Insulin Resistance/ β^2 -Cell Dysfunction and Diabetic Retinopathy among Type 2 Diabetic Patients in Kinmen, Taiwan. <i>Ophthalmologica</i> , 2006, 220, 252-258.	1.0	12
1878	Prevention and early detection of vascular complications of diabetes. <i>BMJ: British Medical Journal</i> , 2006, 333, 475-480.	2.4	164
1879	The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 77-83.	0.4	93
1880	The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 153-160.	0.2	14
1881	Full nursing assessment of patients at risk of diabetic foot ulcers. <i>British Journal of Nursing</i> , 2006, 15, S18-S21.	0.3	15
1882	Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2006, 22, 861-872.	0.9	48
1883	Interventions used to improve control of blood pressure in patients with hypertension. , 2006, , CD005182.		82
1884	Losartan: lessons learned from the RENAAL study. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 623-630.	0.9	8
1885	Is the Third Component of Metabolic Syndrome Really Predictive of Outcomes in Type 2 Diabetic Patients?. <i>Diabetes Care</i> , 2006, 29, 2515-2517.	4.3	17
1886	Response to Are the Eutrophic Effects of Angiotensin Receptor Blockers Real?. <i>Hypertension</i> , 2006, 48, .	1.3	0
1887	Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3472-3481.	3.0	67
1888	Effect of Multifactorial Intervention on Diabetic Macular Edema. <i>Diabetes Care</i> , 2006, 29, 463-464.	4.3	17
1889	Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. <i>Hypertension</i> , 2006, 48, 271-277.	1.3	88
1890	Therapeutic potential of angiotensin receptor blockers in hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 625-635.	1.9	6
1891	Evidence of Nephropathy and Peripheral Neuropathy in US Adults With Undiagnosed Diabetes. <i>Annals of Family Medicine</i> , 2006, 4, 427-432.	0.9	55
1892	ASHP Therapeutic Position Statement on the Treatment of Hypertension. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1074-1080.	0.5	0
1893	Recent Trends in Cardiovascular Complications Among Men and Women With and Without Diabetes. <i>Diabetes Care</i> , 2006, 29, 32-37.	4.3	141
1894	Pitfalls in blood pressure measurement in daily practice. <i>Family Practice</i> , 2006, 23, 20-27.	0.8	22

#	ARTICLE	IF	CITATIONS
1895	Measuring Continuity of Care in Diabetes Mellitus: An Experience-Based Measure. <i>Annals of Family Medicine</i> , 2006, 4, 548-555.	0.9	48
1896	Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 147-158.	0.9	57
1897	Action or Inaction? Decision Making in Patients With Diabetes and Elevated Blood Pressure in Primary Care. <i>Diabetes Care</i> , 2006, 29, 2580-2585.	4.3	41
1898	Antihypertensive Medication Prescribing in 27,822 Elderly Canadians With Diabetes Over the Past Decade. <i>Diabetes Care</i> , 2006, 29, 836-841.	4.3	28
1899	Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. <i>Quality and Safety in Health Care</i> , 2006, 15, 131-135.	2.5	47
1900	Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 8-18.	2.2	166
1901	Prevalence and Risk Factors for Urinary Incontinence in Women With Type 2 Diabetes and Impaired Fasting Glucose: Findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. <i>Diabetes Care</i> , 2006, 29, 1307-1312.	4.3	114
1902	Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events – economic implications?. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 63-70.	0.6	7
1903	Complex Relationship Between Blood Pressure and Mortality in Type 2 Diabetic Patients. <i>Hypertension</i> , 2006, 47, 168-173.	1.3	50
1904	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 193-208.	2.2	58
1907	Ocular manifestations of systemic arterial hypertension. <i>Expert Review of Ophthalmology</i> , 2006, 1, 113-123.	0.3	0
1908	Developing a Church-Based Diabetes Prevention Program With African Americans. <i>The Diabetes Educator</i> , 2006, 32, 901-909.	2.6	42
1909	Review: Comparing cardiovascular outcomes in diabetes studies. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 111-118.	0.6	4
1910	Diabetic neuropathy. <i>Postgraduate Medical Journal</i> , 2006, 82, 95-100.	0.9	223
1911	Long-Term Effect of the Internet-Based Glucose Monitoring System on HbA1c Reduction and Glucose Stability: A 30-month follow-up study for diabetes management with a ubiquitous medical care system. <i>Diabetes Care</i> , 2006, 29, 2625-2631.	4.3	191
1912	Antihypertensive Agents in Patients With Diabetes. <i>The Diabetes Educator</i> , 2006, 32, 596-602.	2.6	4
1913	Logistic support service improves processes and outcomes of diabetes care in general practice. <i>Family Practice</i> , 2006, 24, 20-25.	0.8	20
1914	Achievement of American Diabetes Association Clinical Practice Recommendations Among U.S. Adults With Diabetes, 1999-2002: The National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2006, 29, 531-537.	4.3	401

#	ARTICLE	IF	CITATIONS
1915	Pharmacotherapy of Hypertension. Canadian Pharmacists Journal, 2006, 139, S5-S19.	0.4	0
1916	Derivation and Validation of a Prediction Score for Major Coronary Heart Disease Events in a U.K. Type 2 Diabetic Population. Diabetes Care, 2006, 29, 1231-1236.	4.3	69
1917	The Metabolic Syndrome Is a Risk Indicator of Microvascular and Macrovascular Complications in Diabetes: Results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care, 2006, 29, 2701-2707.	4.3	174
1918	Management of Hypertension in Diabetes. Diabetes Spectrum, 2006, 19, 25-31.	0.4	27
1919	Diabetes Self-Management Education for Older Adults: General Principles and Practical Application. Diabetes Spectrum, 2006, 19, 234-240.	0.4	51
1920	Control of Hypertension in Patients with Hypertension, Diabetes, and Impaired Fasting Glucose by Czech Primary Care Physicians. Kidney and Blood Pressure Research, 2006, 29, 366-372.	0.9	1
1921	Erythrocyte Membrane Anionic Content and Urinary Glycosaminoglycan Excretion in Type 1 Diabetes: Association with Retinopathy. Current Eye Research, 2006, 31, 975-981.	0.7	7
1922	Managing cardiovascular risk in menopausal women. Climacteric, 2006, 9, 19-27.	1.1	27
1923	Diabetic Retinopathy: Seeing a Difference. Canadian Pharmacists Journal, 2006, 139, 30-31.	0.4	3
1924	Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 2006, 55, 1832-1839.	0.3	815
1925	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation, 2006, 114, 2850-2870.	1.6	346
1926	Development and Validation of the Economic Assessment of Glycemic Control and Long-Term Effects of Diabetes (EAGLE) Model. Diabetes Technology and Therapeutics, 2006, 8, 219-236.	2.4	42
1927	Information Technology in Ophthalmology and Medicine: Patient Education Kiosks. , 2006, , 45-49.		0
1928	The effects of thiazolidinediones on blood pressure levels â€“ A systematic review. Blood Pressure, 2006, 15, 135-150.	0.7	62
1929	The Pharmacist's Role in Continuity of Care in Type 2 Diabetes: An Evaluation of a Model. Journal of Pharmacy Technology, 2006, 22, 3-8.	0.5	10
1930	New-Onset Diabetes and Risk of All-Cause and Cardiovascular Mortality: The Cardiovascular Health Study. Diabetes Care, 2006, 29, 2012-2017.	4.3	52
1931	Managing hypertension in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2006, 63, 1140-1149.	0.5	17
1933	Hypertension and antihypertensive treatment of diabetic nephropathy. Nature Clinical Practice Nephrology, 2006, 2, 562-567.	2.0	40

#	ARTICLE	IF	CITATIONS
1934	Existing and potential therapeutic approaches targeting peroxisome proliferator-activated receptors in the management of Type 2 diabetes. Expert Opinion on Therapeutic Patents, 2006, 16, 1713-1733.	2.4	5
1935	What is effective intervention? â€œ using theories of health promotion. British Journal of Nursing, 2006, 15, 248-251.	0.3	19
1936	Is the Number of Documented Diabetes Process-of-Care Indicators Associated With Cardiometabolic Risk Factor Levels, Patient Satisfaction, or Self-Rated Quality of Diabetes Care?: The Translating Research into Action for Diabetes (TRIAD) study. Diabetes Care, 2006, 29, 2108-2113.	4.3	39
1937	Standards of Medical Care in Diabetes-2007. Diabetes Care, 2007, 30, S4-S41.	4.3	1,296
1938	"Damm Sokkor": Factors Associated With the Quality of Care of Patients With Diabetes: A study in primary care in Tunisia. Diabetes Care, 2007, 30, 2013-2018.	4.3	22
1939	Effect of crew resource management on diabetes care and patient outcomes in an inner-city primary care clinic. Quality and Safety in Health Care, 2007, 16, 244-247.	2.5	49
1940	Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments. Diabetes Care, 2007, 30, 2478-2483.	4.3	223
1941	Retinal Vascular Changes in Pre-Diabetes and Prehypertension. Diabetes Care, 2007, 30, 2708-2715.	4.3	215
1942	Internet Diabetic Patient Management Using a Short Messaging Service Automatically Produced by a Knowledge Matrix System. Diabetes Care, 2007, 30, 2857-2858.	4.3	32
1943	Effects of Treatment Targets on Subsequent Cardiovascular Events in Chinese Patients With Type 2 Diabetes. Diabetes Care, 2007, 30, 953-959.	4.3	48
1944	Reduced Incidence of Lower-Limb Amputations in the Diabetic Population of a German City, 1990â€œ2005. Diabetes Care, 2007, 30, 2633-2637.	4.3	112
1945	Screening for and managing diabetic retinopathy: Current approaches. American Journal of Health-System Pharmacy, 2007, 64, S8-S14.	0.5	55
1946	The State of Lipid Control in Patients with Diabetes in a Public Health Care Centre. Asia-Pacific Journal of Public Health, 2007, 19, 16-21.	0.4	7
1947	Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 146-150.	2.2	19
1948	Risk assessment in diabetes management: how do general practitioners estimate risks due to diabetes?. Quality and Safety in Health Care, 2007, 16, 208-212.	2.5	8
1949	Use of Chronic Care Model Elements Is Associated With Higher-Quality Care for Diabetes. Annals of Family Medicine, 2007, 5, 14-20.	0.9	143
1950	Genetic and dietary interactions: role of angiotensin AT1a receptors in response to a high-fructose diet. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1083-H1089.	1.5	42
1951	What Predicts Progression and Regression of Urinary Albumin Excretion in the Nondiabetic Population?. Journal of the American Society of Nephrology: JASN, 2007, 18, 637-645.	3.0	35

#	ARTICLE	IF	CITATIONS
1952	Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. American Journal of Physiology - Renal Physiology, 2007, 292, F820-F827.	1.3	24
1953	Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of "Co-maneuvers" Used in Clinical Trials. Journal of the American Board of Family Medicine, 2007, 20, 469-478.	0.8	14
1954	Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74 914 individuals in the HUNT 1 Study. European Heart Journal, 2007, 28, 2924-2929.	1.0	50
1955	World Hypertension Day 2007. Hypertension, 2007, 49, 939-940.	1.3	11
1956	Improvement of Blood Pressure Control in Hypertensive Patients with Renal Diseases. Hypertension Research, 2007, 30, 295-300.	1.5	1
1957	Summary measures of quality of diabetes care: comparison of continuous weighted performance measurement and dichotomous thresholds. International Journal for Quality in Health Care, 2007, 19, 29-36.	0.9	10
1958	Surgery for Diabetic Retinopathy. Ophthalmologica, 2007, 221, 103-111.	1.0	27
1959	Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 345-350.	0.2	195
1960	Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nature Clinical Practice Nephrology, 2007, 3, 428-438.	2.0	106
1961	The ADVANCE trial: further PROGRESS with HOPE. Journal of Human Hypertension, 2007, 21, 911-913.	1.0	3
1962	Effects of Hypertension and Type 2 Diabetes Mellitus on the Risk of Total Cardiovascular Events in Japanese Patients with Hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT). Hypertension Research, 2007, 30, 119-123.	1.5	9
1963	Is Renoprotection by Angiotensin Receptor Blocker Dependent on Blood Pressure?: The Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) Study. Hypertension Research, 2007, 30, 529-533.	1.5	14
1964	Laser Treatment in Diabetic Retinopathy. Ophthalmologica, 2007, 221, 95-102.	1.0	55
1966	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
1967	Defining Hypertension. , 2007, , 49-57.		2
1968	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 Q.784314 egBT /Ov		195
1969	Genomics of Diabetic Neuropathy. , 2007, , 31-50.		2
1970	End-Digit Preference and the Quality of Blood Pressure Monitoring in Diabetic Adults. Diabetes Care, 2007, 30, 1959-1963.	4.3	22

#	ARTICLE	IF	CITATIONS
1972	Case Against Angioplasty and Stenting of AtheroscleroticRenal Artery Stenosis. <i>Circulation</i> , 2007, 115, 271-276.	1.6	48
1973	Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults. <i>Diabetes Care</i> , 2007, 30, 2874-2879.	4.3	101
1975	Treatment and control of blood pressure in patients with diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 97-103.	0.5	16
1976	Blood pressure and ageing. <i>Postgraduate Medical Journal</i> , 2007, 83, 109-114.	0.9	338
1977	Features of Stroke in Chinese Diabetes Patients: A Hospital-based Study. <i>Journal of International Medical Research</i> , 2007, 35, 540-546.	0.4	9
1978	Retinal Dysfunction in Diabetic Ren-2 Rats Is Ameliorated by Treatment with Valsartan but Not Atenolol. , 2007, 48, 927.		57
1979	The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. <i>Endocrine Research</i> , 2007, 32, 109-142.	0.6	3
1980	Impact of the Metabolic Syndrome on Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2007, 116, 2119-2126.	1.6	85
1981	Endocrine Disorders and the Heart. , 2007, , 2295-2330.		1
1982	Beta-Blockers as First Line Treatment of Hypertension: A Proponents View. <i>Current Hypertension Reviews</i> , 2007, 3, 21-28.	0.5	3
1983	The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence. <i>Cerebrovascular Diseases</i> , 2007, 24, 64-75.	0.8	9
1984	The role of fenofibrate in clinical practice. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S15-S20.	0.9	37
1985	Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1905-1912.	0.3	13
1986	Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. <i>Quality and Safety in Health Care</i> , 2007, 16, 349-353.	2.5	129
1987	Diabetic retinopathy: treatment and prevention. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S9-S11.	0.9	18
1988	Type 2 diabetes patients: profiles, treatment and daily practice. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S12-S16.	0.9	3
1989	Diabetic Neuropathy: Pathogenesis and Treatment. , 2007, , 543-579.		4
1990	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2007, , 3-26.		1

#	ARTICLE	IF	CITATIONS
1991	Prevention and Treatment of Type 2 Diabetes in Youth. <i>Hormone Research in Paediatrics</i> , 2007, 67, 22-34.	0.8	40
1992	Hypertension and Sensorimotor Peripheral Neuropathy in Type 2 Diabetes. <i>European Neurology</i> , 2007, 57, 91-95.	0.6	25
1993	Relationship Between Low-Normal Blood Pressure and Kidney Disease in Type 1 Diabetes. <i>Hypertension</i> , 2007, 49, 48-54.	1.3	16
1994	Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension. <i>Diabetes Care</i> , 2007, 30, 1699-1703.	4.3	104
1995	Gain in Patients' Knowledge of Diabetes Management Targets Is Associated With Better Glycemic Control. <i>Diabetes Care</i> , 2007, 30, 1587-1589.	4.3	69
1997	<scp>l</scp>-Carnosine, a Substrate of Carnosinase-1, Influences Glucose Metabolism. <i>Diabetes</i> , 2007, 56, 2425-2432.	0.3	129
1998	Relationship of Physician Volume With Process Measures and Outcomes in Diabetes. <i>Diabetes Care</i> , 2007, 30, 1442-1447.	4.3	23
2000	Nurse Care Manager Collaboration With Community-Based Physicians Providing Diabetes Care A Randomized Controlled Trial. <i>The Diabetes Educator</i> , 2007, 33, 493-502.	2.6	56
2001	Rationale and Design of a Study to Examine Lower Targets for Low-Density Lipoprotein-Cholesterol and Blood Pressure in Coronary Artery Disease Patients The Japanese Coronary Artery Disease Study II (JCADII). <i>Circulation Journal</i> , 2007, 72, 515-520.	0.7	4
2003	Clinical Manifestations and Current Treatment options for Diabetic Neuropathies. <i>Endocrine Practice</i> , 2007, 13, 550-566.	1.1	69
2004	Development of a Diabetes Prevention Management Program for Clinical Practice. <i>Public Health Reports</i> , 2007, 122, 258-263.	1.3	86
2006	Beta-blockers for hypertension. , 2007, , CD002003.		126
2007	Mortality Trends in Men and Women with Diabetes, 1971 to 2000. <i>Annals of Internal Medicine</i> , 2007, 147, 149.	2.0	392
2009	What is the true place of blood pressure in cardiovascular risk management?. <i>Journal of Hypertension</i> , 2007, 25, 925-928.	0.3	0
2010	Device-guided slow breathing as a non-pharmacological approach to antihypertensive treatment: efficacy, problems and perspectives. <i>Journal of Hypertension</i> , 2007, 25, 57-61.	0.3	33
2011	Predicted Quality-Adjusted Life Years as a Composite Measure of the Clinical Value of Diabetes Risk Factor Control. <i>Medical Care</i> , 2007, 45, 315-321.	1.1	30
2012	Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1027-1034.	0.5	122
2013	Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. <i>Journal of Hypertension</i> , 2007, 25, 241-246.	0.3	58

#	ARTICLE	IF	CITATIONS
2014	Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. <i>Journal of Hypertension</i> , 2007, 25, 1311-1317.	0.3	103
2015	VISUAL SIDE EFFECTS OF SUCCESSFUL SCATTER LASER PHOTOCOAGULATION SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2007, 27, 816-824.	1.0	149
2016	Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F647-F654.	1.3	34
2017	Blood pressure determination by traditionally trained personnel is less reliable and tends to underestimate the severity of moderate to severe hypertension. <i>Blood Pressure Monitoring</i> , 2007, 12, 61-68.	0.4	21
2018	New insights from ADVANCE. <i>Journal of Hypertension</i> , 2007, 25, S23-S30.	0.3	5
2020	Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke. <i>Stroke</i> , 2007, 38, 865-873.	1.0	459
2022	Biologic Risk Factors Associated with Diabetic Retinopathy. <i>Ophthalmology</i> , 2007, 114, 1332-1340.	2.5	100
2023	Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. <i>Ophthalmology</i> , 2007, 114, 743-750.	2.5	318
2024	Pioglitazone Decreases Ambulatory Blood Pressure in Type 2 Diabetics With Difficultâ€”Control Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 530-537.	1.0	15
2025	Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial. <i>Journal of Clinical Hypertension</i> , 2007, 9, 120-127.	1.0	11
2026	Linear Relationship Between Blood Pressure and Stroke: The Jichi Medical School Cohort Study. <i>Journal of Clinical Hypertension</i> , 2007, 9, 677-683.	1.0	16
2027	What Should Our Blood Pressure Goal Be in Patients With Diabetes?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 823-826.	1.0	1
2028	Reducing Cardiovascular Events in Highâ€”Risk Patients: The Challenge of Managing Hypertension in Patients With Diabetic Renal Disease. <i>Journal of Clinical Hypertension</i> , 2007, 9, 16-25.	1.0	3
2029	Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction. <i>Journal of Clinical Hypertension</i> , 2007, 9, 26-32.	1.0	20
2030	Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. <i>American Heart Journal</i> , 2007, 154, 79.e9-79.e15.	1.2	29
2031	Optimizing Cardiovascular Outcomes in Diabetes Mellitus. <i>American Journal of Medicine</i> , 2007, 120, S3-S11.	0.6	157
2032	Effects of angiotensin-converting enzyme inhibitors and Î²-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. <i>Experimental Eye Research</i> , 2007, 84, 745-752.	1.2	34
2033	Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. <i>Experimental Eye Research</i> , 2007, 85, 123-129.	1.2	23

#	ARTICLE	IF	CITATIONS
2034	Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. <i>Experimental Eye Research</i> , 2007, 85, 406-412.	1.2	55
2035	Rationale and design of the AdRem study: Evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. <i>Contemporary Clinical Trials</i> , 2007, 28, 6-17.	0.8	22
2036	PRODIACOR: A patient-centered treatment program for type 2 diabetes and associated cardiovascular risk factors in the city of Corrientes, Argentina. <i>Contemporary Clinical Trials</i> , 2007, 28, 548-556.	0.8	6
2037	Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. <i>Clinical Therapeutics</i> , 2007, 29, 279-289.	1.1	93
2038	Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. <i>Clinical Therapeutics</i> , 2007, 29, 563-580.	1.1	231
2039	Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus. <i>Clinical Therapeutics</i> , 2007, 29, S44-S53.	1.1	2
2040	Quality of life in type 2 diabetes patients under intensive multitherapy. <i>Diabetes and Metabolism</i> , 2007, 33, 54-60.	1.4	32
2041	A case control study of diabetic patients who default from primary care in urban New Zealand. <i>Diabetes and Metabolism</i> , 2007, 33, 109-113.	1.4	8
2042	Short term efficacy of a lifestyle intervention programme on cardiovascular health outcome in overweight Indigenous Australians with and without type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 65-71.	1.1	29
2043	A simple nurse-based prompt increases screening and prevention counseling for diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 81-87.	1.1	10
2044	Cardiovascular risk factor control among diabetic patients attending community-based diabetic care clinics in Italy. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 176-183.	1.1	15
2045	Characteristics of undiagnosed diabetes in community-dwelling French elderly: The 3C study. <i>Diabetes Research and Clinical Practice</i> , 2007, 76, 257-264.	1.1	27
2046	Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, 70-76.	1.1	47
2047	Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: A 10-year observation study. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, 141-147.	1.1	16
2048	Hypertension in people with diabetes in sub-Saharan Africa: Revealing the hidden face of the iceberg. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, 293-299.	1.1	52
2049	Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, 492-493.	1.1	5
2050	The effects of a patient-based risk assessment prompt on diabetes screening. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 102-107.	1.1	2
2051	Quality of diabetes care in Saudi Arabia. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 145-146.	1.1	16

#	ARTICLE	IF	CITATIONS
2052	Glycated albumin is low in obese, type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 51-55.	1.1	58
2053	Effects of thiazolidinediones on the triad of type 2 diabetes mellitus, insulin resistance and cardiovascular disease. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S3-S13.	1.1	2
2054	The eyes in diabetes and diabetes through the eyes. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S51-S58.	1.1	6
2055	Targeting acute hyperglycaemia in clinical practice. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S40-S46.	1.1	0
2056	Heart Failure in Diabetes and Related Conditions. <i>Journal of Cardiac Failure</i> , 2007, 13, 861-873.	0.7	31
2057	Illness representations among patients with type 2 diabetes and their partners: Relationships with self-management behaviors. <i>Journal of Psychosomatic Research</i> , 2007, 63, 175-184.	1.2	78
2060	Is daytime insulin more physiologic and less atherogenic than bedtime insulin?. <i>Medical Hypotheses</i> , 2007, 68, 1228-1232.	0.8	2
2061	Are we misunderstanding beta-blockers. <i>International Journal of Cardiology</i> , 2007, 120, 10-27.	0.8	86
2062	Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 189-199.	2.3	25
2064	The eye in hypertension. <i>Lancet, The</i> , 2007, 369, 425-435.	6.3	492
2065	Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. <i>Lancet, The</i> , 2007, 370, 829-840.	6.3	1,864
2066	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. <i>Lancet, The</i> , 2007, 370, 1687-1697.	6.3	918
2067	GuÃas de prÃictica clÃnica sobre diabetes, prediabetes y enfermedades cardiovasculares: versiÃn resumida. <i>Revista Espanola De Cardiologia</i> , 2007, 60, 525.e1-525.e64.	0.6	13
2068	Glomerulopat?as secundarias y enfermedades renales asociadas a enfermedades metab?licas. <i>Diabetes mellitus. Medicine</i> , 2007, 9, 5157-5163.	0.0	0
2069	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. <i>Clinical Science</i> , 2007, 112, 375-384.	1.8	276
2071	Tratamiento de la hipertensiÃn arterial en los diabÃticos: una revisiÃn crÃtica. <i>Semergen</i> , 2007, 33, 241-249.	0.2	0
2072	Traitement mÃdicamenteux du diabÃte de type 2recommandation de bonne pratique. <i>Diabetes and Metabolism</i> , 2007, 33, S26-S105.	1.4	5
2073	The elderly diabetic's eyes. <i>Diabetes and Metabolism</i> , 2007, 33, S4-S9.	1.4	23

#	ARTICLE	IF	CITATIONS
2074	Diabetic nephropathy in the elderly. <i>Diabetes and Metabolism</i> , 2007, 33, S40-S55.	1.4	48
2075	Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. <i>Canadian Journal of Cardiology</i> , 2007, 23, 783-787.	0.8	20
2076	Hypertension Increases Retinal Inflammation in Experimental Diabetes: A Possible Mechanism for Aggravation of Diabetic Retinopathy by Hypertension. <i>Current Eye Research</i> , 2007, 32, 533-541.	0.7	41
2077	Psychological Insulin Resistance. <i>The Diabetes Educator</i> , 2007, 33, 241S-244S.	2.6	22
2078	Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1209-1226.	1.9	43
2079	Prevention of Hypertension with or without Renin-Angiotensin System Inhibition Precludes Nephron Loss in the Early Stage of Experimental Diabetes Mellitus. <i>Nephron Physiology</i> , 2007, 107, p57-p64.	1.5	7
2080	Exploring Disease Management Programs for Diabetes Mellitus. <i>Disease Management and Health Outcomes</i> , 2007, 15, 73-81.	0.3	6
2081	2007 ESHâ€ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2007, 16, 135-232.	0.7	292
2082	Loss of taste-induced hypertension â€” caveat for taste modulation as a therapeutic option in obesity. <i>Eating and Weight Disorders</i> , 2007, 12, e11-e13.	1.2	6
2083	Treating Hypertension in the Patient With Overt Diabetic Nephropathy. <i>Seminars in Nephrology</i> , 2007, 27, 182-194.	0.6	14
2084	Reaching for Wellness in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 453-479.	0.7	16
2085	After Pregnancy Complicated by Diabetes: Postpartum Care and Education. <i>Obstetrics and Gynecology Clinics of North America</i> , 2007, 34, 335-349.	0.7	18
2086	Therapy Insight: peripheral arterial disease and diabetesâ€”from pathogenesis to treatment guidelines. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 151-162.	3.3	25
2087	Comparative Proteome Analysis of Neural Retinas from Type 2 Diabetic Rats by Two-dimensional Electrophoresis. <i>Current Eye Research</i> , 2007, 32, 891-901.	0.7	29
2088	Composite Endpoints for Clinical Trials. <i>Pharmaceutical Medicine</i> , 2007, 21, 187-198.	0.4	24
2089	Angiotensin II Receptor Antagonists. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 39-47.	1.0	0
2090	Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. <i>BioDrugs</i> , 2007, 21, 245-257.	2.2	63
2091	Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 361-372.	1.0	33

#	ARTICLE	IF	CITATIONS
2092	Effects of Ficus thonningii (Blume) [Moraceae] Stem-Bark Ethanol Extract on Blood Glucose, Cardiovascular and Kidney Functions of Rats, and on Kidney Cell Lines of the Proximal (LLC-PK1) and Distal Tubules (MDBK). <i>Renal Failure</i> , 2007, 29, 389-397.	0.8	33
2093	Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. <i>Current Medical Research and Opinion</i> , 2007, 23, 905-917.	0.9	58
2094	The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3009-3020.	0.9	10
2095	Captopril Inhibits Capillary Degeneration in the Early Stages of Diabetic Retinopathy. <i>Current Eye Research</i> , 2007, 32, 883-889.	0.7	47
2096	Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004. <i>Hypertension</i> , 2007, 49, 69-75.	1.3	1,225
2097	A Qualitative Study in the United Kingdom of Factors Influencing Attendance by Patients with Diabetes at Ophthalmic Outpatient Clinics. <i>Ophthalmic Epidemiology</i> , 2007, 14, 375-380.	0.8	76
2098	A population model of diabetes and pre-diabetes. <i>International Journal of Computer Mathematics</i> , 2007, 84, 57-66.	1.0	18
2099	Comprehensive Management of Post-Transplant Diabetes Mellitus: From Intensive Care to Home Care. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 907-922.	1.2	11
2100	Risk Factor Management and Lifestyle Modification in Heart Failure. , 2007, , 315-330.		0
2101	Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. <i>International Congress Series</i> , 2007, 1303, 10-20.	0.2	2
2102	Physical Activity Advisement Practices in Diabetes Education Centres across Canada. <i>Canadian Journal of Diabetes</i> , 2007, 31, 131-139.	0.4	6
2103	The Management of Type 2 Diabetes Mellitus FOCUS on Quality. <i>Primary Care - Clinics in Office Practice</i> , 2007, 34, 1-38.	0.7	10
2104	Applying Hypertension Guidelines to Reduce the Burden of Heart Failure. <i>Cardiology Clinics</i> , 2007, 25, 507-522.	0.9	6
2106	Developing practice in eye care for patients with diabetes. <i>Optometry - Journal of the American Optometric Association</i> , 2007, 78, 608-612.	0.6	0
2107	Poor control and management of cardiovascular risk factors among Albanian diabetic adult patients. <i>Primary Care Diabetes</i> , 2007, 1, 81-86.	0.9	5
2115	Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. <i>Drugs</i> , 2007, 67, 997-1026.	4.9	117
2116	Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. <i>Drugs</i> , 2007, 67, 1309-1327.	4.9	86
2117	Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2007, 27, 841-849.	1.1	34

#	ARTICLE	IF	CITATIONS
2118	Inverse Relationship of Blood Pressure Levels to Sudden Cardiac Mortality and Benefit of the Implantable Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1427-1433.	1.2	29
2119	Pharmaco-economic issues for diabetes therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 657-685.	2.2	26
2120	Pathogenesis and Classification of Proliferative Diabetic Vitreoretinopathy. <i>Ophthalmologica</i> , 2007, 221, 78-94.	1.0	77
2121	Patient-Motivated Prevention of Lifestyle-Related Disease in Japan. <i>Disease Management and Health Outcomes</i> , 2007, 15, 119-126.	0.3	15
2122	Rosiglitazone for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2007, , CD006063.	1.5	67
2123	Influenza Viruses in Animal Wildlife Populations. <i>Current Topics in Microbiology and Immunology</i> , 2007, 315, 67-83.	0.7	47
2124	Overviews of Pathogen Emergence: Which Pathogens Emerge, When and Why?. <i>Current Topics in Microbiology and Immunology</i> , 2007, 315, 85-111.	0.7	114
2125	Management of hypertension in diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 341-357.	1.2	0
2127	After gestational diabetes. <i>Practice Nursing</i> , 2007, 18, 400-403.	0.1	0
2128	Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. <i>Medical Journal of Australia</i> , 2007, 186, 622-624.	0.8	23
2129	World Health Organization/International Society of Hypertension (WHO/ISH): Hypertension Guidelines and Statements. , 2007, , 1157-1172.		3
2130	Inhibitory activity of <i>Euonymus alatus</i> against alpha-glucosidase <i>in vitro</i> and <i>in vivo</i> . <i>Nutrition Research and Practice</i> , 2007, 1, 184.	0.7	21
2131	Silent myocardial ischemia screening in patients with diabetes mellitus. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 285-293.	1.3	26
2133	Hypoglycemic and hypolipidemic effects of <i>Saururus chinensis</i> Baill in streptozotocin-induced diabetic rats. <i>Nutrition Research and Practice</i> , 2007, 1, 100.	0.7	11
2135	Insulin Resistance and Diabetes in Hypertension. , 2007, , 681-692.		2
2137	The Pharmacist's Role in Maintaining Adherence to Insulin Therapy in Type 2 Diabetes Mellitus Clinical Review. <i>The Consultant Pharmacist</i> , 2007, 22, 320-332.	0.4	12
2138	Control of Blood Glucose and Insulin Resistance. , 2007, , 1105-1112.		1
2139	Hypolipidemic effect of <i>Salicornia herbacea</i> in animal model of type 2 diabetes mellitus. <i>Nutrition Research and Practice</i> , 2007, 1, 371.	0.7	20

#	ARTICLE	IF	CITATIONS
2140	Retinal vascular signs in diabetes and hypertension - review. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 352-362.	1.3	15
2142	Cardiorenal Syndrome at Different Stages of Chronic Kidney Disease. International Journal of Artificial Organs, 2007, 30, 564-576.	0.7	10
2144	Hypertension and Diabetes Mellitus. , 2007, , 406-417.		4
2145	Metabolic Effects of a Conversion from Rosiglitazone to Pioglitazone in Native American Patients with Type 2 Diabetes. Baylor University Medical Center Proceedings, 2007, 20, 349-353.	0.2	3
2146	Target Blood Pressure in Hypertension Treatment: The J-shaped Curve Controversy. , 2007, , 1113-1118.		0
2147	Preventing microalbuminuria in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 100-110.	1.7	18
2148	Effectiveness of a specialist nurse-led intervention clinic in the management of cardiovascular risk factors in diabetes. European Diabetes Nursing, 2007, 4, 100-105.	0.2	8
2149	Preventing another event: Role of the hospitalist in discharge stroke prevention. Journal of Hospital Medicine, 2007, 2, 31-38.	0.7	1
2150	Changing illness perceptions in patients with poorly controlled type 2 diabetes, a randomised controlled trial of a family-based intervention: protocol and pilot study. BMC Family Practice, 2007, 8, 36.	2.9	40
2151	Peer support in type 2 diabetes: a randomised controlled trial in primary care with parallel economic and qualitative analyses: pilot study and protocol. BMC Family Practice, 2007, 8, 45.	2.9	36
2152	Primary care management of diabetes in a low/middle income country: A multi-method, qualitative study of barriers and facilitators to care. BMC Family Practice, 2007, 8, 63.	2.9	42
2153	Microalbuminuria among Type 1 and Type 2 diabetic patients of African origin in Dar Es Salaam, Tanzania. BMC Nephrology, 2007, 8, 2.	0.8	49
2154	Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmology, 2007, 7, 11.	0.6	74
2155	Clinical and medication profiles stratified by household income in patients referred for diabetes care. Cardiovascular Diabetology, 2007, 6, 11.	2.7	19
2156	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998â€“2004: a longitudinal observational study. Cardiovascular Diabetology, 2007, 6, 25.	2.7	20
2157	Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovascular Diabetology, 2007, 6, 33.	2.7	14
2158	The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada. Implementation Science, 2007, 2, 37.	2.5	18
2159	Nurse-led management of uncontrolled hypertension in those with diabetes and high vascular risk. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 92-96.	0.2	3

#	ARTICLE	IF	CITATIONS
2160	Investing in excellent diabetes care now could avert a future NHS cash crisis. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2007, 24, 179-180.	0.2	0
2161	Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997â€“2003. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 412-421.	0.9	27
2162	Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. <i>Nature Medicine</i> , 2007, 13, 181-188.	15.2	304
2163	Blood pressure control in type II diabetics with diabetic retinopathy. <i>Eye</i> , 2007, 21, 708-711.	1.1	15
2164	The relevance of blood pressure measurements in patients attending a diabetic eye clinic: the use of an electronic patient record. <i>Eye</i> , 2007, 21, 1450-1450.	1.1	0
2165	Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070116065049004.	2.2	8
2166	Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 781-791.	2.2	131
2167	The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. <i>Diabetic Medicine</i> , 2007, 24, 137-144.	1.2	306
2168	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	1.2	88
2169	Achievement of metabolic targets for diabetes by English primary care practices under a new system of incentives. <i>Diabetic Medicine</i> , 2007, 24, 505-511.	1.2	67
2170	The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. <i>Diabetic Medicine</i> , 2007, 24, 677-683.	1.2	154
2171	Quality of diabetes care in the UK: comparison of published qualityâ€ofâ€care reports with results of the Quality and Outcomes Framework for Diabetes. <i>Diabetic Medicine</i> , 2007, 24, 1436-1441.	1.2	90
2172	Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease (Review Article). <i>Nephrology</i> , 2007, 12, 81-89.	0.7	33
2173	Diabetes: advances in treatment. <i>Internal Medicine Journal</i> , 2007, 37, 383-388.	0.5	15
2174	Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies?. <i>Acta Ophthalmologica</i> , 2007, 85, 772-776.	0.4	22
2175	Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study. <i>Journal of Clinical Periodontology</i> , 2007, 34, 46-52.	2.3	152
2176	Lack of management of cardiovascular risk factors in type 2 diabetic patients. <i>International Journal of Clinical Practice</i> , 2007, 61, 39-44.	0.8	4
2177	Diabetic macular oedema: a clinical overview. <i>International Journal of Clinical Practice</i> , 2007, 61, 88-97.	0.8	66

#	ARTICLE	IF	CITATIONS
2178	Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. <i>International Journal of Clinical Practice</i> , 2007, 61, 909-915.	0.8	81
2179	Cardiovascular risk management and its impact in Australian general practice patients with type 2 diabetes in urban and rural areas. <i>International Journal of Clinical Practice</i> , 2008, 62, 53-58.	0.8	17
2180	Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. <i>International Journal of Clinical Practice</i> , 2008, 62, 287-299.	0.8	15
2181	Systemic Hypertension. <i>Current Problems in Cardiology</i> , 2007, 32, 201-259.	1.1	99
2182	Diabetes Care for Patients with Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 33, 583-591.	0.8	29
2183	Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor α and Peroxisome Proliferator-Activated Receptor γ Agonists. <i>American Journal of Cardiology</i> , 2007, 99, 27-40.	0.7	119
2184	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189
2185	Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S44-S55.	0.7	125
2186	Rationale, Design, and Methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). <i>American Journal of Cardiology</i> , 2007, 99, S103-S111.	0.7	62
2187	Why Is Blood Pressure So Hard to Control in Patients With Type 2 Diabetes?. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 114-118.	1.7	16
2188	Combination of Chromium and Biotin Improves Coronary Risk Factors in Hypercholesterolemic Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blind Randomized Clinical Trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 91-97.	1.7	35
2189	A Practical Guide for Aggressive Management of Type 2 Diabetes. <i>Journal for Nurse Practitioners</i> , 2007, 3, 259-270.	0.4	2
2190	Diabetic macular edema and its relationship to renal microangiopathy: a sample of Type I diabetes mellitus patients in a 15-year follow-up study. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 172-180.	1.2	33
2191	Antihypertensive Therapy in the Presence of Proteinuria. <i>American Journal of Kidney Diseases</i> , 2007, 49, 12-26.	2.1	671
2193	Comprehensive management of cardiometabolic risk factors. <i>Clinical Cornerstone</i> , 2007, 8, 69-80.	1.0	3
2194	Tratamiento de la hipertensi3n arterial en el enfermo mayor con nefropat3a diab3tica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2007, 7, 54A-62A.	0.2	0
2195	Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. <i>Free Radical Research</i> , 2007, 41, 1151-1158.	1.5	31
2197	Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. <i>Diabetologia</i> , 2007, 50, 250-258.	2.9	50

#	ARTICLE	IF	CITATIONS
2198	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.	2.9	422
2199	Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. <i>Diabetologia</i> , 2007, 50, 2388-2397.	2.9	186
2200	Combination pharmacotherapy in hypertension. <i>International Urology and Nephrology</i> , 2007, 38, 673-682.	0.6	2
2201	The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 541-545.	1.4	19
2202	Cardiovascular disease risk in youth with diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 197-204.	2.6	28
2203	The association of early atherosclerosis and retinopathy in adolescents with type 1 diabetes: preliminary report. <i>Acta Diabetologica</i> , 2007, 44, 131-137.	1.2	18
2205	The impact of diabetes on heart failure: Opportunities for intervention. <i>Current Heart Failure Reports</i> , 2007, 4, 70-77.	1.3	5
2206	JNC-7 guidelines: Are they still relevant?. <i>Current Hypertension Reports</i> , 2007, 9, 380-386.	1.5	8
2207	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. <i>Current Hypertension Reports</i> , 2007, 9, 393-402.	1.5	8
2209	Race-based therapeutics. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 108-117.	0.8	0
2210	Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?. <i>Journal of General Internal Medicine</i> , 2007, 22, 215-222.	1.3	89
2211	Patient Complexity: More Than Comorbidity. The Vector Model of Complexity. <i>Journal of General Internal Medicine</i> , 2007, 22, 382-390.	1.3	268
2216	Early diagnosis and prevention of diabetes in developing countries. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2008, 9, 193-201.	2.6	46
2217	Cardiovascular Prevention in Patients with Diabetes and Prediabetes. <i>Herz</i> , 2008, 33, 170-177.	0.4	16
2218	Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. <i>Diabetologia</i> , 2008, 51, 1127-1134.	2.9	86
2219	Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case-control study. <i>Diabetologia</i> , 2008, 51, 1664-1670.	2.9	37
2222	ADVANCE in management of vascular complications of diabetes. <i>Current Hypertension Reports</i> , 2008, 10, 255-257.	1.5	0
2223	Race-based therapeutics. <i>Current Hypertension Reports</i> , 2008, 10, 276-285.	1.5	18

#	ARTICLE	IF	CITATIONS
2224	Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 12-19.	2.0	23
2225	Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. <i>Advances in Therapy</i> , 2008, 25, 752-774.	1.3	29
2226	Failure to Intensify Antihypertensive Treatment by Primary Care Providers: A Cohort Study in Adults with Diabetes Mellitus and Hypertension. <i>Journal of General Internal Medicine</i> , 2008, 23, 543-550.	1.3	51
2227	Predictors of Sustained Walking among Diabetes Patients in Managed Care: The Translating Research into Action for Diabetes (TRIAD) Study. <i>Journal of General Internal Medicine</i> , 2008, 23, 1194-1199.	1.3	3
2228	Weight Change and Glycemic Control After Diagnosis of Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2008, 23, 1339-1345.	1.3	23
2229	Missed Opportunities in Diabetes Management: A Longitudinal Assessment of Factors Associated with Sub-optimal Quality. <i>Journal of General Internal Medicine</i> , 2008, 23, 1770-1777.	1.3	23
2230	Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 706-716.	1.3	138
2231	Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 2670-2678.	1.3	74
2232	Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2008, 7, 1.	2.7	24
2233	Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). <i>Cardiovascular Diabetology</i> , 2008, 7, 10.	2.7	38
2234	Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse waveform. <i>Cardiovascular Diabetology</i> , 2008, 7, 11.	2.7	24
2235	A group randomized trial of a complexity-based organizational intervention to improve risk factors for diabetes complications in primary care settings: study protocol. <i>Implementation Science</i> , 2008, 3, 15.	2.5	18
2236	Improving eye care for veterans with diabetes: An example of using the QUERI steps to move from evidence to implementation: QUERI Series. <i>Implementation Science</i> , 2008, 3, 18.	2.5	12
2237	Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 54-58.	0.2	1
2238	Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 76-79.	0.2	16
2239	Institute of Diabetes for Older People: surviving a sweet old age. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 221-222.	0.2	1
2240	Advances in diabetes care?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 258-260.	0.2	1
2241	The management of type 1 diabetes: more than just glycaemic control?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 285-289.	0.2	1

#	ARTICLE	IF	CITATIONS
2242	Amputations in diabetes: a changing scene. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 297-299.	0.2	3
2243	Hypertension management in diabetic patients: prescribing trends from 1999 to 2005 in three Japanese university hospitals. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 904-911.	0.9	10
2244	Diabetic retinopathy: a review. <i>Drug Development Research</i> , 2008, 69, 1-14.	1.4	25
2245	Current and Future Status of Beta-blockers in the Treatment of Hypertension. <i>Clinical Cardiology</i> , 2008, 31, 249-252.	0.7	27
2246	Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. <i>Mount Sinai Journal of Medicine</i> , 2008, 75, 558-566.	1.9	13
2247	Update on diabetes mellitus: prevention, treatment, and association with oral diseases. <i>Oral Diseases</i> , 2008, 14, 105-114.	1.5	87
2248	Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. <i>International Journal of Clinical Practice</i> , 2008, 62, 781-790.	0.8	35
2249	Retinal ganglion cells in diabetes. <i>Journal of Physiology</i> , 2008, 586, 4401-4408.	1.3	341
2250	ADVANCES IN REDUCING THE BURDEN OF VASCULAR DISEASE IN TYPE 2 DIABETES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 434-437.	0.9	6
2251	Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHEUS. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 492-497.	2.2	58
2252	Retinopathy in subjects with impaired fasting glucose: the NANSY Eye baseline report. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 646-651.	2.2	26
2253	Isosteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KK Δ mouse. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 939-949.	2.2	39
2254	Prescription charge exemption and Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2008, 25, 113-114.	1.2	1
2255	Blood pressure means rather than nocturnal dipping pattern are related to complications in Type 2 diabetic patients. <i>Diabetic Medicine</i> , 2008, 25, 308-313.	1.2	29
2256	An effective system of nurse-led diabetes care in rural Africa. <i>Diabetic Medicine</i> , 2008, 25, 606-611.	1.2	61
2257	Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. <i>Diabetic Medicine</i> , 2008, 25, 536-542.	1.2	91
2258	Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. <i>Diabetic Medicine</i> , 2008, 25, 631-634.	1.2	13
2259	Glycaemic control in Type 2 diabetes—not for sidelining. <i>Diabetic Medicine</i> , 2008, 25, 639-642.	1.2	1

#	ARTICLE	IF	CITATIONS
2260	Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. <i>Diabetic Medicine</i> , 2008, 25, 25-29.	1.2	143
2261	UKPDS's modelling of cardiovascular risk assessment and lifetime simulation of outcomes. <i>Diabetic Medicine</i> , 2008, 25, 41-46.	1.2	28
2262	Impact of the UKPDS's an overview. <i>Diabetic Medicine</i> , 2008, 25, 2-8.	1.2	30
2263	The UKPDS and its global impact. <i>Diabetic Medicine</i> , 2008, 25, 57-62.	1.2	38
2264	The Hypertension in Diabetes Study (HDS): a catalyst for change. <i>Diabetic Medicine</i> , 2008, 25, 13-19.	1.2	14
2265	What else adds to hypertension in predicting stroke? An incident case's referent study. <i>Journal of Internal Medicine</i> , 2000, 248, 475-482.	2.7	1
2266	Prevention of cardiovascular disease and diabetes: lessons from the Malm's Preventive Project. <i>Journal of Internal Medicine</i> , 2000, 248, 455-462.	2.7	1
2267	Cardiovascular disease in type's 2 diabetes: challenge for treatment and prevention. <i>Journal of Internal Medicine</i> , 2001, 249, 225-235.	2.7	6
2268	Blood pressure in diabetic nephropathy's current controversies. <i>Journal of Internal Medicine</i> , 2001, 249, 215-223.	2.7	0
2269	Choice of first antihypertensive's comparison between the Irish and Dutch setting. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 313-315.	1.1	1
2270	Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: A follow up study. <i>BMC Health Services Research</i> , 2008, 8, 189.	0.9	25
2271	Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study. <i>BMC Health Services Research</i> , 2008, 8, 226.	0.9	17
2272	Type 2 Diabetes Mellitus and Heart Failure. <i>Pharmacotherapy</i> , 2008, 28, 170-192.	1.2	29
2273	Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 455-463.	1.3	60
2274	Beneficial effect of <i>Embelia ribes</i> ethanolic extract on blood pressure and glycosylated hemoglobin in streptozotocin-induced diabetes in rats. <i>F's-terap's</i> , 2008, 79, 351-355.	1.1	26
2275	Delivery of Multifactorial Interventions by Nurse and Dietitian Teams in a Community Setting to Prevent Diabetic Complications: A Quality-Improvement Report. <i>American Journal of Kidney Diseases</i> , 2008, 51, 425-434.	2.1	29
2276	Harnessing endocrine physiology for better clinical outcomes. <i>Clinical Cornerstone</i> , 2008, 9, S28-S40.	1.0	0
2277	Implicaciones del estudio ONTARGET en hipertensi'sn arterial y diabetes tipo 2. <i>Revista Espanola De Cardiologia Suplementos</i> , 2008, 8, 56E-62E.	0.2	0

#	ARTICLE	IF	CITATIONS
2279	Initial Combination Therapy Compared With Monotherapy in Diabetic Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 668-676.	1.0	13
2280	Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy. <i>Journal of Clinical Hypertension</i> , 2008, 10, 761-769.	1.0	21
2281	β-Blockers in the Treatment of Hypertension: New Data, New Directions. <i>Journal of Clinical Hypertension</i> , 2008, 10, 234-238.	1.0	7
2282	Blood Pressure Control in Patients With Comorbidities. <i>Journal of Clinical Hypertension</i> , 2008, 10, 624-631.	1.0	34
2283	Association between diabetes patients' knowledge about medications and their blood glucose control. <i>Research in Social and Administrative Pharmacy</i> , 2008, 4, 37-45.	1.5	84
2284	A Review of Therapeutic Strategies for Risk Reduction of Recurrent Stroke. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 264-273.	1.6	13
2285	Selective 5-HT ₆ receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. , 2008, 117, 207-231.		174
2286	Diabetic retinopathy and systemic vascular complications. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 161-176.	7.3	187
2287	Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2008, 22, 164-170.	1.2	32
2288	Predictors of postoperative complications in the patient with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2008, 22, 24-28.	1.2	15
2289	Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1552-1562.	0.9	9
2290	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2010, 2010, CD006739.	1.5	175
2291	Those who aren't what we call them. <i>Optometry - Journal of the American Optometric Association</i> , 2008, 79, 709-711.	0.6	0
2292	Priorities for diabetes primary care in Europe. <i>Primary Care Diabetes</i> , 2008, 2, 3-8.	0.9	5
2293	Lowering HbA _{1c} in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality. <i>Primary Care Diabetes</i> , 2008, 2, 45-49.	0.9	24
2294	Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney. <i>Primary Care Diabetes</i> , 2008, 2, 201-202.	0.9	1
2296	Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. <i>Medicina Clínica</i> , 2008, 130, 641-644.	0.3	13
2297	The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 95.	1.0	44

#	ARTICLE	IF	CITATIONS
2298	9-Cyano-1-azapallone (Cazpallone), a Glycogen Synthase Kinase-3 (GSK-3) Inhibitor Activating Pancreatic β Cell Protection and Replication. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2196-2207.	2.9	85
2299	Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 580-591.	13.9	3,037
2300	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1577-1589.	13.9	6,543
2301	Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 85-95.	1.0	40
2302	Retinopatía diabética y ceguera en España. <i>Epidemiología y prevención. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2008, 55, 459-475.	0.8	9
2303	Hypertension, Heart Failure, and Beta-Adrenergic Blocking Drugs—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1073-1075.	1.2	3
2304	Renin-angiotensin system blockade in diabetic nephropathy. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 135-158.	1.8	4
2305	Clinical and cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 163-170.	1.8	0
2306	Clinical risk factors and association of hyperhomocysteinemia with diabetic retinopathy in Iranian type 2 diabetes patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 192-201.	1.8	4
2307	Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 301-306.	0.7	16
2308	Review: Stroke prevention: modifying risk factors. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 287-303.	1.0	92
2309	Hypertension and Diabetes—A Toxic Combination. <i>Endocrine Practice</i> , 2008, 14, 1031-1039.	1.1	21
2310	The Kelowna Diabetes Program: Bridging the Gap Between Testing Guidelines and Reality. <i>Canadian Journal of Diabetes</i> , 2008, 32, 107-113.	0.4	11
2311	Systemic Diseases with Renal Manifestations. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, 297-328.	0.7	11
2312	Microvascular and Macrovascular Complications of Diabetes. <i>Clinical Diabetes</i> , 2008, 26, 77-82.	1.2	1,365
2314	Measuring Quality in Pay-for-Performance Programs. <i>Disease Management and Health Outcomes</i> , 2008, 16, 205-216.	0.3	6
2315	Blood pressure control in the year following coronary events. <i>International Journal of Cardiology</i> , 2008, 130, 205-210.	0.8	3
2316	Evaluation of a diabetes management program in China demonstrated association of improved continuity of care with clinical outcomes. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 932-939.	2.4	26

#	ARTICLE	IF	CITATIONS
2317	Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999â€“2004. <i>Annals of Epidemiology</i> , 2008, 18, 222-229.	0.9	206
2318	Prevalence and Risk Factors for Diabetic Retinopathy. <i>Ophthalmology</i> , 2008, 115, 1869-1875.	2.5	354
2319	The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. <i>Ophthalmology</i> , 2008, 115, 1859-1868.	2.5	454
2320	Alcohol and Eye Diseases. <i>Survey of Ophthalmology</i> , 2008, 53, 512-525.	1.7	77
2321	The Importance of Prompt Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2008, 10, 13-19.	1.0	8
2322	Prompt, Aggressive BP Lowering in High-Risk Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 40-48.	1.0	14
2323	Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. <i>Current Therapeutic Research</i> , 2008, 69, 1-15.	0.5	13
2324	To screen or not to screen? High-tech responses to a not so hamletic question. <i>Diabetes and Metabolism</i> , 2008, 34, 189-191.	1.4	1
2325	Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. <i>Diabetes and Metabolism</i> , 2008, 34, 560-567.	1.4	85
2326	Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 377-388.	1.1	66
2327	Quality of diabetes care in Arab Americans. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 249-255.	1.1	19
2328	Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 468-473.	1.1	21
2329	Controlling the ABCs of diabetes in clinical practice: A community-based endocrinology practice experience. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 89-95.	1.1	24
2330	Poor metabolic and blood pressure control in patients with diabetic retinopathy attending a tertiary ophthalmic hospital in Australia. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 208-212.	1.1	10
2331	Risk factors for hospitalization due to diabetes complications. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 244-252.	1.1	25
2332	The gap between guidelines and practice in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2008, 80, 314-320.	1.1	57
2333	Characteristics and blood pressure management in patients with and without diabetes in primary care in rural Victoria. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, 19-24.	1.1	1
2334	Lack of knowledge of glycosylated hemoglobin in patients with diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, e15-e17.	1.1	27

#	ARTICLE	IF	CITATIONS
2335	The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, 127-131.	1.1	36
2337	The progress of coronary heart disease in Type 2 diabetes as measured by coronary calcium score from electron beam computed tomography (EBCT): The PREDICT study. <i>Atherosclerosis</i> , 2008, 197, 777-783.	0.4	22
2339	Manejo general y extrahospitalario del paciente con diabetes. Valoraci3n de la sintomatolog?a. Procesos intercurrentes. <i>Medicine</i> , 2008, 10, 1138-1148.	0.0	2
2340	Protocolo de detecci3n y seguimiento de la retinopat?a diab?tica. <i>Medicine</i> , 2008, 10, 1169-1174.	0.0	0
2341	Monitorizaci3n ambulatoria de presi3n arterial y enfermedad renal cr3nica en pacientes hipertensos diab3ticos tipo 2 y en pacientes hipertensos. <i>Hipertension</i> , 2008, 25, 94-98.	0.0	2
2342	Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect) Tj ETQq1 1 0,784314 rgBT /Oyer 6.3 414	6.3	414
2343	DIRECT new treatments for diabetic retinopathy. <i>Lancet, The</i> , 2008, 372, 1361-1363.	6.3	19
2344	Type 2 diabetes mellitus: prevention of macrovascular complications. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 323-341.	0.6	26
2345	Prevenci3n de la enfermedad cardiovascular en los pacientes diab3ticos: Â¿qu3 hay de nuevo?. <i>Semergen</i> , 2008, 34, 209-213.	0.2	1
2346	Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. <i>Surgery for Obesity and Related Diseases</i> , 2008, 4, 423-429.	1.0	25
2347	Monitorizaci3n ambulatoria de presi3n arterial y enfermedad renal cr3nica en pacientes hipertensos diab3ticos tipo 2 y en pacientes hipertensos. <i>Hipertension Y Riesgo Vascular</i> , 2008, 25, 94-98.	0.3	0
2348	Racial and Ethnic Differences in Trends of End-Stage Renal Disease: United States, 1995 to 2005. <i>Advances in Chronic Kidney Disease</i> , 2008, 15, 147-152.	0.6	54
2349	Caring for the Vulnerable Elderly: Are Available Quality Indicators Appropriate?. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 1-3.	1.2	23
2350	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	0.7	49
2351	Prevalence and Risk Factors of Diabetic Retinopathy in a Multi-Racial Underserved Population. <i>Ophthalmic Epidemiology</i> , 2008, 15, 402-409.	0.8	23
2352	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 47-51.	1.0	4
2353	The Clinical Significance of Blood Pressure Lowering Treatment: Is First-Line Drug Choice Important?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 117-119.	1.0	0
2354	Diabetes in People, Cats, and Dogs: Biomedicine and Manifold Ontologies. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2008, 27, 324-352.	0.6	22

#	ARTICLE	IF	CITATIONS
2355	Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 21-30.	0.1	2
2356	Involvement of Angiotensin II-Dependent Vascular Endothelial Growth Factor Gene Expression via NADPH Oxidase in the Retina in a Type 2 Diabetic Rat Model. <i>Current Eye Research</i> , 2008, 33, 885-891.	0.7	34
2357	Diabetic heart disease. <i>Postgraduate Medical Journal</i> , 2008, 84, 188-192.	0.9	77
2358	Glucose control:What benefit, what cost?. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2008, 14, 14-17.	0.1	2
2359	Complication Reducing Effect of the Information Technology-Based Diabetes Management System on Subjects with Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 76-81.	1.3	11
2360	Proliferative Diabetic Retinopathy. , 2008, , 29-65.		20
2361	Prevention of Coronary Heart Disease in General Practice. <i>InnovAiT</i> , 2008, 1, 14-25.	0.0	0
2362	Effect of Board Certification on Antihypertensive Treatment Intensification in Patients With Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 623-628.	1.6	66
2363	The Paradox of Glycemic Control and Cardiovascular Complications: Sorting Out the Data. <i>Diabetes Spectrum</i> , 2008, 21, 150-152.	0.4	2
2364	Ambulatory Blood Pressure Is a Better Marker Than Clinic Blood Pressure in Predicting Cardiovascular Events in Patients With/Without Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2008, 21, 443-450.	1.0	182
2365	Estimating Physician Effects on Glycemic Control in the Treatment of Diabetes. <i>Diabetes Care</i> , 2008, 31, 869-873.	4.3	53
2366	Impact of White-Coat Hypertension on Microvascular Complications in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2233-2237.	4.3	37
2367	Management of Hypertension in Diabetic Patients With Chronic Kidney Disease. <i>Diabetes Spectrum</i> , 2008, 21, 30-36.	0.4	12
2368	Cardiovascular Risk Education and Social Support (CaRESS): Report of a Randomized Controlled Trial from the Kentucky Ambulatory Network (KAN). <i>Journal of the American Board of Family Medicine</i> , 2008, 21, 269-281.	0.8	14
2369	Screening for type 2 diabetes mellitus in children and adolescents. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 163-168.	0.6	3
2370	Weight Change in Diabetes and Glycemic and Blood Pressure Control. <i>Diabetes Care</i> , 2008, 31, 1960-1965.	4.3	118
2371	Diabetic Retinopathy: More Patients, Less Laser: A longitudinal population-based study in Tayside, Scotland. <i>Diabetes Care</i> , 2008, 31, 1126-1131.	4.3	27
2372	Middle Cerebral Artery Stenosis Increased the Risk of Vascular Disease Mortality among Type 2 Diabetic Patients. <i>Cerebrovascular Diseases</i> , 2008, 25, 261-267.	0.8	20

#	ARTICLE	IF	CITATIONS
2373	Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension. <i>Hypertension Research</i> , 2008, 31, 7-13.	1.5	66
2374	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. <i>Cmaj</i> , 2008, 179, 920-926.	0.9	37
2375	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	1.0	184
2376	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. <i>European Heart Journal</i> , 2008, 29, 2669-2680.	1.0	225
2377	Favorable Trends in the Incidence and Outcome in Stroke in Nondiabetic and Diabetic Subjects. <i>Stroke</i> , 2008, 39, 3137-3144.	1.0	40
2378	The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. <i>Neurological Research</i> , 2008, 30, 669-677.	0.6	3
2379	Effect of Laser Spot Diameter on the Reproducibility of Visual Field Analysis in Diabetic Patients with Upper Temporal Retinal Vein Occlusion. <i>Ophthalmologica</i> , 2008, 222, 64-68.	1.0	0
2380	History and Vision: What is Important for Patients with Diabetes?. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, S-5-S-9.	2.4	7
2381	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1565-1576.	13.9	674
2382	Economic and Clinical Aspects of Diabetes Regarding Self-Monitoring of Blood Glucose. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, S-72-S-81.	2.4	18
2383	Standards of Medical Care in Diabetes—2008. <i>Diabetes Care</i> , 2008, 31, S12-S54.	4.3	1,509
2384	Heritability of Proliferative Diabetic Retinopathy. <i>Diabetes</i> , 2008, 57, 2176-2180.	0.3	155
2385	Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 184-189.	0.9	31
2386	Epidemiology of Diabetes and Diabetes-Related Complications. <i>Physical Therapy</i> , 2008, 88, 1254-1264.	1.1	1,107
2387	Sex Disparities in Control and Treatment of Modifiable Cardiovascular Disease Risk Factors Among Patients With Diabetes. <i>Diabetes Care</i> , 2008, 31, 69-74.	4.3	149
2388	Slowing Nephropathy Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S3-S10.	2.2	103
2390	Clinical features of type 2 diabetes before diagnosis and pathways to the diagnosis: a case-control study. <i>Primary Health Care Research and Development</i> , 2008, 9, .	0.5	0
2391	Article Commentary: The English national screening programme for sight-threatening diabetic retinopathy. <i>Journal of Medical Screening</i> , 2008, 15, 1-4.	1.1	126

#	ARTICLE	IF	CITATIONS
2392	Using placebo in hypertension clinical trials: new information and new opportunities. <i>Journal of Human Hypertension</i> , 2008, 22, 653-655.	1.0	1
2393	Glucometabolic state of in-hospital patients with primary hypertension in sub-population of partial regions in China. <i>Journal of Human Hypertension</i> , 2008, 22, 346-351.	1.0	4
2394	Randomized study of traditional versus aggressive systolic blood pressure control (Cardio-Sis): rationale, design and characteristics of the study population. <i>Journal of Human Hypertension</i> , 2008, 22, 243-251.	1.0	11
2395	Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System. <i>Current Diabetes Reviews</i> , 2008, 4, 63-78.	0.6	6
2396	Practice-Linked Online Personal Health Records for Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1776.	4.3	194
2397	Improving Diabetes Care in Practice. <i>Diabetes Care</i> , 2008, 31, 2238-2243.	4.3	114
2398	Aerobic plus resistance training was more effective than either alone for glycaemic control in type 2 diabetes. <i>Evidence-based Nursing</i> , 2008, 11, 48-48.	0.1	1
2399	Preventing diabetic retinopathy through control of systemic factors. , 2008, , 203-219.		0
2401	Improving Hypertension Control in Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 1361-1368.	1.6	157
2402	Quality of diabetes care among patients managed by teleconsultation. <i>Journal of Telemedicine and Telecare</i> , 2008, 14, 295-299.	1.4	7
2403	Tool to Assess Likelihood of Fasting Glucose Impairment (TAG-IT). <i>Annals of Family Medicine</i> , 2008, 6, 555-561.	0.9	22
2404	Prescribing quality indicators of type 2 diabetes mellitus ambulatory care. <i>Quality and Safety in Health Care</i> , 2008, 17, 318-323.	2.5	31
2406	Ambulatory Blood Pressure vs. Office Blood Pressure in Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2008, 21, 372-372.	1.0	1
2407	Amlodipine Reduces Predicted Risk of Coronary Heart Disease in High-Risk Patients with Hypertension in Spain (The CORONARIA Study). <i>Journal of International Medical Research</i> , 2008, 36, 1399-1417.	0.4	1
2408	Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 316-23.	3.8	1,297
2409	Review: Aldosterone antagonism in type 2 diabetes mellitus "a new therapeutic approach to diabetic macrovascular disease?". <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 16-19.	0.6	0
2410	Chapter 20 Epidemiological implications of primary and secondary stroke prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 92, 389-405.	1.0	0
2412	An Appreciation of Robert Turner. <i>Diabetes</i> , 2008, 57, 2918-2921.	0.3	2

#	ARTICLE	IF	CITATIONS
2413	Future strategies to prevent renal microvascular disease complications in diabetes. <i>Future Cardiology</i> , 2008, 4, 77-83.	0.5	4
2414	Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. <i>Current Medical Research and Opinion</i> , 2008, 24, 2389-2401.	0.9	50
2415	Cardiovascular Disease in Diabetes. <i>Diabetes Care</i> , 2008, 31, 1260-1266.	4.3	20
2416	Improved Survival of Diabetic Foot Ulcer Patients 1995â€“2008. <i>Diabetes Care</i> , 2008, 31, 2143-2147.	4.3	129
2417	Hyperresistinemia Is Associated With Coexistence of Hypertension and Type 2 Diabetes. <i>Hypertension</i> , 2008, 51, 534-539.	1.3	65
2418	Prevention of Heart Failure. <i>Circulation</i> , 2008, 117, 2544-2565.	1.6	485
2419	Diastolic Pressure in Type 2 Diabetes: Can target systolic pressure be reached without "diastolic hypotension"? <i>Diabetes Care</i> , 2008, 31, S249-S254.	4.3	14
2420	Actively Engaging Patients in Treatment Decision Making and Monitoring as a Strategy to Improve Hypertension Outcomes in Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 1355-1357.	1.6	28
2421	Continued High Risk of Stroke in Treated Hypertensives in a General Population: The Jichi Medical School Cohort Study. <i>Hypertension Research</i> , 2008, 31, 1125-1133.	1.5	7
2422	Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2008, 126, 793.	2.6	85
2423	Investigating the links between retinopathy, macular edema and visual acuity in patients with diabetes. <i>Expert Review of Ophthalmology</i> , 2008, 3, 673-688.	0.3	0
2424	Home blood pressure measurements associated with better blood pressure control: the J-HOME study. <i>Journal of Human Hypertension</i> , 2008, 22, 197-204.	1.0	23
2425	UKPDS and the Legacy Effect. <i>New England Journal of Medicine</i> , 2008, 359, 1618-1620.	13.9	221
2426	Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. , 2008, , CD006424.		113
2427	Blood Pressure Is the Main Determinant of the Reflection Wave in Patients with Type 2 Diabetes. <i>Hypertension Research</i> , 2008, 31, 493-499.	1.5	17
2428	Emerging drugs for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 675-694.	1.0	29
2429	Eye on Diabetes. <i>The Diabetes Educator</i> , 2008, 34, 84-89.	2.6	8
2430	Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus. <i>Hypertension Research</i> , 2008, 31, 43-50.	1.5	23

#	ARTICLE	IF	CITATIONS
2431	Impact of Behavioral Adherence on Clinical Improvement and Functional Status in a Diabetes Disease Management Program. <i>Disease Management: DM</i> , 2008, 11, 169-175.	1.0	7
2432	The management of the type 2 diabetic patient with hypertension "too late and too little: Suggested improvements. <i>Blood Pressure</i> , 2008, 17, 250-259.	0.7	7
2433	The eye in hypertension. <i>Yearbook of Cardiology</i> , 2008, 2008, 53-54.	0.0	0
2434	Myogenic tone and small artery remodelling: insight into diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 361-369.	0.4	38
2435	Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy. <i>American Journal of the Medical Sciences</i> , 2008, 335, 284-291.	0.4	67
2436	Peripheral arterial disease in patients with diabetes mellitus. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2008, 69, 570-574.	0.2	3
2437	Effects of diabetes, patient age, and health insurance provider on the number of drugs ordered or provided per physician visit in the USA. <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , 2008, 2, 143-153.	0.7	0
2438	Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT. <i>European Heart Journal Supplements</i> , 2008, 10, G21-G28.	0.0	0
2439	Blood pressure lowering with fixed combination perindopril"indapamide: key findings from ADVANCE. <i>Journal of Hypertension</i> , 2008, 26, S11-S15.	0.3	7
2440	Le profil du patient diabétique de type 2 en France et en Italie. <i>Journal of Hypertension</i> , 2008, 26, S3-S6.	0.3	2
2441	The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 114-125.	2.2	300
2442	Efficacité et tolérance de l'association fixe perindopril / indapamide dans le diabète de type 2: résultats de l'étude ADVANCE. <i>Journal of Hypertension</i> , 2008, 26, S23-S30.	0.3	3
2443	Applications de l'étude ADVANCE en pratique clinique. <i>Journal of Hypertension</i> , 2008, 26, S31-S34.	0.3	4
2444	Influence of microalbuminuria in achieving blood pressure goals. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 457-463.	1.0	16
2445	Development of heart failure in recent hypertension trials. <i>Journal of Hypertension</i> , 2008, 26, 1477-1486.	0.3	105
2446	Management of Metabolic Syndrome in Young Population. <i>American Journal of Therapeutics</i> , 2008, 15, 356-361.	0.5	11
2447	Contrôle tensionnel, facteurs de risque et pronostic cardiovasculaire du patient diabétique: 30 ans de progrès. <i>Journal of Hypertension</i> , 2008, 26, S7-S14.	0.3	27
2448	Using a Multidisciplinary Team and Clinical Redesign to Improve Blood Pressure Control in Patients With Diabetes. <i>Quality Management in Health Care</i> , 2008, 17, 227-233.	0.4	14

#	ARTICLE	IF	CITATIONS
2449	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. <i>Current Opinion in Cardiology</i> , 2008, 23, 502-511.	0.8	39
2450	Secondary Stroke Prevention. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 34-41.	0.6	22
2451	Relationships of Religion and Spirituality to Glycemic Control in Black Women With Type 2 Diabetes. <i>Nursing Research</i> , 2008, 57, 331-339.	0.8	55
2452	Preventing Diabetic Retinopathy in Primary Care. <i>Nurse Practitioner</i> , 2008, 33, 46-47.	0.2	1
2453	Normal blood glucose regulation and diabetes. , 0, , 35-49.		0
2454	Management of increased cardiovascular risk. , 0, , 148-174.		0
2455	Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. <i>Journal of Hypertension</i> , 2008, 26, S7-S13.	0.3	14
2456	Fixed combinations in the management of hypertension: perspectives on lercanidipine & enalapril. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 847-853.	1.0	16
2459	Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2008, 148, 400.	2.0	5
2460	Diabetic retinopathy is associated with early autonomic dysfunction assessed by exercise-related heart rate changes. <i>Brazilian Journal of Medical and Biological Research</i> , 2008, 41, 1110-1115.	0.7	15
2461	The hidden cost of switching medication. <i>British Journal of Health Care Management</i> , 2008, 14, 324-328.	0.1	0
2462	Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. <i>Journal of Hypertension</i> , 2008, 26, S21-S27.	0.3	5
2463	Hypertension and Diabetes: Critical Comorbidities. <i>Journal for Vascular Ultrasound</i> , 2008, 32, 17-20.	0.2	0
2464	Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a236-a236.	2.4	92
2465	Development of Risk Simulation Software for Outcome Prediction and Economic Assessment of Diabetes Mellitus. <i>Asian Pacific Journal of Disease Management</i> , 2008, 2, 111-118.	0.3	0
2467	Changes in Incidence of Diabetes Mellitus-Related Eye Disease Among US Elderly Persons, 1994-2005. <i>JAMA Ophthalmology</i> , 2008, 126, 1548.	2.6	38
2468	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
2469	Estudo comparativo da evoluçÃo e sobrevida de pacientes com claudicaçÃo intermitente, com ou sem limitaçÃo para exercÃcios, acompanhados em ambulatÃrio especÃfico. <i>Jornal Vascular Brasileiro</i> , 2008, 7, 112-122.	0.1	8

#	ARTICLE	IF	CITATIONS
2470	Investigation of cardiovascular risk factors in type 2 diabetes in a rural Australian Division of General Practice. Medical Journal of Australia, 2008, 189, 86-89.	0.8	4
2471	Implications of the ADVANCE study for clinical practice. Journal of Hypertension, 2008, 26, S29-S32.	0.3	2
2472	Profile of patients with type 2 diabetes in France and Italy. Journal of Hypertension, 2008, 26, S3-S6.	0.3	1
2473	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 190, 180-184.	0.8	45
2474	Diabetes Mellitus in the Older Adult. , 0, , 79-88.		0
2476	Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangladesh Medical Research Council Bulletin, 2009, 35, 44-48.	0.1	3
2477	Assist�ncia ao diabetes no Sistema P�blico de Sa�de: an�lise do modelo atual. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 37-48.	1.2	16
2478	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vascular Health and Risk Management, 2009, 5, 411.	1.0	39
2479	Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Frontiers in Bioscience - Landmark, 2009, Volume, 3974.	3.0	100
2480	Effects of efforts to intensify management on blood pressure control among patients with type 2 diabetes mellitus and hypertension: A pilot study. Vascular Health and Risk Management, 2009, 5, 705.	1.0	12
2481	Effects of Pitavastatin on Serum Lipids and High Sensitivity C-Reactive Protein in Type 2 Diabetic Patients. Journal of Atherosclerosis and Thrombosis, 2009, 16, 546-552.	0.9	20
2482	Surgical Treatment of Carotid Disease. , 2009, , 606-629.		0
2483	Metabolic Surgery For Treatment Of Type 2 Diabetes Mellitus. Endocrine Practice, 2009, 15, 624-631.	1.1	19
2484	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 883-892.	3.0	245
2485	Benefits of ACE Inhibitors in Diabetes. Clinical Medicine Therapeutics, 2009, 1, CMT.S2027.	0.1	8
2486	Quality of Diabetes Care at a Student-Run Free Clinic. Journal of Health Care for the Poor and Underserved, 2009, 20, 969-981.	0.4	61
2487	Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vascular Health and Risk Management, 2009, 5, 859.	1.0	30
2489	Antioxidant effect of garlic and aged black garlic in animal model of type 2 diabetes mellitus. Nutrition Research and Practice, 2009, 3, 156.	0.7	130

#	ARTICLE	IF	CITATIONS
2490	Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis. PLoS ONE, 2009, 4, e4144.	1.1	315
2491	Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema. Korean Journal of Ophthalmology: KJO, 2009, 23, 17.	0.5	24
2492	Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 39-46.	0.6	58
2493	A risk management partnership. Practice Nursing, 2009, 20, 86-90.	0.1	9
2494	Diabetic Retinopathy Screening Update. Clinical Diabetes, 2009, 27, 140-145.	1.2	82
2495	Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Current Medical Research and Opinion, 2009, 25, 1197-1207.	0.9	32
2496	Rosiglitazone in Canada: experience in clinical practice. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 441-448.	1.5	1
2497	Diabetic Retinal Neurodegeneration Is Associated With Mitochondrial Oxidative Stress and Is Improved by an Angiotensin Receptor Blocker in a Model Combining Hypertension and Diabetes. Diabetes, 2009, 58, 1382-1390.	0.3	123
2498	Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. Circulation, 2009, 120, 212-220.	1.6	223
2499	Reexamining Misconceptions About β -Blockers in Patients With Diabetes. Clinical Diabetes, 2009, 27, 36-46.	1.2	5
2500	Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy, 2009, 7, 1349-1361.	0.6	12
2501	Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care, 2009, 32, 1556-1562.	4.3	124
2502	How to Define Prehypertension in Diabetes/Metabolic Syndrome. Diabetes Care, 2009, 32, S275-S279.	4.3	5
2503	Combination Effects of Enalapril and Losartan on Lipid Peroxidation in the Kidneys of KK-A ^{yc} /Ta Mice. Nephron Experimental Nephrology, 2009, 113, e66-e76.	2.4	21
2504	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, e391-479.	1.6	2,001
2505	Identification of Compounds That Inhibit IGF-I Signaling in Hyperglycemia. Experimental Diabetes Research, 2009, 2009, 1-10.	3.8	9
2506	Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Family Practice, 2009, 26, 428-436.	0.8	76
2507	Telemedicine Influence on the Follow-Up of Type 2 Diabetes Patients. Diabetes Technology and Therapeutics, 2009, 11, 431-437.	2.4	67

#	ARTICLE	IF	CITATIONS
2508	Recent clinical trials in diabetes – implications for managing older patients. <i>Reviews in Clinical Gerontology</i> , 2009, 19, 25-33.	0.5	0
2509	Personalized care planning for diabetes: policy lessons from systematic reviews of consultation and self-management interventions. <i>Primary Health Care Research and Development</i> , 2009, 10, 210.	0.5	17
2510	Beyond Health Information Technology: Critical Factors Necessary for Effective Diabetes Disease Management. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 452-460.	1.3	21
2511	Should We Treat Prehypertension in Diabetes?: What are the cons?. <i>Diabetes Care</i> , 2009, 32, S280-S283.	4.3	4
2512	Changes in Albumin Excretion in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2009, 32, 720-725.	4.3	22
2513	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. <i>Circulation</i> , 2009, 120, 1296-1336.	1.6	117
2514	Targeting blood pressure in the management of total cardiovascular risk. <i>European Heart Journal Supplements</i> , 2009, 11, F27-F32.	0.0	3
2515	Improving Microvascular Outcomes in Patients with Diabetes through Management of Hypertension. <i>Postgraduate Medicine</i> , 2009, 121, 89-101.	0.9	37
2516	Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder. <i>Postgraduate Medicine</i> , 2009, 121, 68-81.	0.9	25
2517	Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1. <i>Hypertension Research</i> , 2009, 32, 770-774.	1.5	17
2518	EGFR-PLC β 1 signaling mediates high glucose-induced PKC δ 1-Akt activation and collagen I upregulation in mesangial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F822-F834.	1.3	28
2519	Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2286-2287.	0.4	1
2520	Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E889-E897.	1.8	20
2521	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	4.3	230
2522	Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 686-697.	0.8	20
2523	Prevalence of Diabetes Mellitus, Glycemic Control, and Associated Factors in a Malay Population in Singapore. <i>Asia-Pacific Journal of Public Health</i> , 2009, 21, 385-398.	0.4	30
2524	The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2975-2983.	0.4	11
2525	Improvement of Blood Pressure Control in a Hypertension Clinic in Japan: A 15-Year Follow-Up Study. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 553-559.	0.5	8

#	ARTICLE	IF	CITATIONS
2526	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. <i>Cmaj</i> , 2009, 181, 37-44.	0.9	179
2527	The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2009, 121, 94-107.	0.9	80
2528	Green tea (<i>Camellia sinensis</i>) Attenuates Nephropathy by Downregulating Nox4 NADPH Oxidase in Diabetic Spontaneously Hypertensive Rats. <i>Journal of Nutrition</i> , 2009, 139, 96-100.	1.3	59
2529	Antioxidant SOD Mimetic Prevents NADPH Oxidase-Induced Oxidative Stress and Renal Damage in the Early Stage of Experimental Diabetes and Hypertension. <i>American Journal of Nephrology</i> , 2009, 29, 309-318.	1.4	69
2530	Health Technologies for Monitoring and Managing Diabetes: A Systematic Review. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1460-1471.	1.3	77
2532	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.3	1,236
2533	Secular Trends in Diabetes-Related Preventable Hospitalizations in the United States, 1998-2006. <i>Diabetes Care</i> , 2009, 32, 1213-1217.	4.3	53
2534	Community Pharmacists Provided Extended Diabetes Care. <i>Annals of Pharmacotherapy</i> , 2009, 43, 882-889.	0.9	70
2535	Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1565.	3.8	928
2536	Eutrophic Remodeling of Small Arteries in Type 1 Diabetes Mellitus Is Enabled by Metabolic Control. <i>Hypertension</i> , 2009, 54, 134-141.	1.3	25
2537	Stevioside and related compounds: Therapeutic benefits beyond sweetness. , 2009, 121, 41-54.		324
2538	An update on preventive and regenerative therapies in diabetes mellitus. , 2009, 121, 317-331.		47
2539	Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 273-282.	1.2	36
2540	Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 160-166.	1.2	30
2541	Diabetes mellitus and cerebrovascular disease: which are the actual data?. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 283-296.	1.2	23
2542	Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 185-193.	1.2	50
2543	Trends in cardiovascular risk factors and lifestyle behaviors among Spanish adults with diabetes (1993-2003). <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 394-400.	1.2	11
2544	Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 349-359.	1.2	18

#	ARTICLE	IF	CITATIONS
2545	The ADDITION-Cambridge trial protocol: a cluster " randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. <i>BMC Public Health</i> , 2009, 9, 136.	1.2	75
2546	Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): trial protocol. <i>BMC Public Health</i> , 2009, 9, 63.	1.2	10
2547	Diabetes Control and Cardiovascular Risk, Part II: Intensive Glucose Control " UKPDS Follow-up. <i>Preventive Cardiology</i> , 2009, 12, 51-58.	1.1	1
2548	Computer Confirmation of Improved Blood Pressure Control in Diabetic Patients. <i>Preventive Cardiology</i> , 2009, 12, 149-154.	1.1	0
2549	ADVANCE: Blood Pressure Lowering in Diabetes. <i>Journal of Clinical Hypertension</i> , 2009, 11, 109-110.	1.0	0
2550	Cost Effectiveness Analysis of a Hypertension Management Program in Patients With Type 2 Diabetes. <i>Journal of Clinical Hypertension</i> , 2009, 11, 116-124.	1.0	8
2551	Blood Pressure Goals and Arterial Stiffness in Chronic Kidney Disease. <i>Journal of Clinical Hypertension</i> , 2009, 11, 201-206.	1.0	5
2552	Lower Blood Pressure Goals for Cardiovascular and Renal Risk Reduction: Are They Defensible?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 345-347.	1.0	10
2553	Association of Glycemic Control with Risk of Erectile Dysfunction in Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2009, 6, 1719-1728.	0.3	68
2554	Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: A retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. <i>Clinical Therapeutics</i> , 2009, 31, 1946-1956.	1.1	5
2555	Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: Potential roles of vascular endothelial growth factor and nitric oxide. <i>European Journal of Pharmacology</i> , 2009, 606, 187-190.	1.7	14
2556	The Kidney Disease Initiative and the Division of Diabetes Translation at the Centers for Disease Control and Prevention. <i>American Journal of Kidney Diseases</i> , 2009, 53, S121-S125.	2.1	16
2558	Investing time in health: do socioeconomically disadvantaged patients spend more or less extra time on diabetes self-care?. <i>Health Economics (United Kingdom)</i> , 2009, 18, 645-663.	0.8	27
2559	The understanding of terms in evidence-based medicine: a pilot study. <i>European Diabetes Nursing</i> , 2009, 6, 95-99.	0.2	1
2560	Circulatory parameters in the retrobulbar central retinal artery and vein of patients with diabetes and medically treated systemic hypertension. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 53-58.	1.0	10
2561	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.0	83
2562	Morphometry of surgically removed internal limiting membrane during vitrectomy in diabetic macular edema. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1307-1314.	1.0	9
2563	Anemia and hypertension are risk factors for both renal prognosis and survival in patients with diabetes mellitus. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 473-479.	0.7	8

#	ARTICLE	IF	CITATIONS
2564	Evidence-based Practice Guideline for the Treatment of CKD. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 537-566.	0.7	106
2565	Exercise therapy in Type 2 diabetes. <i>Acta Diabetologica</i> , 2009, 46, 263-278.	1.2	101
2566	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. <i>Acta Diabetologica</i> , 2009, 46, 173-181.	1.2	22
2568	More Clinical Lessons from the FIELD Study. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 235-241.	1.3	8
2569	Improvement of diabetes indices of care by a short pharmaceutical care program. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 689-695.	1.4	19
2570	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	0.8	14
2571	Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. <i>Current Diabetes Reports</i> , 2009, 9, 229-237.	1.7	10
2572	Retinal vascular changes and diabetic retinopathy. <i>Current Diabetes Reports</i> , 2009, 9, 277-283.	1.7	88
2573	Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?. <i>Current Hypertension Reports</i> , 2009, 11, 363-367.	1.5	1
2574	Effect of blood pressure lowering on markers of kidney disease progression. <i>Current Hypertension Reports</i> , 2009, 11, 368-374.	1.5	4
2575	Trends in hypertension treatment in diabetes. <i>Current Hypertension Reports</i> , 2009, 11, 437-443.	1.5	1
2577	Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2009, 19, 357-362.	1.1	102
2578	Key priorities in managing glucose control in older people with diabetes. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 685-691.	1.5	36
2579	Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 50-59.	2.9	70
2580	Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 2027-2036.	2.9	150
2582	Obesity and Diabetes: The Impact of Bariatric Surgery on Type 2 Diabetes. <i>World Journal of Surgery</i> , 2009, 33, 2014-21.	0.8	55
2583	Algorithm for the introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2009, 26, 70-77.	0.2	13
2584	Risk factors for visual impairment registration due to diabetic retinopathy in Leeds, 2002-2005. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2009, 26, 103-106.	0.2	2

#	ARTICLE	IF	CITATIONS
2585	Quality of diabetes care in India, China, Brazil, Mexico and Russia. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2009, 26, 195.	0.2	5
2586	Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 983-991.	0.9	52
2587	DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. <i>BMC Endocrine Disorders</i> , 2009, 9, 13.	0.9	1
2588	Diabetes prevalence and diagnosis in US states: analysis of health surveys. <i>Population Health Metrics</i> , 2009, 7, 16.	1.3	102
2589	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. <i>Implementation Science</i> , 2009, 4, 41.	2.5	42
2590	Multiple goals and time constraints: perceived impact on physicians' performance of evidence-based behaviours. <i>Implementation Science</i> , 2009, 4, 77.	2.5	50
2591	A combined diabetes renal clinic improves risk factor management and progression of renal disease in a district general hospital. <i>Journal of Evaluation in Clinical Practice</i> , 2009, 15, 832-835.	0.9	10
2592	Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 861-874.	1.1	72
2593	Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy. <i>Eye</i> , 2009, 23, 209-214.	1.1	5
2594	Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?. <i>Eye</i> , 2009, 23, 997-1003.	1.1	21
2595	Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. <i>Eye</i> , 2009, 23, 1496-1508.	1.1	282
2596	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 417-430.	21.5	285
2597	Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 140-148.	1.4	40
2598	Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. <i>International Journal of Clinical Practice</i> , 2010, 64, 267-276.	0.8	52
2599	Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). <i>Australasian journal of optometry, The</i> , 2009, 92, 34-37.	0.6	20
2600	Assessment and management of hypertension in patients with type 2 diabetes. <i>Internal Medicine Journal</i> , 2009, 39, 143-149.	0.5	9
2601	INERTIA OR INACTION? BLOOD PRESSURE MANAGEMENT AND CARDIOVASCULAR RISK IN DIABETES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, 643-647.	0.9	13
2602	Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 150-156.	2.2	44

#	ARTICLE	IF	CITATIONS
2603	Treatment of diabetic hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 433-444.	2.2	16
2604	Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 757-769.	2.2	19
2605	Impact of glucagon-like peptide-1 on endothelial function. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 19-25.	2.2	21
2606	Implementation of a systematic approach to diabetes in primary care in Bahia, Brazil improves metabolic outcomes: PRODIBA-Programa de Interioriza�o da Assist�ncia ao Diabetes na Bahia (Project for Dissemination of Diabetes Care in the State of Bahia). <i>Diabetic Medicine</i> , 2009, 26, 286-292.	1.2	5
2607	Prescription charge exemption and Type 2 diabetes mellitus - a survey of diabetologists' understanding. <i>Diabetic Medicine</i> , 2009, 26, 827-828.	1.2	1
2608	A national survey of the current state of screening services for diabetic retinopathy: ABCD-Diabetes UK survey of specialist diabetes services 2006. <i>Diabetic Medicine</i> , 2009, 26, 1301-1305.	1.2	15
2609	Short report: suboptimal diabetes care in high-risk diabetic patients attending a specialist retina clinic. <i>Diabetic Medicine</i> , 2009, 26, 1296-1300.	1.2	5
2610	Effects of systolic and diastolic blood pressures on incident coronary heart disease and all-cause death in Chinese women with Type 2 diabetes: The Hong Kong Diabetes Registry. <i>Journal of Diabetes</i> , 2009, 1, 90-98.	0.8	5
2611	Diabetes-Related Risk Factors Across Hispanic Subgroups in the Hispanic Health and Nutritional Examination Survey (1982-1984). <i>Public Health Nursing</i> , 2009, 26, 23-38.	0.7	19
2612	Characteristics of patients with coronary artery disease and hypertension: A report from INVEST. <i>Clinical Cardiology</i> , 2001, 24, V-6-V-8.	0.7	0
2613	The patient with diabetes: Preventing cardiovascular complications. <i>Clinical Cardiology</i> , 2009, 29, 13-20.	0.7	9
2614	Angiotensin AT1 Receptor Antagonism Ameliorates Murine Retinal Proteome Changes Induced by Diabetes. <i>Journal of Proteome Research</i> , 2009, 8, 5541-5549.	1.8	28
2615	Longitudinal Relations among Perceived Autonomy Support from Health Care Practitioners, Motivation, Coping Strategies and Dietary Compliance in a Sample of Adults with Type 2 Diabetes. <i>Journal of Health Psychology</i> , 2009, 14, 457-470.	1.3	31
2616	The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 623-633.	2.4	61
2617	Combination of cardiorespiratory reflex parameters and heart rate variability power spectrum analysis for early diagnosis of diabetic cardiac autonomic neuropathy. <i>Diabetes and Metabolism</i> , 2009, 35, 305-311.	1.4	8
2618	Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). <i>Diabetes and Metabolism</i> , 2009, 35, 439-446.	1.4	41
2619	Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. <i>Diabetes and Metabolism</i> , 2009, 35, 425-430.	1.4	8
2620	Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. <i>Diabetes Research and Clinical Practice</i> , 2009, 83, 241-248.	1.1	15

#	ARTICLE	IF	CITATIONS
2621	Cost of medical care among type 2 diabetic patients with a co-morbid condition—Hypertension in India. <i>Diabetes Research and Clinical Practice</i> , 2009, 83, 263-267.	1.1	29
2622	Preventing diabetic complications: A primary care perspective. <i>Diabetes Research and Clinical Practice</i> , 2009, 84, 107-116.	1.1	33
2623	Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2009, 86, 74-81.	1.1	29
2624	Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Research and Clinical Practice</i> , 2009, 86, 104-110.	1.1	43
2625	Microvascular diabetic complications are more prevalent in India compared to Mauritius and the UK due to poorer diabetic control. <i>Diabetes Research and Clinical Practice</i> , 2009, 86, e39-e40.	1.1	22
2626	High-salt loading exacerbates increased retinal content of aquaporins AQP1 and AQP4 in rats with diabetic retinopathy. <i>Experimental Eye Research</i> , 2009, 89, 741-747.	1.2	28
2627	Mobile diabetes intervention study: Testing a personalized treatment/behavioral communication intervention for blood glucose control. <i>Contemporary Clinical Trials</i> , 2009, 30, 334-346.	0.8	65
2628	Small artery remodeling in diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 587-592.	1.1	52
2629	Prevalence of Diabetic Retinopathy in Rural China: The Handan Eye Study. <i>Ophthalmology</i> , 2009, 116, 461-467.	2.5	210
2630	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.	2.5	125
2631	Significant lower VVH7-like immunoreactivity serum level in diabetic patients: Evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV. <i>Peptides</i> , 2009, 30, 256-261.	1.2	23
2632	The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. <i>International Journal of Cardiology</i> , 2009, 131, 298-304.	0.8	54
2633	Retinopathy in Nondiabetic Persons with the Metabolic Syndrome: Findings from the Third National Health and Nutrition Examination Survey. <i>American Journal of Ophthalmology</i> , 2009, 147, 934-944.e2.	1.7	23
2634	Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006. <i>American Journal of Medicine</i> , 2009, 122, 443-453.	0.6	309
2635	Beta-Blockers and Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2105-2106.	1.2	1
2636	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1364-1405.	1.2	80
2637	Diabetic cardiomyopathy — a distinct disease?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 347-360.	2.2	58
2638	Compliance with the quality standards of National Diabetic Retinopathy Screening Committee. <i>Primary Care Diabetes</i> , 2009, 3, 67-72.	0.9	19

#	ARTICLE	IF	CITATIONS
2639	Perceptions of heart attack risk amongst individuals with diabetes. Primary Care Diabetes, 2009, 3, 239-244.	0.9	6
2640	Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment. Current Medical Research and Opinion, 2009, 25, 879-890.	0.9	23
2641	Hypertension in diabetes mellitus. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56, 63-66.	0.8	0
2642	Nuevas perspectivas en el tratamiento del paciente diabético. Estudio ADVANCE. Hipertension Y Riesgo Vascular, 2009, 26, 80-83.	0.3	0
2643	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	0.7	351
2644	Diabetic nephropathy. Diabetology and Metabolic Syndrome, 2009, 1, 10.	1.2	101
2645	Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation. Diabetology and Metabolic Syndrome, 2009, 1, 13.	1.2	10
2646	First-line drugs for hypertension. The Cochrane Library, 2009, , CD001841.	1.5	130
2647	Stroke and Diabetes Mellitus. , 2009, , 183-218.		1
2648	Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. The Cochrane Library, 2009, , CD006296.	1.5	211
2649	Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. Journal of Human Hypertension, 2009, 23, 77-85.	1.0	15
2650	Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Current Medical Research and Opinion, 2009, 25, 421-430.	0.9	16
2651	Treating hypertension in type II diabetic patients with device-guided breathing: a randomized controlled trial. Journal of Human Hypertension, 2009, 23, 325-331.	1.0	61
2652	The Improvement of Hypertension by Probiotics: Effects on Cholesterol, Diabetes, Renin, and Phytoestrogens. International Journal of Molecular Sciences, 2009, 10, 3755-3775.	1.8	193
2653	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine, 2009, 360, 129-139.	13.9	4,197
2654	Treatment blood pressure targets for hypertension. The Cochrane Library, 2009, , CD004349.	1.5	137
2656	Standards of Medical Care in Diabetes—2009. Diabetes Care, 2009, 32, S13-S61.	4.3	1,606
2657	Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Review of Cardiovascular Therapy, 2009, 7, 1363-1371.	0.6	17

#	ARTICLE	IF	CITATIONS
2658	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	0.6	2
2659	Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 111-118.	1.2	1
2660	Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study*. <i>Current Medical Research and Opinion</i> , 2009, 25, 691-700.	0.9	45
2661	Diabetic macular edema: a growing global problem, in search of a leaner and clearer vision for the future. <i>Expert Review of Ophthalmology</i> , 2009, 4, 215-218.	0.3	0
2662	Pathophysiology and management of diabetic retinopathy. <i>Expert Review of Ophthalmology</i> , 2009, 4, 627-647.	0.3	18
2663	Metabolic Effects of Manidipine. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 163-176.	1.0	14
2664	The ADVANCE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 283-291.	1.0	6
2665	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 446-456.	2.2	295
2666	The Role of Genetics in Susceptibility to Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 35-52.	0.3	88
2667	Medical versus surgical interventions for the metabolic complications of obesity in children. <i>Seminars in Pediatric Surgery</i> , 2009, 18, 168-175.	0.5	4
2668	2009 Canadian Hypertension Education Program recommendations: The scientific summary "an annual update. <i>Canadian Journal of Cardiology</i> , 2009, 25, 271-277.	0.8	35
2669	Hypertension in diabetes: A call to action. <i>Canadian Journal of Cardiology</i> , 2009, 25, 299-302.	0.8	32
2670	Blood pressure drugs have no mortality benefit in diabetic patients. <i>Canadian Journal of Cardiology</i> , 2009, 25, 594.	0.8	0
2671	Pharmaco-economic issues for diabetes therapy. <i>Insulin</i> , 2009, 4, 32-60.	0.2	0
2673	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009, 373, 1765-1772.	6.3	1,234
2674	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , 2009, 374, 525-533.	6.3	391
2675	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 53, e1-e90.	1.2	1,386
2676	Association between serum lipoprotein (a) level and progression of nonproliferative diabetic retinopathy in Type 2 diabetes. <i>Acta Ophthalmologica</i> , 2009, 87, 501-505.	0.6	17

#	ARTICLE	IF	CITATIONS
2677	Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions. <i>Cardiovascular Therapeutics</i> , 2009, 27, 275-288.	1.1	12
2678	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. <i>Journal of Neurology</i> , 2009, 256, 1603-1619.	1.8	47
2679	Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. <i>Mayo Clinic Proceedings</i> , 2009, 84, 741-757.	1.4	111
2680	Glycaemic control and cardiovascular morbi-mortality: The contribution of the 2008 studies. <i>Annales D'Endocrinologie</i> , 2009, 70, 48-54.	0.6	9
2681	La mesure ambulatoire de la pression artérielle (MAPA) chez les diabétiques. <i>Medecine Des Maladies Metaboliques</i> , 2009, 3, 169-173.	0.1	3
2682	Glomerulonephritis and Managing the Risks of Chronic Renal Disease. <i>Pediatric Clinics of North America</i> , 2009, 56, 1363-1382.	0.9	11
2683	Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2009, 84, 34-36.	1.4	7
2684	Prevalence and determinants of retinopathy in a cohort of Lebanese type II diabetic patients. <i>Canadian Journal of Ophthalmology</i> , 2009, 44, 308-313.	0.4	16
2685	Î2-Blocker Use for the Stages of Heart Failure. <i>Mayo Clinic Proceedings</i> , 2009, 84, 718-729.	1.4	74
2686	Diabetic Nephropathy in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 373-389.	1.0	10
2687	Proteomics and Diabetic Retinopathy. <i>Clinics in Laboratory Medicine</i> , 2009, 29, 139-149.	0.7	11
2688	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009, 27, 673-679.	0.3	53
2689	Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. <i>Journal of Hypertension</i> , 2009, 27, 1509-1520.	0.3	91
2690	Diabetes and Poor Disease Control: Is Comorbid Depression Associated With Poor Medication Adherence or Lack of Treatment Intensification?. <i>Psychosomatic Medicine</i> , 2009, 71, 965-972.	1.3	119
2691	An Algorithm for the Care of Type 2 Diabetes. <i>Critical Pathways in Cardiology</i> , 2009, 8, 156-165.	0.2	4
2692	Update on Laser Treatment of Diabetic Macular Edema. <i>International Ophthalmology Clinics</i> , 2009, 49, 87-94.	0.3	8
2693	When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. <i>Journal of Hypertension</i> , 2009, 27, 923-934.	0.3	243
2694	Update on Systemic Management of Diabetes. <i>International Ophthalmology Clinics</i> , 2009, 49, 13-33.	0.3	2

#	ARTICLE	IF	CITATIONS
2695	Heart protection: a key target in the management of patients with diabetes. <i>Journal of Hypertension</i> , 2009, 27, S9-S13.	0.3	0
2696	Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. <i>Journal of Hypertension</i> , 2009, 27, S19-S23.	0.3	12
2697	Changing paradigms in the treatment of diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 532-538.	1.3	15
2698	Primary prevention of heart failure: what is the evidence?. <i>Current Opinion in Cardiology</i> , 2009, 24, 142-147.	0.8	6
2699	Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004. <i>Journal of Hypertension</i> , 2009, 27, 1908-1916.	0.3	86
2700	Defining blood pressure goals: is it enough to manage total cardiovascular risk?. <i>Journal of Hypertension</i> , 2009, 27, S3-S8.	0.3	10
2701	Herbal medicine for diabetic retinopathy. <i>The Cochrane Library</i> , 2009, , .	1.5	1
2702	7. Management of Risk Factor. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 1305-1310.	0.0	0
2703		0.0	0
2704	Linking diabetes and atherosclerosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 603-624.	1.2	8
2705	Role of PPAR γ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. <i>Clinical Science</i> , 2009, 116, 17-26.	1.8	55
2706	Comparison of the retinal microvasculature in European and African-Caribbean people with diabetes. <i>Clinical Science</i> , 2009, 117, 229-236.	1.8	13
2707	Patient-centred care planning. <i>Practice Nursing</i> , 2009, 20, 18-23.	0.1	8
2708	Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. <i>British Journal of General Practice</i> , 2009, 59, 43-48.	0.7	66
2709	Ambulatory Blood Pressure Monitoring and Serum Nitric Oxide Concentration in Type 1 Diabetic Children. <i>Endocrine Journal</i> , 2009, 56, 477-485.	0.7	12
2710	Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 515-529.	0.2	0
2711	Fifty Years of Thiazide Diuretic Therapy for Hypertension. <i>Archives of Internal Medicine</i> , 2009, 169, 1851.	4.3	52
2712	Medicare Spending for Previously Uninsured Adults. <i>Annals of Internal Medicine</i> , 2009, 151, 757.	2.0	37

#	ARTICLE	IF	CITATIONS
2713	Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2009, 151, 394.	2.0	308
2714	Prevention of risk factors: beta-blockade and hypertension. <i>European Heart Journal Supplements</i> , 2009, 11, A3-A8.	0.0	8
2715	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>Yearbook of Cardiology</i> , 2009, 2009, 49-51.	0.0	0
2716	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <i>Yearbook of Vascular Surgery</i> , 2009, 2009, 5-6.	0.0	1
2717	Characteristics of Insured Patients With Persistent Gaps in Diabetes Care Services. <i>Medical Care</i> , 2010, 48, 31-37.	1.1	26
2718	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2010, 170, 1037.	4.3	52
2719	Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. <i>The Cochrane Library</i> , 2010, , CD007185.	1.5	28
2720	Clinical Complexity in Middle-Aged and Older Adults With Diabetes. <i>Medical Care</i> , 2010, 48, 327-334.	1.1	79
2721	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Yearbook of Medicine</i> , 2010, 2010, 397-398.	0.1	0
2722	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Yearbook of Cardiology</i> , 2010, 2010, 4-5.	0.0	0
2724	Treatment blood pressure targets for hypertension. <i>Yearbook of Cardiology</i> , 2010, 2010, 37-39.	0.0	0
2725	Cost-Effectiveness of a Quality Improvement Collaborative Focusing on Patients With Diabetes. <i>Medical Care</i> , 2010, 48, 884-891.	1.1	33
2726	Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 340-347.	0.8	23
2727	Nebivolol Lowers Blood Pressure and Increases Weight Loss in Patients With Hypertension and Diabetes in Regard to Age. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 275-281.	0.8	19
2728	Blood pressure targets: are clinical guidelines wrong?. <i>Current Opinion in Cardiology</i> , 2010, 25, 350-354.	0.8	10
2729	MACULAR PERFUSION DETERMINED BY FUNDUS FLUORESCIN ANGIOGRAPHY AT THE 4-MONTH TIME POINT IN A PROSPECTIVE RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB OR LASER THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA (BOLT STUDY). <i>Retina</i> , 2010, 30, 781-786.	1.0	72
2730	Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. <i>Blood Pressure Monitoring</i> , 2010, 15, 1-7.	0.4	34
2731	Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. <i>Journal of Hypertension</i> , 2010, 28, 2076-2083.	0.3	31

#	ARTICLE	IF	CITATIONS
2732	Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Journal of Hypertension</i> , 2010, 28, 2026-2035.	0.3	40
2733	Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. <i>Vascular Health and Risk Management</i> , 2010, 6, 821.	1.0	14
2735	Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. <i>Endocrine Journal</i> , 2010, 57, 423-430.	0.7	17
2736	Effective Antihypertensive Strategies for High-Risk Patients With Diabetic Nephropathy. <i>Journal of Investigative Medicine</i> , 2010, 58, 950-956.	0.7	3
2738	Mobile Telemonitoring for Achieving Tighter Targets of Blood Pressure Control in Patients with Complicated Diabetes: A Pilot Study. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 575-579.	2.4	56
2740	High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. <i>Diabetologia</i> , 2010, 53, 1199-1209.	2.9	48
2741	Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. <i>Diabetologia</i> , 2010, 53, 2442-2451.	2.9	68
2742	The big fat bariatric bandwagon. <i>Diabetologia</i> , 2010, 53, 1815-1822.	2.9	31
2743	Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes. <i>EPMA Journal</i> , 2010, 1, 78-81.	3.3	9
2746	Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. <i>Endocrine</i> , 2010, 37, 455-459.	1.1	30
2747	Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. <i>Current Atherosclerosis Reports</i> , 2010, 12, 432-439.	2.0	72
2748	Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 16-23.	1.7	17
2749	The "œ Curve" Problem Revisited: Old and New Findings. <i>Current Hypertension Reports</i> , 2010, 12, 290-295.	1.5	18
2750	Patient and Physician Beliefs About Control over Health: Association of Symmetrical Beliefs with Medication Regimen Adherence. <i>Journal of General Internal Medicine</i> , 2010, 25, 397-402.	1.3	60
2751	The Pharmaceutical care of patients with type 2 diabetes mellitus. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 730-736.	1.4	37
2752	Blood Pressure Control in Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1029-1031.	2.1	4
2753	Undetected Hypertension and Prehypertension in Children with Diabetes Need Attention. <i>Journal of Pediatrics</i> , 2010, 157, 182-184.	0.9	1
2754	The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. <i>Progress in Retinal and Eye Research</i> , 2010, 29, 284-311.	7.3	123

#	ARTICLE	IF	CITATIONS
2755	Comparison of diabetes management in five countries for general and indigenous populations: an internet-based review. <i>BMC Health Services Research</i> , 2010, 10, 169.	0.9	48
2756	Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats. <i>European Journal of Pharmacology</i> , 2010, 641, 179-186.	1.7	37
2757	Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-group study. <i>Clinical Therapeutics</i> , 2010, 32, 1270-1284.	1.1	11
2758	Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus. <i>Gender Medicine</i> , 2010, 7, 600-615.	1.4	34
2759	Small artery remodeling in diabetes. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, no-no.	1.6	22
2760	Antihypertensive Therapy in African Americans: Findings From an Inner-City Ambulatory Clinic. <i>Journal of Clinical Hypertension</i> , 2010, 12, 187-192.	1.0	4
2761	Efficacy and Safety of Irbesartan/HCTZ in Severe Hypertension According to Cardiometabolic Factors. <i>Journal of Clinical Hypertension</i> , 2010, 12, 487-494.	1.0	3
2762	Is There Accord in ACCORD? Lower Blood Pressure Targets in Type 2 Diabetes Does Not Lead to Fewer Cardiovascular Events Except for Reductions in Stroke. <i>Journal of Clinical Hypertension</i> , 2010, 12, 472-477.	1.0	5
2763	Assessing quality of diabetes care and its variation in Aboriginal community health centres in Australia. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 464-473.	1.7	36
2764	The global challenge of type 2 diabetes and the strategies for response in ethnic minority groups. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 421-432.	1.7	31
2767	Diabetes: cost of illness in Norway. <i>BMC Endocrine Disorders</i> , 2010, 10, 15.	0.9	31
2768	Daily steps are low year-round and dip lower in fall/winter: findings from a longitudinal diabetes cohort. <i>Cardiovascular Diabetology</i> , 2010, 9, 81.	2.7	50
2769	Evaluation of a toolkit to improve cardiovascular disease screening and treatment for people with type 2 diabetes: protocol for a cluster-randomized pragmatic trial. <i>Trials</i> , 2010, 11, 44.	0.7	17
2770	Short- and long-term effects of a quality improvement collaborative on diabetes management. <i>Implementation Science</i> , 2010, 5, 94.	2.5	22
2771	Half full, half empty, or negative? Results of recent clinical trials. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010, 27, 174-175.	0.2	0
2772	Diabetes specialist nursing in the UK: the judgement call? A review of existing literature. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010, 27, 248-253.	0.2	3
2773	Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT) observational study. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1078-1086.	0.9	13
2774	Diminishing Efficacy of Combination Therapy, Response Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. <i>Health Services Research</i> , 2010, 45, 437-456.	1.0	26

#	ARTICLE	IF	CITATIONS
2775	Reducing Potentially Avoidable Complications in Patients with Chronic Diseases: The Prometheus Payment Approach. <i>Health Services Research</i> , 2010, 45, 1854-1871.	1.0	17
2776	Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. <i>Value in Health</i> , 2010, 13, 196-208.	0.1	66
2777	Combined therapy in the treatment of hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 3-8.	1.0	24
2778	Preventing diabetes complications: are we too glucocentric?. <i>International Journal of Clinical Practice</i> , 2010, 64, 1024-1027.	0.8	7
2779	Clinical experience with liraglutide. <i>International Journal of Clinical Practice</i> , 2010, 64, 44-48.	0.8	4
2780	Liraglutide: effects beyond glycaemic control in diabetes treatment. <i>International Journal of Clinical Practice</i> , 2010, 64, 28-34.	0.8	12
2781	Caring for uninsured patients with diabetes: designing and evaluating a novel chronic care model for diabetes care. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 700-706.	0.9	6
2782	The impact of diabetes education on blood glucose self-monitoring among older adults. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 790-793.	0.9	11
2783	Sudden cardiac death among people with diabetes: preventive measures documented in their medical records. <i>Journal of Clinical Nursing</i> , 2010, 19, 3401-3409.	1.4	1
2784	Hypertension in patients with diabetes: questions. <i>Journal of Diabetes</i> , 2010, 2, 128-129.	0.8	2
2785	Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 26-34.	2.2	17
2786	How can structured self-management patient education improve outcomes in people with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 12-19.	2.2	80
2787	Understanding the interrelationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 431-436.	2.2	34
2788	Screening for type 2 diabetes: an update of the evidence. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 838-844.	2.2	38
2789	Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study. <i>Diabetic Medicine</i> , 2010, 27, 46-53.	1.2	33
2790	The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. <i>Diabetic Medicine</i> , 2010, 27, 887-895.	1.2	151
2791	Nurse-led clinics for strict hypertension control are effective long term: a 7-year follow-up study. <i>Diabetic Medicine</i> , 2010, 27, 933-937.	1.2	7
2792	Nurse-led interventions used to improve control of high blood pressure in people with diabetes: a systematic review and meta-analysis. <i>Diabetic Medicine</i> , 2011, 28, 250-261.	1.2	47

#	ARTICLE	IF	CITATIONS
2793	Prevention and management of chronic kidney disease in type 2 diabetes. <i>Nephrology</i> , 2010, 15, S162-94.	0.7	17
2794	Challenges in secondary stroke prevention: prevalence of multiple metabolic risk factors, including abnormal glycaemia, in ischaemic stroke and transient ischaemic attack. <i>Internal Medicine Journal</i> , 2010, 40, 275-280.	0.5	10
2795	The status and perspective of diabetes health education in China: Inspiration from Australia. <i>International Journal of Nursing Practice</i> , 2010, 16, 92-98.	0.8	9
2796	Present and Prospective Clinical Therapeutic Options for the Elderly Patient with Hypertension. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2110.	0.4	0
2797	Improvements in Indicators of Diabetes-related Health Status Among First Nations Individuals Enrolled in a Community-driven Diabetes Complications Mobile Screening Program in Alberta, Canada. <i>Canadian Journal of Public Health</i> , 2010, 101, 410-414.	1.1	17
2798	Evidence-based approach for managing hypertension in type 2 diabetes. <i>Integrated Blood Pressure Control</i> , 2010, 3, 31.	0.4	2
2799	Clinical Profile of Haemodialysis Patients with Diabetic Nephropathy Leading to End Stage Renal Disease. <i>Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria</i> , 2010, 19, 153-6.	0.0	1
2800	Looking at basics: World Kidney Day and diabetes. <i>Journal of Renal Nursing</i> , 2010, 2, 56-56.	0.1	0
2801	Retinal Nerve Fiber Layer Decrease during Glycemic Control in Type 2 Diabetes. <i>Journal of Ophthalmology</i> , 2010, 2010, 1-6.	0.6	20
2802	The Correlation between CVR-R and Carotid Atherosclerosis in Type 2 Diabetes Mellitus Patients with Diabetic Neuropathy. <i>Journal of Physiological Anthropology</i> , 2010, 29, 149-152.	1.0	7
2803	Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy. <i>PLoS ONE</i> , 2010, 5, e10424.	1.1	4
2804	Relationship between diabetic retinopathy severity and the timespan between the endocrinopathy diagnosis and the first ophthalmic examination. <i>Arquivos Brasileiros De Oftalmologia</i> , 2010, 73, 240-243.	0.2	4
2805	Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk. <i>International Journal of Hypertension</i> , 2010, 2010, 1-8.	0.5	7
2806	Diabetic microvascular complications: possible targets for improved macrovascular outcomes. <i>International Journal of Nephrology and Renovascular Disease</i> , 2011, 4, 1.	0.8	9
2808	Exogenous SOD Mimetic Tempol Ameliorates the Early Retinal Changes Reestablishing the Redox Status in Diabetic Hypertensive Rats. , 2010, 51, 4327.		30
2809	Knowledge of and attitude to foot care amongst Type 2 diabetes patients attending a university-based primary care clinic in Nigeria. <i>African Journal of Primary Health Care and Family Medicine</i> , 2010, 2, .	0.3	8
2810	Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence. <i>Vascular Health and Risk Management</i> , 2010, 6, 363.	1.0	12
2811	Prevalence of Diabetic Retinopathy in the United States, 2005-2008. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 649.	3.8	895

#	ARTICLE	IF	CITATIONS
2812	Review Paper: The Use of Quality Improvement and Health Information Technology Approaches to Improve Diabetes Outcomes in African American and Hispanic Patients. <i>Medical Care Research and Review</i> , 2010, 67, 163S-197S.	1.0	34
2813	Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2010, 23, 334-339.	1.0	170
2814	Health Insurance Status and Control of Diabetes and Coronary Artery Disease Risk Factors on Enrollment Into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. <i>The Diabetes Educator</i> , 2010, 36, 774-783.	2.6	2
2815	Blood Pressure Control in Diabetes: Temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Diabetes Care</i> , 2010, 33, 798-803.	4.3	24
2816	Cardiovascular risk and prevention in diabetes mellitus. <i>Clinical Medicine</i> , 2010, 10, 495-499.	0.8	5
2817	Management of High Blood Pressure in Blacks. <i>Hypertension</i> , 2010, 56, 780-800.	1.3	398
2818	An Overview of Diabetic Eye Disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 224-230.	0.6	1
2819	Evidence-based mechanistic reasoning. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 433-441.	1.1	81
2821	Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 285-293.	1.0	3
2822	Are Individuals With Diabetes Seeing Better?. <i>Diabetes</i> , 2010, 59, 1853-1860.	0.3	83
2823	Evidence-based commissioning: using population impact measures to help primary care trusts estimate the benefit of interventions in diabetes and heart failure. <i>Quality and Safety in Health Care</i> , 2010, 19, 31-36.	2.5	4
2824	Common Carotid Artery Intima-media Thickness is not Increased but Distensibility is Reduced in Normotensive Patients with Type 2 Diabetes compared with Control Subjects. <i>Journal of International Medical Research</i> , 2010, 38, 860-869.	0.4	7
2825	Monitoring and treatment for cardiovascular risk. <i>Primary Health Care Research and Development</i> , 2010, 11, 29.	0.5	0
2826	Controlling Evening BP As Well As Morning BP Is Important in Hypertensive Patients With Prediabetes/Diabetes: The JMS-1 Study. <i>American Journal of Hypertension</i> , 2010, 23, 522-527.	1.0	15
2827	Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. <i>Annals of the New York Academy of Sciences</i> , 2010, 1212, 29-40.	1.8	22
2828	Health Systems, Patients Factors, and Quality of Care for Diabetes. <i>Diabetes Care</i> , 2010, 33, 940-947.	4.3	69
2829	Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus. <i>Hypertension</i> , 2010, 56, 68-74.	1.3	53
2830	Strategies and Goals for Hypertension Control in Patients With Diabetes Mellitus. <i>Hypertension</i> , 2010, 56, 24-25.	1.3	0

#	ARTICLE	IF	CITATIONS
2831	Insulin intensification for people with type 2 diabetes: a practical approach. <i>Australasian Medical Journal</i> , 2010, , 808-813.	0.1	2
2832	Valsartanâ€“amlodipineâ€“hydrochlorothiazide: the definitive fixed combination?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1609-1618.	0.6	5
2833	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. <i>Clinical Lipidology</i> , 2010, 5, 811-826.	0.4	23
2834	A Survey of the Management, Control, and Complications of Diabetes Mellitus in Patients Attending a Diabetes Clinic in Blantyre, Malawi, an Area of High HIV Prevalence. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 575-581.	0.6	46
2835	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 61.	3.8	578
2836	Life Expectancy in Individuals With Type 2 Diabetes: Implications for Annuities. <i>Medical Decision Making</i> , 2010, 30, 409-414.	1.2	7
2837	After Cardiac Surgery, How Does Nutrition Fit in With Risk Factors?. <i>Journal of Parenteral and Enteral Nutrition</i> , 2010, 34, 163-168.	1.3	4
2838	The Prevalence of Self-Monitoring of Blood Glucose and Costs of Glucometer Strips in a Nationwide Cohort. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 701-705.	2.4	18
2839	Diabetic macular edema. , 2010, , 519-526.		2
2840	BP reduction in patients with diabetesâ€”uncertainties remain. <i>Nature Reviews Cardiology</i> , 2010, 7, 609-611.	6.1	0
2841	Insulin Dose Titration System in Diabetes Patients Using a Short Messaging Service Automatically Produced by a Knowledge Matrix. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 663-669.	2.4	48
2842	Very Intensive Blood Pressure Control Does Not Clearly Reduce Combined Incidence of Cardiovascular Events. <i>Clinical Diabetes</i> , 2010, 28, 163-165.	1.2	0
2844	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1575-1585.	13.9	3,117
2845	Blood pressure lowering and stroke. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 225-241.	1.4	12
2846	Blood Pressure Management in Patients With Diabetes. <i>Clinical Diabetes</i> , 2010, 28, 107-114.	1.2	14
2847	Vascular damage in diabetic retinopathy. , 2010, , 506-513.		3
2848	The tubulointerstitium in early diabetic nephropathy: Prime target or bystander?. <i>International Journal of Diabetes in Developing Countries</i> , 2010, 30, 185.	0.3	3
2849	Managing diabetic nephropathy. <i>Clinical Medicine</i> , 2010, 10, 500-504.	0.8	20

#	ARTICLE	IF	CITATIONS
2850	The Role of the Chronic Kidney Disease Clinic. , 2010, , 75-86.		1
2851	Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. American Journal of Health-System Pharmacy, 2010, 67, 290-294.	0.5	14
2852	Beneficial Effect of Combination Therapy Comprising Angiotensin II Receptor Blocker Plus Calcium Channel Blocker on Plasma Adiponectin Levels. Clinical and Experimental Hypertension, 2010, 32, 21-28.	0.5	6
2853	Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. American Journal of Physiology - Renal Physiology, 2010, 298, F125-F132.	1.3	60
2854	The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat. Mediators of Inflammation, 2010, 2010, 1-12.	1.4	15
2855	Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure“Lowering Medications. Hypertension, 2010, 56, 1060-1068.	1.3	41
2856	A pilot quality improvement intervention in patients with diabetes and hypertension in primary care settings of Cyprus. Family Practice, 2010, 27, 263-270.	0.8	18
2857	Incidence of Treatment for End-Stage Renal Disease Among Individuals With Diabetes in the U.S. Continues to Decline. Diabetes Care, 2010, 33, 73-77.	4.3	135
2858	Strategies for Improving the Acquisition and Integration of Evidence Into Diabetes Care. Diabetes Spectrum, 2010, 23, 246-253.	0.4	0
2859	Mobile healthcare in the US army. , 2010, , .		4
2860	Renoprotective Effect of Calcium Channel Blockers in Combination with an Angiotensin Receptor Blocker in Elderly Patients with Hypertension. A Randomized Crossover Trial Between Benidipine and Amlodipine. Clinical and Experimental Hypertension, 2010, 32, 1-7.	0.5	15
2861	Mortality Trends in Subjects With and Without Diabetes During 33 Years of Follow-up. Diabetes Care, 2010, 33, 551-556.	4.3	65
2862	Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. Diabetes and Vascular Disease Research, 2010, 7, 6-13.	0.9	36
2863	Coping as a Mediator in the Relationships of Spiritual Well-Being to Mental Health in Black Women with Type 2 Diabetes. International Journal of Psychiatry in Medicine, 2010, 40, 439-459.	0.8	10
2864	Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective. Current Medical Research and Opinion, 2010, 26, 289-296.	0.9	8
2865	Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. European Heart Journal, 2010, 31, 2837-2840.	1.0	62
2866	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 233-244.	13.9	1,091
2867	Exenatide is Non-inferior to Insulin in Reducing HbA_{1c}: An Integrated Analysis of 1423 Patients with Type 2 Diabetes. Postgraduate Medicine, 2010, 122, 118-128.	0.9	28

#	ARTICLE	IF	CITATIONS
2868	Mortality patterns among type 2 diabetes mellitus patients in Ilorin, Nigeria. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2010, 15, 79-82.	0.4	22
2869	Diabetes outpatient care before and after admission for diabetic foot complications. <i>Journal of Wound Care</i> , 2010, 19, 150-152.	0.5	5
2870	Clinical evaluation of combined therapy for type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2010, 26, 1171-1183.	0.9	9
2871	Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 199-209.	0.6	16
2872	Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2010, 26, 721-728.	0.9	23
2873	Lower Blood Pressure Goals in High-Risk Cardiovascular Patients: Are They Defensible?. <i>Cardiology Clinics</i> , 2010, 28, 447-452.	0.9	2
2874	Respuesta de la Dra. Lourdes del Santo Mora. <i>Avances En DiabetologÃa</i> , 2010, 26, 261-264.	0.1	0
2875	Beyond Expectations: Why Do Aboriginal and Euro-Canadian Patients with Type 2 Diabetes on a Northern, Rural Island Demonstrate Better Outcomes for Glycemic, Blood Pressure and Lipid Management than Comparison Populations?. <i>Canadian Journal of Diabetes</i> , 2010, 34, 127-135.	0.4	2
2876	Control de las cifras de presiÃ³n arterial en diabÃ©ticos tipo 2 tratados con insulina. <i>Avances En DiabetologÃa</i> , 2010, 26, 424-429.	0.1	0
2879	Aspects Ã©pidÃ©miologiques et angiofluorographiques de la rÃ©tinopathie diabÃ©tique Ã Marrakech (Maroc). <i>Medicine Des Maladies Metaboliques</i> , 2010, 4, 700-703.	0.1	3
2880	Medication Issues in Older Individuals WithÃCKD. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 320-328.	0.6	16
2881	Epidemiology of Hypertension in the Elderly With Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 329-340.	0.6	14
2882	Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1459-1466.	0.9	34
2883	Effect of systemic medications on onset and progression of diabetic retinopathy. <i>Nature Reviews Endocrinology</i> , 2010, 6, 494-508.	4.3	42
2888	Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 2171-2174.	13.9	12
2889	Ocular Retinopathies and Clinical Control of Angiogenesis. , 2010, , 27-65.		1
2890	Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2010, 4, 150-154.	1.8	16
2891	The elusive type 2 diabetes individual achieving tight blood pressure target: A phenotypic study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2010, 4, 215-219.	1.8	3

#	ARTICLE	IF	CITATIONS
2892	Glucose, Obesity, Metabolic Syndrome, and Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 283-293.	1.2	174
2893	The relationship between socioeconomic deprivation and metabolic/cardiovascular risk factors in a cohort of patients with type 2 diabetes mellitus. <i>Primary Care Diabetes</i> , 2010, 4, 241-249.	0.9	18
2894	Increased heart rate variability during sleep is a predictor for future cardiovascular events in patients with type 2 diabetes. <i>Hypertension Research</i> , 2010, 33, 737-742.	1.5	30
2895	Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. <i>Drugs</i> , 2010, 70, 2171-2200.	4.9	34
2896	Diabetic Macular Edema. <i>Drug Safety</i> , 2010, 33, 643-652.	1.4	13
2897	Comanagement of elderly patients with type 2 diabetes: better adherence to ADA guidelines?. <i>Osteopathic Family Physician</i> , 2010, 2, 160-164.	0.2	1
2898	Hypertensive Treatment in Patients With Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 95-104.	0.5	4
2899	Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: A randomized prospective study using intravascular ultrasound. <i>International Journal of Cardiology</i> , 2010, 138, 157-165.	0.8	30
2900	Determinants of left main calcifications in a cohort of 2136 diabetes patients. <i>International Journal of Cardiology</i> , 2010, 142, e48-e50.	0.8	2
2902	Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, e38-e43.	0.7	0
2903	Section 5: Management of Asymptomatic Patients with Reduced Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2010, 16, e57-e60.	0.7	1
2904	Trends from 1995 to 2006 in the prevalence of self-reported cardiovascular risk factors among elderly Spanish diabetics. <i>Diabetes and Metabolism</i> , 2010, 36, 29-35.	1.4	7
2905	Start improving the quality of care for people with type 2 diabetes through a general practice support program: A cluster randomized trial. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 56-64.	1.1	37
2906	Achievement of management targets associated with incident and long-term diagnosed diabetes among a representative population sample. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 322-327.	1.1	4
2907	The cardiorenal syndrome in diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 201-208.	1.1	37
2908	Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. <i>European Journal of Internal Medicine</i> , 2010, 21, 236-239.	1.0	21
2909	Micronutrients and Diabetic Retinopathy. <i>Ophthalmology</i> , 2010, 117, 71-78.	2.5	43
2910	The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus. <i>Ophthalmology</i> , 2010, 117, 63-70.	2.5	151

#	ARTICLE	IF	CITATIONS
2911	Use of Eye Care Services among Diabetic Patients in Urban and Rural China. <i>Ophthalmology</i> , 2010, 117, 1755-1762.	2.5	73
2912	A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study). <i>Ophthalmology</i> , 2010, 117, 1078-1086.e2.	2.5	473
2913	Myopia and Diabetic Retinopathy. <i>Ophthalmology</i> , 2010, 117, 2040.	2.5	3
2914	Color Doppler Imaging of Retinal Diseases. <i>Survey of Ophthalmology</i> , 2010, 55, 193-214.	1.7	95
2915	Control de la presi3n arterial en una poblaci3n hipertensa diab3tica asistida en atenci3n primaria. «Estudio PRESCAP-Diabetes». <i>Semergen</i> , 2010, 36, 307-316.	0.2	3
2916	The Role of Vasodilating β -Blockers in Patients with Hypertension and the Cardiometabolic Syndrome. <i>American Journal of Medicine</i> , 2010, 123, S21-S26.	0.6	24
2917	Retinal Vasculopathies: Diabetic Retinopathy. , 2010, , 109-117.		2
2918	N3ophropathie diab3tique. , 2010, , 207-233.		0
2919	Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. <i>Acta Ophthalmologica</i> , 2010, 88, 279-291.	0.6	106
2920	Association of preoperative vitreous IL6 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2010, 88, e311-6.	0.6	31
2921	Complications of Type 1 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010, 39, 625-640.	1.2	152
2922	Candesartan Cilexetil/Hydrochlorothiazide Treatment in High-Risk Patients with Type 2 Diabetes Mellitus and Microalbuminuria. <i>Clinical Drug Investigation</i> , 2010, 30, 301-311.	1.1	5
2923	Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 843-854.	1.1	15
2924	Level of blood pressure above goal and clinical inertia in a Medicaid population. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 244-254.	2.3	27
2925	Early recognition and prevention of chronic kidney disease. <i>Lancet, The</i> , 2010, 375, 1296-1309.	6.3	494
2926	Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. <i>Lancet, The</i> , 2010, 375, 906-915.	6.3	657
2927	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010, 376, 419-430.	6.3	1,182
2928	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet, The</i> , 2010, 376, 103-111.	6.3	216

#	ARTICLE	IF	CITATIONS
2929	Mixed messages on systemic therapies for diabetic retinopathy. <i>Lancet, The</i> , 2010, 376, 1461.	6.3	9
2930	Standards of Medical Care in Diabetes—2010. <i>Diabetes Care</i> , 2010, 33, S11-S61.	4.3	2,863
2931	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 501-508.	0.4	8
2932	Association Between Albuminuria and Duration of Diabetes and Myocardial Dysfunction and Peripheral Arterial Disease Among Patients With Stable Coronary Artery Disease in the BARI 2D Study. <i>Mayo Clinic Proceedings</i> , 2010, 85, 41-46.	1.4	20
2933	Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus. <i>Drugs and Aging</i> , 2010, 27, 871-883.	1.3	41
2934	Interventions used to improve control of blood pressure in patients with hypertension. <i>The Cochrane Library</i> , 2010, , CD005182.	1.5	367
2935	Reduction of Inducible Nitric Oxide Synthase via Angiotensin Receptor Blocker Prevents the Oxidative Retinal Damage in Diabetic Hypertensive Rats. <i>Current Eye Research</i> , 2010, 35, 519-528.	0.7	16
2936	Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1647-1657.	0.9	6
2937	The relationship between ACE gene insertion/deletion polymorphism and diabetic retinopathy in Iranian patients with type 2 diabetes. <i>Ophthalmic Genetics</i> , 2010, 31, 108-113.	0.5	15
2938	Type 2 diabetes and cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2011, 27, 1-5.	0.9	16
2939	Multifocal Electroretinograms Predict Onset of Diabetic Retinopathy in Adult Patients with Diabetes. , 2011, 52, 772.		176
2940	Special considerations for treatment of type 2 diabetes mellitus in the elderly. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 500-509.	0.5	32
2941	Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2011, 27, 73-84.	0.9	4
2942	The ACCORD Study: The Devil Is in the Details. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 81-84.	0.5	3
2943	Hypertension and its management in countries in Africa and the Middle East, with special reference to the place of β -blockade. <i>Current Medical Research and Opinion</i> , 2011, 27, 1223-1236.	0.9	10
2944	The importance of managing diabetes correctly to prevent heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 257-259.	0.6	5
2945	Comparative risk of microalbuminuria and proteinuria in UK residents of south Asian and white European ethnic background with type 2 diabetes: a report from UKADS. <i>Current Medical Research and Opinion</i> , 2011, 27, 47-55.	0.9	20
2946	Blood pressure lowering in patients with diabetes—“one level might not fit all. <i>Nature Reviews Cardiology</i> , 2011, 8, 42-49.	6.1	16

#	ARTICLE	IF	CITATIONS
2947	Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 327-333.	1.0	12
2948	Controversies in the cardiovascular management of type 2 diabetes. <i>Heart</i> , 2011, 97, 6-14.	1.2	24
2949	Management issues in hypertensive diabetics. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2011, 53, 144-148.	0.2	1
2950	Effects of aerobic versus resistance training on glycaemic control in men with type 2 diabetes. <i>European Journal of Sport Science</i> , 2011, 11, 365-374.	1.4	11
2951	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 444-456.	1.4	104
2952	Mapping Choroidal and Retinal Thickness Variation in Type 2 Diabetes using Three-Dimensional 1060-nm Optical Coherence Tomography. , 2011, 52, 5311.		219
2953	Lâ€™autosurveillance de la pression artÃ©rielle, en pratique. <i>Medecine Des Maladies Metaboliques</i> , 2011, 5, 169-172.	0.1	2
2954	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 153-159.	1.2	106
2955	Diabetic retinopathy: Pathogenic mechanisms and current treatments. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2011, 5, 165-172.	1.8	52
2956	Prevalence of hypertension, control of blood pressure and treatment in hypertensive with type 2 diabetes in Hospital University Sains Malaysia. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2011, 5, 115-119.	1.8	10
2957	Diabetes and Insulin Resistance in Older People. <i>Medical Clinics of North America</i> , 2011, 95, 615-629.	1.1	24
2958	Special considerations on the management of Latino patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2011, 27, 969-979.	0.9	16
2960	The quality of diabetes care: A comparison between patients enrolled and not enrolled on a regional diabetes register. <i>Primary Care Diabetes</i> , 2011, 5, 131-137.	0.9	8
2962	Diabetes and Frailty. , 2011, , 101-121.		0
2964	Manipine for Hypertension not Controlled by Dual Therapy in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2011, 31, 427-434.	1.1	9
2965	Effects on diabetes management of a health-care provider mediated, remote coaching system via a PDA-type glucometer and the Internet. <i>Journal of Telemedicine and Telecare</i> , 2011, 17, 365-370.	1.4	49
2966	Endothelial dysfunction as a potential contributor in diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2011, 7, 36-44.	4.1	159
2967	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. <i>Hypertension Research</i> , 2011, 34, 714-721.	1.5	28

#	ARTICLE	IF	CITATIONS
2968	Risk of Macrovascular Complications in Type 2 Diabetes Mellitus: Endothelial Microparticle Profiles. <i>Cerebrovascular Diseases</i> , 2011, 31, 485-493.	0.8	43
2969	Are primary care practitioners in Barbados following diabetes guidelines? - a chart audit with comparison between public and private care sectors. <i>BMC Research Notes</i> , 2011, 4, 199.	0.6	12
2970	Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. <i>Drugs and Aging</i> , 2011, 28, 945-960.	1.3	15
2971	Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus. <i>Drugs in R and D</i> , 2011, 11, 251-257.	1.1	3
2972	Artist [®] Tablets (Carvedilol) for Hypertensive Patients in Japan. <i>Drugs in R and D</i> , 2011, 11, 191-205.	1.1	2
2974	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2011, 42, 517-584.	1.0	1,289
2975	The 5-HT ₆ Receptor as a Target for Developing Novel Antiobesity Drugs. <i>International Review of Neurobiology</i> , 2011, 96, 73-109.	0.9	24
2977	Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2011, 23, 230-239.	0.4	0
2978	Lipids, lipid-lowering therapy and diabetes complications. <i>Diabetes and Metabolism</i> , 2011, 37, 15-24.	1.4	25
2979	Ethnic differences in the relationship of prediabetes with the presence of target-organ disease. <i>Diabetes and Metabolism</i> , 2011, 37, 403-409.	1.4	8
2980	Silent myocardial ischaemia and risk factors in a diabetic Afro-Caribbean population. <i>Diabetes and Metabolism</i> , 2011, 37, 533-539.	1.4	9
2981	Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 280-285.	1.1	6
2982	Risk of progression of nephropathy in a population-based sample with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 246-252.	1.1	19
2983	Progression of glycaemia and cardiovascular risk factors in patients of different age groups with new type 2 diabetes over 5 years of follow-up in a diabetes quality improvement initiative. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, 357-362.	1.1	3
2984	Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, 123-130.	1.1	40
2985	Translating diabetes research into global communities. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, 443-445.	1.1	9
2986	Pragmatic vs. explanatory: An adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1095-1101.	2.4	54
2989	Management of type 2 diabetes mellitus in the elderly. <i>Maturitas</i> , 2011, 70, 151-159.	1.0	33

#	ARTICLE	IF	CITATIONS
2990	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. <i>Cardiology Clinics</i> , 2011, 29, 47-70.	0.9	19
2991	Can informed choice invitations lead to inequities in intentions to make lifestyle changes among participants in a primary care diabetes screening programme? Evidence from a randomized trial. <i>Public Health</i> , 2011, 125, 645-652.	1.4	8
2992	Advances in the treatment of diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 113-122.	0.3	12
2993	Diabetic retinopathy – An update. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 99-111.	0.3	58
2994	Expert consensus on management of diabetic patients with impairment of renal function. <i>Diabetes and Metabolism</i> , 2011, 37, S1-S25.	1.4	16
2995	European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary. <i>Diabetes and Metabolism</i> , 2011, 37, S27-S38.	1.4	266
2996	The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. <i>Hypertension Research</i> , 2011, 34, 413-422.	1.5	56
2997	Endothelial Factors and Diabetic Nephropathy. <i>Diabetes Care</i> , 2011, 34, S291-S296.	4.3	33
2998	Therapeutic management of diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2011, 2, 248-254.	1.1	12
2999	Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients. <i>Journal of Diabetes Investigation</i> , 2011, 2, 490-496.	1.1	2
3000	Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus. <i>Cardiovascular Therapeutics</i> , 2011, 29, 46-53.	1.1	15
3001	Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. <i>Cardiovascular Therapeutics</i> , 2011, 29, e31-e42.	1.1	23
3002	VLED and formula LED in the management of type 2 diabetes: defining the clinical need and research requirements. <i>Clinical Obesity</i> , 2011, 1, 41-49.	1.1	11
3003	From pancreatic extracts to artificial pancreas: History, science and controversies about the discovery of the pancreatic antidiabetic hormone. <i>Avances En Diabetologia</i> , 2011, 27, 27-38.	0.1	5
3004	Cumulative glycemia and microangiopathy in subjects with impaired glucose regulation in the Inter99 study. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 226-232.	1.1	9
3005	Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy – Friend or foe?. <i>Pharmacological Research</i> , 2011, 64, 187-194.	3.1	100
3007	Manifestaciones y complicaciones oculares de las enfermedades sistémicas. <i>Medicine</i> , 2011, 10, 6167-6179.	0.0	0
3008	Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. <i>Lancet</i> , The, 2011, 378, 129-139.	6.3	249

#	ARTICLE	IF	CITATIONS
3009	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. <i>Lancet</i> , The, 2011, 378, 156-167.	6.3	406
3010	Heart Failure as a Consequence of Hypertension. , 2011, , 435-444.		0
3011	High-sensitivity C-reactive Protein Can Predict Major Adverse Cardiovascular Events in Korean Patients with Type 2 Diabetes. <i>Journal of Korean Medical Science</i> , 2011, 26, 1322.	1.1	14
3012	Management of Blood Pressure in Patients with Type 2 Diabetes Mellitus: A Nationwide Survey in Korean. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 348.	1.8	6
3013	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. <i>Endocrine Practice</i> , 2011, 17, 1-53.	1.1	387
3014	Urinary Proteomics and Candidate Biomarker Discovery for Diabetic Nephropathy. , 2011, , 351-366.		2
3015	The Appropriate Interpretation of Recent Clinical Trials -How to Read RCT in the Era of Advertizing-based Medicine-. <i>Journal of the Korean Society of Hypertension</i> , 2011, 17, 1.	0.2	1
3016	Current Controversies over the Management of Elderly Hypertension with Impaired Renal Function. <i>Journal of the Korean Society of Hypertension</i> , 2011, 17, 148.	0.2	0
3018	Ambulatory Blood Pressure Monitoring in Diabetes and Obesityâ€™A Review. <i>International Journal of Hypertension</i> , 2011, 2011, 1-8.	0.5	20
3019	Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 580.	1.8	5
3020	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. <i>Patient Related Outcome Measures</i> , 2011, 2, 27.	0.7	6
3021	Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 337.	1.8	6
3022	Antihypertensive Treatment in Type 2 Diabetic Patients. , 2011, , .		0
3023	Racial Differences in the Prevalence of Diabetes but Not Diabetic Retinopathy in a Multi-ethnic Asian Population. , 2011, 52, 7586.		47
3024	Sociodemographic differences in diabetic retinopathy screening; using patient-level primary care data for health equity audit. <i>Clinical Audit</i> , 2011, , 7.	0.4	4
3025	Minimally Invasive Sensing. , 2011, , .		0
3026	Structured assessments of diabetic residents. <i>Nursing and Residential Care</i> , 2011, 13, 19-25.	0.1	0
3027	How Much Do We Lower the Blood Pressure in Hypertensive Patients with Diabetes?. <i>Journal of the Korean Society of Hypertension</i> , 2011, 17, 10.	0.2	1

#	ARTICLE	IF	CITATIONS
3028	Chairside assessment of peripheral arterial disease in diabetes patients. <i>British Journal of Community Nursing</i> , 2011, 16, S24-S33.	0.2	2
3029	Unit 3. Creating a risk-management partnership. <i>Practice Nursing</i> , 2011, 22, 1-4.	0.1	0
3030	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-13.	0.6	44
3031	Association between retinoid-X receptor-gamma genetic polymorphisms and diabetic retinopathy. <i>Genetics and Molecular Research</i> , 2011, 10, 3545-3551.	0.3	14
3032	Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 571.	1.8	41
3033	Diabetes and diabetic retinopathy. <i>International Journal of Ophthalmic Practice</i> , 2011, 2, 181-185.	0.0	3
3034	Insulin and antihyperglycemic drugs. , 0, , 874-889.		0
3035	What should be the blood pressure target for diabetic patients?. <i>Current Opinion in Cardiology</i> , 2011, 26, 308-313.	0.8	9
3036	EFFECT OF RUBOXISTAURIN (RBX) ON VISUAL ACUITY DECLINE OVER A 6-YEAR PERIOD WITH CESSATION AND REINSTITUTION OF THERAPY. <i>Retina</i> , 2011, 31, 1053-1059.	1.0	29
3037	Atherosclerotic renal artery stenosis. <i>Current Opinion in Cardiology</i> , 2011, 26, 463-471.	0.8	13
3038	The Wrong Tool for the Job: Diabetes Public Health Programs and Practice Guidelines. <i>American Journal of Public Health</i> , 2011, 101, 1871-1873.	1.5	0
3039	The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the Diabetic REtinopathy Candesartan Trials-Protect 2 study. <i>Journal of Hypertension</i> , 2011, 29, 1457-1462.	0.3	17
3040	Physician attitudes to blood pressure control. <i>Journal of Hypertension</i> , 2011, 29, 1633-1640.	0.3	37
3041	Advances in the Treatment of Type 2 Diabetes Mellitus. <i>American Journal of Therapeutics</i> , 2011, 18, 117-152.	0.5	134
3042	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. <i>Diabetes Management</i> , 2011, 1, 615-626.	0.5	0
3045	Reducing cardiovascular risk factors in patients with prediabetes. <i>Diabetes Management</i> , 2011, 1, 423-438.	0.5	1
3046	Chinese herbal medicine for diabetic peripheral neuropathy. , 2011, , CD007796.		10
3047	Use of Eye Care Services Among Diabetic Patients in Urban Indonesia. <i>JAMA Ophthalmology</i> , 2011, 129, 930.	2.6	52

#	ARTICLE	IF	CITATIONS
3048	Encounter Frequency and Serum Glucose Level, Blood Pressure, and Cholesterol Level Control in Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2011, 171, 1542.	4.3	94
3049	The challenge of managing hypertension in chronic renal disease. <i>Journal of Renal Nursing</i> , 2011, 3, 58-62.	0.1	0
3050	Update in Endocrinology: Evidence Published in 2010. <i>Annals of Internal Medicine</i> , 2011, 154, 684.	2.0	0
3051	Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. <i>American Journal of the Medical Sciences</i> , 2011, 341, 132-140.	0.4	6
3052	New approaches to the treatment of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 784-790.	2.2	20
3053	Incidence of diabetic retinopathy in a Hong Kong Chinese population. <i>Australasian journal of optometry, The</i> , 2011, 94, 563-567.	0.6	15
3054	Changes in blood pressure in the sitting and standing positions in hypertensive patients. <i>International Journal of Nursing Practice</i> , 2011, 17, 105-109.	0.8	1
3055	Diabetes management in an Australian primary care population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 664-672.	0.7	25
3056	Structured primary care for type 2 diabetes has positive effects on clinical outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 1083-1088.	0.9	12
3057	A role for regulatory focus in explaining and combating clinical inertia. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 1147-1152.	0.9	8
3058	Medication Use in Older <sc>U.S.</sc> Adults with Diabetes Mellitus and the Potential Ramifications of Raising the Glycemic Target. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2381-2383.	1.3	4
3059	Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. <i>International Journal of Clinical Practice</i> , 2011, 65, 148-153.	0.8	40
3060	Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. <i>International Journal of Clinical Practice</i> , 2011, 65, 613-623.	0.8	3
3061	Prioritization of care in adults with diabetes and comorbidity. <i>Annals of the New York Academy of Sciences</i> , 2011, 1243, 69-87.	1.8	39
3062	Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. <i>Journal of Diabetes</i> , 2011, 3, 257-260.	0.8	3
3063	Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β -Blockers. <i>Journal of Clinical Hypertension</i> , 2011, 13, 52-59.	1.0	66
3064	Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. <i>Journal of Clinical Hypertension</i> , 2011, 13, 422-430.	1.0	9
3065	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	1.0	333

#	ARTICLE	IF	CITATIONS
3066	Hypertension in Diabetes: Treatment Considerations. <i>Journal of Clinical Hypertension</i> , 2011, 13, 314-318.	1.0	5
3067	Diabetes and Hypertension: A Comprehensive Report on Management and the Prevention of Cardiovascular and Renal Complications. <i>Journal of Clinical Hypertension</i> , 2011, 13, 221-223.	1.0	2
3068	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 889-897.	1.0	6
3069	Relationship between diet, exercise habits, and health status among patients with diabetes. <i>Research in Social and Administrative Pharmacy</i> , 2011, 7, 151-161.	1.5	14
3070	Inflammation in diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2011, 30, 343-358.	7.3	879
3071	Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population. <i>Clinical Therapeutics</i> , 2011, 33, 1904-1913.	1.1	5
3072	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1856-1861.	0.7	15
3073	Best Clinical Trials Reported in 2010. <i>American Journal of Cardiology</i> , 2011, 108, 162-168.	0.7	0
3074	Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. <i>American Journal of Cardiology</i> , 2011, 108, 25B-32B.	0.7	35
3075	Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. <i>American Journal of Cardiology</i> , 2011, 108, 59B-67B.	0.7	20
3078	Maternal complications in diabetic pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 77-90.	1.4	37
3079	Target blood pressure in diabetes patients with hypertension –What is the accumulated evidence in 2011?. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 611-623.	1.3	12
3080	Management of hypertension in diabetic patients: outstanding issues. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 721-728.	0.6	2
3082	Lack of correlation between short-term dynamics of diabetic retinopathy lesions and the arterial blood pressure. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 267-271.	1.0	12
3083	Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 848-853.	0.7	17
3084	Uncontrolled home blood pressure in the morning is associated with nephropathy in Japanese type 2 diabetes. <i>Heart and Vessels</i> , 2011, 26, 609-615.	0.5	27
3086	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. <i>Diabetologia</i> , 2011, 54, 2237-2246.	2.9	55
3087	Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. <i>Diabetologia</i> , 2011, 54, 2525-2532.	2.9	122

#	ARTICLE	IF	CITATIONS
3088	Prognostic importance of home blood pressure measurement in patients with diabetic nephropathy. <i>Diabetology International</i> , 2011, 2, 10-18.	0.7	2
3089	A 60-year old patient with mild complications who developed type 1 diabetes with coma at 1Âyear and 7Âmonths. <i>Diabetology International</i> , 2011, 2, 154-158.	0.7	0
3092	Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 6-13.	0.4	1
3093	The Goal of Blood Pressure Control for Prevention of Early Diabetic Microvascular Complications. <i>Current Diabetes Reports</i> , 2011, 11, 323-329.	1.7	8
3094	Does Therapy Targeting Normal SBP of Less than 120Âmm Hg Reduce Major CV Events in T2DM Patients?. <i>Current Diabetes Reports</i> , 2011, 11, 233-235.	1.7	0
3095	Protocol for the ADDITION-Plus study: a randomised controlled trial of an individually-tailored behaviour change intervention among people with recently diagnosed type 2 diabetes under intensive UK general practice care. <i>BMC Public Health</i> , 2011, 11, 211.	1.2	21
3096	Assessment of quality of care given to diabetic patients at Jimma University Specialized Hospital diabetes follow-up clinic, Jimma, Ethiopia. <i>BMC Endocrine Disorders</i> , 2011, 11, 19.	0.9	54
3097	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	2.7	137
3098	Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. <i>Cardiovascular Diabetology</i> , 2011, 10, 31.	2.7	54
3099	Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. <i>Cardiovascular Diabetology</i> , 2011, 10, 39.	2.7	40
3100	Identifying changes in diabetes care. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2011, 28, 31-34.	0.2	4
3102	Patient education on retinopathy. <i>European Diabetes Nursing</i> , 2011, 8, 62-66a.	0.2	0
3103	Diabetes specialist nursing in the UK: the judgement call? A review of existing literature. <i>European Diabetes Nursing</i> , 2011, 8, 108-113a.	0.2	7
3104	Macrovascular angiopathy in children and adolescents with type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 436-460.	1.7	45
3105	A Comparison of the Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination Therapy with Irbesartan Monotherapy in the Treatment of Moderate or Severe Hypertension in Diabetic and Obese Hypertensive Patients: A Post-Hoc Analysis Review. <i>Postgraduate Medicine</i> , 2011, 123, 126-134.	0.9	4
3106	Risk factors for the development of albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register (NDR). <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1236-1243.	0.4	110
3107	The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy. <i>Postgraduate Medicine</i> , 2011, 123, 109-121.	0.9	11
3108	Diabetic Retinopathy in Africa: Advantages of Screening. <i>Postgraduate Medicine</i> , 2011, 123, 119-125.	0.9	45

#	ARTICLE	IF	CITATIONS
3109	Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. <i>Eye</i> , 2011, 25, 843-849.	1.1	58
3110	Telehealth Practice Recommendations for Diabetic Retinopathy, Second Edition. <i>Telemedicine Journal and E-Health</i> , 2011, 17, 814-837.	1.6	99
3111	A call for wider use of ambulatory blood pressure monitoring in patients with diabetes. <i>Hypertension Research</i> , 2011, 34, 1171-1172.	1.5	2
3112	One-Year Efficacy and Safety of the Telehealth System in Poorly Controlled Type 2 Diabetic Patients Receiving Insulin Therapy. <i>Telemedicine Journal and E-Health</i> , 2011, 17, 683-687.	1.6	17
3113	Comparison of illness representations dimensions and illness representation clusters in predicting outcomes in the first year following diagnosis of type 2 diabetes: Results from the DESMOND trial. <i>Psychology and Health</i> , 2011, 26, 321-335.	1.2	42
3114	Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus. <i>Journal of the American Board of Family Medicine</i> , 2011, 24, 391-398.	0.8	22
3115	Self-Monitoring Technologies for Type 2 Diabetes and the Prevention of Cardiovascular Complications: Perspectives from End Users. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 394-401.	1.3	11
3116	Blood Pressure Trajectories Prior to Death in Patients With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1534-1539.	4.3	17
3117	Association Between Plasma Vitamin C Concentrations and Blood Pressure in the European Prospective Investigation Into Cancer-Norfolk Population-Based Study. <i>Hypertension</i> , 2011, 58, 372-379.	1.3	30
3118	Are Population-Based Diabetes Models Useful for Individual Risk Estimation?. <i>Journal of the American Board of Family Medicine</i> , 2011, 24, 399-406.	0.8	7
3119	Management of Blood Pressure in Patients With Diabetes. <i>American Journal of Hypertension</i> , 2011, 24, 863-875.	1.0	33
3120	The Association between Left Ventricular Diastolic Function and a Mild-to-Moderate Decrease in Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus. <i>Journal of International Medical Research</i> , 2011, 39, 2178-2186.	0.4	9
3121	Clinical Practice Recommendations. <i>Clinical Diabetes</i> , 2011, 29, 163-166.	1.2	86
3122	Review of therapeutic advances in diabetic retinopathy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 39-53.	1.4	18
3123	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 1060-1068.	1.0	14
3124	Disparities in Blood Pressure Control Within a Community-Based Provider Network: An Exploratory Analysis. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1473-1482.	0.9	25
3125	Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 17-26.	1.4	28
3126	Diabetes and Technology for Increased Activity (DaTA) Study: Results of a Remote Monitoring Intervention for Prevention of Metabolic Syndrome. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 928-935.	1.3	44

#	ARTICLE	IF	CITATIONS
3127	Clinical Perspective on the Management of Hypertension. Indian Journal of Clinical Medicine, 2011, 2, IJCM.S5475.	0.2	0
3128	Control of Blood Pressure in Chronic Kidney Disease: How Low to Go. Nephron Clinical Practice, 2011, 119, c324-c332.	2.3	6
3129	Intensive Blood Pressure Control Affects Cerebral Blood Flow in Type 2 Diabetes Mellitus Patients. Hypertension, 2011, 57, 738-745.	1.3	48
3130	Candidate Gene Association Study for Diabetic Retinopathy in Persons with Type 2 Diabetes: The Candidate Gene Association Resource (CARE). , 2011, 52, 7593.		82
3131	Prediction, by Retinal Location, of the Onset of Diabetic Edema in Patients with Nonproliferative Diabetic Retinopathy. , 2011, 52, 6825.		31
3132	Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial. Diabetes Care, 2011, 34, 34-38.	4.3	83
3133	Blood Pressure: The Lower, the Better: The con side. Diabetes Care, 2011, 34, S308-S312.	4.3	24
3134	A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Pressure, 2011, 20, 322-334.	0.7	9
3135	Adherence to Guidelines for Youths With Diabetes Mellitus. Pediatrics, 2011, 128, 531-538.	1.0	48
3136	Lowering systolic blood pressure below 130 mm Hg does not improve cardiovascular outcomes in hypertensive patients with diabetes and coronary artery disease. Evidence-Based Medicine, 2011, 16, 24-26.	0.6	4
3137	Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. New England Journal of Medicine, 2011, 365, 1520-1526.	13.9	109
3138	Management of diabetic hypertensives. Indian Journal of Endocrinology and Metabolism, 2011, 15, 374.	0.2	15
3139	Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes. Clinical and Experimental Hypertension, 2011, 33, 56-62.	0.5	12
3140	The Role of Occupational Therapy in Diabetes Self-Management Interventions. OTJR Occupation, Participation and Health, 2011, 31, 89-96.	0.4	15
3141	Effect of Combination Therapy with Angiotensin Receptor Blocker and 1,25-Dihydroxyvitamin D₃ in Type 2 Diabetic Nephropathy in KK-A^y/Ta Mice. Nephron Experimental Nephrology, 2011, 117, e124-e132.	2.4	33
3142	Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrology Dialysis Transplantation, 2011, 26, 2238-2244.	0.4	12
3143	Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal, 2011, 32, 2247-2255.	1.0	39
3144	Adherence to clinical practice guidelines and outcomes in diabetic patients. International Journal for Quality in Health Care, 2011, 23, 413-419.	0.9	39

#	ARTICLE	IF	CITATIONS
3145	Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension. <i>Diabetes Care</i> , 2011, 34, S297-S303.	4.3	34
3146	Standards of Medical Care in Diabetes—2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	4.3	2,448
3147	Mixed Messages on Blood Pressure Goals. <i>Hypertension</i> , 2011, 57, 1039-1040.	1.3	22
3148	Cardiovascular Outcomes in Framingham Participants With Diabetes. <i>Hypertension</i> , 2011, 57, 891-897.	1.3	217
3149	Diabetic Retinopathy in 2011: Further Insights From New Epidemiological Studies and Clinical Trials. <i>Diabetes Care</i> , 2011, 34, 1066-1067.	4.3	23
3150	Diabetes, Hypertension, and Outcome Studies: Overview 2010. <i>Diabetes Care</i> , 2011, 34, S109-S113.	4.3	16
3151	Microangiopathy and visual deficits characterize the retinopathy of a spontaneously hypertensive rat model with type 2 diabetes and metabolic syndrome. <i>Hypertension Research</i> , 2011, 34, 103-112.	1.5	7
3152	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. <i>Journal of Human Hypertension</i> , 2011, 25, 354-363.	1.0	16
3153	Response of Rat Retinal Capillary Pericytes and Endothelial Cells to Glucose. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 7-15.	0.6	16
3154	Management of patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2011, 27, 1931-1947.	0.9	12
3155	Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration. <i>Diabetes Care</i> , 2011, 34, 968-974.	4.3	213
3156	Screening for Type 2 Diabetes and Dysglycemia. <i>Epidemiologic Reviews</i> , 2011, 33, 63-87.	1.3	70
3157	Blood Pressure Control in Diabetes Mellitus. <i>Circulation</i> , 2011, 123, 2776-2778.	1.6	28
3158	Animal Models of Retinal Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 100, 211-286.	0.9	89
3159	Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects. <i>Scandinavian Journal of Primary Health Care</i> , 2011, 29, 85-91.	0.6	4
3160	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	1.1	13
3161	Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review. <i>Medical Care Research and Review</i> , 2011, 68, 263-289.	1.0	93
3162	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001293.	3.9	389

#	ARTICLE	IF	CITATIONS
3163	Diabetes and Coronary Heart Disease: A Risk Factor for the Global Epidemic. <i>International Journal of Hypertension</i> , 2012, 2012, 1-7.	0.5	67
3164	The Relationship Between Financial Incentives and Quality of Diabetes Care in Ontario, Canada. <i>Diabetes Care</i> , 2012, 35, 1038-1046.	4.3	61
3165	Masked Hypertension, Endothelial Dysfunction, and Arterial Stiffness in Type 2 Diabetes Mellitus: A Pilot Study. <i>American Journal of Hypertension</i> , 2012, 25, 165-170.	1.0	40
3166	Glucose Metabolism in Outpatients with New-Onset Hypertension in Chinese Han Population. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 474-481.	0.5	7
3167	Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience. <i>Heart Asia</i> , 2012, 4, 69-76.	1.1	4
3168	Monitoring Performance for Blood Pressure Management Among Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2012, 172, 938.	4.3	56
3169	New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. <i>Eye</i> , 2012, 26, 485-493.	1.1	104
3170	Chronic Kidney Disease in Disadvantaged Populations. <i>International Journal of Nephrology</i> , 2012, 2012, 1-6.	0.7	22
3171	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. <i>International Journal of Hypertension</i> , 2012, 2012, 1-9.	0.5	26
3172	Diabetes nursing: a personal reflection of the last 60 years. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 311-314.	0.6	1
3173	Blockade of the renin-angiotensin system for the primary prevention of diabetic nephropathy. <i>Diabetes Management</i> , 2012, 2, 55-64.	0.5	1
3174	Can a Patient-Centered Medical Home Lead to Better Patient Outcomes? The Quality Implications of Geisinger's ProvenHealth Navigator. <i>American Journal of Medical Quality</i> , 2012, 27, 210-216.	0.2	61
3175	Falling mortality rates in Type 2 diabetes mellitus in the Wirral Peninsula: a longitudinal and retrospective cohort population-based study. <i>Postgraduate Medical Journal</i> , 2012, 88, 679-683.	0.9	15
3176	Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems. <i>Circulation</i> , 2012, 125, 2863-2872.	1.6	105
3177	Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment. <i>Diabetes Care</i> , 2012, 35, 218-225.	4.3	108
3178	Hyperglycemia and Renin-Dependent Hypertension Synergize to Model Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 405-411.	3.0	40
3179	Prevention and management of diabetic retinopathy in young persons with Type 1 diabetes. <i>Diabetes Management</i> , 2012, 2, 559-569.	0.5	2
3180	What Should the Blood Pressure Goal Be in Patients with Hypertension Who Are at High Risk for Cardiovascular Disease?. <i>Hospital Practice (1995)</i> , 2012, 40, 28-32.	0.5	0

#	ARTICLE	IF	CITATIONS
3181	Blood pressure treatment target in patients with diabetes mellitus—current evidence. <i>Annals of Medicine</i> , 2012, 44, S36-S42.	1.5	8
3182	Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. <i>BMJ, The</i> , 2012, 345, e5567-e5567.	3.0	76
3183	Glycemic and blood-pressure control—lower is not better. <i>Nature Reviews Nephrology</i> , 2012, 8, 199-200.	4.1	0
3184	The role of Dietary Approaches to Stop Hypertension (DASH) diet food groups in blood pressure in type 2 diabetes. <i>British Journal of Nutrition</i> , 2012, 108, 155-162.	1.2	42
3185	Beta-blockers for hypertension. , 2012, , CD002003.		24
3186	Post-marketing surveillance study of valsartan/amlodipine combination in Taiwanese hypertensive patients. <i>Blood Pressure</i> , 2012, 21, 11-19.	0.7	2
3187	Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. <i>Current Medical Research and Opinion</i> , 2012, 28, 1647-1656.	0.9	28
3188	Hypertension Prevalence, Awareness, Treatment, Control, and Associated Factors in Adults in Southern China. <i>American Journal of Hypertension</i> , 2012, 25, 590-596.	1.0	74
3189	Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. <i>Kidney International Supplements</i> , 2012, 2, 363-369.	4.6	24
3191	The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management. <i>Clinical Diabetes</i> , 2012, 30, 151-155.	1.2	16
3192	Diabetic Autonomic Imbalance and Glycemic Variability. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1207-1215.	1.3	59
3193	Effect of Intensive Multifactorial Treatment Compared With Routine Care on Aortic Stiffness and Central Blood Pressure Among Individuals With Screen-Detected Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2207-2214.	4.3	24
3194	New Bundled World: Quality of Care and Readmission in Diabetes Patients. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 563-571.	1.3	24
3195	GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 95-108.	0.9	78
3196	Prevalence and Risk Factors of Diabetic Retinopathy in Subjects with Suboptimal Glycemic, Blood Pressure and Lipid Control. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, Report 33). <i>Current Eye Research</i> , 2012, 37, 513-523.	0.7	22
3197	Metabolic Memory for Vascular Disease in Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, S-68-S-74.	2.4	48
3198	Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1467-1470.	0.6	6
3199	Lipids and diabetic retinopathy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 93-105.	1.4	49

#	ARTICLE	IF	CITATIONS
3200	Retinal Micropseudocysts in Diabetic Retinopathy: Prospective Functional and Anatomic Evaluation. <i>Ophthalmic Research</i> , 2012, 48, 6-11.	1.0	3
3201	Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes. <i>Diabetes Care</i> , 2012, 35, 2706-2717.	4.3	126
3202	Comparable short-term prognosis in diabetic and non-diabetic patients with acute coronary syndrome after cardiac rehabilitation. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 15-22.	0.8	15
3203	Glucose, Blood Pressure, and Cardiovascular Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 145-147.	0.9	6
3204	Aquaporin Changes during Diabetic Retinopathy in Rats Are Accelerated by Systemic Hypertension and Are Linked to the Renin-Angiotensin System. , 2012, 53, 3047.		17
3205	Ocular Blood Flow in Diabetes: Contribution to the Microvascular Lesions of Diabetic Retinopathy. , 2012, , 365-387.		0
3206	Lifestyle Counseling in Routine Care and Long-Term Glucose, Blood Pressure, and Cholesterol Control in Patients With Diabetes. <i>Diabetes Care</i> , 2012, 35, 334-341.	4.3	48
3207	Diabetic macular edema: Current and emerging therapies. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 4.	0.5	38
3208	Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 884-886.	2.2	0
3209	Current therapeutic agents and anesthetic considerations for diabetes mellitus. <i>Korean Journal of Anesthesiology</i> , 2012, 63, 195.	0.9	3
3210	Epidemiology of Cardiovascular Disease. , 2012, , 256-260.		0
3211	Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 3026-3032.	0.3	12
3212	Vascular disease and foot assessment in diabetes. <i>Practice Nursing</i> , 2012, 23, 187-193.	0.1	1
3213	The importance of screening for Charcot neuroarthropathy. <i>Practice Nursing</i> , 2012, 23, 401-405.	0.1	0
3216	Should diabetes still be considered a coronary artery disease equivalent?. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 760-765.	0.6	0
3217	Blood Pressure, Vessel Caliber, and Retinal Thickness in Diabetes. <i>Optometry and Vision Science</i> , 2012, 89, 1715-1720.	0.6	11
3218	Blood pressure and risk of cardiovascular diseases in type 2 diabetes. <i>Journal of Hypertension</i> , 2012, 30, 2020-2030.	0.3	51
3219	Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. <i>Journal of Hypertension</i> , 2012, 30, 235-237.	0.3	6

#	ARTICLE	IF	CITATIONS
3220	Screening for diabetes. <i>Pathology</i> , 2012, 44, 110-114.	0.3	7
3221	Different Antidiabetic Regimens and the Development of Renal Dysfunction in US Veterans With Type 2 Diabetes Mellitus. <i>Journal of Investigative Medicine</i> , 2012, 60, 1009-1014.	0.7	0
3222	Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort. <i>British Journal of General Practice</i> , 2012, 62, e396-e402.	0.7	9
3223	Diabetic retinopathy management guidelines. <i>Expert Review of Ophthalmology</i> , 2012, 7, 417-439.	0.3	76
3224	Proactive Cardiovascular Risk Management versus Usual Care in Patients with and without Diabetes Mellitus: CRUCIAL Trial Subanalysis. <i>Postgraduate Medicine</i> , 2012, 124, 41-53.	0.9	9
3226	Prevention and treatment of diabetic retinopathy. <i>NursePrescribing</i> , 2012, 10, 22-24.	0.1	1
3227	Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease. <i>Clinical Lipidology</i> , 2012, 7, 689-695.	0.4	2
3228	Ageing, Diabetes, and the Public Health System in the United States. <i>American Journal of Public Health</i> , 2012, 102, 1482-1497.	1.5	123
3229	Diabetes and hypertension: the bad companions. <i>Lancet, The</i> , 2012, 380, 601-610.	6.3	498
3230	Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	1.0	3
3231	Management of Hypertension in People with Diabetes Mellitus: Translating the 2012 Canadian Hypertension Education Program Recommendations into Practice. <i>Canadian Journal of Diabetes</i> , 2012, 36, 345-353.	0.4	4
3232	Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2489.	3.8	571
3233	Medical Nutrition Therapy for Diabetes: Prioritizing Recommendations Based on Evidence. , 2012, , 101-125.		0
3234	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. <i>American Heart Journal</i> , 2012, 164, 672-680.	1.2	56
3235	Effect of Sahaja Yoga Meditation on Quality of Life, Anxiety, and Blood Pressure Control. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 589-596.	2.1	44
3236	Should we change the target blood pressure in diabetic patients?. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 1-7.	1.7	1
3237	What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 60-66.	1.7	13
3238	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414

#	ARTICLE	IF	CITATIONS
3239	Extended longitudinal analysis of arterial pressure and heart rate control in unanesthetized rats with type 1 diabetes. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012, 170, 20-29.	1.4	1
3240	Diabetes and the Risk of Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 125-133.	1.0	55
3241	Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 7-22.	1.0	65
3242	Epidemiology, risk factors and management of paediatric diabetic retinopathy: Table 1. <i>British Journal of Ophthalmology</i> , 2012, 96, 312-317.	2.1	29
3243	Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa. <i>British Journal of Ophthalmology</i> , 2012, 96, 156-161.	2.1	50
3244	Screening for hyperglycemia in the developing world: Rationale, challenges and opportunities. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 199-208.	1.1	25
3245	High Risk of ESRD in Type 1 Diabetes: New Strategies Are Needed to Retard Progressive Renal Function Decline. <i>Seminars in Nephrology</i> , 2012, 32, 407-414.	0.6	37
3247	The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S95.	0.4	11
3248	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
3249	Vitamin D Insufficiency in Diabetic Retinopathy. <i>Endocrine Practice</i> , 2012, 18, 185-193.	1.1	103
3250	Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. <i>Journal of Drug Assessment</i> , 2012, 1, 1-10.	1.1	3
3251	Diabetic macular edema: new trends in management. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 55-68.	1.3	4
3252	The 2012 SEMDSA Guideline for the Management of type 2 Diabetes. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S94.	0.4	54
3253	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	4.3	1,956
3254	DialBetics: Smartphone-Based Self-Management for Type 2 Diabetes Patients. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 983-985.	1.3	18
3256	A Methodological Review of Faith-Based Health Promotion Literature: Advancing the Science to Expand Delivery of Diabetes Education to Black Americans. <i>Journal of Religion and Health</i> , 2012, 51, 1075-1097.	0.8	66
3257	The Influence of Risk Factors for Metabolic Syndrome on Vascular Complications. <i>Angiology</i> , 2012, 63, 86-91.	0.8	1
3258	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359

#	ARTICLE	IF	CITATIONS
3259	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1717-1724.	3.0	80
3260	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	2.6	53
3261	The retinal renin-angiotensin system: Roles of angiotensin II and aldosterone. <i>Peptides</i> , 2012, 36, 142-150.	1.2	72
3262	Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. <i>Survey of Ophthalmology</i> , 2012, 57, 347-370.	1.7	299
3263	Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1741-1748.	6.3	199
3264	Fenofibrate - A Potential Systemic Treatment for Diabetic Retinopathy?. <i>American Journal of Ophthalmology</i> , 2012, 154, 6-12.	1.7	89
3265	Diabetic Retinopathy and Age-Related Macular Degeneration in the U.S. <i>American Journal of Preventive Medicine</i> , 2012, 43, 48-54.	1.6	40
3266	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 132-141.	2.3	31
3267	Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 57-62.	1.1	11
3268	Long-term changes of the prevalence and control rate of hypertension among Korean adults with diagnosed diabetes: 1998-2008 Korean National Health and Nutrition Examination Survey. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 151-157.	1.1	13
3269	A patient-based study on the adherence of physicians to guidelines for the management of type 2 diabetes in Turkey. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 75-82.	1.1	27
3270	Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study. <i>BMC Nephrology</i> , 2012, 13, 48.	0.8	12
3271	Hospitalized cardiovascular events in patients with diabetic macular edema. <i>BMC Ophthalmology</i> , 2012, 12, 11.	0.6	32
3272	What are patient factors associated with the quality of diabetes care?: results from the Korean National Health and Nutrition Examination Survey. <i>BMC Public Health</i> , 2012, 12, 689.	1.2	16
3273	Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial. <i>BMC Health Services Research</i> , 2012, 12, 183.	0.9	10
3274	A simple diabetes vascular severity staging instrument and its application to a Torres Strait Islander and Aboriginal adult cohort of north Australia. <i>BMC Health Services Research</i> , 2012, 12, 185.	0.9	15
3275	A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators. <i>BMC Health Services Research</i> , 2012, 12, 191.	0.9	7
3276	Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. <i>BMC Health Services Research</i> , 2012, 12, 388.	0.9	37

#	ARTICLE	IF	CITATIONS
3277	Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. <i>Cardiovascular Diabetology</i> , 2012, 11, 118.	2.7	7
3278	Vascular memory: can we broaden the concept of the metabolic memory?. <i>Cardiovascular Diabetology</i> , 2012, 11, 44.	2.7	27
3279	Beta-blockers for hypertension. , 2012, 11, CD002003.		80
3280	Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. <i>Diabetic Medicine</i> , 2012, 29, e409-16.	1.2	15
3285	Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin. <i>Clinical Pharmacokinetics</i> , 2012, 51, 147-162.	1.6	90
3286	Heart Failure in Hypertension. <i>Drugs</i> , 2012, 72, 1373-1398.	4.9	16
3287	Management and Prevention of Diabetic Complications. , 2012, , 233-248.		1
3288	Antihypertensive agents for preventing diabetic kidney disease. <i>The Cochrane Library</i> , 2012, 12, CD004136.	1.5	68
3289	Evaluating a web-based self-management program for employees with hypertension and prehypertension: A randomized clinical trial. <i>American Heart Journal</i> , 2012, 164, 625-631.	1.2	46
3290	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 74-83.	1.2	164
3291	Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival. <i>American Journal of Cardiology</i> , 2012, 110, 58B-68B.	0.7	64
3292	I-COMBINE Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled With Amlodipine 5 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded-End Point Evaluation Study. <i>Clinical Therapeutics</i> , 2012, 34, 1705-1719.	1.1	15
3293	I-ADD Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled With Irbesartan 150 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded-End Point Evaluation Study. <i>Clinical Therapeutics</i> , 2012, 34, 1720-1734.e3.	1.1	11
3294	Hypertension and ischemic heart disease. <i>Cor Et Vasa</i> , 2012, 54, e433-e438.	0.1	22
3295	Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007). <i>Diabetes and Metabolism</i> , 2012, 38, 558-566.	1.4	50
3296	ACE inhibitors or ARBs for diabetic nephropathy: The unrelenting debate. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2012, 6, 215-217.	1.8	7
3297	Complicaciones macrovasculares del paciente diabético. <i>Medicine</i> , 2012, 11, 1011-1020.	0.0	0
3298	Protocolo diagnóstico y seguimiento de las complicaciones microvasculares de la diabetes mellitus. Nefropatía y retinopatía diabéticas. <i>Medicine</i> , 2012, 11, 1055-1058.	0.0	0

#	ARTICLE	IF	CITATIONS
3299	Trends in chronic complications of type 2 diabetic patients from Spanish primary health care centres (GEDAPS study): Ten year-implementation of St. Vincent recommendations. <i>Primary Care Diabetes</i> , 2012, 6, 11-18.	0.9	23
3300	Adherence to hypoglycaemic medication among people with type 2 diabetes in primary care. <i>Primary Care Diabetes</i> , 2012, 6, 27-33.	0.9	19
3301	The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes. <i>Primary Care Diabetes</i> , 2012, 6, 67-73.	0.9	4
3303	Epidemiology of Hypertension in Diabetes. , 2012, , 1-14.		1
3305	Blood Pressure Measurement: Clinic, Home, Ambulatory, and Beyond. <i>American Journal of Kidney Diseases</i> , 2012, 60, 449-462.	2.1	81
3307	Diabetes and the Heart. , 2012, , 165-189.		0
3308	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1091-1099.	0.9	10
3309	In Vitro Antioxidant Effects of Aloe barbadensis Miller Extracts and the Potential Role of These Extracts as Antidiabetic and Antilipidemic Agents on Streptozotocin-Induced Type 2 Diabetic Model Rats. <i>Molecules</i> , 2012, 17, 12851-12867.	1.7	45
3310	Diabetic Considerations in Cerebrovascular Disease. , 2012, , 181-195.		0
3311	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	0.8	224
3312	A Pharmacist Care Program. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 57-64.	1.0	66
3313	What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy?. <i>Current Cardiology Reports</i> , 2012, 14, 651-659.	1.3	14
3314	Should African Americans Have a Lower Blood Pressure Goal than Other Ethnic Groups to Prevent Organ Damage?. <i>Current Cardiology Reports</i> , 2012, 14, 660-666.	1.3	9
3315	Impact of Arterial Hypertension on the Eye. <i>Current Hypertension Reports</i> , 2012, 14, 581-590.	1.5	27
3316	Therapeutic Modalities in Diabetic Nephropathy: <i>Future Approaches</i>. <i>Open Journal of Nephrology</i> , 2012, 02, 5-18.	0.0	11
3317	Human pericyte"endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. <i>Acta Diabetologica</i> , 2012, 49, 141-151.	1.2	31
3318	The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. <i>Diabetologia</i> , 2012, 55, 2946-2953.	2.9	84
3319	VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 1666-1673.	1.5	37

#	ARTICLE	IF	CITATIONS
3320	Fixed-Dose Combination Therapy in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 51-54.	1.0	15
3321	Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Canadian Journal of Ophthalmology, 2012, 47, S1-S30.	0.4	51
3322	Colesevelam for type 2 diabetes mellitus. The Cochrane Library, 2012, 12, CD009361.	1.5	23
3323	Diabetes MILES â€” The Netherlands: rationale, design and sample characteristics of a national survey examining the psychosocial aspects of living with diabetes in Dutch adults. BMC Public Health, 2012, 12, 925.	1.2	28
3324	Estimate of the diabetic retinopathy hazard rates in type 2 diabetic patients with current status data. International Journal of Diabetes in Developing Countries, 2012, 32, 203-208.	0.3	2
3325	Combination Therapy for Diabetic Macular Edema. Journal of Ophthalmology, 2012, 2012, 1-6.	0.6	8
3326	Overview of Type 2 Diabetes. , 2012, , 15-27.		0
3327	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vascular Health and Risk Management, 2012, 8, 255.	1.0	21
3328	Nutritional profile and presence of risk factors and protection for non-communicable chronic diseases in diabetics. Acta Scientiarum - Health Sciences, 2012, 34, .	0.2	0
3329	Disease profile: diabetic nephropathy. Journal of Renal Nursing, 2012, 4, 78-80.	0.1	0
3330	Hypertensive chronic kidney disease in African Americans: Strategies for improving care. Cleveland Clinic Journal of Medicine, 2012, 79, 726-734.	0.6	23
3331	Managing blood pressure and lipids in diabetes in primary care. Practice Nursing, 2012, 23, 82-87.	0.1	1
3332	Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Preference and Adherence, 2012, 6, 449.	0.8	14
3333	A Parametric Approach to Estimate Survival Time of Diabetic Nephropathy with Left Truncated and Right Censored Data. International Journal of Statistics and Probability, 2012, 1, .	0.1	4
3334	Diabetic Retinopathy. New England Journal of Medicine, 2012, 366, 1227-1239.	13.9	1,363
3335	Quality assurance in the diabetic retinopathy screening programme: evaluating the benefit of universal regrading of the normal primary grade. Diabetic Medicine, 2012, 29, 287-288.	1.2	2
3336	The effect of glucagon-like peptide 1 on cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 209-222.	6.1	131
3337	Diabetic Macular Edema: Therapeutic Options. Diabetes Therapy, 2012, 3, 1-14.	1.2	5

#	ARTICLE	IF	CITATIONS
3338	Use of a new high-sensitivity assay for cardiac troponin T to stratify the risk of cardiovascular disease in outpatients with type-2 diabetes. <i>Diabetology International</i> , 2012, 3, 29-36.	0.7	5
3339	Spirolactone treatment in patients with diabetic microalbuminuria and resistant hypertension. <i>International Journal of Diabetes in Developing Countries</i> , 2012, 32, 33-36.	0.3	6
3341	Protective Effects of Adeno-associated Virus Mediated Brain-derived Neurotrophic Factor Expression on Retinal Ganglion Cells in Diabetic Rats. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 467-475.	1.7	32
3342	Evaluation of educational needs in patients with diabetes mellitus in respect of medication use in Austria. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 490-500.	1.0	5
3343	Surgical Treatment of Type 2 Diabetes in Patients with BMI Below 35: Mid-term Outcomes of the Laparoscopic Ileal Interposition Associated with a Sleeve Gastrectomy in 202 Consecutive Cases. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 967-976.	0.9	53
3344	Impact of Delaying Blood Pressure Control in Patients with Type 2 Diabetes: Results of a Decision Analysis. <i>Journal of General Internal Medicine</i> , 2012, 27, 640-646.	1.3	6
3345	Corticosteroid Use for Diabetic Macular Edema: Old Fad or New Trend?. <i>Current Diabetes Reports</i> , 2012, 12, 364-375.	1.7	67
3346	Screening for Diabetic Retinopathy and Diabetic Macular Edema in the United Kingdom. <i>Current Diabetes Reports</i> , 2012, 12, 338-345.	1.7	59
3347	Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division. <i>Endocrine</i> , 2012, 42, 174-181.	1.1	6
3348	Prevention of Type 2 Diabetes and Its Complications in Developing Countries: A Review. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 121-133.	0.8	113
3349	Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension. <i>Journal of Diabetes</i> , 2012, 4, 22-29.	0.8	9
3350	What matters in ADVANCE and ADVANCE-ON. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 20-29.	2.2	19
3351	Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003-2008. <i>Diabetic Medicine</i> , 2012, 29, 198-206.	1.2	11
3352	Prehypertension: how low to go and do drugs have a role?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 187-193.	1.1	8
3353	Trends and transient change in end-digit preference in blood pressure recording: studies of sequential and longitudinal collected primary care data. <i>International Journal of Clinical Practice</i> , 2012, 66, 37-43.	0.8	19
3354	Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. <i>International Journal of Clinical Practice</i> , 2012, 66, 281-288.	0.8	11
3355	Analysis of intracranial pressure pulse waveform and brain capillary morphology in type 2 diabetes mellitus rats. <i>Brain Research</i> , 2012, 1460, 73-77.	1.1	9
3356	Diabetes, hyperglycaemia, and acute ischaemic stroke. <i>Lancet Neurology</i> , The, 2012, 11, 261-271.	4.9	377

#	ARTICLE	IF	CITATIONS
3357	Guidelines adherence and hypertension control at a tertiary hospital in Malaysia. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 798-804.	0.9	18
3358	The unexpected pathway to the creation of the HbA1c test and the discovery of ACEâ€™s. <i>Journal of Internal Medicine</i> , 2012, 271, 219-226.	2.7	15
3359	A 48-week study of amlodipine plus amiloride/â€™hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension. <i>International Journal of Clinical Practice</i> , 2012, 66, 792-799.	0.8	6
3360	Aggressive Blood Pressureâ€™Lowering Therapy Guided by Home Blood Pressure Monitoring Improves Target Organ Damage in Hypertensive Patients With Type 2 Diabetes/Prediabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 422-428.	1.0	22
3361	Retinopathy and visual impairment in diabetes, impaired glucose tolerance and normal glucose tolerance: the Nordâ€™Trâ€™ndelag Health Study (the HUNT study). <i>Acta Ophthalmologica</i> , 2012, 90, 237-243.	0.6	12
3362	Visitâ€™oâ€™visit variability in blood pressure strongly predicts allâ€™cause mortality in patients with type 2 diabetes: a 5â€™-5â€™year prospective analysis. <i>European Journal of Clinical Investigation</i> , 2012, 42, 245-253.	1.7	101
3363	â€™Omicsâ€™driven discoveries in prevention and treatment of type 2 diabetes. <i>European Journal of Clinical Investigation</i> , 2012, 42, 579-588.	1.7	15
3364	Rosiglitazone, a peroxisome proliferatorâ€™activated receptor Î³ stimulant, abrogates diabetesâ€™evoked hypertension by rectifying abnormalities in vascular reactivity. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 643-649.	0.9	12
3365	Methodology and early findings of the Diabetes Management Project: a cohort study investigating the barriers to optimal diabetes care in diabetic patients with and without diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2012, 40, 73-82.	1.3	33
3366	Clinical development of new treatments for diabetic macular oedema. <i>Australasian journal of optometry</i> , The, 2012, 95, 297-305.	0.6	4
3367	Alternative pathways in the development of diabetic retinopathy: the reninâ€™angiotensin and kallikreinâ€™kinin systems. <i>Australasian journal of optometry</i> , The, 2012, 95, 282-289.	0.6	15
3368	Longâ€™term multiple risk factor interventions in Japanese elderly diabetic patients: The Japanese Elderly Diabetes Intervention Trial â€™ study design, baseline characteristics and effects of intervention. <i>Geriatrics and Gerontology International</i> , 2012, 12, 7-17.	0.7	65
3369	Nonâ€™highâ€™density lipoprotein cholesterol: An important predictor of stroke and diabetesâ€™related mortality in Japanese elderly diabetic patients. <i>Geriatrics and Gerontology International</i> , 2012, 12, 18-28.	0.7	40
3370	Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 424-432.	2.2	42
3371	Liraglutide in oral antidiabetic drug combination therapy. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 13-19.	2.2	14
3372	Trends in the incidence of visual impairment certification secondary to diabetic retinopathy in the Leeds metropolitan area, 2005â€™2010. <i>Diabetic Medicine</i> , 2012, 29, e112-6.	1.2	12
3373	Provider and Systems Factors in Diabetes Quality of Care. <i>Current Cardiology Reports</i> , 2012, 14, 97-105.	1.3	0
3374	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 89-96.	1.3	21

#	ARTICLE	IF	CITATIONS
3375	Glycation in diabetic nephropathy. <i>Amino Acids</i> , 2012, 42, 1185-1192.	1.2	22
3376	Diabetes in rural towns: effectiveness of continuing education and feedback for healthcare providers in altering diabetes outcomes at a population level: protocol for a cluster randomised controlled trial. <i>Implementation Science</i> , 2013, 8, 30.	2.5	16
3377	Clinical course and visual outcome in patients with diabetes mellitus and uveitis. <i>BMC Research Notes</i> , 2013, 6, 167.	0.6	26
3378	The role of glycemia and blood pressure control on the rate of decline in glomerular filtration rate in Vietnamese type 2 diabetes patients. <i>International Journal of Diabetes in Developing Countries</i> , 2013, 33, 96-100.	0.3	1
3379	Adherence to clinical guidelines in management of diabetes and prevention of cardiovascular disease in Qatar. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 101-112.	1.0	18
3380	Diabetes Mellitus Prevention and Treatment. , 2013, , 63-79.		0
3381	Are recommended standards for diabetes care met in Central and South America? A systematic review. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, 306-329.	1.1	26
3382	Study design of DIACORE (DIAbetes COhoRtE) â€” a cohort study of patients with diabetes mellitus type 2. <i>BMC Medical Genetics</i> , 2013, 14, 25.	2.1	25
3383	Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report. <i>Cardiovascular Diabetology</i> , 2013, 12, 71.	2.7	8
3386	Diabetes Mellitus and Periodontal Diseases. <i>Current Diabetes Reports</i> , 2013, 13, 445-452.	1.7	43
3387	Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes. <i>Current Hypertension Reports</i> , 2013, 15, 137-142.	1.5	3
3388	Type 2 Diabetes in Older People; The Importance of Blood Pressure Control. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 233-237.	0.8	8
3391	Medical management for the prevention and treatment of diabetic macular edema. <i>Survey of Ophthalmology</i> , 2013, 58, 459-465.	1.7	43
3392	Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study. <i>Acta Diabetologica</i> , 2013, 50, 873-877.	1.2	29
3393	Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. <i>Diabetic Medicine</i> , 2013, 30, 640-650.	1.2	209
3394	Medical strategies to reduce amputation in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 893-900.	1.2	32
3395	Traitement de lâ€™hypertension. <i>Canadian Journal of Diabetes</i> , 2013, 37, S492-S493.	0.4	0
3397	Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 245-262.	1.0	1

#	ARTICLE	IF	CITATIONS
3399	Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications. <i>American Journal of Preventive Medicine</i> , 2013, 45, 253-261.	1.6	184
3400	The Role of Physical Activity in Chronic Kidney Disease in the Presence of Diabetes Mellitus: A Prospective Cohort Study. <i>American Journal of Nephrology</i> , 2013, 38, 509-516.	1.4	14
3402	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. <i>Diabetes Care</i> , 2013, 36, 1541-1546.	4.3	21
3403	Perception of uncontrolled blood pressure and non-adherence to anti-hypertensive agents in diabetic hypertensive patients. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 477-483.	2.3	12
3404	How useful are hypertension guidelines for diabetes?. <i>Diabetes Management</i> , 2013, 3, 115-121.	0.5	0
3405	Blood pressure targets for hypertension in people with diabetes mellitus. <i>The Cochrane Library</i> , 2013, , CD008277.	1.5	68
3406	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	1.0	282
3407	Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications. <i>Circulation</i> , 2013, 128, 2309-2317.	1.6	80
3408	Trends in cardiovascular risk factors among people with diabetes in a population based study, Health Survey for England 1994-2009. <i>Primary Care Diabetes</i> , 2013, 7, 193-198.	0.9	16
3409	Diabetic retinopathy: Neuron protection as a therapeutic target. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1525-1529.	1.2	39
3410	Pharmacist-Physician Collaboration for Diabetes Care. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1471-1477.	0.9	24
3411	American Association of Clinical Endocrinologists™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
3412	Tailored Case Management for Diabetes and Hypertension (TEACH-DM) in a community population: Study design and baseline sample characteristics. <i>Contemporary Clinical Trials</i> , 2013, 36, 298-306.	0.8	19
3413	Optimal treatment of diabetic retinopathy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2013, 4, 61-71.	1.4	18
3414	La néphropathie chronique en présence de diabète. <i>Canadian Journal of Diabetes</i> , 2013, 37, S504-S512.	0.4	1
3415	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
3416	Hypoglycaemia is associated with the absence of a decrease in diurnal macular thickness in patients with diabetic macular oedema. <i>Diabetes and Metabolism</i> , 2013, 39, 169-173.	1.4	4
3418	Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. <i>Diabetologia</i> , 2013, 56, 2601-2608.	2.9	142

#	ARTICLE	IF	CITATIONS
3419	Hypertension management algorithm for type 2 diabetic patients applied in primary care. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 52.	1.2	5
3420	Management of diabetes mellitus and associated cardiovascular risk factors in Brazil – the Brazilian study on the practice of diabetes care. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 46.	1.2	4
3421	Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. <i>Cardiovascular Diabetology</i> , 2013, 12, 131.	2.7	9
3422	A systematic review of evidence on the association between hospitalisation for chronic disease related ambulatory care sensitive conditions and primary health care resourcing. <i>BMC Health Services Research</i> , 2013, 13, 336.	0.9	107
3423	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. <i>BMC Medical Research Methodology</i> , 2013, 13, 107.	1.4	10
3424	Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic. <i>BMC Medicine</i> , 2013, 11, 157.	2.3	50
3425	Structured personal care of type 2 diabetes: a 19-year follow-up of the study Diabetes Care in General Practice (DCGP). <i>Diabetologia</i> , 2013, 56, 1243-1253.	2.9	41
3426	Challenging evidence and assumptions: is there a role for self-monitoring of blood glucose in people with type 2 diabetes not using insulin?. <i>Current Medical Research and Opinion</i> , 2013, 29, 161-168.	0.9	18
3427	Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study. <i>Journal of Internal Medicine</i> , 2013, 274, 469-479.	2.7	26
3428	Management of hypertension in patients with type 2 diabetes mellitus. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2013, 55, 41-44.	0.2	0
3429	Vibration perception threshold for sight-threatening retinopathy screening in type 2 diabetic outpatients. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 525-531.	1.7	5
3431	Mechanisms of Diabetic Complications. <i>Physiological Reviews</i> , 2013, 93, 137-188.	13.1	1,943
3432	Coming full circle in diabetes mellitus: from complications to initiation. <i>Nature Reviews Endocrinology</i> , 2013, 9, 113-123.	4.3	66
3433	The Epidemiology of Diabetic Retinopathy. , 2013, , 907-924.		8
3435	Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema. , 2013, , 940-968.		23
3436	Higher age at onset of type 1 diabetes increases risk of macular oedema. <i>Acta Ophthalmologica</i> , 2013, 91, 709-715.	0.6	6
3437	U.S. and Canadian Hypertension Guidelines. , 2013, , 425-432.		0
3438	Hypertension and Diabetes Mellitus. , 2013, , 313-319.		0

#	ARTICLE	IF	CITATIONS
3439	Pathophysiology and treatment of diabetic retinopathy. Acta Diabetologica, 2013, 50, 1-20.	1.2	132
3440	Rétinopathie. Canadian Journal of Diabetes, 2013, 37, S513-S517.	0.4	0
3442	Treatment of Hypertension. Canadian Journal of Diabetes, 2013, 37, S117-S118.	0.4	10
3443	Screening for type 2 diabetes and population mortality over 10 years – Authors' reply. Lancet, The, 2013, 381, 903.	6.3	15
3444	A structured, group-based diabetes self-management education (DSME) programme for people, families and whanau with type 2 diabetes (T2DM) in New Zealand: An observational study. Primary Care Diabetes, 2013, 7, 151-158.	0.9	14
3445	Retinopathy. Canadian Journal of Diabetes, 2013, 37, S137-S141.	0.4	27
3446	Relationship between BNP level and renal function in diabetic nephropathy with microalbuminuria. Journal of Diabetes and Its Complications, 2013, 27, 92-97.	1.2	14
3447	Hypertension, coronary heart disease and stroke: Should the blood pressure J-curve be a concern?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 139-144.	0.2	5
3448	Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients. American Journal of Medicine, 2013, 126, 925.e11-925.e22.	0.6	174
3449	Insulin Degludec: A Novel Basal Insulin Analogue. Annals of Pharmacotherapy, 2013, 47, 269-277.	0.9	11
3450	Lowering blood pressure limits in patients with type 2 diabetes: Is it still warranted?. Journal of Diabetes and Its Complications, 2013, 27, 415-416.	1.2	0
3451	Efficacité de la vitrectomie dans l'œdème maculaire diabétique associé à une membrane épimaculaire. Journal Francais D'Ophtalmologie, 2013, 36, 830-835.	0.2	0
3452	Diabetes and kidney disease. Apollo Medicine, 2013, 10, 118-125.	0.0	2
3453	Optimizing Diabetes Literacy: Lessons from African Canadians in Calgary about Type 2 Diabetes Diagnosis. Canadian Journal of Diabetes, 2013, 37, 231-236.	0.4	3
3454	Retinopathy. Canadian Journal of Diabetes, 2013, 37, S332-S333.	0.4	1
3455	Diabetic Kidney Disease and the Cardiorenal Syndrome. Endocrinology and Metabolism Clinics of North America, 2013, 42, 789-808.	1.2	33
3456	Impact of thiazolidinediones on macular thickness and volume in diabetic eyes. Canadian Journal of Ophthalmology, 2013, 48, 312-316.	0.4	8
3457	Temporal Trends in Prevalence of CKD: The Glass Is Half Full and Not Half Empty. American Journal of Kidney Diseases, 2013, 62, 214-216.	2.1	6

#	ARTICLE	IF	CITATIONS
3458	Chronic Kidney Disease in Diabetes. Canadian Journal of Diabetes, 2013, 37, S129-S136.	0.4	53
3459	Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients. Clinical Endocrinology, 2013, 78, 278-284.	1.2	25
3460	Mortality and excess risk in US adults with pre-diabetes and diabetes: a comparison of two nationally representative cohorts, 1988-2006. Population Health Metrics, 2013, 11, 3.	1.3	14
3461	All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database. Diabetes Care, 2013, 36, 2366-2371.	4.3	121
3462	Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clinical Science, 2013, 124, 597-615.	1.8	120
3463	Advances in our understanding of diabetic retinopathy. Clinical Science, 2013, 125, 1-17.	1.8	144
3464	The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease. Medical Clinics of North America, 2013, 97, 31-51.	1.1	15
3465	Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2013, 15, 392-402.	2.2	45
3466	Antihypertensive treatment in diabetic patients. Review of current data. Maturitas, 2013, 75, 142-147.	1.0	2
3467	The Role of Diet in the Prevention and Treatment of Diabetes. , 2013, , 615-628.		0
3468	Renal Antifibrotic Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in Diabetic Rats. American Journal of Nephrology, 2013, 37, 65-73.	1.4	28
3469	Standards of Medical Care in Diabetes-2013. Diabetes Care, 2013, 36, S11-S66.	4.3	3,076
3470	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2013, 62, 201-213.	2.1	174
3471	Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients. Diabetes Care, 2013, 36, 3287-3296.	4.3	47
3472	Diabetic Retinopathy: The Need for Predictive, Preventive and Personalized Approach to Management. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 211-232.	0.6	0
3473	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	0.7	355
3474	Blood Pressure and Stroke Risk Among Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3653-3662.	1.8	37
3475	Setting clinical priorities: A framework for incorporating individual patient preferences. Patient Education and Counseling, 2013, 90, 141-143.	1.0	2

#	ARTICLE	IF	CITATIONS
3476	Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 603-612.	1.3	4
3477	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
3478	Blood pressure and diabetes: vicious twins. <i>Heart</i> , 2013, 99, 577-585.	1.2	27
3479	The implementation of guidelines in a South African population with type 2 diabetes. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2013, 18, 154-158.	0.4	8
3480	Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis. <i>Clinical Therapeutics</i> , 2013, 35, 880-899.	1.1	71
3481	Screening, Prevention, and Ambitious Management of Diabetic Macular Edema in Patients with Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2013, 13, 679-686.	1.7	4
3482	The Lower, the Better?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 135-138.	1.0	2
3484	The significance of reduced kidney function among hospitalized acute general medical patients. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 59-65.	0.2	14
3485	Chinese herbal medicine for diabetic peripheral neuropathy. <i>The Cochrane Library</i> , 2013, , CD007796.	1.5	21
3486	Current and future management of diabetic retinopathy: a personalized evidence-based approach. <i>Diabetes Management</i> , 2013, 3, 481-494.	0.5	10
3487	Association Between Depression and Functional Vision Loss in Persons 20 Years of Age or Older in the United States, NHANES 2005-2008. <i>JAMA Ophthalmology</i> , 2013, 131, 573.	1.4	191
3488	The J-Curve Limbo: How Low Can You Go?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3588-3591.	1.8	1
3489	Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2013, 125, 21-32.	0.9	20
3490	Blood pressure goals in T2DM: a Latin American perspective. <i>Nature Reviews Endocrinology</i> , 2013, 9, 138-139.	4.3	1
3491	A review of late-stage CNS drug candidates for the treatment of obesity. <i>International Journal of Obesity</i> , 2013, 37, 107-117.	1.6	17
3492	Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease. <i>International Journal of Inflammation</i> , 2013, 2013, 1-8.	0.9	51
3493	Challenges in the Management of Type 2 Diabetes Mellitus and Cardiovascular Risk Factors in Obese Subjects: What Is the Evidence and What Are the Myths?. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-10.	0.6	11
3494	Change of the Management of Treated Hypertensive Patients with or without Diabetes in Japan. <i>Clinical and Experimental Hypertension</i> , 2013, 35, 79-86.	0.5	2

#	ARTICLE	IF	CITATIONS
3495	Primary Prevention of Macroangiopathy in Patients With Short-Duration Type 2 Diabetes by Intensified Multifactorial Intervention. <i>Diabetes Care</i> , 2013, 36, 978-984.	4.3	28
3496	Prevalence of microvascular complications in newly diagnosed patients with Type 2 diabetes. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 899-902.	0.3	43
3497	Should we start all patients with diabetic retinopathy on fenofibrates?. <i>Middle East African Journal of Ophthalmology</i> , 2013, 20, 309.	0.5	1
3498	Does contact with a podiatrist prevent the occurrence of a lower extremity amputation in people with diabetes? A systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002331.	0.8	11
3499	Systemic medical management of diabetic retinopathy. <i>Middle East African Journal of Ophthalmology</i> , 2013, 20, 301.	0.5	17
3500	Impact of lifestyle modification on glycemic control in patients with type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 1030.	0.2	34
3501	Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. <i>Clinical Science</i> , 2013, 124, 17-26.	1.8	52
3502	Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes. <i>Diabetes Care</i> , 2013, 36, S312-S324.	4.3	130
3503	Evaluation of Serum Zinc Status and Glycated Hemoglobin of Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital of Assam. <i>Journal of Laboratory Physicians</i> , 2013, 5, 30-33.	0.4	18
3504	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2013, 347, f5680-f5680.	3.0	209
3505	Management of Type 2 Diabetes Mellitus in Children and Adolescents. <i>Pediatrics</i> , 2013, 131, e648-e664.	1.0	80
3506	Tip of the Iceberg. <i>Asia-Pacific Journal of Ophthalmology</i> , 2013, 2, 76-78.	1.3	3
3507	Renal Lesions Predict Progression of Diabetic Nephropathy in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1175-1181.	3.0	99
3508	Health-Related Quality of Life, Disease Severity, and Anticipated Trajectory of Diabetes. <i>The Diabetes Educator</i> , 2013, 39, 83-91.	2.6	35
3509	Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. <i>Cmaj</i> , 2013, 185, 963-967.	0.9	15
3510	Association of retinopathy with coronary atherosclerosis determined by coronary 64-slice multidetector computed tomography angiography in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 161-168.	0.9	12
3511	Effect of Pay-for-Performance Incentives on Quality of Care in Small Practices With Electronic Health Records. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1051.	3.8	101
3512	Anti-vascular endothelial growth factor therapy for diabetic macular edema. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2013, 4, 151-169.	1.4	145

#	ARTICLE	IF	CITATIONS
3513	Generic Medications and Blood Pressure Control in Diabetic Hypertensive Subjects: Results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Diabetes Care</i> , 2013, 36, 591-597.	4.3	11
3514	Achievement of Goals in U.S. Diabetes Care, 1999-2010. <i>New England Journal of Medicine</i> , 2013, 368, 1613-1624.	13.9	851
3515	Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus. <i>Hypertension</i> , 2013, 62, e21.	1.3	1
3516	Choice of anti-hypertensive agents in diabetic subjects. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 385-396.	0.9	17
3517	Epidemiological issues in diabetic retinopathy. <i>Middle East African Journal of Ophthalmology</i> , 2013, 20, 293.	0.5	80
3518	Diabetic retinopathy and its risk factors at the University Hospital in Jamaica. <i>Middle East African Journal of Ophthalmology</i> , 2013, 20, 321.	0.5	12
3519	Impact of Diabetes on Cardiovascular Disease: An Update. <i>International Journal of Hypertension</i> , 2013, 2013, 1-15.	0.5	321
3520	An evidence-based shared decision making programme on the prevention of myocardial infarction in type 2 diabetes: protocol of a randomised-controlled trial. <i>BMC Family Practice</i> , 2013, 14, 155.	2.9	7
3521	Use of Continuous Glucose Monitoring as an Educational Tool in the Primary Care Setting. <i>Diabetes Spectrum</i> , 2013, 26, 120-123.	0.4	6
3522	Insulin Sensitivity and Beta-Cell Function Are Associated with Arterial Stiffness in Individuals without Hypertension. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	1.0	10
3523	The Rising Burden of Diabetes and Hypertension in Southeast Asian and African Regions: Need for Effective Strategies for Prevention and Control in Primary Health Care Settings. <i>International Journal of Hypertension</i> , 2013, 2013, 1-14.	0.5	121
3524	Sex Disparities in Diabetes Process of Care Measures and Self-Care in High-Risk Patients. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	1.0	44
3525	Evidence underlying the clinical management of diabetic macular oedema. <i>Clinical Medicine</i> , 2013, 13, 353-357.	0.8	3
3526	Effect of an educational intervention in primary care physicians on the compliance of indicators of good clinical practice in the treatment of type 2 diabetes mellitus [OBTEDIGA project]. <i>International Journal of Clinical Practice</i> , 2013, 67, 750-758.	0.8	15
3527	Diabetic retinal disease: an update on the use of anti-VEGF agents. <i>Practical Diabetes</i> , 2013, 30, 50.	0.1	0
3528	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 2027-2037.	1.3	56
3529	The magnitude of diabetes and its association with obesity in the slums of Nairobi, Kenya: results from a cross-sectional survey. <i>Tropical Medicine and International Health</i> , 2013, 18, 1520-1530.	1.0	40
3531	Effects of 6-months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 770-773.	2.2	29

#	ARTICLE	IF	CITATIONS
3532	Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1095-1105.	0.8	25
3533	Hypoglycemia Observed During Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Treated by Subcutaneous Insulin Injection. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 586-590.	2.4	3
3534	Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2013, 67, 1261-1266.	0.8	16
3535	Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. <i>Diabetic Medicine</i> , 2013, 30, 1272-1292.	1.2	53
3536	Type 2 diabetes patients educated by other patients perform at least as well as patients trained by professionals. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 152-160.	1.7	75
3537	Blood pressure targets for patients with chronic kidney disease. <i>Blood Pressure</i> , 2013, 22, 395-396.	0.7	2
3538	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	4.3	20
3539	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 209-217.	0.8	26
3540	Management of the patient with diabetes and coronary artery disease: a contemporary review. <i>Future Cardiology</i> , 2013, 9, 387-403.	0.5	8
3541	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2013, 27, 715-720.	1.0	18
3542	Prevalence, awareness, treatment and control of hypertension in adults with diagnosed diabetes: The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV). <i>Journal of Human Hypertension</i> , 2013, 27, 381-387.	1.0	29
3543	Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. <i>International Journal of Impotence Research</i> , 2013, 25, 29-33.	1.0	14
3544	Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. <i>Cmaj</i> , 2013, 185, 949-957.	0.9	232
3545	Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3388-3395.	4.3	46
3546	Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. <i>Diabetes Care</i> , 2013, 36, 322-327.	4.3	20
3547	Cohort Profile: The Fremantle Diabetes Study. <i>International Journal of Epidemiology</i> , 2013, 42, 412-421.	0.9	111
3548	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. <i>Endocrine Journal</i> , 2013, 60, 563-570.	0.7	13
3549	Relationship between Coronary Artery Disease and Retinopathy in Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2013, 52, 2483-2487.	0.3	8

#	ARTICLE	IF	CITATIONS
3550	A social network analysis on clinical education of diabetic foot. <i>Journal of Diabetes and Metabolic Disorders</i> , 2013, 12, 44.	0.8	4
3551	Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study. <i>BMC Nephrology</i> , 2013, 14, 198.	0.8	17
3552	Contributions to management of hypertension from papers in the current issue. <i>Journal of Hypertension</i> , 2013, 31, 845-847.	0.3	0
3553	Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. <i>Journal of Hypertension</i> , 2013, 31, 223-238.	0.3	61
3554	Should diabetic blood pressure targets be the same in elderly compared with younger patients?. <i>Diabetes Management</i> , 2013, 3, 315-321.	0.5	0
3555	Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?. <i>Diabetes Management</i> , 2013, 3, 367-378.	0.5	5
3556	A preliminary study of the relationship between general practice care and hospitalisation using a diabetes register, CARDIAB. <i>Australian Health Review</i> , 2013, 37, 210.	0.5	9
3560	Effect of bis-1,4-Dihydropyridine in the Kidney of Diabetic Rats. <i>Journal of Pharmacological Sciences</i> , 2013, 122, 184-192.	1.1	7
3561	Comparison of Choroidal Thickness in Patients with Diabetes by Spectral-domain Optical Coherence Tomography. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 433.	0.5	65
3562	Characteristics of nurses providing diabetes community and outpatient care in Auckland. <i>Journal of Primary Health Care</i> , 2013, 5, 19.	0.2	13
3563	Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes. <i>International Journal of General Medicine</i> , 2013, 6, 799.	0.8	25
3564	Refocusing Peroxisome Proliferator Activated Receptor- α : A New Insight for Therapeutic Roles in Diabetes. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 326.	1.8	34
3565	Pharmaceutical care – impact on quality of life in patients with type 2 diabetes: a review. <i>Clinical Audit</i> , 0, , 17.	0.4	6
3566	The Potential Association between Obstructive Sleep Apnea and Diabetic Retinopathy in Severe Obesityâ€™The Role of Hypoxemia. <i>PLoS ONE</i> , 2013, 8, e79521.	1.1	52
3567	The Impact of a Diabetes Local Enhanced Service on Quality Outcome Framework Diabetes Outcomes. <i>PLoS ONE</i> , 2013, 8, e83738.	1.1	8
3568	Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 327.	1.1	255
3569	Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. <i>Drug Design, Development and Therapy</i> , 2013, 7, 425.	2.0	7
3570	Diagnosis and Treatment of Ischemic Heart Disease in Women. , 2013, , 975-989.		0

#	ARTICLE	IF	CITATIONS
3571	The Genetics of Diabetic Nephropathy. <i>Genes</i> , 2013, 4, 596-619.	1.0	36
3572	Proteinuria and its relation to cardiovascular disease. <i>International Journal of Nephrology and Renovascular Disease</i> , 2013, 7, 13.	0.8	67
3574	Diabetes mellitus and stroke. <i>Nosotchu</i> , 2014, 36, 105-112.	0.0	0
3575	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 169.	1.1	135
3576	Trends in Hypertension Prevalence, Awareness, Treatment and Control in an Adult Type 2 Diabetes Spanish Population between 2003 and 2009. <i>PLoS ONE</i> , 2014, 9, e86713.	1.1	27
3577	Cardiometabolic Risk Profiles Associated with Chronic Complications in Overweight and Obese Type 2 Diabetes Patients in South China. <i>PLoS ONE</i> , 2014, 9, e101289.	1.1	13
3578	All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. <i>PLoS ONE</i> , 2014, 9, e109501.	1.1	18
3579	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. <i>British Journal of General Practice</i> , 2014, 64, e208-e216.	0.7	11
3580	Telehealth Technologies: Changing the Way We Deliver Efficacious and Cost-Effective Diabetes Self-Management Education. <i>Journal of Health Care for the Poor and Underserved</i> , 2014, 25, 1853-1897.	0.4	26
3581	Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2014, 8, 1185.	0.8	38
3582	State of the art paper Heart failure in the diabetic population – pathophysiology, diagnosis and management. <i>Archives of Medical Science</i> , 2014, 3, 546-556.	0.4	74
3583	Revisiting the J-curve Phenomenon. An Old New Concept?. <i>Current Hypertension Reviews</i> , 2014, 10, 14-19.	0.5	1
3584	CONTROL OF HYPERTENSION AFTER ROUX-EN-Y GASTRIC BYPASS AMONG OBESE DIABETIC PATIENTS. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 21-24.	0.3	12
3585	Rationale and design of the Miami Healthy Heart Initiative: a randomized controlled study of a community health worker intervention among Latino patients with poorly controlled diabetes. <i>International Journal of General Medicine</i> , 2014, 7, 115.	0.8	21
3586	Mechanotransduction and the Myogenic Response in Diabetes. <i>Studies in Mechanobiology, Tissue Engineering and Biomaterials</i> , 2014, , 233-270.	0.7	0
3587	Stage A: Can Heart Failure Be Prevented?. <i>Current Cardiology Reviews</i> , 2014, 11, 4-9.	0.6	4
3588	Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 760-766.	4.3	10
3589	Factors Influencing the Decline in Stroke Mortality. <i>Stroke</i> , 2014, 45, 315-353.	1.0	655

#	ARTICLE	IF	CITATIONS
3591	Update on Clinical Guidelines for Treatment of Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	0
3592	Chapter 3. Principles of treatment. <i>Hypertension Research</i> , 2014, 37, 279-285.	1.5	1
3593	Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. <i>Kidney International</i> , 2014, 85, 536-546.	2.6	64
3594	Is home blood pressure reporting in patients with type 2 diabetes reliable?. <i>Hypertension Research</i> , 2014, 37, 741-745.	1.5	17
3595	Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats. <i>Hypertension Research</i> , 2014, 37, 901-907.	1.5	9
3596	Diabetic retinopathy: current and future methods for early screening from a retinal hemodynamic and geometric approach. <i>Expert Review of Ophthalmology</i> , 2014, 9, 431-442.	0.3	16
3597	Chapter 7. Hypertension complicated by other diseases. <i>Hypertension Research</i> , 2014, 37, 315-324.	1.5	2
3599	The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2565-2585.	0.9	27
3600	Dietary Hyperlipidemia and Retinal Microaneurysms. , 2014, , 613-618.		0
3601	The Association Between Patient-Reported Self-management Behavior, Intermediate Clinical Outcomes, and Mortality in Patients With Type 2 Diabetes: Results From the KORA-A Study. <i>Diabetes Care</i> , 2014, 37, 1604-1612.	4.3	32
3602	Endothelial Progenitor Cells in Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2014, 5, 44.	1.5	67
3603	Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2014, 5, 86.	1.5	72
3604	In search for the "sweet spot"™ for blood pressure level in diabetes: Table 1. <i>Heart</i> , 2014, 100, 1404-1405.	1.2	3
3605	Bariatric surgery relieves type 2 diabetes and modulates inflammatory factors and coronary endothelium eNOS/iNOS expression in <i>db/db</i> mice. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 70-77.	0.7	14
3606	Effect of Aerobic Training on Glucose Control and Blood Pressure in T2DDM East African Males. <i>Isrn Endocrinology</i> , 2014, 2014, 1-6.	2.0	17
3607	Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study. <i>BMJ Open</i> , 2014, 4, e005859.	0.8	30
3608	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
3609	Challenges in Elucidating the Genetics of Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2014, 132, 96.	1.4	85

#	ARTICLE	IF	CITATIONS
3611	A Cascade of Care for Diabetes in the United States: Visualizing the Gaps. <i>Annals of Internal Medicine</i> , 2014, 161, 681.	2.0	139
3612	Trends of hypertension prevalence, awareness, treatment and control in rural areas of northern China during 1991–2011. <i>Journal of Human Hypertension</i> , 2014, 28, 25-31.	1.0	75
3613	Reabilitação cardíaca em doentes coronários com diabetes mellitus tipo 2: Estudo comparativo. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 599-608.	0.2	8
3614	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2014, , CD008721.	1.5	43
3615	Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F1123-F1131.	1.3	48
3616	Type 2 diabetes in the child and adolescent. <i>Pediatric Diabetes</i> , 2014, 15, 26-46.	1.2	152
3617	Severe obesity and diabetes self-care attitudes, behaviours and burden: implications for weight management from a matched case-control study. Results from Diabetes <scp>MILES</scp>—Australia. <i>Diabetic Medicine</i> , 2014, 31, 232-240.	1.2	19
3618	Cardiovascular Autonomic Neuropathy Is Associated With Macrovascular Risk Factors in Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 874-880.	1.3	19
3619	Systemic Therapies for Diabetic Retinopathy. <i>Ophthalmology</i> , 2014, 121, 2295-2296.	2.5	13
3620	Combination therapy with metformin plus sulphonylureas versus metformin plus <scp>DPP</scp>4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 977-983.	2.2	62
3621	Improved Diabetes Screening Using an Extended Predictive Feature Search. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 166-171.	2.4	6
3622	The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking. <i>Hypertension Research</i> , 2014, 37, 391-392.	1.5	9
3623	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Clinical Hypertension</i> , 2014, 16, 14-26.	1.0	768
3624	Review of the role of refined dietary sugars (fructose and glucose) in the genesis of retinal disease. <i>Clinical and Experimental Ophthalmology</i> , 2014, 42, 564-573.	1.3	14
3625	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2014, 37, 2015-2023.	4.3	56
3626	Expert consensus on blood pressure management of diabetic patients in <scp>C</scp>hina (ã·½ç³—ã°¿ç—...æ,èç...èìãžç®¿ç+ä,ã·® of Diabetes, 2014, 6, 202-211.	0.8	0
3627	Osteoprotegerin Is Associated With Subclinical Left Ventricular Systolic Dysfunction in Diabetic Hypertensive Patients: A Speckle Tracking Study. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1529-1534.	0.8	10
3628	Do primary health care nurses address cardiovascular risk in diabetes patients?. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 212-220.	1.1	8

#	ARTICLE	IF	CITATIONS
3629	New technologies and drugs in the management of diabetic retinopathy. <i>Practical Diabetes</i> , 2014, 31, 275-280a.	0.1	1
3630	A novel model enhances <sc>HbA1c</sc>-based diabetes screening using simple anthropometric, anamnestic, and demographic information. <i>Diabetes Care</i> , 2014, 37, 1211-1216.	0.8	1
3631	Modulation of the Pancreatic Islet-Stress Axis as a Novel Potential Therapeutic Target in Diabetes Mellitus. <i>Vitamins and Hormones</i> , 2014, 95, 195-222.	0.7	8
3632	Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve. <i>Hypertension</i> , 2014, 63, 29-36.	1.3	101
3633	Sex-based disparities in cardioprotective medication use in adults with diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 117.	1.2	12
3634	Decreased diabetes-induced glycemic impairment in WKY and SHR involves enhanced skeletal muscle Slc2a4/GLUT4 expression. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 97.	1.2	11
3635	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 641-658.	1.2	1
3636	Renal effects of dapagliflozin in patients with type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 53-61.	1.4	55
3637	The Synergistic Effects of HIV, Diabetes, and Aging on Cognition. <i>Journal of Neuroscience Nursing</i> , 2014, 46, 292-305.	0.7	28
3638	Effects of an energy-restricted diet rich in plant-derived ω -3-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits. <i>British Journal of Nutrition</i> , 2014, 112, 1315-1322.	1.2	44
3639	Characteristics of diabetic patients associated with achieving and maintaining blood pressure targets in the Adherence and Intensification of Medications program. <i>Chronic Illness</i> , 2014, 10, 60-73.	0.6	4
3640	OCULAR FINDINGS AT INITIAL PAN RETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY PREDICT THE NEED FOR FUTURE PARS PLANA VITRECTOMY. <i>Retina</i> , 2014, 34, 1997-2002.	1.0	13
3641	Risk Factor Management for Stroke Prevention. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 296-308.	0.4	14
3642	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2014, 32, 2285-2295.	0.3	267
3643	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
3644	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. <i>Postgraduate Medicine</i> , 2014, 126, 190-204.	0.9	11
3645	Revolution to a New Standard Treatment of Diabetic Macular Edema. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2269.	3.8	40
3646	Interarm Blood Pressure Difference in People With Diabetes: Measurement and Vascular and Mortality Implications. <i>Diabetes Care</i> , 2014, 37, 1613-1620.	4.3	59

#	ARTICLE	IF	CITATIONS
3647	Listening to Older Adults' Values and Preferences for Type 2 Diabetes Care: A Qualitative Study. <i>Diabetes Spectrum</i> , 2014, 27, 44-49.	0.4	26
3648	Systolic Blood Pressure Levels Among Adults With Hypertension and Incident Cardiovascular Events. <i>JAMA Internal Medicine</i> , 2014, 174, 1252.	2.6	50
3649	Clinical therapeutic strategies for early stage of diabetic kidney disease. <i>World Journal of Diabetes</i> , 2014, 5, 342.	1.3	42
3650	Epidemiologic Evidence on Antioxidant-related Micronutrients and Diabetic Retinopathy. , 2014, , 231-236.		1
3651	Intraocular surgery in a large diabetes patient population: risk factors and surgical results. <i>Acta Ophthalmologica</i> , 2014, 92, 1-13.	0.6	13
3652	Non-proliferative Diabetic Retinopathy. , 2014, , 19-63.		3
3653	Activation of adenosine receptors improves renal antioxidant status in diabetic Wistar but not SHR rats. <i>Upsala Journal of Medical Sciences</i> , 2014, 119, 10-18.	0.4	16
3654	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 8.	2.9	35
3655	Influence of pulse pressure and spontaneous variations of macular thickness in patients with diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2014, 92, e372-6.	0.6	5
3656	High prevalence in Malawi of sight-threatening retinopathy and visual impairment caused by diabetes: identification of population-specific targets for intervention. <i>Diabetic Medicine</i> , 2014, 31, 1643-1650.	1.2	26
3657	Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*. <i>Diabetic Medicine</i> , 2014, 31, 2-14.	1.2	36
3658	The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 577-584.	1.1	4
3659	Diabetes knowledge of nurses providing community care for diabetes patients in Auckland, New Zealand. <i>Primary Care Diabetes</i> , 2014, 8, 215-223.	0.9	13
3660	Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010. <i>Annals of Epidemiology</i> , 2014, 24, 516-521.e1.	0.9	19
3661	Effect of prescription refill on quality of care among patients with type 2 diabetes: An exploratory study. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 110-118.	1.1	2
3662	Profile of adults with type 2 diabetes and uptake of clinical care best practices: Results from the 2011 Survey on Living with Chronic Diseases in Canada - Diabetes component. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 11-19.	1.1	10
3663	Elevated fasting serum insulin level predicts future development of hypertension. <i>International Journal of Cardiology</i> , 2014, 172, 450-455.	0.8	9
3664	Status of hypertension and coronary stenosis in asymptomatic type 2 diabetic patients: Analysis from Coronary Computed Tomographic Angiography Registry. <i>International Journal of Cardiology</i> , 2014, 174, 282-287.	0.8	8

#	ARTICLE	IF	CITATIONS
3665	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	1.2	75
3667	The changing role of the endocrinologist in the care of patients with diabetic retinopathy. <i>Endocrine</i> , 2014, 46, 199-208.	1.1	9
3668	The 16-year incidence, progression and regression of diabetic retinopathy in a young population-based Danish cohort with type 1 diabetes mellitus: The Danish cohort of pediatric diabetes 1987 (DCPD1987). <i>Acta Diabetologica</i> , 2014, 51, 413-420.	1.2	41
3669	The relationship between central hemodynamics, morning blood pressure surge, glycemic control and sodium intake in patients with type 2 diabetes and essential hypertension. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 420-426.	1.1	10
3670	Profils metabolique et clinique avant, pendant et apres la periode du ramadan chez des Maliens atteints de diabete de type 2. <i>Nutrition Clinique Et Metabolisme</i> , 2014, 28, 83-89.	0.2	6
3671	Allosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness. <i>Archives of Pharmacal Research</i> , 2014, 37, 285-298.	2.7	7
3672	Anti-hyperglycemic activity of <i>Centella asiatica</i> is partly mediated by carbohydrase inhibition and glucose-fiber binding. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 31.	3.7	50
3673	The gutrenal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014, 10, 88-103.	4.1	155
3674	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. <i>IJC Metabolic & Endocrine</i> , 2014, 2, 1-10.	0.5	3
3675	Changes in Diabetes-Related Complications in the United States, 19902010. <i>New England Journal of Medicine</i> , 2014, 370, 1514-1523.	13.9	1,374
3676	Management Paradigms for Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2014, 157, 505-513.e8.	1.7	89
3677	DPP-IV inhibitors: Beyond glycaemic control?. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 157-164.	2.3	7
3678	Diabetes Mellitus and Peripheral Vascular Disease. <i>Clinics in Podiatric Medicine and Surgery</i> , 2014, 31, 11-26.	0.2	16
3679	Nophropathie diabotique. , 2014, , 229-250.		0
3680	Dsordres cliniques et biologiques associs. , 2014, , 71-88.		0
3681	Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. <i>International Journal of Cardiology</i> , 2014, 174, 702-709.	0.8	18
3682	Management of hypertension in CKD. <i>Clinical Queries Nephrology</i> , 2014, 3, 1-4.	0.2	0
3683	Lipids and lipid management in diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 325-338.	2.2	72

#	ARTICLE	IF	CITATIONS
3684	Comparison of four cardiovascular risk prediction functions among Chinese patients with diabetes mellitus in the primary care setting. <i>Journal of Diabetes Investigation</i> , 2014, 5, 606-614.	1.1	12
3685	Hypertension in Diabetes Mellitus. , 2014, , 119-134.		0
3686	Diabetic Eye Disease. , 2014, , 153-161.		0
3687	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1721-1728.	4.3	217
3688	Cardiovascular Complications of Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 273-280.	0.6	181
3689	The pathobiology of diabetic vascular complications—cardiovascular and kidney disease. <i>Journal of Molecular Medicine</i> , 2014, 92, 441-452.	1.7	58
3690	Antioxidant Supplements and Diabetic Retinopathy. , 2014, , 213-222.		1
3691	The ocular renin-angiotensin system: A therapeutic target for the treatment of ocular disease. , 2014, 142, 11-32.		51
3692	Cardiac rehabilitation in patients with type 2 diabetes mellitus and coronary disease: A comparative study. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 599-608.	0.2	6
3693	Clinical Outcomes and Cost-effectiveness of Continuous Positive Airway Pressure to Manage Obstructive Sleep Apnea in Patients With Type 2 Diabetes in the U.K.. <i>Diabetes Care</i> , 2014, 37, 1263-1271.	4.3	64
3694	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2014, 45, 3754-3832.	1.0	1,621
3695	Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up. <i>Diabetic Medicine</i> , 2014, 31, 1055-1063.	1.2	11
3696	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 2014, 16, 457.	2.0	30
3697	Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: Data from the Adult Diabetes Control and Management. <i>Geriatrics and Gerontology International</i> , 2014, 14, 130-137.	0.7	17
3698	Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2014, 14, 526.	1.7	29
3699	Novel effective drugs for diabetic kidney disease? or not?. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 571-601.	1.0	15
3700	Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2014, 37, 2782-2788.	4.3	23
3701	Assessment of Central Blood Pressure in Patients With Type 2 Diabetes: A Comparison Between Sphygmocor and Invasively Measured Values. <i>American Journal of Hypertension</i> , 2014, 27, 169-176.	1.0	40

#	ARTICLE	IF	CITATIONS
3703	Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 3-22.	1.0	166
3704	Progress in reducing vascular complications of diabetes. Nature Reviews Endocrinology, 2014, 10, 451-453.	4.3	5
3705	III.L. Proliferative Diabetic Vitreoretinopathy. , 2014, , 421-434.		1
3706	Updated National and International Hypertension Guidelines: A Review of Current Recommendations. Drugs, 2014, 74, 2033-2051.	4.9	95
3707	Maximum home systolic blood pressure is a useful indicator of arterial stiffness in patients with type 2 diabetes mellitus: Post hoc analysis of a cross-sectional multicenter study. Diabetes Research and Clinical Practice, 2014, 105, 344-351.	1.1	17
3708	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 145-151.	1.8	17
3710	Testing for Albuminuria in 2014. Canadian Journal of Diabetes, 2014, 38, 372-375.	0.4	5
3711	Treating hypertension in type 2 diabetes. Expert Opinion on Pharmacotherapy, 2014, 15, 2131-2140.	0.9	9
3712	Blood pressure and heart failure risk among diabetic patients. International Journal of Cardiology, 2014, 176, 125-132.	0.8	14
3713	Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population. Journal of the American College of Cardiology, 2014, 64, 588-597.	1.2	138
3714	Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet, The, 2014, 384, 591-598.	6.3	510
3715	Evaluating the effectiveness of opportunistic eye screening model for people with Diabetes attending Diabetes clinic at Mnazi Mmoja hospital, Zanzibar. BMC Ophthalmology, 2014, 14, 81.	0.6	5
3716	Prevalence of retinopathy among adults with self-reported diabetes mellitus: the Sri Lanka diabetes and Cardiovascular Study. BMC Ophthalmology, 2014, 14, 100.	0.6	28
3717	Coincidence of diabetes mellitus and hypertension in a semi-urban Cameroonian population: a cross-sectional study. BMC Public Health, 2014, 14, 696.	1.2	23
3718	Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes. Diabetology and Metabolic Syndrome, 2014, 6, 81.	1.2	5
3719	The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetology and Metabolic Syndrome, 2014, 6, 31.	1.2	28
3720	Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. Diabetology and Metabolic Syndrome, 2014, 6, 46.	1.2	21
3721	The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States. Diabetology and Metabolic Syndrome, 2014, 6, 50.	1.2	151

#	ARTICLE	IF	CITATIONS
3722	Association between socioeconomic status, type 2 diabetes and its chronic complications in Argentina. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 241-247.	1.1	12
3723	Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience. <i>Canadian Journal of Cardiology</i> , 2014, 30, 544-552.	0.8	89
3724	Standards of Medical Care in Diabetes—2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	4.3	3,893
3725	Evidence-based carotid artery–based interventions for stroke risk reduction. <i>Current Problems in Surgery</i> , 2014, 51, 198-242.	0.6	3
3727	Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial. <i>Diabetes Therapy</i> , 2014, 5, 267-283.	1.2	67
3728	DialBetics. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 209-215.	1.3	175
3729	Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. <i>Contemporary Clinical Trials</i> , 2014, 39, 124-131.	0.8	9
3730	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.4	106
3731	Association between Physical Activity Advice Only or Structured Exercise Training with Blood Pressure Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Sports Medicine</i> , 2014, 44, 1557-1572.	3.1	49
3732	Prevalence and risk factors for diabetic retinopathy in Asian Indians with young onset Type 1 and Type 2 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 291-297.	1.2	68
3733	Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009. <i>Value in Health</i> , 2014, 17, 51-61.	0.1	5
3734	Selective enrichment of bioactive properties during ultrafiltration of a tryptic digest of β 2-lactoglobulin. <i>Journal of Functional Foods</i> , 2014, 9, 38-47.	1.6	75
3735	Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 281-286.	0.6	51
3736	The prevalence of diabetes complications and associated risk factors in Pacific Islands countries. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 114-118.	1.1	39
3738	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 869-887.	2.1	31
3739	Atherogenic lipids and vascular complications in a selected diabetic population with normal urinary albumin/creatinine ratios. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 124-127.	1.8	3
3741	Type 2 Diabetes Mellitus and Hypertension. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 103-122.	1.2	231
3742	Diabetic kidney disease: from physiology to therapeutics. <i>Journal of Physiology</i> , 2014, 592, 3997-4012.	1.3	142

#	ARTICLE	IF	CITATIONS
3743	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , The, 2014, 383, 2008-2017.	6.3	194
3744	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 507.	3.8	6,625
3745	Association of endothelial lipase Thr111Ile polymorphism with proliferative retinopathy in type 2 diabetes patients. <i>Diabetes and Metabolism</i> , 2014, 40, 452-458.	1.4	8
3746	The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan—Implications for the Evaluation of Diabetes Mellitus Therapies. <i>Value in Health Regional Issues</i> , 2014, 3, 108-116.	0.5	18
3747	Prevalence of obesity and systemic hypertension among diabetes mellitus patients attending an out-patient diabetes clinic in a Ghanaian Teaching Hospital. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 67-71.	1.8	19
3748	Combined effects of type 2 diabetes and hypertension associated with cortical thinning and impaired cerebrovascular reactivity relative to hypertension alone in older adults. <i>NeuroImage: Clinical</i> , 2014, 5, 36-41.	1.4	69
3749	Diabetes-induced increase of renal medullary hydrogen peroxide and urinary angiotensinogen is similar in normotensive and hypertensive rats. <i>Life Sciences</i> , 2014, 108, 71-79.	2.0	10
3750	Top 10 landmark studies in hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 437-447.	2.3	7
3751	Time-to-effect relationships between systolic blood pressure and the risks of nephropathy and retinopathy in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 674-678.	1.2	6
3752	Diabetes and age-related demographic differences in risk factor control. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 394-404.	2.3	11
3753	Interventions to maintain cardiac risk control after discharge from a cardiovascular risk reduction clinic: A randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 327-335.	1.1	12
3755	The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. <i>Acta Ophthalmologica</i> , 2014, 92, 133-137.	0.6	48
3756	Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2014, 61, 1011-1018.	0.7	48
3758	The J-Curve in Arterial Hypertension: Fact or Fallacy?. <i>Cardiology</i> , 2014, 129, 126-135.	0.6	23
3759	Long Term Complications of Diabetes – A Review. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2014, 21, 347-355.	0.3	0
3760	CHOROIDAL THICKNESS CHANGES AFTER DIABETES TYPE 2 AND BLOOD PRESSURE CONTROL IN A HOSPITALIZED SITUATION. <i>Retina</i> , 2014, 34, 1190-1198.	1.0	29
3762	Noninvasive Measurement of Glucose in Artificial Plasma with Near-Infrared and Raman Spectroscopy. <i>Applied Spectroscopy</i> , 2014, 68, 428-433.	1.2	16
3763	Swiss Quality and Outcomes Framework: Quality Indicators for Diabetes Management in Swiss Primary Care Based on Electronic Medical Records. <i>Gerontology</i> , 2014, 60, 263-273.	1.4	18

#	ARTICLE	IF	CITATIONS
3764	Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus. The Cochrane Library, 2014, 2014, CD006424.	1.5	111
3765	Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies. Canadian Journal of Diabetes, 2015, 39, S176-S182.	0.4	2
3767	The Kidney Awareness Registry and Education (KARE) study: protocol of a randomized controlled trial to enhance provider and patient engagement with chronic kidney disease. BMC Nephrology, 2015, 16, 166.	0.8	30
3768	Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice, 2015, 69, 531-549.	0.8	11
3769	The role of point of care testing in diabetes management. British Journal of Health Care Management, 2015, 21, 63-67.	0.1	3
3770	Diabetic kidney disease. Nature Reviews Disease Primers, 2015, 1, 15018.	18.1	542
3771	Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 2015, 163, 861-868.	2.0	253
3772	Head-to-head comparison of intensive lifestyle intervention (U-TURN) versus conventional multifactorial care in patients with type 2 diabetes: protocol and rationale for an assessor-blinded, parallel group and randomised trial. BMJ Open, 2015, 5, e009764.	0.8	23
3773	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan " 2015. Endocrine Practice, 2015, 21, 1-87.	1.1	443
3774	Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. BMJ Open, 2015, 5, e009116-e009116.	0.8	36
3775	Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study. Journal of Diabetes and Metabolic Disorders, 2015, 15, 28.	0.8	2
3779	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
3780	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology, 2015, 14, 116.	2.7	39
3781	Comparison of the Adherence to the American Diabetes Association Guidelines of Diabetes Care in Primary Care and Subspecialty Clinics. Journal of Diabetes and Metabolic Disorders, 2015, 14, 35.	0.8	9
3782	Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study. Cardiovascular Diabetology, 2015, 14, 105.	2.7	38
3783	Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision (London, England), 2015, 2, 17.	1.4	1,032
3784	Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center. Journal of Hospital Medicine, 2015, 10, 228-235.	0.7	3
3785	A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication. American Journal of Therapeutics, 2015, 22, 322-341.	0.5	19

#	ARTICLE	IF	CITATIONS
3786	Improvements in Cardiometabolic Risk Factors Among Overweight and Obese Employees Participating in a University Worksite Wellness Program. <i>Health Promotion Practice</i> , 2015, 16, 805-813.	0.9	6
3787	Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany - a retrospective cohort and case control study in claims data of a large statutory health insurance. <i>BMC Public Health</i> , 2015, 15, 855.	1.2	55
3788	Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial. <i>Implementation Science</i> , 2015, 10, 83.	2.5	17
3789	Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 95.	1.2	16
3790	Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in patients with type 2 diabetes mellitus. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 444-450.	0.9	9
3791	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <i>Diabetic Medicine</i> , 2015, 32, 1530-1540.	1.2	40
3792	Optimal SBP targets for the prevention of progression of type 2 diabetic nephropathy. <i>Journal of Hypertension</i> , 2015, 33, 1758-1760.	0.3	1
3793	Diabetes quality of care at a university community in <sc>B</sc>eirut. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 824-830.	0.9	5
3794	Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data. <i>Diabetic Medicine</i> , 2015, 32, 951-957.	1.2	41
3795	Metformin monotherapy for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2015, , CD002966.	1.5	2
3796	Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2015, 33, 2091-2098.	0.3	17
3797	The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients: A Nationwide Cross-Sectional Study in Thailand. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 395.	1.8	33
3798	Managing hypertension in diabetes. <i>Independent Nurse</i> , 2015, 2015, 22-26.	0.0	1
3799	Incidence Density and Risk Factors of Diabetic Retinopathy Within Type 2 Diabetes: A Five-Year Cohort Study in China (Report 1). <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 7899-7909.	1.2	45
3800	Five-Year Incidence of Chronic Kidney Disease (Stage 3-5) and Associated Risk Factors in a Spanish Cohort: The MADIABETES Study. <i>PLoS ONE</i> , 2015, 10, e0122030.	1.1	24
3801	Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. <i>PLoS ONE</i> , 2015, 10, e0127188.	1.1	46
3802	Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. <i>PLoS ONE</i> , 2015, 10, e0132228.	1.1	23
3803	The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. <i>PLoS ONE</i> , 2015, 10, e0139755.	1.1	11

#	ARTICLE	IF	CITATIONS
3804	Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility. <i>PLoS ONE</i> , 2015, 10, e0145109.	1.1	26
3805	PPAR- α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. <i>PPAR Research</i> , 2015, 2015, 1-8.	1.1	17
3806	Yang Deficiency Body Constitution Acts as a Predictor of Diabetic Retinopathy in Patients with Type 2 Diabetes: Taichung Diabetic Body Constitution Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	13
3807	Protective Effects of Scutellarin on Type II Diabetes Mellitus-Induced Testicular Damages Related to Reactive Oxygen Species/Bcl-2/Bax and Reactive Oxygen Species/Microcirculation/Staving Pathway in Diabetic Rat. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	1.0	52
3808	Assessment of Glomerular Filtration Rate Based on Alterations of Serum Brain-Derived Neurotrophic Factor in Type 2 Diabetic Subjects Treated with Amlodipine/Benazepril or Valsartan/Hydrochlorothiazide. <i>Disease Markers</i> , 2015, 2015, 1-8.	0.6	1
3809	Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. <i>Journal of Medical Economics</i> , 2015, 18, 808-820.	1.0	11
3810	Con: Biomarkers in glomerular diseases: putting the cart before the wheel?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 885-890.	0.4	6
3811	Benefit of Blood Pressure Control in Diabetic Patients. <i>Current Hypertension Reports</i> , 2015, 17, 50.	1.5	4
3812	Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2015, 162, 765-776.	2.0	112
3813	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
3814	Limited evidence to assess the impact of primary health care system or service level attributes on health outcomes of Indigenous people with type 2 diabetes: a systematic review. <i>BMC Health Services Research</i> , 2015, 15, 154.	0.9	16
3815	Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2015, 15, 44.	1.7	14
3816	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1449-1461.	0.9	43
3817	INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA. <i>Retina</i> , 2015, 35, 2440-2449.	1.0	80
3818	Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). <i>British Journal of Ophthalmology</i> , 2015, 99, 1628-1633.	2.1	40
3819	Mindfulness: Enhancing physical and mental wellbeing. <i>Practice Nursing</i> , 2015, 26, 450-453.	0.1	6
3820	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
3821	Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. <i>Revista Clinica Espanola</i> , 2015, 215, 505-514.	0.2	12

#	ARTICLE	IF	CITATIONS
3822	Supervised pharmacy student-led medication review in primary care for patients with type 2 diabetes: a randomised controlled pilot study. <i>BMJ Open</i> , 2015, 5, e009246.	0.8	16
3823	Prevalence of microvascular diseases among tertiary care Chinese with early versus late onset of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 32-37.	1.2	40
3824	Patient characteristics predicting failure to receive indicated care for type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 247-258.	1.1	5
3825	Serum total bilirubin concentration is negatively associated with increasing severity of retinopathy in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 218-221.	1.2	27
3826	A profile of diabetes in Pacific Island Countries and Territories. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 233-246.	1.1	32
3827	Quality of diabetes care in low- and middle-income Asian and Middle Eastern countries (1993â€“2012) â€“ 20-Year systematic review. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 203-223.	1.1	48
3828	â€œMild dysglycemiaâ€ in type 2 diabetes: to be neglected or not?. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 451-458.	1.2	20
3829	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 1-47.	0.6	183
3830	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
3831	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2015, 1, CD006127.	1.5	91
3832	Secondary Prevention After Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2015, 131, 927-964.	1.6	313
3834	The impact of diabetesâ€™related complications on healthcare costs: new results from the UKPDS (UKPDS) Tj ETQq1_1 0.784314 rgBT O 1.2 160	1.2	160
3835	Change in Medical Spending Attributable to Diabetes: National Data From 1987 to 2011. <i>Diabetes Care</i> , 2015, 38, dc141687.	4.3	63
3836	Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. <i>Journal of Human Hypertension</i> , 2015, 29, 473-477.	1.0	6
3837	Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 263-274.	5.5	99
3839	Facilitators, barriers and expectations in the self-management of type 2 diabetesâ€™a qualitative study from Portugal. <i>European Journal of General Practice</i> , 2015, 21, 103-110.	0.9	58
3840	The prognosis of diabetic retinopathy in patients with type 2 diabetes since 1996â€“1998: the Skaraborg Diabetes Register. <i>International Ophthalmology</i> , 2015, 35, 503-511.	0.6	8
3841	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. <i>Value in Health</i> , 2015, 18, 308-314.	0.1	32

#	ARTICLE	IF	CITATIONS
3842	Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 1-13.	0.8	13
3843	The performance of diabetes risk prediction models in new populations: the role of ethnicity of the development cohort. <i>Acta Diabetologica</i> , 2015, 52, 91-101.	1.2	12
3844	Efficacy of an empowerment program for Taiwanese patients with type 2 diabetes: A randomized controlled trial. <i>Applied Nursing Research</i> , 2015, 28, 366-373.	1.0	23
3845	Effects of β -Blocker Therapy on Active Duty Military and Military Retirees for Benign Prostatic Hypertrophy on Diabetic Complications. <i>Military Medicine</i> , 2015, 180, 355-360.	0.4	0
3846	Hypertension: Introduction, Types, Causes, and Complications. , 2015, , 635-653.		3
3847	Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2015, 38, 1290-1298.	4.3	30
3848	Food protein-derived bioactive peptides in management of type 2 diabetes. <i>European Journal of Nutrition</i> , 2015, 54, 863-880.	1.8	149
3849	Calcium Channel Blockers in the Treatment of Hypertension. , 2015, , 807-822.		0
3850	Recidivism to uncontrolled blood pressure in patients with previously controlled hypertension. <i>American Heart Journal</i> , 2015, 169, 791-797.	1.2	11
3851	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. <i>Medical Principles and Practice</i> , 2015, 24, 401-415.	1.1	1,060
3852	The Health System and Population Health Implications of Large-Scale Diabetes Screening in India: A Microsimulation Model of Alternative Approaches. <i>PLoS Medicine</i> , 2015, 12, e1001827.	3.9	25
3853	Update on Blood Pressure Goals in Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2015, 17, 37.	1.3	6
3854	Optimal blood pressure targets in 2014 – Does the guideline recommendation match the evidence base?. <i>Hypertension Y Riesgo Vascular</i> , 2015, 32, 71-82.	0.3	0
3855	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 367-381.	5.5	75
3856	Association of ABC (HbA1c, blood pressure, LDL-cholesterol) goal attainment with depression and health-related quality of life among adults with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 794-800.	1.2	10
3857	Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1526-1533.	0.4	39
3858	A perspective on the 2013 US guidelines for hypertension: Where does the so called ‘Evidence based approach’ fall short?. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S10-S14.	0.1	0
3859	Treatment of diabetic maculopathy. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 35-40.	0.2	1

#	ARTICLE	IF	CITATIONS
3860	Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2015, 58, 1203-1211.	2.9	18
3861	Distinct HbA1c trajectories in a type 2 diabetes cohort. <i>Acta Diabetologica</i> , 2015, 52, 267-275.	1.2	49
3862	Measurement of glycated hemoglobin levels using an integrated microfluidic system. <i>Microfluidics and Nanofluidics</i> , 2015, 18, 613-621.	1.0	14
3863	Diabetes: Christian Worldview, Medical Distrust and Self-Management. <i>Journal of Religion and Health</i> , 2015, 54, 1157-1172.	0.8	6
3864	Implementing Quality Measures for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2015, 17, 14.	1.1	21
3865	Hypertension in type 2 diabetes mellitus: effect of the disease and treatment on development of peripheral artery disease. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 380-384.	0.3	2
3866	The effect of hypertension comorbidity on the development of hypoglycemia in patients with type 2 diabetes. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 598-603.	0.3	0
3867	An informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trial. <i>BMC Family Practice</i> , 2015, 16, 43.	2.9	8
3868	Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015, 14, 14.	2.7	23
3870	Effects of vitamin D receptor gene polymorphism and clinical characteristics on risk of diabetic retinopathy in Han Chinese type 2 diabetes patients. <i>Gene</i> , 2015, 566, 212-216.	1.0	35
3871	Glucagon-Like Peptide-1 and Blood Pressure in Young and Healthy Adults from the General Population. <i>Hypertension</i> , 2015, 65, 306-312.	1.3	17
3872	Plasma Adrenomedullin and Allelic Variation in the <i>ADM</i> Gene and Kidney Disease in People With Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 3262-3272.	0.3	12
3873	Telehealth Program for Type 2 Diabetes: Usability, Satisfaction, and Clinical Usefulness in an Urban Community Health Center. <i>Telemedicine Journal and E-Health</i> , 2015, 21, 395-403.	1.6	48
3874	9. Microvascular Complications and Foot Care. <i>Diabetes Care</i> , 2015, 38, S58-S66.	4.3	111
3875	Standardized nursing care plans in patients with type 2 diabetes mellitus: Are they effective in the long-term?. <i>Atencion Primaria</i> , 2015, 47, 186-189.	0.6	2
3876	Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. <i>Ophthalmologica</i> , 2015, 233, 169-175.	1.0	57
3877	Effects of Blood Pressure Reduction in Mild Hypertension. <i>Annals of Internal Medicine</i> , 2015, 162, 184-191.	2.0	219
3878	Evaluation of a community diabetes initiative: Integrating diabetes care. <i>Primary Care Diabetes</i> , 2015, 9, 203-210.	0.9	11

#	ARTICLE	IF	CITATIONS
3879	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2015, 33, 195-211.	0.3	221
3880	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. <i>Cardiovascular Endocrinology</i> , 2015, 4, 11-16.	0.8	0
3881	Randomized Controlled Trials of Blood Pressure Lowering in Hypertension. <i>Circulation Research</i> , 2015, 116, 1058-1073.	2.0	131
3885	Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 591-598.	2.2	60
3886	1 The Global Burden of Obesity and Diabetes. , 2015, , 1-6.		1
3887	Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension. <i>Diabetes Care</i> , 2015, 38, 420-428.	4.3	372
3888	Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 699-706.	1.2	9
3889	Central hemodynamics, vascular stiffness, and nocturia in patients with type 2 diabetes. <i>Renal Failure</i> , 2015, 37, 359-365.	0.8	6
3890	Economics of Team-based Care in Controlling Blood Pressure. <i>American Journal of Preventive Medicine</i> , 2015, 49, 772-783.	1.6	34
3891	Excess Mortality among Persons with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 1720-1732.	13.9	777
3892	Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy. <i>Current Diabetes Reports</i> , 2015, 15, 118.	1.7	39
3893	High B-Type Natriuretic Peptide Hypertensives at Target Blood Pressure. <i>Hypertension</i> , 2015, 66, 927-932.	1.3	3
3894	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. <i>Circulation</i> , 2015, 132, 691-718.	1.6	303
3895	Early risk stratification in paediatric type 1 diabetes. <i>Acta Ophthalmologica</i> , 2015, 93, 1-19.	0.6	24
3896	Associations of retinal oximetry in persons with diabetes. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 124-131.	1.3	13
3897	C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register. <i>Diabetic Medicine</i> , 2015, 32, 85-89.	1.2	18
3898	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <i>Diabetology International</i> , 2015, 6, 151-187.	0.7	65
3899	Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 347-374.	1.1	41

#	ARTICLE	IF	CITATIONS
3900	A New Proposal for the Target Value for Home BP in Type 2 Diabetes Patients: The J-HOP Study. American Journal of Hypertension, 2015, 28, 971-979.	1.0	3
3901	Hypertension Management in Diabetic Kidney Disease. Diabetes Spectrum, 2015, 28, 175-180.	0.4	26
3902	The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. Diabetes Care, 2015, 38, 1930-1936.	4.3	35
3903	Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2015, 12, 352-358.	0.9	68
3904	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	4.3	346
3905	Management of proliferative diabetic retinopathy. , 2015, , 105-120.		0
3906	Obstructive Sleep Apnea and Diabetic Microvascular Complications. , 2015, , 213-224.		0
3907	The relationship between depressive symptoms, diabetes symptoms, and self-management among an urban, low-income Latino population. Journal of Diabetes and Its Complications, 2015, 29, 1003-1008.	1.2	17
3908	Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy, 2015, 32, 768-782.	1.3	43
3911	Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. Revista Clnica Espanõla, 2015, 215, 505-514.	0.3	3
3912	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, The, 2015, 351, h5364.	3.0	53
3913	Hypertension and Diabetic Kidney Disease in Children and Adolescents. Diabetes Spectrum, 2015, 28, 220-224.	0.4	5
3915	Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes. Current Diabetes Reports, 2015, 15, 85.	1.7	12
3916	Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy, 2015, 32, 1085-1103.	1.3	21
3917	Selecting an A1C Point-of-Care Instrument. Diabetes Spectrum, 2015, 28, 201-208.	0.4	42
3918	An estimation of the prevalence of diabetes mellitus and diabetic retinopathy in adults in Timor-Leste. BMC Research Notes, 2015, 8, 249.	0.6	10
3919	Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 132-139.	4.3	137
3920	White coat effect and masked uncontrolled hypertension in treated hypertensiveædiabetic patients: Prevalence and target organ damage. Journal of Diabetes, 2015, 7, 699-707.	0.8	8

#	ARTICLE	IF	CITATIONS
3921	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 108-114.	1.2	26
3922	The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. <i>Clinical and Experimental Hypertension</i> , 2015, 37, 177-183.	0.5	4
3923	Management of diabetes in the community. <i>Medicine</i> , 2015, 43, 54-56.	0.2	1
3924	Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 68, 18-26.	1.9	16
3925	Screening and Treatment by the Primary Care Provider of Common Diabetes Complications. <i>Medical Clinics of North America</i> , 2015, 99, 201-219.	1.1	16
3928	Macrovascular disease: pathogenesis and risk assessment. <i>Medicine</i> , 2015, 43, 1-6.	0.2	2
3929	Ophthalmic Issues in Chronic Kidney Disease. , 2015, , 237-248.		0
3930	Feasibility of Telemedicine in Detecting Diabetic Retinopathy and Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2015, 30, 81-95.	0.8	23
3931	FACTORS ASSOCIATED WITH HYPERTENSION PREVALENCE AND CONTROL AMONG LEBANESE TYPE 2 DIABETIC PATIENTS. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 8, 153.	0.3	14
3932	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
3933	Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?. <i>Monaldi Archives for Chest Disease</i> , 2016, 84, 726.	0.3	1
3934	Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 482.	1.8	40
3935	The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, α 1-glycerol phosphate and highly sensitive C-reactive protein. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 246-254.	1.1	5
3936	Preventing all the complications of hyperglycaemia: not a straightforward task. <i>Medical Journal of Australia</i> , 2016, 205, 160-161.	0.8	0
3937	Risk Factors for Macro- and Microvascular Complications among Older Adults with Diagnosed Type 2 Diabetes: Findings from The Irish Longitudinal Study on Ageing. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	1.0	15
3938	Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-13.	1.0	66
3939	Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting. Part 1: Pathophysiology and Associated Disease States. <i>Anesthesia Progress</i> , 2016, 63, 208-215.	0.2	6
3940	Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 393-405.	1.0	51

#	ARTICLE	IF	CITATIONS
3941	A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 63-73.	0.5	49
3942	Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 493-515.	0.5	108
3943	Antianginal drugs. , 2016, , 530-532.		0
3944	Timeline of History of Hypertension Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 3.	1.1	65
3945	Diabetes Mellitus, ArterialWall, and Cardiovascular Risk Assessment. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 201.	1.2	57
3946	Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1498.	1.8	82
3948	Uncontrolled Hypertension and Its Determinants in Patients with Concomitant Type 2 Diabetes Mellitus (T2DM) in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0150033.	1.1	67
3949	Future opportunities in diabetic retinopathy research. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 91-96.	1.2	11
3950	Limited sampling strategy for determining metformin area under the plasma concentrationâ€time curve. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1002-1010.	1.1	9
3951	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , 2016, 34, 788-797.	0.3	26
3952	High blood pressure in US diabetic veterans with normal renal function. <i>Journal of Hypertension</i> , 2016, 34, 836-837.	0.3	0
3953	Diabetes and Hypertension: A Comparative Review of Current Guidelines. <i>Journal of Clinical Hypertension</i> , 2016, 18, 95-100.	1.0	94
3954	Longâ€term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 766-774.	2.2	24
3955	Effects of the behavior of elderly typeâ€2 diabetic patients and their relatives as caregivers on diabetes followâ€up parameters in <sc>B</sc>olu, <sc>T</sc>urkey. <i>Geriatrics and Gerontology International</i> , 2016, 16, 182-190.	0.7	1
3956	Exposure to Racial Discrimination and Ambulatory Blood Pressure in Women with Type 2 Diabetes. <i>Stress and Health</i> , 2016, 32, 337-345.	1.4	7
3957	Improving visual prognosis of the diabetic patients during the past 30Âyears based on the data of theÅFinnish Register of Visual Impairment. <i>Acta Ophthalmologica</i> , 2016, 94, 226-231.	0.6	13
3958	Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (<sc>JADE</sc>) Registry. <i>Diabetic Medicine</i> , 2016, 33, 1230-1239.	1.2	33
3959	Blood pressure and disabilityâ€free survival among communityâ€dwelling diabetic and nonâ€diabetic elderly patients receiving antihypertensive treatment. <i>Geriatrics and Gerontology International</i> , 2016, 16, 365-373.	0.7	0

#	ARTICLE	IF	CITATIONS
3960	Vascular Complications of Diabetes. <i>Circulation Research</i> , 2016, 118, 1771-1785.	2.0	262
3961	Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. <i>The Cochrane Library</i> , 2016, 2016, CD011745.	1.5	15
3963	Cardiovascular complications of diabetes. <i>InnovAiT</i> , 2016, 9, 694-701.	0.0	1
3964	Several Aspects of Internet and Web-Based Technology in Diabetes Management. <i>Diabetes Spectrum</i> , 2016, 29, 245-248.	0.4	3
3965	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101.	2.7	17
3966	Statins and fibrates as the treatment of nonproliferative diabetic retinopathy in type 2 diabetes mellitus. <i>Spektrum Der Augenheilkunde</i> , 2016, 30, 111-116.	0.2	3
3969	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals. <i>Annals of Internal Medicine</i> , 2016, 165, 399.	2.0	87
3976	Management Protocols of stable coronary artery disease in India: Executive summary. <i>Indian Heart Journal</i> , 2016, 68, 868-873.	0.2	6
3977	Pharmacological options for managing type 2 diabetes. <i>NursePrescribing</i> , 2016, 14, 330-338.	0.1	0
3978	The Role of Beta-Blockers in the Treatment of Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 149-166.	0.8	35
3980	Management standards for stable coronary artery disease in India. <i>Indian Heart Journal</i> , 2016, 68, S31-S49.	0.2	11
3981	Diabetes mellitus in the older adult. , 2016, , 421-435.		0
3982	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. <i>Journal of Hypertension</i> , 2016, 34, 2090-2098.	0.3	28
3983	Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 68, 322-326.	0.8	7
3984	Updates on the Management of Diabetic Macular Edema with New-Generation Intravitreal Injectable Drugs. <i>Advances in Ophthalmology and Optometry</i> , 2016, 1, 111-128.	0.3	0
3985	Prevençã³n primaria de diabetes tipo 2 en Argentina: estudio piloto en la provincia de Buenos Aires. <i>Revista Argentina De Endocrinología Y Metabolismo</i> , 2016, 53, 135-141.	0.0	3
3986	<sc>LEADER</sc> and the new â€œcardiovascularâ€™™ glucoseâ€lowering agents. <i>Practical Diabetes</i> , 2016, 33, 187-189.	0.1	1
3987	Ãdme maculaire diabÃ©tique et autres maculopathies du sujet ÃgÃ© diabÃ©tique. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2016, 16, 83-91.	0.1	0

#	ARTICLE	IF	CITATIONS
3988	Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. <i>Diabetes Spectrum</i> , 2016, 29, 44-49.	0.4	4
3989	Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: Temporal trends from 1998 to 2009. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1273-1281.	0.8	10
3990	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	1.0	5,370
3991	Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes. <i>American Journal of the Medical Sciences</i> , 2016, 351, 366-373.	0.4	304
3993	When should we treat hypertension in patients with diabetes?. <i>Nature Reviews Cardiology</i> , 2016, 13, 252-253.	6.1	0
3994	Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. <i>American Journal of the Medical Sciences</i> , 2016, 351, 380-386.	0.4	371
3995	Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes – A real-world population study in Taiwan. <i>International Journal of Cardiology</i> , 2016, 215, 114-119.	0.8	13
3997	<i>Clostridium difficile</i> infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 68-79.	1.1	10
3998	MANEJO DE LA HIPERTENSIÓN ARTERIAL EN DIABETES MELLITUS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 204-212.	0.2	1
3999	LEADER-4. <i>Journal of Hypertension</i> , 2016, 34, 1140-1150.	0.3	13
4000	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.4	1,189
4001	SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2073-2084.	0.9	18
4002	Simultaneous control of glycemic, blood pressure, and lipid significantly reduce the risk of renal progression in diabetes patients. <i>European Journal of Internal Medicine</i> , 2016, 36, 87-92.	1.0	5
4004	Selecting Optimum Antihypertensive Therapy. , 2016, , 217-247.		0
4005	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes Research and Clinical Practice</i> , 2016, 121, 204-214.	1.1	40
4006	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1071-1078.	1.1	13
4007	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , 2016, 16, 42.	0.9	12
4008	Metoprolol decreases the plasma exposure of metformin via the induction of liver, kidney and muscle uptake in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 511-521.	1.1	5

#	ARTICLE	IF	CITATIONS
4009	Metformin and Angiogenesis in Cancer - Revisited. <i>Oncology</i> , 2016, 91, 179-184.	0.9	16
4010	Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 387-399.	1.2	6
4011	Standards of care for type 2 diabetes in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 442-458.	1.7	236
4012	Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. <i>Diabetic Medicine</i> , 2016, 33, 886-895.	1.2	11
4013	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1045-1053.	1.0	2
4014	Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 111-115.	0.7	7
4015	Diabetic retinopathy in Tanzania: prevalence and risk factors at entry into a regional screening programme. <i>Tropical Medicine and International Health</i> , 2016, 21, 417-426.	1.0	30
4016	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
4017	The Perfect Clinical Trial. <i>International Review of Neurobiology</i> , 2016, 127, 27-41.	0.9	7
4018	Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 55-60.	0.1	0
4019	Clinical Case 2: Adult Patient with Hypertension and Diabetes. <i>Practical Case Studies in Hypertension Management</i> , 2016, , 17-32.	0.0	0
4020	Clinical Case 3: Patient with Diabetes Mellitus. <i>Practical Case Studies in Hypertension Management</i> , 2016, , 41-60.	0.0	0
4021	Fenofibrate and Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2016, 16, 90.	1.7	31
4022	Trends in Prevalence of Chronic Kidney Disease in the United States. <i>Annals of Internal Medicine</i> , 2016, 165, 473.	2.0	432
4023	Management of mild hypertension in adults. <i>BMJ, The</i> , 2016, 355, i5719.	3.0	18
4024	Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2218-2224.	4.3	25
4025	Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 2004-2010.	4.3	15
4026	More Versus Less Blood Pressure Lowering: An Update. <i>Clinical Therapeutics</i> , 2016, 38, 2135-2141.	1.1	11

#	ARTICLE	IF	CITATIONS
4027	Osmotic expression of aldose reductase in retinal pigment epithelial cells: involvement of NFAT5. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2387-2400.	1.0	10
4028	First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa. <i>Ophthalmology</i> , 2016, 123, 1919-1925.	2.5	11
4029	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.4	415
4030	Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. <i>Diabetes Research and Clinical Practice</i> , 2016, 121, 69-85.	1.1	13
4031	More Versus Less Intensive Blood Pressure Lowering Strategy. <i>Hypertension</i> , 2016, 68, 642-653.	1.3	75
4032	What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?. <i>Diabetes Care</i> , 2016, 39, S234-S243.	4.3	21
4033	Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 383-389.	0.6	26
4034	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. <i>International Journal of Cardiology</i> , 2016, 221, 114-121.	0.8	39
4035	Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report. , 2016, , 131-150.		0
4036	Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , 2016, 33, 2091-2109.	1.3	4
4037	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e535-e578.	1.6	285
4038	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	1.2	21
4039	Diabetic retinopathy. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16012.	18.1	661
4041	How information about the time requirements and legacy effects of treatments influence decision-making in patients with diabetes and hypertension. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000210.	1.2	3
4042	Correlation of global risk assessment with cardiovascular complications in patients with diabetes mellitus living in Puerto Rico. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000279.	1.2	3
4043	Hypertension in type 2 diabetes: impact of glucose-lowering medications. <i>Cardiovascular Endocrinology</i> , 2016, 5, 137-143.	0.8	0
4044	Blood pressure targets in type 2 diabetes: a general perspective. <i>Cardiovascular Endocrinology</i> , 2016, 5, 122-126.	0.8	0
4045	Diabetes and hypertension: too many guidelines, not enough data. <i>Cardiovascular Endocrinology</i> , 2016, 5, 127-132.	0.8	0

#	ARTICLE	IF	CITATIONS
4046	Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. <i>BMC Family Practice</i> , 2016, 17, 144.	2.9	14
4047	Prevalence of undiagnosed diabetic retinopathy among inpatients with diabetes: the diabetic retinopathy inpatient study (DRIPS). <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000164.	1.2	21
4048	Identifying the optimal blood pressure target for ideal health. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 1-6.	1.0	7
4049	Economic aspects in the management of diabetes in Italy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000197.	1.2	22
4050	Relation between primary care physician supply and diabetes care and outcomes: a cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E80-E87.	1.1	13
4051	Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes. <i>Diabetology International</i> , 2016, 7, 119-123.	0.7	4
4052	Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. <i>BMC Research Notes</i> , 2016, 9, 187.	0.6	15
4053	Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 257-262.	1.3	19
4054	International Models of Care that Address the Growing Diabetes Prevalence in Developing Countries. <i>Current Diabetes Reports</i> , 2016, 16, 69.	1.7	7
4055	Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 355-364.	0.6	6
4056	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 613-622.	0.3	254
4057	Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes—Network meta-analysis of randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1192-1200.	1.2	31
4058	Coronary artery disease and diabetes mellitus. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 330-338.	0.5	8
4059	What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. <i>European Journal of Health Economics</i> , 2016, 17, 1125-1140.	1.4	29
4060	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. <i>Endocrine</i> , 2016, 54, 32-37.	1.1	1
4061	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. <i>BMC Health Services Research</i> , 2016, 16, 124.	0.9	14
4062	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 277.	0.7	7
4063	Simulation of a computed HbA1c using a weighted average glucose. <i>SpringerPlus</i> , 2016, 5, 226.	1.2	5

#	ARTICLE	IF	CITATIONS
4064	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016, 39, 1089-1100.	4.3	119
4065	Compression of disability between two birth cohorts of US adults with diabetes, 1992â€“2012: a prospective longitudinal analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 686-694.	5.5	15
4066	PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. <i>Retina</i> , 2016, 36, 2357-2363.	1.0	26
4067	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
4068	Managing hypertension in type 2 diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 445-454.	2.2	36
4069	Renal denervation with standard radiofrequency ablation catheter is effective in 24-hour ambulatory blood pressure reduction â€“ follow-up at 1/3/6/12Âmonths. <i>Netherlands Heart Journal</i> , 2016, 24, 449-455.	0.3	4
4070	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
4071	Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, 248-254.	0.4	10
4072	Regularity of follow-up, glycemic burden, and risk of microvascular complications in patients with type 2 diabetes: a 9-year follow-up study : Reply to Dr. Tasci et al.. <i>Acta Diabetologica</i> , 2016, 53, 131-132.	1.2	1
4073	Effect of cinnamon, cardamom, saffron and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. <i>Blood Pressure</i> , 2016, 25, 133-140.	0.7	95
4074	Blood pressure and all-cause mortality among patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2016, 206, 116-121.	0.8	10
4075	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	0.5	1
4076	Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?. <i>Blood Purification</i> , 2016, 41, 139-143.	0.9	22
4077	Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a <i>post hoc</i> analysis (ORIENT-blood pressure). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 447-454.	0.4	18
4078	Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninâ€“angiotensin system blockade. <i>Blood Pressure</i> , 2016, 25, 93-103.	0.7	90
4079	9. Microvascular Complications and Foot Care. <i>Diabetes Care</i> , 2016, 39, S72-S80.	4.3	126
4080	A case study of a patient with diabetic retinopathy. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, 166-168.	1.8	1
4081	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure â€“ meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016, 34, 373-384.	0.3	75

#	ARTICLE	IF	CITATIONS
4082	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	13.9	208
4083	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referral health centre in Minas Gerais, Brazil. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 739-746.	1.3	30
4084	Risk factors for diabetic retinopathy in people with Type 2 diabetes: A case-control study in a UK primary care setting. <i>Primary Care Diabetes</i> , 2016, 10, 300-308.	0.9	18
4085	Prevalence and management of hypertensive patients in clinical practice: Cross-sectional registry in five countries outside the European Union. <i>Blood Pressure</i> , 2016, 25, 104-116.	0.7	10
4086	Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 208, 141-146.	0.8	17
4087	Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes. <i>Medicina Clínica</i> , 2016, 146, 55-60.	0.3	1
4089	The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts. <i>Current Diabetes Reports</i> , 2016, 16, 27.	1.7	28
4090	Undiagnosed hypertension in a rural district in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES). <i>Journal of Human Hypertension</i> , 2016, 30, 252-259.	1.0	31
4091	Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 609-618.	0.7	15
4092	Adiposity, hypertension and weight management behaviours in Ghanaian type 2 diabetes mellitus patients aged 20-70 years. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S79-S85.	1.8	11
4093	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 957-967.	6.3	2,464
4094	The impact of gender on the long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13-year follow-up study. <i>Diabetologia</i> , 2016, 59, 275-285.	2.9	37
4095	Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 314-323.	1.3	78
4096	Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. <i>Journal of Epidemiology and Global Health</i> , 2016, 6, 29.	1.1	10
4097	Preventing a First Stroke. , 2016, , 280-291.		1
4098	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 435-443.	6.3	792
4099	Lower blood pressure targets: to whom do they apply?. <i>Lancet, The</i> , 2016, 387, 405-406.	6.3	12
4100	Toward Big Data Analytics. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 27-34.	1.3	73

#	ARTICLE	IF	CITATIONS
4101	Structural Changes by Spectral Domain Optical Coherence Tomography in Patients With Type 1 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 271-276.	1.3	10
4102	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
4103	The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. <i>Quality of Life Research</i> , 2016, 25, 175-182.	1.5	78
4104	Telemedicine compared with standard care in type 2 diabetes mellitus: A randomized trial in an outpatient clinic. <i>Journal of Telemedicine and Telecare</i> , 2016, 22, 363-368.	1.4	47
4105	Diabetic nephropathy: What does the future hold?. <i>International Urology and Nephrology</i> , 2016, 48, 99-113.	0.6	33
4106	The progress in understanding and treatment of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2016, 51, 156-186.	7.3	730
4107	Approach to diabetes management in patients with CVD. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 165-179.	2.3	38
4108	Diabetic Eye Disease. , 2016, , 907-919.e5.		0
4109	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€”the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	1.0	13
4110	Diabetes 2030: Insights from Yesterday, Today, and Future Trends. <i>Population Health Management</i> , 2017, 20, 6-12.	0.8	445
4111	Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. <i>Acta Physiologica</i> , 2017, 219, 138-151.	1.8	83
4112	Blood pressure control in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017, 16, 3.	2.7	77
4113	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2017, 130, 707-719.e8.	0.6	142
4114	Beta-blockers for hypertension. <i>The Cochrane Library</i> , 2017, 2017, CD002003.	1.5	205
4115	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. <i>Nature Reviews Endocrinology</i> , 2017, 13, 365-374.	4.3	29
4116	Evidence-Based Treatment of Diabetic Macular Edema. <i>Seminars in Ophthalmology</i> , 2017, 32, 56-66.	0.8	20
4117	Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?. , 2017, 173, 1-18.		34
4118	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes and Metabolism</i> , 2017, 43, 99-109.	1.4	41

#	ARTICLE	IF	CITATIONS
4119	Blood pressure goals in type 2 diabetes—assessing the evidence. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 319-321.	5.5	4
4120	Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2877.	1.7	2
4121	Multistrategic approach to improve quality of care of people with diabetes at the primary care level: Study design and baseline data. <i>Primary Care Diabetes</i> , 2017, 11, 193-200.	0.9	10
4122	Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. <i>Journal of Drug Targeting</i> , 2017, 25, 386-405.	2.1	25
4124	Correlation of retinal arterial wall thickness with atherosclerosis predictors in type 2 diabetes without clinical retinopathy. <i>British Journal of Ophthalmology</i> , 2017, 101, 69-74.	2.1	14
4125	Diabetic Retinopathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 412-418.	4.3	596
4126	Hypotensive effects of genistein: From chemistry to medicine. <i>Chemico-Biological Interactions</i> , 2017, 268, 37-46.	1.7	56
4127	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 109-119.	0.7	13
4128	Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. <i>Diabetology International</i> , 2017, 8, 76-86.	0.7	12
4129	Are diabetes guidelines truly evidence based?. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 70-79.	1.1	5
4130	Diagnosis and Management of Type 2 Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1366-1373.	2.2	227
4131	Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2017, 8, 416-427.	1.1	59
4132	Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004–2014. <i>BMJ Open</i> , 2017, 7, e014444.	0.8	79
4133	Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 1-9.	1.1	7
4134	Epidemiology in diabetes mellitus and cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 8-16.	0.8	109
4135	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1407-1418.	13.9	880
4136	Hypertension in diabetes and the risk of cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 33-38.	0.8	20
4137	Intensive blood pressure lowering in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 197-204.	1.0	2

#	ARTICLE	IF	CITATIONS
4138	Prevalence of primary aldosteronism among patients with type 2 diabetes. <i>Clinical Endocrinology</i> , 2017, 87, 233-241.	1.2	12
4139	Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry. <i>Journal of Clinical Hypertension</i> , 2017, 19, 757-763.	1.0	8
4140	A review of chemical therapies for treating diabetic hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 909-923.	0.9	8
4141	Blood pressure management in patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , 2017, 40, 721-729.	1.5	7
4142	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
4144	Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. <i>Eye</i> , 2017, 31, S1-S20.	1.1	25
4145	Guidelines on the management of arterial hypertension and related comorbidities in Latin America. <i>Journal of Hypertension</i> , 2017, 35, 1529-1545.	0.3	58
4146	Improving diabetes care at primary care level with a multistrategic approach: results of the DIAPREM programme. <i>Acta Diabetologica</i> , 2017, 54, 853-861.	1.2	12
4147	Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong. <i>Diabetic Medicine</i> , 2017, 34, 1276-1283.	1.2	22
4148	Black patients sustain vision loss while White and South Asian patients gain vision following delamination or segmentation surgery for tractional complications associated with proliferative diabetic retinopathy. <i>Eye</i> , 2017, 31, 1468-1474.	1.1	11
4149	Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. <i>Diabetes Care</i> , 2017, 40, 1103-1110.	4.3	37
4150	Screening for Diabetic Eye Disease among Samoan Adults: A Pilot Study. <i>Ophthalmology and Therapy</i> , 2017, 6, 187-194.	1.0	1
4151	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	1.0	11
4152	Diabetic macular oedema: clinical risk factors and emerging genetic influences. <i>Australasian journal of optometry</i> , The, 2017, 100, 569-576.	0.6	15
4153	Contribution of family social support to the metabolic control of people with diabetes mellitus: A randomized controlled clinical trial. <i>Applied Nursing Research</i> , 2017, 36, 68-76.	1.0	31
4154	Preparation, Characterization and Applications of Enzyme-Free Glucose Sensors. <i>Key Engineering Materials</i> , 2017, 730, 172-176.	0.4	1
4155	Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. <i>Physiological Reports</i> , 2017, 5, e13228.	0.7	64
4156	The prevalence of hypertension in relation with the normal albuminuria range in type 2 diabetes mellitus within the South Korean population: The Korean National Health and Nutrition Examination Survey, 2011–2012. <i>Primary Care Diabetes</i> , 2017, 11, 281-287.	0.9	2

#	ARTICLE	IF	CITATIONS
4157	Trajectory of systolic blood pressure in a low-income, racial/ethnic minority cohort with diabetes and baseline uncontrolled hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 722-730.	1.0	3
4158	Prediction of treatment response in patients with newly diagnosed type 2 diabetes: the Skaraborg diabetes register. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 854-858.	1.2	4
4159	Screening for Diabetic Retinopathy in Youth-Onset Diabetes. <i>Ophthalmology</i> , 2017, 124, 422-423.	2.5	3
4160	Anti-hyperglycaemic activity of <i>Moringa oleifera</i> is partly mediated by carbohydrase inhibition and glucose-fibre binding. <i>Bioscience Reports</i> , 2017, 37, .	1.1	37
4161	The Real Role of β -Blockers in Daily Cardiovascular Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 361-373.	1.0	79
4162	The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. <i>Ophthalmology</i> , 2017, 124, 596-603.	2.5	42
4163	Factors determining uptake of diabetic retinopathy screening in Oxfordshire. <i>Diabetic Medicine</i> , 2017, 34, 993-999.	1.2	31
4164	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
4165	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. <i>Diabetes Care</i> , 2017, 40, 476-484.	4.3	9
4166	Type 2 Diabetes Genetic Variants and Risk of Diabetic Retinopathy. <i>Ophthalmology</i> , 2017, 124, 336-342.	2.5	21
4167	Hypertensive eye disease: a review. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 45-53.	1.3	98
4168	Apolipoprotein C ϵ plays a role in the pathogenesis of glomerulosclerosis. <i>Journal of Pathology</i> , 2017, 241, 589-599.	2.1	24
4169	10. Microvascular Complications and Foot Care. <i>Diabetes Care</i> , 2017, 40, S88-S98.	4.3	131
4170	Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2017, 52, S45-S74.	0.4	18
4171	Structured lifestyle intervention based on a trans-cultural diabetes-specific nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000384.	1.2	25
4172	Hypertension: An Evidence Informed, Case Based Approach. <i>Physician Assistant Clinics</i> , 2017, 2, 557-570.	0.1	0
4173	Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetic Medicine</i> , 2017, 34, 1747-1755.	1.2	32
4174	Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1263-1271.	1.3	44

#	ARTICLE	IF	CITATIONS
4175	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	4.3	462
4176	Evolving Role of Regional Depot Corticosteroids in Management of Diabetic Macular Edema. <i>Retina</i> , 2017, 37, 2201-2207.	1.0	0
4177	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure. <i>Journal of Hypertension</i> , 2017, 35, 2138-2149.	0.3	23
4178	Retinal Microaneurysm Detection Using Clinical Report Guided Multi-sieving CNN. <i>Lecture Notes in Computer Science</i> , 2017, , 525-532.	1.0	14
4179	Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. <i>Medicine (United States)</i> , 2017, 96, e7638.	0.4	28
4180	A Practical Approach to Hypertension Management in Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 981-989.	1.2	17
4181	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 459-470.	1.3	4
4182	Life Expectancy Predictions for Older Diabetic Patients as Estimated by Physicians and a Prognostic Model. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771371.	0.5	4
4183	Overweight, hyperglycemia and tobacco use are modifiable risk factors for onset of retinopathy 9 and 17 years after the diagnosis of diabetes – A retrospective observational nation-wide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 21-29.	1.1	9
4184	Diabetic retinopathy, metabolic memory and epigenetic modifications. <i>Vision Research</i> , 2017, 139, 30-38.	0.7	66
4185	Effect of nurse-led randomised control trials on cardiovascular risk factors and HbA1c in diabetes patients: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 187-199.	1.1	25
4186	Effects of Two Different Doses of Ranibizumab on Diabetic Retinopathy Severity. <i>Ophthalmology Retina</i> , 2017, 1, 566-567.	1.2	2
4187	The Elusive Search for Optimal Blood Pressure Targets. <i>Current Hypertension Reports</i> , 2017, 19, 63.	1.5	2
4188	Academic and Government Partnerships to Address Diabetes in the USA: a Narrative Review. <i>Current Diabetes Reports</i> , 2017, 17, 75.	1.7	2
4189	Diabetes Care in Brazil. <i>Journal of Ambulatory Care Management</i> , 2017, 40, S12-S23.	0.5	29
4190	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	1.2	125
4191	Pharmacotherapy for hypertension in adults aged 18 to 59 years. <i>The Cochrane Library</i> , 2017, 2017, CD008276.	1.5	32
4192	Area under the curve during <sc>OGTT</sc> in first-degree relatives of diabetic patients as an efficient indicator of future risk of type 2 diabetes and prediabetes. <i>Clinical Endocrinology</i> , 2017, 87, 696-705.	1.2	13

#	ARTICLE	IF	CITATIONS
4193	Home Blood Pressure Variability From the Stored Memory Is Correlated With Albuminuria, but From the Logbook Is not. <i>American Journal of Hypertension</i> , 2017, 30, 993-998.	1.0	6
4194	Type 2 diabetes in general practice in Norway 2005â€“2014: moderate improvements in risk factor control but still major gaps in complication screening. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000459.	1.2	35
4195	Initial Singleâ€“Pill Blood Pressureâ€“Lowering Therapy: Should It Be for Most People?. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	3
4196	Amelioration of arterial pressure lability: an unmissable target for diabetes management. <i>Hypertension Research</i> , 2017, 40, 629-631.	1.5	1
4197	Diabetes in sub-Saharan Africa: from clinical care to health policy. <i>Lancet Diabetes and Endocrinology,the</i> , 2017, 5, 622-667.	5.5	328
4198	Clinical Implications of Different Blood Pressure Measurement Techniques. <i>Current Hypertension Reports</i> , 2017, 19, 54.	1.5	12
4199	Diabetes care in a complex humanitarian emergency setting: a qualitative evaluation. <i>BMC Health Services Research</i> , 2017, 17, 431.	0.9	31
4200	Introduction of the DiaGene study: clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 47.	1.2	18
4201	Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1389-1393.	1.2	11
4202	Development of validated HPLC-UV method for simultaneous determination of Metformin, Amlodipine, Glibenclamide and Atorvastatin in human plasma and application to protein binding studies. <i>Bulletin of Faculty of Pharmacy, Cairo University</i> , 2017, 55, 129-139.	0.2	11
4203	Cardiovascular complications and drug prescriptions in subjects with and without diabetes in a Northern region of Italy, in 2002 and 2012. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 54-62.	1.1	5
4205	Progression of Peripheral Artery Disease to Critical Limb Ischemia. , 2017, , 121-129.		0
4206	Mechanistic Insights into Pathological Changes in the Diabetic Retina. <i>American Journal of Pathology</i> , 2017, 187, 9-19.	1.9	157
4207	Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy. <i>Ophthalmology and Therapy</i> , 2017, 6, 105-114.	1.0	3
4208	An evaluation of diabetes targeted apps for Android smartphone in relation to behaviour change techniques. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 326-338.	1.3	39
4209	The cardiometabolic risk profile of Chinese adults with diabetes: A nationwide cross-sectional survey. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 43-52.	1.2	7
4210	Diabetic macular oedema. <i>Lancet Diabetes and Endocrinology,the</i> , 2017, 5, 143-155.	5.5	242
4212	Evidence-Based Treatment of Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 2017, 32, 67-74.	0.8	49

#	ARTICLE	IF	CITATIONS
4213	Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 195-201.	1.2	24
4214	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	1.2	13
4215	Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 121-127.	0.9	12
4216	Exploring Approaches to Facilitate Diabetes Therapy Intensification in Primary Care. <i>Clinical Diabetes</i> , 2017, 35, 100-105.	1.2	0
4217	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	1.8	323
4218	Type 2 diabetes in primary care. <i>InnovAiT</i> , 2017, 10, 705-712.	0.0	0
4219	Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015. <i>BMJ: British Medical Journal</i> , 2017, 358, j3984.	2.4	57
4220	Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting: Part 2: Pharmacology and Guidelines for Perioperative Management. <i>Anesthesia Progress</i> , 2017, 64, 39-44.	0.2	10
4221	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!. , 2017, , .		0
4222	5. Diabetes and renal function. <i>British Journal of Healthcare Assistants</i> , 2017, 11, 66-71.	0.1	1
4223	Diabetes and visual problems. <i>Practice Nursing</i> , 2017, 28, 242-247.	0.1	0
4224	Combined Interval Training and Post-exercise Nutrition in Type 2 Diabetes: A Randomized Control Trial. <i>Frontiers in Physiology</i> , 2017, 8, 528.	1.3	32
4225	Awareness and Use of mHealth Apps: A Study from England. <i>Pharmacy (Basel, Switzerland)</i> , 2017, 5, 33.	0.6	105
4226	Cerebral Hemodynamic and White Matter Changes of Type 2 Diabetes Revealed by Multi-TI Arterial Spin Labeling and Double Inversion Recovery Sequence. <i>Frontiers in Neurology</i> , 2017, 8, 717.	1.1	19
4227	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	1.0	13
4228	Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). <i>Journal of Ophthalmology</i> , 2017, 2017, 1-10.	0.6	54
4229	Applying artificial intelligence to disease staging: Deep learning for improved staging of diabetic retinopathy. <i>PLoS ONE</i> , 2017, 12, e0179790.	1.1	183
4230	Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: A randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0186554.	1.1	8

#	ARTICLE	IF	CITATIONS
4231	Sensitivity and specificity of automated analysis of single-field non-mydratiac fundus photographs by Bosch DR Algorithmâ€”Comparison with mydratiac fundus photography (ETDRS) for screening in undiagnosed diabetic retinopathy. PLoS ONE, 2017, 12, e0189854.	1.1	39
4232	Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988â€”2014. BMC Public Health, 2017, 17, 893.	1.2	20
4233	A combination of process of care and clinical target among type 2 diabetes mellitus patients in general medical clinics and specialist diabetes clinics at hospital levels. BMC Health Services Research, 2017, 17, 533.	0.9	5
4234	Diabetic retinopathy: research to clinical practice. Clinical Diabetes and Endocrinology, 2017, 3, 9.	1.3	41
4236	Clinical Analysis of Newly Diagnosed Diabetes Mellitus Patients by Abnormal Fundus Examination. Journal of Korean Ophthalmological Society, 2017, 58, 1050.	0.0	0
4238	Target goal blood pressure in hypertension management. Journal of the Korean Medical Association, 2017, 60, 819.	0.1	1
4239	Diabetic Retinopathy: Focus on Minority Populations. International Journal of Clinical Endocrinology and Metabolism, 2017, 3, 034-045.	1.2	30
4240	Response: Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea (Diabetes Metab J2016;40:482-93). Diabetes and Metabolism Journal, 2017, 41, 77.	1.8	0
4241	The Role of Diet in the Prevention and Treatment of Diabetes. , 2017, , 691-707.		0
4242	Vasculoprotective Effects of Water Extracts of Black, Green and Dark Tea in Vitro. Natural Product Communications, 2017, 12, 1934578X1701200.	0.2	4
4243	Pros and Cons of Intensive Systolic Blood Pressure Lowering. Current Hypertension Reports, 2018, 20, 16.	1.5	2
4244	Association of serum vitamin D levels and diabetic retinopathy in Asian Indians with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 139, 308-313.	1.1	22
4245	Legacy effect in combined diabetic-renal multifactorial intervention in patients with advanced diabetic nephropathy. Journal of Diabetes and Its Complications, 2018, 32, 474-479.	1.2	8
4246	Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Metabolism: Clinical and Experimental, 2018, 85, 14-22.	1.5	5
4247	Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the â€”DR-Pro-DEX Studyâ€”™. Acta Diabetologica, 2018, 55, 541-547.	1.2	74
4248	Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population. Hypertension Research, 2018, 41, 531-538.	1.5	9
4249	Hypertension in patients with type 2 diabetes mellitus: Targets and management. Maturitas, 2018, 112, 71-77.	1.0	55
4250	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	1.1	158

#	ARTICLE	IF	CITATIONS
4251	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. <i>Diabetic Medicine</i> , 2018, 35, 707-713.	1.2	4
4252	Awareness of diabetic retinopathy among people with diabetes in Jeddah, Saudi Arabia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 103-112.	1.4	45
4253	Chronic Kidney Disease in Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S201-S209.	0.4	57
4254	Behavioral economics and diabetic eye exams. <i>Preventive Medicine</i> , 2018, 112, 76-87.	1.6	16
4255	Treatment of Hypertension. <i>Canadian Journal of Diabetes</i> , 2018, 42, S186-S189.	0.4	15
4256	Neurological Complications in Patients with Type 1 Diabetes Mellitus with Different Methods of Insulin Therapy. <i>Neuroscience and Behavioral Physiology</i> , 2018, 48, 69-73.	0.2	0
4257	Panvascular risk factor - Diabetes. <i>Cor Et Vasa</i> , 2018, 60, e18-e29.	0.1	8
4258	Obstructive sleep apnoea. <i>Eye</i> , 2018, 32, 889-903.	1.1	37
4259	Functional interplay between liver X receptor and AMP-activated protein kinase \pm inhibits atherosclerosis in apolipoprotein E-deficient mice: a new anti-atherogenic strategy. <i>British Journal of Pharmacology</i> , 2018, 175, 1486-1503.	2.7	39
4260	Hypertension in Adults With Type 2 Diabetes: A Review of Blood Pressure Measurement Methods, Targets and Therapy. <i>Canadian Journal of Diabetes</i> , 2018, 42, 188-195.	0.4	15
4261	Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience. <i>Canadian Journal of Diabetes</i> , 2018, 42, 205-208.	0.4	3
4262	Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness. <i>Pharmacological Research</i> , 2018, 130, 191-197.	3.1	13
4263	Clinical Report Guided Retinal Microaneurysm Detection With Multi-Sieving Deep Learning. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 1149-1161.	5.4	113
4264	Target home morning SBP be below 125 mmHg in type 2 diabetes patients. <i>Journal of Hypertension</i> , 2018, 36, 1284-1290.	0.3	5
4265	What Is New and What Is Different in Recent Guidelines on Antihypertensive Treatment? Looking Forward to Guidelines Reappraisal. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 839-851.	0.1	0
4266	Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina. <i>Advanced Drug Delivery Reviews</i> , 2018, 126, 127-144.	6.6	28
4267	Increased serum periostin concentrations are associated with the presence of diabetic retinopathy in patients with type 2 diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 937-945.	1.8	14
4268	Diabetic retinopathy in a remote Indigenous primary healthcare population: a Central Australian diabetic retinopathy screening study in the Telehealth Eye and Associated Medical Services Network project. <i>Diabetic Medicine</i> , 2018, 35, 630-639.	1.2	27

#	ARTICLE	IF	CITATIONS
4269	Blood Pressure Control and Cardiovascular/Renal Outcomes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 175-184.	1.2	8
4270	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 1-32.	1.2	16
4271	Hypertension with diabetes mellitus complications. <i>Hypertension Research</i> , 2018, 41, 147-156.	1.5	86
4272	The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future. <i>Diabetes Care</i> , 2018, 41, 209-218.	4.3	20
4273	Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. <i>Diabetologia</i> , 2018, 61, 517-525.	2.9	19
4274	Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?. <i>Canadian Journal of Diabetes</i> , 2018, 42, 166-172.	0.4	3
4275	Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers. <i>Canadian Journal of Diabetes</i> , 2018, 42, 118-123.	0.4	5
4276	Anti-diabetic activity of a polyphenol-rich extract from <i>Phellinus igniarius</i> in KK-Ay mice with spontaneous type 2 diabetes mellitus. <i>Food and Function</i> , 2018, 9, 614-623.	2.1	39
4277	Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. <i>American Journal of Ophthalmology</i> , 2018, 187, 138-147.	1.7	17
4278	Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2018, 38, 309-318.	1.2	35
4279	Demographic and lifestyle factors that affect HbA1c awareness amongst type II diabetic patients in Trinidad. <i>Archives of Physiology and Biochemistry</i> , 2018, 124, 397-400.	1.0	1
4280	Diabetic nephropathy: Is there a role for oxidative stress?. <i>Free Radical Biology and Medicine</i> , 2018, 116, 50-63.	1.3	152
4281	Impact of an integrated care program on glycemic control and cardiovascular risk factors in patients with type 2 diabetes in Saudi Arabia: an interventional parallel-group controlled study. <i>BMC Family Practice</i> , 2018, 19, 1.	2.9	96
4282	The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. <i>BMC Ophthalmology</i> , 2018, 18, 91.	0.6	35
4283	Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring. <i>Journal of UOEH</i> , 2018, 40, 11-18.	0.3	7
4284	Peripheral vascular disease risk in diabetic individuals without coronary heart disease. <i>Atherosclerosis</i> , 2018, 275, 419-425.	0.4	25
4285	First-line drugs for hypertension. <i>The Cochrane Library</i> , 2018, 2018, CD001841.	1.5	197
4286	Retinopathy. <i>Canadian Journal of Diabetes</i> , 2018, 42, S210-S216.	0.4	19

#	ARTICLE	IF	CITATIONS
4287	Reliability of single office blood pressure measurements. <i>Heart</i> , 2018, 104, 1173-1179.	1.2	42
4288	Preventing the development and progression of diabetic kidney disease: Where do we stand?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 585-590.	1.8	4
4289	Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 727-734.	2.2	7
4290	Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 158-165.	0.6	6
4292	Association of disease-specific causes of visual impairment and 10-year mortality amongst Indigenous Australians: the Central Australian Ocular Health Study. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 18-24.	1.3	6
4293	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018, 42, 130-137.	0.4	25
4294	BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 383-388.	3.0	31
4295	Modelling incremental benefits on complications rates when targeting lower HbA _{1c} levels in people with Type 2 diabetes and cardiovascular disease. <i>Diabetic Medicine</i> , 2018, 35, 72-77.	1.2	17
4296	Effectiveness of certified diabetes educators following pre-approved protocols to redesign diabetes care delivery in primary care: Results of the REMEDIES 4D trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 201-209.	0.8	14
4297	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 629-637.	2.2	5
4298	Antidiabetic drugs and stroke risk. Current evidence. <i>European Journal of Internal Medicine</i> , 2018, 48, 1-5.	1.0	36
4299	Editor's Choice "Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 3-81.	0.8	934
4300	10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes"2018". <i>Diabetes Care</i> , 2018, 41, S105-S118.	4.3	269
4301	Management of diabetic macular edema in Japan: a review and expert opinion. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 1-23.	0.9	44
4302	Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 68-76.	0.9	5
4303	Blood Pressure "Lowering Targets in Patients With Diabetes Mellitus. <i>Canadian Journal of Cardiology</i> , 2018, 34, 644-652.	0.8	1
4304	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2176-2198.	1.2	138
4305	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, e127-e248.	1.2	4,042

#	ARTICLE	IF	CITATIONS
4306	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e13-e115.	1.3	3,332
4307	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e116-e135.	1.3	118
4308	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. <i>Canadian Journal of Diabetes</i> , 2018, 42, 325-334.	0.4	11
4309	Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. <i>JBI Database of Systematic Reviews and Implementation Reports</i> , 2018, 16, 1823-1873.	1.7	17
4311	Patient expectations of hypertension and diabetes medication: Excessive focus on short-term benefits. <i>SAGE Open Medicine</i> , 2018, 6, 205031211882111.	0.7	9
4312	Traitements ophtalmologiques de la rÃ©tinopathie diabÃ©tique. <i>Medicine Des Maladies Metaboliques</i> , 2018, 12, 584-588.	0.1	1
4313	Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner. <i>Biomolecules and Therapeutics</i> , 2018, 26, 599-607.	1.1	19
4314	The Ongoing Saga of Optimal Blood Pressure Level in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, e010752.	1.6	9
4315	Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. <i>Journal of Clinical Hypertension</i> , 2019, 21, 4-15.	1.0	51
4317	Type-2 diabetes mellitus and cardiovascular disease. <i>Future Cardiology</i> , 2018, 14, 491-509.	0.5	197
4318	Nurse-Led Diabetes Self-Management Education Improves Clinical Parameters in Ethiopia. <i>Frontiers in Public Health</i> , 2018, 6, 302.	1.3	29
4319	Single herbal medicine for diabetic retinopathy. <i>The Cochrane Library</i> , 2018, 2018, CD007939.	1.5	32
4320	Idegliira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared With Insulin Glargine U100 Plus Insulin Aspart in the U.S.. <i>Endocrine Practice</i> , 2018, 24, 796-804.	1.1	6
4321	Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. <i>BMJ Open</i> , 2018, 8, e020584.	0.8	28
4322	Optimal medical treatment of hypertension in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 815-823.	0.6	4
4323	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. <i>Current Cardiology Reports</i> , 2018, 20, 112.	1.3	6
4324	Antihypertensive treatment and renal protection: Is there a J-curve relationship?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1560-1574.	1.0	17
4325	Clinical management of type 2 diabetes in south Asia. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 979-991.	5.5	49

#	ARTICLE	IF	CITATIONS
4326	CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB. <i>Retina</i> , 2018, 38, 1896-1904.	1.0	38
4327	Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy?. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 80.	2.0	36
4328	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
4329	Complications of diabetes: Keeping an eye on retinopathy. <i>Independent Nurse</i> , 2018, 2018, 15-18.	0.0	1
4330	Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 73.	1.2	8
4331	How good are GPs at adhering to a pragmatic trial protocol in primary care? Results from the ADDITION-Cambridge cluster-randomised pragmatic trial. <i>BMJ Open</i> , 2018, 8, e015295.	0.8	3
4332	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2018, 138, e484-e594.	1.6	330
4333	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> . 2018. 138. e595-e616.	1.6	76
4334	Evidence-based Danish guidelines for screening of diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, 763-769.	0.6	41
4335	Control of blood pressure and cardiovascular outcomes in type 2 diabetes. <i>Open Medicine (Poland)</i> , 2018, 13, 304-323.	0.6	7
4336	Milk Powder Co-supplemented with Inulin and Resistant Dextrin Improves Glycemic Control and Insulin Resistance in Elderly Type 2 Diabetes Mellitus: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1800865.	1.5	31
4337	Estimated Resting Metabolic Rate and Body Composition Measures Are Strongly Associated With Diabetic Retinopathy in Indonesian Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2377-2384.	4.3	19
4338	Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. <i>Translational Metabolic Syndrome Research</i> , 2018, 1, 1-8.	0.2	20
4339	Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. <i>BioMed Research International</i> , 2018, 2018, 1-16.	0.9	49
4340	Hypertension Management in Diabetes: 2018 Update. <i>Diabetes Spectrum</i> , 2018, 31, 218-224.	0.4	51
4342	The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2371-2378.	2.2	14
4343	Is there a relationship between body mass index and diabetic retinopathy in type II diabetic patients? A cross sectional study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 63-69.	0.8	15
4344	Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mmHg in Patients With Diabetes Mellitus Participating in ACCORD?. <i>Hypertension</i> , 2018, 72, 291-293.	1.3	4

#	ARTICLE	IF	CITATIONS
4345	Effect of Modifiable Risk Factors on the Incidence and Progression of Diabetic Retinopathy. , 2018, , 41-51.		0
4346	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2598-2607.	2.2	48
4347	An Overview of Diabetic Retinopathy. , 2018, , 139-154.		0
4348	Prevalence of Chronic Complications, Their Risk Factors, and the Cardiovascular Risk Factors among Patients with Type 2 Diabetes Attending the Diabetic Clinic at a Tertiary Care Hospital in Sri Lanka. Journal of Diabetes Research, 2018, 2018, 1-10.	1.0	32
4349	The Constellation of Macrovascular Risk Factors in Early Onset T2DM: A Cross-Sectional Study in Xinjiang Province, China. Journal of Diabetes Research, 2018, 2018, 1-8.	1.0	4
4350	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. Journal of Human Hypertension, 2018, 32, 641-650.	1.0	12
4351	Long-Term Risk of Hypertension in Normoglycemia and Prediabetes, and Their Relation to the Change of Glycemic State. American Journal of Hypertension, 2018, 31, 1042-1048.	1.0	10
4352	The Relationship between Diabetes-Related Complications and Obstructive Sleep Apnea in Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	40
4353	Primary care provider adherence to an alert for intensification of diabetes blood pressure medications before and after the addition of a â€œchart closureâ€ hard stop. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1167-1174.	2.2	19
4354	Characterization of dry skin associating with type 2 diabetes mellitus using a KK- <i>A</i> ^{sup>y</sup></i>/Tajl mouse model. Cutaneous and Ocular Toxicology, 2018, 37, 391-395.}	0.5	10
4355	Hypertension and Diabetes. Endocrinology, 2018, , 1-22.	0.1	0
4356	Diabetes and the Eye. Endocrinology, 2018, , 1-44.	0.1	0
4357	Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. International Journal of Behavioral Nutrition and Physical Activity, 2018, 15, 72.	2.0	216
4358	Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sciences, 2018, 208, 253-261.	2.0	40
4359	Hypertension and Diabetes. , 2018, , 180-185.		2
4360	Association Trends Between Antihypertensive Drug Therapies and Diastolic Hypotension in Emirati Patients with Type 2 Diabetes: A Single-Center Retrospective Longitudinal Study. Diabetes Therapy, 2018, 9, 1853-1868.	1.2	0
4361	Modeling of Diabetes and Its Clinical Impact. Journal of Diabetes Science and Technology, 2018, 12, 976-984.	1.3	20
4363	Association of characteristics of people with type 2 diabetes mellitus with discordant values of fasting glucose and HbA1c. Journal of Diabetes, 2018, 10, 934-941.	0.8	11

#	ARTICLE	IF	CITATIONS
4364	Effects of High Blood Pressure on Cardiovascular Disease Events Among Chinese Adults With Different Glucose Metabolism. <i>Diabetes Care</i> , 2018, 41, 1895-1900.	4.3	19
4365	ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. <i>Pediatric Diabetes</i> , 2018, 19, 28-46.	1.2	180
4366	Pharmacological management of hypertension in the elderly and frail populations. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 805-817.	1.3	10
4367	Impact of written information on control and adherence in type 2 diabetes. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 140-147.	0.3	17
4368	Family-based interventions for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2018, , .	1.5	2
4369	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	0.7	215
4370	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. <i>Cardiovascular Diabetology</i> , 2018, 17, 9.	2.7	31
4371	Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. <i>Cardiovascular Diabetology</i> , 2018, 17, 56.	2.7	135
4372	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 217-232.	0.6	52
4373	Endocrine Hypertension. , 2018, , 390-401.		0
4374	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
4375	Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1581-1589.	0.8	10
4376	Predicting diabetic retinopathy and identifying interpretable biomedical features using machine learning algorithms. <i>BMC Bioinformatics</i> , 2018, 19, 283.	1.2	69
4377	Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. <i>PLoS ONE</i> , 2018, 13, e0202103.	1.1	26
4378	Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031878932.	1.0	20
4379	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. <i>Journal of Hypertension</i> , 2018, 36, 1637-1647.	0.3	59
4380	Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000521.	1.2	42
4381	Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi. <i>PLoS ONE</i> , 2018, 13, e0190742.	1.1	13

#	ARTICLE	IF	CITATIONS
4382	Des normes et des cibles chez les patients diabétiques. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 260-267.	0.1	0
4383	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 691-704.	5.5	460
4384	Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. <i>Endocrine</i> , 2019, 63, 252-258.	1.1	7
4385	Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 103-111.	2.2	6
4386	Uncontrolled Hypertension Is Common in Glaucoma Clinics. <i>American Journal of Hypertension</i> , 2019, 32, 88-93.	1.0	2
4387	Advances in the treatment of diabetic retinopathy. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107417.	1.2	43
4388	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. <i>Clinical Hypertension</i> , 2019, 25, 19.	0.7	31
4389	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. <i>Clinical Hypertension</i> , 2019, 25, 20.	0.7	193
4390	HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000668.	1.2	2
4391	Hospitalisation of Type 2 diabetes mellitus patients with and without major depressive disorder in a private managed healthcare organisation. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2019, 24, 70-76.	0.4	1
4392	Plasma selenium levels and risk of new-onset diabetes in hypertensive adults. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 56, 6-12.	1.5	12
4393	Risk factors for diabetic nephropathy complications in community patients with type 2 diabetes mellitus in Shanghai: Logistic regression and classification tree model analysis. <i>International Journal of Health Planning and Management</i> , 2019, 34, 1013-1024.	0.7	16
4394	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). <i>Hypertension Research</i> , 2019, 42, 1235-1481.	1.5	1,047
4395	Retinopathy among Chinese subjects with type 2 diabetes mellitus in Shanghai: A community-based follow-up study. <i>International Journal of Health Planning and Management</i> , 2019, 34, 998-1012.	0.7	1
4396	Readiness for weight change and its association with diet knowledge and skills, diet decision making and diet and exercise barriers in patients with type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2889-2895.	1.8	5
4397	The "Old" Oral Antidiabetics. , 2019, , 501-513.		0
4398	Current Management of Patients With Acquired Solitary Kidney. <i>Kidney International Reports</i> , 2019, 4, 1205-1218.	0.4	55
4399	Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2019, 26, 347-357.	1.2	12

#	ARTICLE	IF	CITATIONS
4400	Evaluation of Dyslipidaemia Using an Algorithm of Lipid Profile Measures among Newly Diagnosed Type II Diabetes Mellitus Patients: A Cross-Sectional Study at Dormaa Presbyterian Hospital, Ghana. <i>Medicina (Lithuania)</i> , 2019, 55, 392.	0.8	4
4401	Treatment of Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2019, 19, 68.	1.7	83
4402	Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2405-2412.	2.2	10
4403	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. <i>Future Medicinal Chemistry</i> , 2019, 11, 1285-1303.	1.1	15
4405	Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 938-948.	5.5	240
4406	Risk Factors Management in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2019, 20, 157.	0.1	1
4407	Hypertension Treatment in Diabetes. <i>Heart Failure Clinics</i> , 2019, 15, 551-563.	1.0	4
4408	Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study. <i>PLoS ONE</i> , 2019, 14, e0224549.	1.1	23
4409	Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	0.5	8
4410	The effect of guideline revisions on vascular complications of type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	4
4411	Does delay in planned diabetes care influence outcomes for aboriginal Australians? A study of quality in health care. <i>BMC Health Services Research</i> , 2019, 19, 582.	0.9	5
4412	Prevalence of micro albuminuria and diagnostic accuracy of urine dipstick for the screening of diabetic nephropathy in type 2 diabetes patients. <i>Biocatalysis and Agricultural Biotechnology</i> , 2019, 21, 101316.	1.5	2
4413	Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial. <i>Kidney Medicine</i> , 2019, 1, 242-252.	1.0	10
4414	Quality of Life and Associated Factors among Primary Care Asian Patients with Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3561.	1.2	22
4415	Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms. <i>Experimental Eye Research</i> , 2019, 188, 107788.	1.2	15
4416	Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 31-47.	0.1	2
4417	Glycemic control through pharmaceutical care: a meta-analysis of randomized controlled trials. <i>Journal of Pharmaceutical Health Services Research</i> , 2019, 10, 35-44.	0.3	3
4418	A deletion in the Ctns gene causes renal tubular dysfunction and cystine accumulation in LEA/Tohm rats. <i>Mammalian Genome</i> , 2019, 30, 23-33.	1.0	12

#	ARTICLE	IF	CITATIONS
4419	The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study. Scientific Reports, 2019, 9, 7709.	1.6	19
4420	Prevention begets prevention – lessons from the Da Qing Study. Nature Reviews Endocrinology, 2019, 15, 442-443.	4.3	5
4421	Individualised screening for diabetic retinopathy: the ISDR study – rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening. BMJ Open, 2019, 9, e025788.	0.8	18
4422	Neuroprotective effect of levetiracetam in mouse diabetic retinopathy: Effect on glucose transporter-1 and GAP43 expression. Life Sciences, 2019, 232, 116588.	2.0	29
4423	Dietary Hyperlipidemia and Retinal Microaneurysms. , 2019, , 73-84.		0
4424	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. British Journal of Clinical Pharmacology, 2019, 85, 2218-2227.	1.1	7
4425	Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Research, 2019, 62, 211-217.	1.0	130
4426	Enablers and barriers to effective diabetes self-management: A multi-national investigation. PLoS ONE, 2019, 14, e0217771.	1.1	171
4427	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in Therapy, 2019, 36, 2034-2051.	1.3	11
4428	Short-term effects of perindopril + amlodipine vs perindopril + indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blind randomized controlled trial. Journal of Clinical Hypertension, 2019, 21, 1002-1008.	1.0	5
4429	The profile of sight-threatening diabetic retinopathy in patients attending a specialist eye clinic in Hangzhou, China. BMJ Open Ophthalmology, 2019, 4, e000236.	0.8	16
4430	Effect of lifestyle focused text messaging on risk factor modification in patients with diabetes and coronary heart disease: A sub-analysis of the TEXT ME study. Diabetes Research and Clinical Practice, 2019, 153, 184-190.	1.1	11
4431	Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials. Kidney and Blood Pressure Research, 2019, 44, 384-395.	0.9	4
4432	Impact of Endocrine Disorders on Blood Pressure. Endocrinology, 2019, , 1-30.	0.1	0
4433	Pulse Pressure and Diabetic Eye Disease. Journal of the American Heart Association, 2019, 8, e012491.	1.6	1
4434	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy, 2019, 10, 1297-1317.	1.2	23
4435	Prevalence of vascular risk factors in patients with and without type 2 diabetes mellitus admitted to hospital for stroke in the 2011–2013 period. Endocrinology & Diabetes & Nutrition (English Ed), 2019, 66, 150-156.	0.1	1
4436	Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension. Hypertension, 2019, 73, 1138-1149.	1.3	111

#	ARTICLE	IF	CITATIONS
4437	Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes – a nation-wide study from Finland in 1996–2012. <i>Annals of Medicine</i> , 2019, 51, 174-181.	1.5	5
4438	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COHoRtE (DIACORE) study. <i>PLoS ONE</i> , 2019, 14, e0213157.	1.1	8
4439	Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA–HBP study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1543-1549.	1.1	7
4440	C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register. <i>Diabetes Research and Clinical Practice</i> , 2019, 150, 174-183.	1.1	14
4441	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	4.3	42
4442	Epidemiology of Diabetes Mellitus and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 21.	1.3	363
4443	Glycaemic control among adults with self-reported diabetes in health and demographic surveillance site (HDSS) of rural North India. <i>International Journal of Diabetes in Developing Countries</i> , 2019, 39, 707-714.	0.3	0
4444	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	2.1	24
4445	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	1.8	305
4446	Decision Making in Proliferative Diabetic Retinopathy Treatment. <i>Current Ophthalmology Reports</i> , 2019, 7, 45-50.	0.5	3
4447	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 35.	1.3	14
4448	Prevalence and risk factors for diabetic retinopathy in north-central Nigeria. <i>Ghana Medical Journal</i> , 2019, 52, 215.	0.1	4
4451	Blood Pressure-Lowering Treatment and the Prevention of Heart Failure: Differences and Similarities of Antihypertensive Drug Classes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 285-298.	0.1	0
4453	Impact of a Collaborative Pharmaceutical Care Service Among Patients With Diabetes in an Ambulatory Care Setting in Qatar: A Multiple Time Series Study. <i>Value in Health Regional Issues</i> , 2019, 19, 45-50.	0.5	8
4454	Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis. <i>Hypertension Research</i> , 2019, 42, 483-495.	1.5	31
4455	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 208-230.	0.4	147
4456	Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications. <i>Diabetes Therapy</i> , 2019, 10, 575-585.	1.2	19
4457	Applications of stem cells and bioprinting for potential treatment of diabetes. <i>World Journal of Stem Cells</i> , 2019, 11, 13-32.	1.3	23

#	ARTICLE	IF	CITATIONS
4458	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2019, 79, 231-242.	4.9	18
4459	Identifying asymptomatic patients at high-risk for stroke. <i>Journal of Cardiovascular Surgery</i> , 2019, 60, 332-344.	0.3	3
4460	Evaluating All Potential Oral Complications of Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2019, 10, 56.	1.5	155
4461	Association between Continuity of Care and the Onset of Thyroid Disorder among Diabetes Patients in Korea. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 233.	1.2	4
4462	11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes 2019. <i>Diabetes Care</i> , 2019, 42, S124-S138.	4.3	337
4463	Rapid increase in the incidence of end-stage renal disease in patients with type 1 diabetes having HbA1c 10% or higher for 15 years. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 113-125.	0.4	2
4464	Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. <i>BMJ Open</i> , 2019, 9, e028438.	0.8	6
4465	Describing medicine therapy management of type 2 diabetes mellitus at primary health care facilities in Cape Town. <i>Health SA Gesondheid</i> , 2019, 24, 1051.	0.3	5
4466	Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000705.	1.2	26
4467	Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e026807.	0.8	13
4468	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2019, 18, 160.	2.7	14
4469	Investigating the cost-effectiveness of structured diabetes education. <i>British Journal of Health Care Management</i> , 2019, 25, 1-15.	0.1	1
4470	Metformin use in type 2 diabetic patients is not associated with lower arterial stiffness. <i>Journal of Hypertension</i> , 2019, 37, 365-371.	0.3	8
4471	Emerging Concepts in the Treatment of Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2019, 19, 137.	1.7	23
4472	Evidence for and Against ACC/AHA 2017 Guideline for Target Systolic Blood Pressure of $\leq 130\text{ mmHg}$ in Persons with Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 149.	1.3	9
4474	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. <i>Journal of Hypertension</i> , 2019, 37, 1126-1147.	0.3	29
4475	De la « force » du sang à l'hypertension artérielle : naissance d'une maladie-facteur de risque. <i>Medicine Des Maladies Metaboliques</i> , 2019, 13, 465-471.	0.1	1
4476	PPARG Polymorphisms Are Associated with Unexplained Mild Vision Loss in Patients with Type 2 Diabetes Mellitus. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-7.	0.6	9

#	ARTICLE	IF	CITATIONS
4477	Epidemiology, Risk Factors, and Pathophysiology of Diabetic Retinopathy. , 2019, , 1-19.		3
4478	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes, Obesity and Metabolism, 2019, 21, 454-466.	2.2	129
4479	Diabetes Self-Management Education and Medical Nutrition Therapy: A Multisite Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions in the Management of Glycemic Control and Diabetic Dyslipidemia through Retrospective Chart Review. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 449-463.	0.4	28
4480	Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats. Acta Diabetologica, 2019, 56, 97-104.	1.2	19
4481	Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework. Therapeutic Innovation and Regulatory Science, 2019, 53, 535-541.	0.8	2
4482	A systematic review of risk factors for cataract in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3073.	1.7	58
4483	Quality of life in subjects with type 2 diabetes mellitus with diabetic retinopathy: A caseâ€“control study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 947-952.	1.8	9
4484	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy, 2019, 10, 159-176.	1.2	11
4485	Prevalencia de los factores de riesgo vascular entre los casos con diabetes mellitus tipo 2 y sin diabetes hospitalizados de 2011 a 2013 por accidentes cerebrovasculares. Endocrinología, Diabetes Y NutriciÃ“n, 2019, 66, 150-156.	0.1	2
4486	The effectiveness of self-care and family-oriented interventions in patients with diabetes mellitus. Family Practice, 2019, 36, 375-377.	0.8	0
4487	Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus. Hypertension Research, 2019, 42, 59-66.	1.5	17
4488	Evidenceâ€“based diabetes care for older people with Type 2 diabetes: a critical review. Diabetic Medicine, 2019, 36, 399-413.	1.2	59
4489	Medical Biostatistics: Basic Concepts. , 2019, , 19-53.		1
4490	Management of Hypertension in Diabetes Mellitus. , 2019, , 115-133.		0
4492	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
4493	Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stressâ€“mediated Wnt/ β -catenin pathway activation. Cell and Tissue Research, 2019, 376, 165-177.	1.5	32
4494	Higher pulse pressure predicts initiation of dialysis in Japanese patients with diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3120.	1.7	8
4495	Impact of Duodeno-Jejunal Bypass Liner (EndoBarrierTM) Implantation on Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus (T2DM): A Study Protocol for a Pilot Trial. Diabetes Therapy, 2019, 10, 299-309.	1.2	5

#	ARTICLE	IF	CITATIONS
4496	Metas de control de la presión arterial e impacto sobre desenlaces cardiovasculares en pacientes con diabetes mellitus tipo 2: un análisis crítico de la literatura. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 31-47.	0.4	2
4497	Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. <i>BMC Nephrology</i> , 2019, 20, 22.	0.8	8
4498	Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. <i>BMC Endocrine Disorders</i> , 2019, 19, 4.	0.9	30
4499	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. <i>Statistical Regression Modeling to Predict Diabetic Proteinuria. Current Diabetes Reviews</i> , 2019, 15, 486-496.	0.6	6
4500	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 611-621.	2.2	35
4501	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.0	0
4502	Hypertension and Type 2 Diabetes Mellitus in Children and Adolescents. , 2019, , 37-45.		0
4503	Diabetic Retinopathy in Youth-Onset Type 2 Diabetes Mellitus. , 2019, , 55-68.		0
4504	Reactive oxygen species (ROS) in macrophage activation and function in diabetes. <i>Immunobiology</i> , 2019, 224, 242-253.	0.8	333
4505	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 69-74.	1.2	3
4506	Personalized risk-based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 560-568.	2.2	16
4507	EVALUATION OF OBSTRUCTIVE SLEEP APNEA SYNDROME AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE II DIABETES. <i>Retina</i> , 2019, 39, 274-280.	1.0	23
4508	Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 69-78.	1.5	59
4509	Smartphone use in ophthalmology: What is their place in clinical practice?. <i>Survey of Ophthalmology</i> , 2020, 65, 250-262.	1.7	50
4510	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. <i>Journal of Medical Economics</i> , 2020, 23, 193-203.	1.0	17
4511	Which is the worst risk factor for the long-term clinical outcome? Comparison of long-term clinical outcomes between antecedent hypertension and diabetes mellitus in South Korean acute myocardial infarction patients after stent implantation. <i>Journal of Diabetes</i> , 2020, 12, 119-133.	0.8	6
4512	Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> , 2020, 127, P66-P145.	2.5	341
4513	Long noncoding RNA MALAT1 participates in the pathological angiogenesis of diabetic retinopathy in an oxygen-induced retinopathy mouse model by sponging miR-203a-3p. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 219-227.	0.7	30

#	ARTICLE	IF	CITATIONS
4514	Vascular adenosine monophosphate-activated protein kinase: Enhancer, brake or both?. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 81-91.	1.2	7
4515	Ophthalmic Issues in Chronic Kidney Disease. , 2020, , 425-439.		0
4516	Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?. Diabetes, Obesity and Metabolism, 2020, 22, 12-18.	2.2	0
4517	Time-averaged serum uric acid and 10-year incident diabetic kidney disease: A prospective study from China. Journal of Diabetes, 2020, 12, 169-178.	0.8	5
4518	Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. Pharmacoepidemiology and Drug Safety, 2020, 29, 35-44.	0.9	9
4519	A combined effect of Curcumin, Eicosapentaenoic acid (Omega-3s), Astaxanthin and Gamma-linolenic acid (Omega-6) (CEAG) in healthy volunteers- a randomized, double-blind, placebo-controlled study. Clinical Nutrition ESPEN, 2020, 35, 174-179.	0.5	20
4520	Effectiveness of short message service intervention to improve glycosylated hemoglobin control and medication adherence in type-2 diabetes: A meta-analysis of prospective studies. Primary Care Diabetes, 2020, 14, 356-363.	0.9	11
4521	The long-term effectiveness of metabolic control on cardiovascular disease in patients with diabetes in a real-world health care setting – A prospective diabetes management study. Primary Care Diabetes, 2020, 14, 274-281.	0.9	7
4522	Are large simple trials for dementia prevention possible?. Age and Ageing, 2020, 49, 154-160.	0.7	17
4523	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 364-371.	1.4	11
4524	Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial. International Journal of Clinical Practice, 2020, 74, e13450.	0.8	13
4525	β-blockers: Their new life from hypertension to cancer and migraine. Pharmacological Research, 2020, 151, 104587.	3.1	50
4526	The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 424-431.	1.2	0
4527	Trends in Diabetes Management Among US Adults: 1999–2016. Journal of General Internal Medicine, 2020, 35, 1427-1434.	1.3	40
4528	Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. Journal of the Chinese Medical Association, 2020, 83, 900-905.	0.6	4
4529	Healthful aging mediated by inhibition of oxidative stress. Ageing Research Reviews, 2020, 64, 101194.	5.0	118
4531	Chronic Kidney Disease among Diabetes Patients in Ethiopia: A Systematic Review and Meta-Analysis. International Journal of Nephrology, 2020, 2020, 1-15.	0.7	11
4532	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology, 2020, 19, 175.	2.7	1

#	ARTICLE	IF	CITATIONS
4533	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. <i>Diabetes Therapy</i> , 2020, 11, 2887-2908.	1.2	3
4535	Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. <i>Scientific Reports</i> , 2020, 10, 11724.	1.6	12
4536	Antioxidant supplementation in diabetic retinopathy. , 2020, , 169-185.		0
4537	Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2020, 6, 13.	0.4	7
4538	Is Neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus?. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13206.	1.7	68
4539	ADIPS 2020 guideline for pre-existing diabetes and pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, E18-E52.	0.4	29
4540	Identifying gaps in patient access to diabetic screening eye examinations in Ontario: a provincially representative cross-sectional study. <i>Canadian Journal of Ophthalmology</i> , 2021, 56, 223-230.	0.4	7
4541	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	1.0	20
4542	Essentials of a Robust Deep Learning System for Diabetic Retinopathy Screening: A Systematic Literature Review. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-11.	0.6	10
4543	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet</i> , The, 2020, 396, 2019-2082.	6.3	327
4544	Association between interarm blood pressure differences and diabetic retinopathy in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094591.	0.9	3
4545	Implication of Hyperhomocysteinemia in Blood Retinal Barrier (BRB) Dysfunction. <i>Biomolecules</i> , 2020, 10, 1119.	1.8	40
4546	Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. <i>Journal of Hypertension</i> , 2020, 38, 1669-1681.	0.3	36
4547	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
4548	Biomarkers in essential hypertension. , 2020, , 247-288.		2
4549	Retinopathy in adults with hypertension and diabetes mellitus in Western Tanzania: a cross-sectional study. <i>Tropical Medicine and International Health</i> , 2020, 25, 1214-1225.	1.0	6
4550	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
4551	Reversal of diabetic tractional retinal detachment attributed to keto diet. <i>BMJ Case Reports</i> , 2020, 13, e235873.	0.2	9

#	ARTICLE	IF	CITATIONS
4552	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. <i>BMJ Open</i> , 2020, 10, e034883.	0.8	2
4553	Primary care visits can reduce the risk of potentially avoidable hospitalizations among persons with diabetes in France. <i>European Journal of Public Health</i> , 2020, 30, 1056-1061.	0.1	3
4554	<p>>Prevalence and Determinants of Hypertension Among Diabetic Patients in Jimma University Medical Center, Southwest Ethiopia, 2019</p><p>>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2317-2325.	1.1	23
4555	Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2084-2092.	1.0	3
4556	The Story of the Silent Killer. <i>Current Hypertension Reports</i> , 2020, 22, 72.	1.5	31
4557	Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2020, 10, 14158.	1.6	8
4558	100 most-cited articles on diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2021, 105, 1329-1336.	2.1	13
4559	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 522-530.	1.4	6
4560	Blood pressure targets in adults with hypertension. <i>The Cochrane Library</i> , 2020, 2020, CD004349.	1.5	12
4561	Stroke Type, Etiology, Clinical Features and Prognosis of Diabetic Patients in Southern China. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962097309.	0.7	1
4562	Vascular risk factors for optical coherence tomographyâ€detected macular cysts: The Maastricht Study. <i>Acta Ophthalmologica</i> , 2021, 99, e860-e868.	0.6	1
4563	11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetesâ€™2020</i>. <i>Diabetes Care</i> , 2020, 43, S135-S151.	4.3	337
4564	Impact of glycemic control over cardiac autonomic neuropathy. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1339-1344.	0.8	4
4565	Early worsening of diabetic retinopathy after simultaneous pancreas and kidney transplantationâ€Myth or reality?. <i>American Journal of Transplantation</i> , 2020, 20, 2832-2841.	2.6	7
4566	Genetics of diabetes mellitus and diabetes complications. <i>Nature Reviews Nephrology</i> , 2020, 16, 377-390.	4.1	657
4567	Early-onset type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e20189.	0.4	7
4568	A comparative analysis of current blood pressure management guidelines in people with and without diabetes. <i>Journal of Diabetes</i> , 2020, 12, 781-790.	0.8	3
4569	Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A subâ€analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1070-1079.	1.0	5

#	ARTICLE	IF	CITATIONS
4570	Carotid Free-Floating Thrombus in a Stent 6 Months After Carotid Artery Stenting. <i>World Neurosurgery</i> , 2020, 141, 236-239.	0.7	3
4571	Filling the Public Health Science Gaps for Diabetes With Natural Experiments. <i>Medical Care</i> , 2020, 58, S1-S3.	1.1	1
4572	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	1.1	104
4573	Frequency and Antimicrobial Susceptibility Patterns of Diabetic Foot Infection of Patients from Bandar Abbas District, Southern Iran. <i>Journal of Pathogens</i> , 2020, 2020, 1-10.	0.9	11
4574	Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 24.	0.9	10
4575	Hypertension, blood pressure control and diabetic retinopathy in a large population-based study. <i>PLoS ONE</i> , 2020, 15, e0229665.	1.1	48
4576	Systemic Factors Associated with Treatment Response in Diabetic Macular Edema. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-6.	0.6	14
4577	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	2.2	8
4578	The Legacy Effect in Treating Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 291-298.	1.0	4
4579	Dopamine metabolite levels in the vitreous of diabetic and non-diabetic humans. <i>Experimental Eye Research</i> , 2020, 195, 108040.	1.2	4
4580	Evaluating the treatment and control of modifiable cardiovascular disease risk factors among patients with diabetes in the Inner Mongolia, China: A cross-sectional study. <i>Preventive Medicine</i> , 2020, 139, 106174.	1.6	3
4581	A systematic review of trends in all-cause mortality among people with diabetes. <i>Diabetologia</i> , 2020, 63, 1718-1735.	2.9	37
4582	The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier. <i>American Journal of Pathology</i> , 2020, 190, 1971-1981.	1.9	22
4583	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. <i>Pharmacological Research</i> , 2020, 160, 105052.	3.1	34
4584	Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review. <i>Acta Ophthalmologica</i> , 2020, 98, 329-336.	0.6	12
4585	Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108073.	1.1	3
4586	Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22). <i>Diabetes Therapy</i> , 2020, 11, 885-903.	1.2	5
4587	Diabetic Retinopathy, Classified Using the Lesion-Aware Deep Learning System, Predicts Diabetic End-Stage Renal Disease in Chinese Patients. <i>Endocrine Practice</i> , 2020, 26, 429-443.	1.1	31

#	ARTICLE	IF	CITATIONS
4588	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. <i>Population Health Management</i> , 2020, 23, 467-475.	0.8	13
4589	Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. <i>Journal of Clinical Hypertension</i> , 2020, 22, 212-220.	1.0	14
4590	Major Improvement in Wound Healing Through Pharmacologic Mobilization of Stem Cells in Severely Diabetic Rats. <i>Diabetes</i> , 2020, 69, 699-712.	0.3	19
4591	Access to CKD Care in Rural Communities of India: a qualitative study exploring the barriers and potential facilitators. <i>BMC Nephrology</i> , 2020, 21, 26.	0.8	17
4592	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000902.	1.2	31
4593	Comments on "Management of diabetic macular edema patients in clinical practice in Spain" <i>European Journal of Ophthalmology</i> , 2020, 30, NP3-NP4.	0.7	0
4594	Renal arteriolar hyalinosis, not intimal thickening in large arteries, is associated with cardiovascular events in people with biopsy-proven diabetic nephropathy. <i>Diabetic Medicine</i> , 2020, 37, 2143-2152.	1.2	10
4595	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 33-42.	2.2	7
4596	Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2712.	1.8	20
4597	Yoga-based lifestyle treatment and composite treatment goals in Type 2 Diabetes in a rural South Indian setup- a retrospective study. <i>Scientific Reports</i> , 2020, 10, 6402.	1.6	7
4598	An evaluation of empagliflozin and its applicability to hypertension as a therapeutic option. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1157-1166.	0.9	4
4599	How to Manage Hypertension in People With Diabetes. <i>American Journal of Hypertension</i> , 2020, 33, 935-943.	1.0	4
4600	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020, 11, 108.	1.6	79
4601	Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. <i>Transplant International</i> , 2021, 34, 27-48.	0.8	57
4602	Diagnosis of complications of type 2 diabetes based on weighted multi-label small sphere and large margin machine. <i>Applied Intelligence</i> , 2021, 51, 223-236.	3.3	6
4603	Feature-transfer network and local background suppression for microaneurysm detection. <i>Machine Vision and Applications</i> , 2021, 32, 1.	1.7	58
4604	Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMH Hypertension Study). <i>Primary Care Diabetes</i> , 2021, 15, 332-339.	0.9	13
4605	Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P1-P29.	2.5	11

#	ARTICLE	IF	CITATIONS
4606	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. <i>Annals of Internal Medicine</i> , 2021, 174, 58-68.	2.0	47
4607	11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetesâ€™2021</i>. <i>Diabetes Care</i> , 2021, 44, S151-S167.	4.3	247
4608	Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1322-1325.	1.1	137
4609	Midfoot Charcot Neuro-arthropathy Precipitated by First or Fifth ray Amputation. <i>Foot and Ankle Surgery</i> , 2021, 27, 673-676.	0.8	3
4610	Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110206.	1.4	8
4611	Comorbidities and Diabetes Type 2. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2020, , 46-61.	0.3	0
4612	Well Controlled Blood Pressure in Turkish Patients: How Many Drugs Are Required to Attain and Maintain the Blood Pressure Goal?. <i>International Journal of Clinical Medicine</i> , 2021, 12, 23-33.	0.1	0
4613	An Observational Study on the Association between Diabetic Retinopathy and Serum Lipid Levels in a Tertiary Centre in Thiruvananthapuram. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 131-135.	0.0	0
4614	The role of pulse pressure in navigating the paradigm of chronic kidney disease progression in type 2 diabetes mellitus. <i>Journal of Nephrology</i> , 2021, 34, 1429-1444.	0.9	1
4615	Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 699-706.	4.3	31
4616	Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-19.	2.0	3
4618	Metformin - its anti-cancer effects in hematologic malignancies. <i>Oncology Reviews</i> , 2021, 15, 514.	0.8	14
4619	How Should We Measure and Deal with Office Blood Pressure in 2021?. <i>Diagnostics</i> , 2021, 11, 235.	1.3	6
4620	Development of a diabetic retinopathy screening model for a district health system in Limpopo Province, South Africa. <i>African Vision and Eye Health</i> , 2021, 80, .	0.1	1
4621	Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. <i>Npj Digital Medicine</i> , 2021, 4, 24.	5.7	49
4622	The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathyâ€™A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 705.	1.0	9
4623	The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 621938.	1.5	34
4624	Microvascular complications and frailty can predict adverse outcomes in older patients with diabetes. <i>Geriatrics and Gerontology International</i> , 2021, 21, 359-363.	0.7	8

#	ARTICLE	IF	CITATIONS
4625	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <i>Kidney International</i> , 2021, 99, S1-S87.	2.6	497
4626	Treatment Dilemmas in Hypertension Management in Diabetes. <i>RUHS Journal of Health Sciences</i> , 2021, 6, .	0.1	0
4627	Predicting unplanned medical visits among patients with diabetes: translation from machine learning to clinical implementation. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 111.	1.5	6
4628	Gender, sex hormones and diabetic retinopathy: A review. <i>Indian Journal of Clinical and Experimental Ophthalmology</i> , 2021, 7, 181-189.	0.1	1
4629	Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1254.	1.0	10
4630	Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107840.	1.2	4
4631	A Multifactorial Approach in Type 2 Diabetes Over 3 Years Decelerates Progression of Subclinical Arterial Disease in Routine Clinical Practice. <i>Angiology</i> , 2021, 72, 923-933.	0.8	1
4632	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 332-342.	0.3	3
4633	Albuminuria increased the risk of left ventricular hypertrophy in type 2 diabetes patients with early renal insufficiency. <i>International Journal of Diabetes in Developing Countries</i> , 2021, 41, 621-627.	0.3	0
4634	Prevalence of Hypertension and Albuminuria in Pediatric Type 2 Diabetes. <i>JAMA Network Open</i> , 2021, 4, e216069.	2.8	25
4635	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>European Cardiology Review</i> , 2021, 16, e14.	0.7	4
4636	Rates and risk factors for amputation in people with diabetes in Japan: a historical cohort study using a nationwide claims database. <i>Journal of Foot and Ankle Research</i> , 2021, 14, 29.	0.7	9
4637	Role of Oral Antioxidant Supplementation in the Current Management of Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4020.	1.8	15
4639	Structured hypertension education program for people with type 2 diabetes, the SHED study. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108773.	1.1	1
4640	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. <i>Hypertension Research</i> , 2021, 44, 897-905.	1.5	13
4641	The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108759.	1.1	7
4642	High adherence to recommended diabetes follow-up procedures by general practitioners is associated with lower estimated cardiovascular risk. <i>Diabetic Medicine</i> , 2021, 38, e14586.	1.2	6
4643	Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108776.	1.1	9

#	ARTICLE	IF	CITATIONS
4644	Diabetic and Retinal Vascular Eye Disease. <i>Medical Clinics of North America</i> , 2021, 105, 455-472.	1.1	12
4645	Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. <i>Nature Reviews Endocrinology</i> , 2021, 17, 400-420.	4.3	169
4646	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	10
4647	Paradoxical association between lipoprotein cholesterol levels and left atrial function in hypertensive diabetic patients: A speckle tracking study. <i>Journal of Clinical Ultrasound</i> , 2021, 49, 667-673.	0.4	0
4648	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1671-1690.	1.1	5
4649	Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. <i>British Journal of Ophthalmology</i> , 2022, 106, 1496-1502.	2.1	2
4650	How We Got Where We Are in Blood Pressure Targets. <i>Current Hypertension Reports</i> , 2021, 23, 33.	1.5	3
4651	Distribution of DD Genotype of Angiotensin-Converting Enzyme Gene and Its Correlation with Diabetic Retinopathy. <i>Trends in Medical Sciences</i> , 2021, 1, .	0.1	0
4652	Thermo-Responsive Hydrogels: From Recent Progress to Biomedical Applications. <i>Gels</i> , 2021, 7, 77.	2.1	92
4653	Association Between Obstructive Sleep Apnea and Diabetic Macular Edema in Patients with Type 2 Diabetes. <i>American Journal of Ophthalmology</i> , 2021, 226, 217-225.	1.7	8
4654	Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. <i>New England Journal of Medicine</i> , 2021, 384, 2219-2228.	13.9	327
4655	Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies. <i>Cells</i> , 2021, 10, 1913.	1.8	12
4656	EFFECTS OF GLYCEMIC VARIABILITY ON THE PROGRESSION OF DIABETIC RETINOPATHY AMONG PATIENTS WITH TYPE 2 DIABETES. <i>Retina</i> , 2021, 41, 1487-1495.	1.0	10
4658	Visualizing the intellectual structure and recent research trends of diabetic retinopathy. <i>International Journal of Ophthalmology</i> , 2021, 14, 1248-1259.	0.5	4
4659	Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population. <i>Journal of Clinical Medicine</i> , 2021, 10, 3851.	1.0	11
4660	Prevention of Worsening Diabetes through Behavioral Changes by an IoT-based Self-Monitoring System in Japan (PRISM-J): Study design and rationale for a multicenter, open-label, randomized parallel-group trial. <i>GHM Open</i> , 2021, 1, 3-11.	0.1	0
4661	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87
4662	EFFECT OF INTRAVITREALANTI VEGF COMBINED WITH MACULAR LASER IN A CASE OF PROLIFERATIVE DIABETIC RETINOPATHY WITH CLINICALLY SIGNIFICANT MACULAR EDEMA. , 2021, , 3-3.		0

#	ARTICLE	IF	CITATIONS
4663	Screening for Prediabetes and Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2021, 326, 744.	3.8	40
4664	Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7). Acta Diabetologica, 2021, , 1.	1.2	1
4665	Microvascular Complications of Diabetes Mellitus: Focus on Diabetic Retinopathy (DR) and Diabetic Foot Ulcer (DFU). , 0, , .		2
4666	The role of Optical Coherence Tomography Angiography to detect early microvascular changes in Diabetic Retinopathy: a systematic review. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1957-1974.	0.8	9
4667	Low-volume walking HIIT: Efficient strategy to improve physical capacity and reduce the risk of cardiovascular disease in older women with type 2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102233.	1.8	9
4668	Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese. Cardiovascular Diabetology, 2021, 20, 174.	2.7	4
4669	Incidence and risk factors of severe nonâ€proliferative/proliferative diabetic retinopathy: More than a decade follow up in the Tehran Lipids and Glucose Study. Journal of Diabetes Investigation, 2021, , .	1.1	5
4670	The Importance of Close Follow-Up in Patients with Early-Grade Diabetic Retinopathy: A Taiwan Population-Based Study Grading via Deep Learning Model. International Journal of Environmental Research and Public Health, 2021, 18, 9768.	1.2	4
4671	ADVANCE research 20 years later. Eurasian Heart Journal, 2021, , 36-45.	0.2	0
4672	Low prevalence of diabetic retinopathy in patients with long-term type 1 diabetes and current good glycemic control - one-center retrospective assessment. Endocrine, 2022, 75, 427-436.	1.1	3
4674	Using Metabolic and Biochemical Indicators to Predict Diabetic Retinopathy by Back-Propagation Artificial Neural Network. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4031-4041.	1.1	2
4675	Screening for Diabetes and Prediabetes. Endocrinology and Metabolism Clinics of North America, 2021, 50, 369-385.	1.2	26
4676	Oral Glucose Tolerance Test (OGTT): Undeniably the First Choice Investigation of Dysglycaemia, Reproducibility can be Improved. , 0, , .		0
4677	Mitochondrial DNA A3243G variant-associated retinopathy: Current perspectives and clinical implications. Survey of Ophthalmology, 2021, 66, 838-855.	1.7	12
4678	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	1.4	3
4679	Risk Factors and Prevention. , 2022, , 187-206.e6.		0
4680	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110263.	1.1	5
4681	Trends in Complexity of Diabetes Care in the United States From 1991 to 2000. Archives of Internal Medicine, 2004, 164, 1134-1139.	4.3	93

#	ARTICLE	IF	CITATIONS
4687	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
4693	Fluorescence Biosensors for Continuously Monitoring the Blood Glucose Level of Diabetic Patients. , 2006, , 117-130.		1
4694	Diabetes and Oxidant Stress. , 2008, , 123-158.		1
4695	Diabetic Macular Edema. , 2010, , 141-202.		6
4696	Treatment of Proliferative Diabetic Retinopathy. , 2010, , 227-304.		4
4697	Diabetes Care for the Older Patient. , 2012, , .		1
4698	Diabetes Mellitus and Cardiovascular Disease. , 2011, , 227-252.		2
4699	Diabetic Foot Disease and Wound Healing. , 2012, , 17-38.		1
4700	Retinopathy in Diabetes. Advances in Experimental Medicine and Biology, 2013, 771, 88-106.	0.8	33
4701	Microalbuminuria, Blood Pressure and Diabetic Renal Disease: Origin and Development of Ideas. , 2000, , 655-706.		9
4702	Diabetic Nephropathy: An Overview. Methods in Molecular Biology, 2020, 2067, 3-7.	0.4	161
4703	Hypertension As a Risk Factor for Stroke. , 2004, , 35-50.		1
4705	Diabetic Retinopathy and Nephropathy. , 2006, , 473-498.		12
4706	Nonproliferative Diabetic Retinopathy. , 2008, , 3-27.		13
4707	The Epidemiology of Diabetic Retinopathy. , 2008, , 67-107.		27
4708	Beta-Blockers. Contemporary Cardiology, 2015, , 1-68.	0.0	1
4709	Diabetes Mellitus and Chronic Kidney Disease (Stages 1â€“5). , 2014, , 103-136.		1
4710	Diastolic Disturbances in Diabetes Mellitus. , 2008, , 271-284.		3

#	ARTICLE	IF	CITATIONS
4711	Preface: A New Disease?. , 2019, , 1-8.		2
4712	Diabetes Management in Asia. , 2019, , 239-253.		3
4713	Collaborative Denoising Autoencoder for High Glycated Haemoglobin Prediction. Lecture Notes in Computer Science, 2019, , 338-350.	1.0	6
4714	A Primary Health-Care System Approach to Improving Quality of Care and Outcomes in People with Diabetes: The University of Pittsburgh Medical Center Experience. , 2017, , 51-64.		2
4716	Diabetic Macular Edema: Current Treatments. , 2007, , 131-146.		3
4717	A State-Based Model for Management of Type II Diabetes. Studies in Computational Intelligence, 2007, , 27-61.	0.7	3
4718	Epidemiology, Risk Factors, and Pathophysiology of Diabetic Retinopathy. , 2014, , 1-17.		2
4719	Systemic Hypertension. , 2002, , 1015-1064.		2
4720	Prevention of Peripheral Artery Atherosclerosis. , 2002, , 1347-1350.		2
4721	Akuter Myokardinfarkt. , 2000, , 393-442.		1
4722	NHG-Standaard Diabetes mellitus type 2. , 2009, , 160-191.		17
4724	Diabetic Macular Edema. , 2002, , 47-58.		2
4725	Patient-Centered Care or Drug-Centered Care: The Influence of Pharmaceutical Marketing on Medical Science and Public Health. Philosophy and Medicine, 2017, , 109-124.	0.3	1
4726	Diabetes and Diabetic Retinopathy: Overview of a Worldwide Epidemic. , 2017, , 1-27.		4
4727	Diet and risk of diabetic retinopathy: a systematic review. European Journal of Epidemiology, 2018, 33, 141-156.	2.5	81
4728	DIABETES MELLITUS Secondary Complications. , 2003, , 1800-1804.		1
4729	Etiologic Mechanisms in Diabetic Retinopathy. , 2006, , 1241-1270.		23
4730	Nonproliferative Diabetic Retinopathy. , 2006, , 1271-1284.		9

#	ARTICLE	IF	CITATIONS
4731	The Epidemiology of Diabetic Retinopathy. , 2006, , 1503-1521.		2
4732	Anesthetic Implications of Concurrent Diseases. , 2010, , 1067-1149.		35
4733	The Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). , 2005, , 325-339.		2
4734	Fixed Combination Antihypertensive Therapy. , 2005, , 522-529.		5
4735	INTRODUCTION TO THE PRIMARY EYE CARE EXAMINATION. , 2007, , 11-28.		1
4737	The Role of the Chronic Kidney Disease Clinic. , 2005, , 71-85.		2
4738	Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HF, heart failure;. , 2007, , 625-646.		4
4740	Ophthalmology in the Tropics and Subtropics. , 2009, , 283-332.		2
4741	Pathogenesis and Pathophysiology of Diabetic Nephropathy. , 2009, , 214-223.		4
4743	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
4745	Diabetes and behavioral medicine: the second decade. Journal of Consulting and Clinical Psychology, 2002, 70, 611-25.	1.6	84
4746	Oxidative stress and reactive oxygen species: a review of their role in ocular disease. Clinical Science, 2017, 131, 2865-2883.	1.8	122
4747	Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science, 2019, 133, 2121-2141.	1.8	12
4748	What else adds to hypertension in predicting stroke? An incident case-referent study. Journal of Internal Medicine, 2000, 248, 475-482.	2.7	19
4749	Prevention of cardiovascular disease and diabetes: lessons from the Malmo Preventive Project. Journal of Internal Medicine, 2000, 248, 455-462.	2.7	30
4750	Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. Journal of Internal Medicine, 2001, 249, 225-235.	2.7	167
4751	Blood pressure in diabetic nephropathy - current controversies. Journal of Internal Medicine, 2001, 249, 215-223.	2.7	6
4752	The United Kingdom Prospective Diabetes Study â€“ everything you needed to know about diabetes but were afraid to ask?. European Heart Journal, 1999, 20, 781-783.	1.0	8

#	ARTICLE	IF	CITATIONS
4754	In memory of a legendary athlete: Measured success in diabetic nephropathy. <i>Seminars in Nephrology</i> , 2001, 21, 124-132.	0.6	2
4755	Diabetes management in older people: a focus on cardiovascular risk reduction. <i>Postgraduate Medicine</i> , 2017, 129, 169-177.	0.9	3
4756	Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. <i>Ophthalmic Epidemiology</i> , 2016, 23, 209-222.	0.8	107
4757	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1201-1217.	0.9	2
4759	Diabetes Prevention and Control Programs in Developing Countries. , 2010, , 603-622.		2
4760	Metabolic syndrome, diabetes, and coronary heart disease. , 2005, , 311-330.		1
4761	Evidence supporting secondary prevention strategies. <i>Current Opinion in Cardiology</i> , 1999, 14, 303-309.	0.8	6
4762	New drugs for the treatment of hypertension. <i>Current Opinion in Cardiology</i> , 1999, 14, 375.	0.8	7
4763	Postpartum Care of the Woman With Diabetes. <i>Clinical Obstetrics and Gynecology</i> , 2000, 43, 75-86.	0.6	26
4764	Diabetic Retinopathy in African Americans: Vision Impairment, Prevalence, Incidence, and Risk Factors. <i>International Ophthalmology Clinics</i> , 2003, 43, 105-122.	0.3	13
4765	1999 WHO/ISH hypertension guidelines - highlights & esh update. <i>Journal of Hypertension</i> , 2001, 19, 2285-2288.	0.3	32
4766	1999 WHO/ISH Hypertension guidelines - highlights & ESH update. <i>Journal of Hypertension</i> , 2002, 20, 153-155.	0.3	42
4767	Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 926-931.	0.8	21
4768	Department of Veterans Affairs' Quality Enhancement Research Initiative for Diabetes Mellitus. <i>Medical Care</i> , 2000, 38, 1-38-1-48.	1.1	41
4769	Angiotensin converting enzyme inhibitors: first line therapy in patients with diabetic hypertension?. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 333-334.	1.0	4
4770	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 271-277.	1.5	2
4771	International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. <i>Journal of Hypertension</i> , 2003, 21, 651-63.	0.3	37
4772	Prevalence of Patients with Type 2 Diabetes Mellitus Reaching the American Diabetes Association's Target Guidelines in a University Primary Care Setting. <i>Southern Medical Journal</i> , 2004, 97, 145-148.	0.3	18

#	ARTICLE	IF	CITATIONS
4792	Imaging and Quantification of Subbasal Nerve Plexus in Healthy Volunteers and Diabetic Patients with or without Retinopathy. PLoS ONE, 2013, 8, e52157.	1.1	85
4793	Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes. PLoS ONE, 2014, 9, e103217.	1.1	40
4794	Prevalence and Control of Hypertension and Albuminuria in South Korea: Focus on Obesity and Abdominal Obesity in the Korean National Health and Nutrition Examination Survey, 2011-2012. PLoS ONE, 2014, 9, e111179.	1.1	5
4795	The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review. PLoS ONE, 2014, 9, e112593.	1.1	15
4796	Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study. PLoS ONE, 2016, 11, e0159071.	1.1	40
4797	Association between Sickle Cell Trait and the Prevalence and Severity of Diabetic Retinopathy. PLoS ONE, 2016, 11, e0159215.	1.1	11
4798	Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS ONE, 2016, 11, e0165629.	1.1	23
4799	Incidence and progression of diabetic retinopathy in Sub-Saharan Africa: A five year cohort study. PLoS ONE, 2017, 12, e0181359.	1.1	5
4800	The United Kingdom's first NHS Endobarrier service for advanced diabetes: 1-year outcomes for all 62 treated patients. British Journal of Diabetes, 2019, 19, 110-117.	0.1	8
4802	Clinical Diabetes Care of Patients with Type 2 Diabetes at a Major Tertiary Care Hospital in the United Arab Emirates. Journal of Diabetes, Metabolic Disorders & Control, 2015, 2, .	0.2	2
4803	Prevention and Treatment of Type 2 Diabetes Mellitus in Children, With Special Emphasis on American Indian and Alaska Native Children. Pediatrics, 2003, 112, 328e-328.	1.0	93
4804	Do our elderly diabetic patients keep the diet?. Acta Alimentaria, 2006, 35, 479-486.	0.3	2
4806	Metformin and the united kingdom prospective diabetes study: a commentary. Arquivos Brasileiros De Endocrinologia E Metabologia, 2000, 44, 121-124.	1.3	1
4807	Estatura final de pacientes com diabetes mellitus do tipo 1. Arquivos Brasileiros De Endocrinologia E Metabologia, 2001, 45, 108-114.	1.3	8
4808	Tratamento de Diabetes e Hipertenso no Paciente Obeso. Arquivos Brasileiros De Endocrinologia E Metabologia, 2002, 46, 137-142.	1.3	8
4813	Controle de diabetes Mellitus e hipertenso arterial com grupos de interveno educacional e teraputica em seguimento ambulatorial de uma Unidade Bsica de Sade. Saude E Sociedade, 2006, 15, 180-189.	0.1	25
4815	The dilemma of diabetes: health care crisis in the Caribbean. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2001, 9, 61-64.	0.6	4
4816	The diabetes-related attitudes of health care professionals and persons with diabetes in Argentina. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2007, 22, 304-307.	0.6	23

#	ARTICLE	IF	CITATIONS
4817	Blood pressure control, hypertension, awareness, and treatment in adults with diabetes in the United States-Mexico border region. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2010, 28, 164-73.	0.6	20
4818	Pharmacotherapy for mild hypertension. <i>Sao Paulo Medical Journal</i> , 2012, 130, 417-418.	0.4	8
4819	Physical Activity for the Prevention of Cardiometabolic Disease. , 2017, , 79-99.		12
4820	Effects of Aggressive Approach to the Multiple Risk Factors for Diabetic Nephropathy on Proteinuria Reduction in Diabetes Type 2 Patients. <i>Bosnian Journal of Basic Medical Sciences</i> , 2009, 9, 44-48.	0.6	1
4821	Diabetic macular edema. Epidemiology, pathogenesis, diagnosis, clinical features, treatment. <i>Kazan Medical Journal</i> , 2015, 96, 70-76.	0.1	17
4822	Collaborating with Community Pharmacists to Improve the Quality of Diabetes Care in an IPA-model HMO. <i>Journal of Managed Care Pharmacy</i> , 2001, 7, 292-296.	2.2	5
4823	Serious Complications for Patients, Care Providers and Policy Makers: Tackling the Structural Violence of First Nations People Living with Diabetes in Canada. <i>International Indigenous Policy Journal</i> , 2011, 2, .	0.3	5
4824	Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. <i>Aging</i> , 2020, 12, 10317-10336.	1.4	21
4825	Use of currently available p-adrenohlockers in arterial hypertension in patients with metabolic syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2005, 11, 149-153.	0.1	1
4826	Prevalence of Diabetic Retinopathy and Cataract in Adult Patients With Type 1 And Type 2 Diabetes in Russia. <i>Review of Diabetic Studies</i> , 2009, 6, 124-129.	0.5	20
4827	Etude ADVANCE : objectifs, protocole et ??tat actuel. <i>Drugs</i> , 2003, 63, 39-44.	4.9	5
4828	Nouveaux objectifs dans la prise en charge de l???hypertension. <i>Drugs</i> , 2003, 63, 45-47.	4.9	6
4829	Fixed-Dose Combination Therapy in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 51-54.	1.0	10
4830	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. <i>Current Medicinal Chemistry</i> , 2020, 27, 6682-6702.	1.2	16
4831	Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall. <i>Current Vascular Pharmacology</i> , 2018, 17, 6-15.	0.8	12
4832	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. <i>Current Diabetes Reviews</i> , 2011, 7, 190-200.	0.6	37
4833	SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. <i>Current Diabetes Reviews</i> , 2019, 15, 349-356.	0.6	5
4834	Many Faces of Renin-angiotensin System - Focus on Eye. <i>Open Ophthalmology Journal</i> , 2017, 11, 122-142.	0.1	109

#	ARTICLE	IF	CITATIONS
4835	Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options. <i>The Open Circulation & Vascular Journal</i> , 2012, 3, 30-42.	0.4	5
4836	Screening for Type 2 Diabetes in Adults: An Updated Systematic Review. <i>The Open Diabetes Journal</i> , 2013, 6, 1-13.	0.4	9
4837	PREVALENCE AND RISK FACTORS OF DIABETIC RETINOPATHY IN SAUDI DIABETICS IN MAJMAAH CITY. <i>Australasian Medical Journal</i> , 2016, 9, .	0.1	2
4838	Considerations for the Development of Mobile Phone Apps to Support Diabetes Self-Management: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10115.	1.8	49
4839	Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record. <i>JMIR Medical Informatics</i> , 2018, 6, e10780.	1.3	12
4840	Information Literacy in Food and Activity Tracking Among Parkrunners, People With Type 2 Diabetes, and People With Irritable Bowel Syndrome: Exploratory Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13652.	2.1	8
4841	Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. <i>Journal of Medical Internet Research</i> , 2020, 22, e16791.	2.1	141
4842	Using mHealth to Provide Mobile App Users With Visualization of Health Checkup Data and Educational Videos on Lifestyle-Related Diseases: Methodological Framework for Content Development. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20982.	1.8	8
4843	Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>JMIR MHealth and UHealth</i> , 2017, 5, e4.	1.8	223
4844	Impact of β-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes. <i>Clinical and Investigative Medicine</i> , 2007, 30, 257.	0.3	5
4846	Hypertension and Diabetes. , 2007, , 417-436.		1
4847	Cardiovascular Disease Risk Factors. , 2008, , 235-249.		1
4848	Diabetes Mellitus and Cardiovascular Disease in the Elderly. <i>Fundamental and Clinical Cardiology</i> , 2008, , 179-214.	0.0	4
4849	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. <i>Health Technology Assessment</i> , 2016, 20, 1-86.	1.3	12
4850	Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-218.	1.3	62
4851	Diabetes and macrovasculopathy: Double trouble!. <i>South East Asia Journal of Public Health</i> , 2014, 3, 1-3.	0.3	2
4852	Hepatic steatosis: A benign disease or a silent killer. <i>World Journal of Gastroenterology</i> , 2008, 14, 4120.	1.4	72
4853	Complications and Comorbidities of Type 2 Diabetes. <i>Pediatric Annals</i> , 2005, 34, 710-718.	0.3	5

#	ARTICLE	IF	CITATIONS
4854	Atorvastatin for Diabetic Macular Edema in Patients With Diabetes Mellitus and Elevated Serum Cholesterol. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 316-322.	0.4	28
4855	Spousal Support in Diabetes Self-Management Among Korean Immigrant Older Adults. <i>Research in Gerontological Nursing</i> , 2015, 8, 94-104.	0.2	13
4856	Detecting and controlling diabetic nephropathy: What do we know?. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 209-217.	0.6	11
4857	Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus. <i>American Journal of Critical Care</i> , 2002, 11, 504-519.	0.8	17
4859	Diabetes Management System Based on Ubiquitous Healthcare. <i>Journal of Korean Diabetes</i> , 2011, 12, 133.	0.1	3
4860	Perspectives of "Ubiquitous Health Care System" for Diabetes Management. <i>The Journal of Korean Diabetes Association</i> , 2006, 30, 87.	0.1	9
4861	Current Status of Diabetes Management in Korea Using National Health Insurance Database. <i>The Journal of Korean Diabetes Association</i> , 2007, 31, 362.	0.1	32
4862	Clinical Characteristics and Direct Medical Costs of Type 2 Diabetic Patients. <i>Korean Diabetes Journal</i> , 2008, 32, 358.	0.8	15
4863	Relationship Between Metabolic Syndrome and Risk of Chronic Complications in Koreans with Type 2 Diabetes. <i>Korean Diabetes Journal</i> , 2009, 33, 392.	0.8	7
4864	Effect of Diabetes Education Program on Glycemic Control and Self Management for Patients with Type 2 Diabetes Mellitus. <i>Korean Diabetes Journal</i> , 2009, 33, 518.	0.8	25
4865	Prevalence of hypertension amongst persons with diabetes mellitus in Benin City, Nigeria. <i>Nigerian Journal of Clinical Practice</i> , 2011, 14, 300.	0.2	40
4866	The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE System of Intensive Diabetes Self-Management—2002 Update. <i>Endocrine Practice</i> , 2002, 8, 40-82.	1.1	201
4867	The Unholy Alliance between Obesity, Type-2 Diabetes, the Sympathetic Nervous System, and Hypertension in Young/Middle-Aged Subjects. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2014, 02, .	0.1	1
4868	Impact of Anesthesia on Systemic and Cerebral Glucose Metabolism in Diabetes Patients Undergoing Neurosurgery ?Updates of Diabetes and Neurosurgical Anesthesia?. <i>Journal of Diabetes & Metabolism</i> , 2013, 04, .	0.2	1
4869	Diabetes and Hypertension. <i>Journal of Hypertension: Open Access</i> , 2013, 03, .	0.2	1
4870	Association of Serum Lipids with High Blood Pressure and Hypertension among Diabetic Patients. Mathematical Regression Models to Predict Blood Pressure from Lipids. An Experience from 12-year Follow Up of more than 9000 Patients' Cohort. <i>General Medicine (Los Angeles, Calif)</i> , 2017, 05, .	0.2	3
4871	Clinical critics in the management of diabetes mellitus. <i>Health</i> , 2012, 04, 537-548.	0.1	1
4872	Pharmacist intervention in home care program for diabetes patients. <i>Journal of Diabetes Mellitus</i> , 2012, 02, 279-293.	0.1	2

#	ARTICLE	IF	CITATIONS
4873	Prevalence and Correlates of Prediabetes and Diabetes Results-I: A Screening Plan in a Selected Military Community in Central Saudi Arabia. <i>Journal of Diabetes Mellitus</i> , 2017, 07, 12-30.	0.1	4
4874	Comparison of awareness of diabetes mellitus type II with treatment's outcome in term of direct cost in a hospital in Saudi Arabia. <i>World Journal of Diabetes</i> , 2019, 10, 463-472.	1.3	8
4875	Ranibizumab in diabetic macular edema. <i>World Journal of Diabetes</i> , 2013, 4, 310.	1.3	20
4876	Automated Diagnosis Non-proliferative Diabetic Retinopathy in Fundus Images using Support Vector Machine. <i>International Journal of Computer Applications</i> , 2015, 125, 7-10.	0.2	13
4877	Microalbuminuria and Associated Factors in Bahraini Patients with Type 2 Diabetes Mellitus. <i>Annals of Saudi Medicine</i> , 2000, 20, 157-160.	0.5	12
4878	The Need for Evidence in Hypertension Management: Historical Perspective. <i>Annals of Saudi Medicine</i> , 2005, 25, 368-374.	0.5	1
4879	Diabetes care and control: the effect of frequent visits to diabetes care center. <i>Annals of Saudi Medicine</i> , 2014, 34, 229-234.	0.5	14
4880	Should we shift toward higher blood pressure targets in patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 673-685.	0.9	4
4881	Quality of diabetes care in Dutch care groups: no differences between diabetes patients with and without co-morbidity. <i>International Journal of Integrated Care</i> , 2013, 13, e057.	0.1	12
4882	Antihypertensive drug utilization pattern and awareness in diabetic hypertensive patients at tertiary care centre. <i>International Journal of Research in Medical Sciences</i> , 2015, 3, 461.	0.0	2
4883	Arterial Wall Elasticity Measured Using the Phased Tracking Method and Atherosclerotic Risk Factors in Patients with Type 2 Diabetes. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 678-687.	0.9	10
4884	Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 138-145.	0.9	10
4885	Screening for Diabetes: Can We Afford Not To Screen?. <i>Annals of Internal Medicine</i> , 2004, 140, 756.	2.0	10
4886	Therapeutic approaches to slowing the progression of diabetic nephropathy "is less best?. <i>Drugs in Context</i> , 2013, 2013, 1-12.	1.0	13
4887	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 281-288.	2.2	5
4888	Clinical predictors of severe dengue: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 123.	1.5	32
4889	Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials. <i>Therapie</i> , 2022, 77, 413-423.	0.6	10
4890	Anatomie und Pathologie des Koronargefäßsystems, Physiologie und Pathophysiologie der Koronardurchlutung, Pathogenese der Atherosklerose. , 2000, , 295-326.		0

#	ARTICLE	IF	CITATIONS
4891	Klinik und Diagnostik der koronaren Herzkrankheit. , 2000, , 327-353.		0
4892	Scientific Basis for New Guidelines for the Treatment of Hypertension in Type 2 Diabetes. , 2000, , 611-621.		0
4893	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria. , 2000, , 441-459.		5
4894	Arterielle Hypertonie. , 2000, , 259-268.		0
4895	Nierenkrankheiten. , 2000, , 578-581.		0
4896	Weitere kardiovaskuläre Risikofaktoren. , 2000, , 269-291.		0
4897	Therapie der stabilen und instabilen Angina pectoris. , 2000, , 355-391.		0
4899	Retinopathy in Relation to Albuminuria and Blood Pressure in IDDM. , 2000, , 29-38.		0
4900	Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes. , 2000, , 601-610.		0
4902	Therapie des Diabetes mellitus. , 2000, , 459-503.		0
4903	Fettstoffwechsel, Übergewicht und Ernährung, Diabetes. , 2000, , 239-257.		0
4904	Microalbuminuria and Cardiovascular Disease. , 2000, , 39-53.		1
4905	Glukose. , 2001, , 605-805.		0
4906	Prevalence of Cardiovascular Risk Factors in Canadians with Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2001, 498, 373-380.	0.8	2
4907	Pathophysiologie der Hyperglykämie. , 2001, , 17-33.		0
4908	Antihypertensive Therapie bei Diabetes mellitus. , 2001, , 191-206.		1
4909	The Diabetic Hypertensive (or Hypertensive Diabetic) - A Compelling Need to Optimize Blood Pressure. Advances in Experimental Medicine and Biology, 2001, 498, 119-125.	0.8	0
4910	Medikamentöse Behandlung der arteriellen Hypertonie bei Zusatzerkrankungen. , 2001, , 360-391.		0

#	ARTICLE	IF	CITATIONS
4911	The Effect of Hypertension in Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2001, 498, 115-117.	0.8	0
4912	Epidemiology and Problems with Diagnosis of Heart Failure. , 2001, , 54-68.		0
4913	Diabetische Retinopathie. , 2001, , 207-218.		0
4914	Pathophysiologie der Hyperglykämie. , 2001, , 17-33.		0
4915	Medical Nutrition Therapy for Diabetes. , 2001, , 167-193.		0
4916	Matching the right drug to the right patient in essential hypertension. <i>Heart</i> , 2001, 86, 113-120.	1.2	1
4917	Diabetische Nephropathie. <i>Pharma-Kritik (discontinued)</i> , 2001, 23, .	0.0	0
4918	Proliferative Diabetic Retinopathy: Current Treatment Strategies for Progression. , 2002, , 89-104.		0
4919	Microalbuminuria in Perspectives. , 2002, , 105-120.		2
4920	Medical Approaches to Preventing Vision Loss from Diabetic Retinopathy. , 2002, , 67-74.		0
4921	Antihypertensiva. <i>Springer-Lehrbuch</i> , 2002, , 361-391.	0.1	0
4922	A review: "In-Home Healthcare" projects in the USA. , 2002, , 601-606.		0
4923	Vascular Disease in Diabetes Mellitus. , 2002, , 995-1008.		0
4924	Home health monitoring and diabetes: a web-based approach to achieving better control. , 2002, , 607-611.		0
4926	Hypertension, Diabetes and the Heart. , 2002, , 65-84.		0
4927	Hypertension, Diabetes, and the Heart. , 2002, , .		0
4928	Management of Patients with Diabetes and Coronary Artery Disease. , 2002, , 185-209.		1
4929	Treatment of Diabetes. , 2002, , .		0

#	ARTICLE	IF	CITATIONS
4930	Management of type 2 diabetes. , 2002, , 1-24.		0
4931	Blutdruckbehandlung bei Diabetes mellitus. Pharma-Kritik (discontinued), 2002, 24, .	0.0	0
4932	Point-of-Care Testing in the Management of Diabetes Mellitus. , 2002, , 215-233.		0
4934	Vascular Complications in Diabetes: Risk Factors and Pathogenic Correlates. Progress in Experimental Cardiology, 2003, , 97-107.	0.0	0
4935	Recent Therapeutic Trials. , 2003, , 175-184.		0
4937	Microalbuminuria and Cardiovascular Disease in Type 2 Diabetes. , 2003, , 85-97.		0
4938	Hypertension in Type 2 Diabetes Mellitus. , 2003, , 63-84.		1
4939	Le rein, organe-cible chez le diabétique hypertendu. Drugs, 2003, 63, 31-37.	4.9	3
4940	Transmural Pressure Control of Prorenin Processing and Secretion in Diabetic Rat Juxtaglomerular Cells.. Hypertension Research, 2003, 26, 493-501.	1.5	2
4941	Zerebrale Durchblutungsstörungen. , 2003, , 1285-1299.		0
4942	3.ç³-â°¿ç—...æ€šè³çç-†ã@ãÿ°çŽã*è†ã°š. The Journal of the Japanese Society of Internal Medicine, 2003, 92, 55-59.	0.0	0
4943	Global Approach to Cardiovascular Risk in Type 2 Diabetic Persons. , 2003, , 240-276.		1
4953	Le diabète non-insulinodépendant : une affection en expansion Ophtalmopathie diabétique : Actualités de la rétinopathie diabétique. Bulletin De L'Academie Nationale De Medecine, 2003, 187, 1317-1325.	0.0	0
4955	The Diabetic Eye. , 2003, , 107-122.		0
4956	Albuminuria. , 2003, , 73-87.		0
4957	Treatment of arterial hypertension in patients with diabetes mellitus and nephropathy: current potentialities of renin-angiotensin-aldosterone system block. Arterial Hypertension (Russian) Tj ETQq1 1 0.784314 çgBT /Overlock 10 Tff		0
4958	Coronary Artery Disease and Cardiomyopathy. , 2004, , 685-700.		0
4959	Arterielle Hypertonie. , 2004, , 1169-1183.		0

#	ARTICLE	IF	CITATIONS
4960	Inhibitors of the RAS: Evidence-Based Medicine. Handbook of Experimental Pharmacology, 2004, , 545-592.	0.9	0
4961	Zerebrale Durchblutungsstörungen. , 2004, , 403-410.		0
4963	Prevention of Microvascular Complications of Diabetes. , 2004, , 619-638.		0
4964	Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 485-516.	0.9	0
4965	Herz, GefäÙe, Lunge. , 2004, , 81-196.		0
4966	Hypertension in Chronic Kidney Disease. , 2004, , 39-62.		0
4967	Diabetische Nephropathie. , 2004, , 305-316.		0
4971	Diabetes und Auge. , 2004, , 295-304.		0
4972	Effects of Pancreas Transplantation on Secondary Complications of Diabetes. , 2004, , 455-508.		1
4974	Hypertonie bei Diabetes mellitus. , 2004, , 353-365.		0
4977	The poorly controlled type 2 diabetic patient. , 2004, , 197-231.		1
4979	Combined pharmacotherapy for arterial hypertension in patients with type 2 diabetes mellitus. Arterial Hypertension (Russian Federation), 2004, 10, 118-121.	0.1	0
4980	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. , 2005, , 543-556.		0
4982	Critical Assessment of Hypertension Guidelines. , 2005, , 391-399.		0
4985	Pervye rezul'taty Rossiyskoy programmy Â«Aprel'Â» (effektivnost' primeneniya akarbozy u patsientov s Tj ETQq0 0 0 rgBT /Overlock 10 13-18.	0.4	2
4986	Screening for type 2 diabetes. , 2005, , 714-750.		0
4987	Intervention in high risk groups: hypertension. , 2005, , 865-892.		0
4988	Antidiabetic Drugs. , 2005, , 363-372.		0

#	ARTICLE	IF	CITATIONS
4989	Sovremennye podkhody k diagnostike i lecheniyu arterial'noy gipertenzii. Obesity and Metabolism, 2005, 2, 2-10.	0.4	0
4990	Management of Type 2 Diabetes in Underrepresented Minorities in the U.S.. , 2005, , 227-247.		0
4991	Deterioration of Retinopathy After Starting Interferon Therapy for Chronic Hepatitis C with Diabetic Triopathy.. Kitakanto Medical Journal, 2006, 56, 339-342.	0.0	0
4996	Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. , 2006, , 411-432.		0
4997	Hoe groot is de kans op nierinsufficiÃ«ntie bij de oudere patiÃ«nt met diabetes en licht verhoogde bloedsuikers?. , 2006, , 2395-2396.		0
4998	Mag een bÃ«tablokker worden voorgeschreven aan een patiÃ«nt met diabetes?. , 2006, , 2186-2187.		0
5000	Diabetes and Cardiovascular Disease. , 2006, , 293-306.		0
5001	Antianginal drugs. , 2006, , 260-263.		0
5002	Gene Expression Profiling in the Investigation of Diabetic Nephropathy. , 2006, , 277-288.		0
5003	Arterial Hypertension. Fundamental and Clinical Cardiology, 2006, , 19-62.	0.0	0
5004	Type 1 Diabetes Mellitus. Fundamental and Clinical Cardiology, 2006, , 147-186.	0.0	0
5005	Type 2 Diabetes. Fundamental and Clinical Cardiology, 2006, , 187-254.	0.0	0
5007	Kidney Disease in Hypertension. , 2007, , 351-360.		0
5008	Pharmacotherapy of Diabetic Retinopathy. , 2007, , 255-260.		1
5009	Angiotensin II and Inflammation. , 2007, , 91-110.		0
5010	Cerebrovascular Disease/Transient Ischemic Attack. , 2007, , 1911-1921.		0
5011	Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients. , 2007, , 205-222.		0
5012	A new page in hypertension management in diabetes mellitus type 2. ADVANCE study first results. Arterial Hypertension (Russian Federation), 2007, 13, 212-219.	0.1	1

#	ARTICLE	IF	CITATIONS
5013	Type 1 Diabetes Mellitus. , 2007, , 147-185.		0
5014	Arterial Hypertension. , 2007, , 19-61.		1
5015	Intracellular Signaling Pathways and Peroxisome Proliferator-Activated Receptors in Vascular Health in Hypertension and in Diabetes. Oxidative Stress and Disease, 2007, , 195-210.	0.3	0
5017	Nutrition in Diabetes Mellitus. , 2007, , 785-813.		0
5018	Organoprotective properties of fixed-drug combination verapamil-SR and trandolapril. Arterial Hypertension (Russian Federation), 2007, 13, 266-274.	0.1	0
5019	"White coat hypertension" in type 2 diabetic patients. Polish Archives of Internal Medicine, 2007, 117, 452-455.	0.3	1
5020	Renal Dysfunction and Hypertension. , 2007, , 263-276.		0
5021	The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. , 2007, , 437-461.		0
5022	Epidemiology of Type 2 Diabetes in Children and Adolescents. , 2007, , 357-374.		0
5026	Diabetes in Women. , 2008, , 155-182.		0
5027	Diabetic Neuropathies. , 2008, , 109-134.		1
5028	Treatment of Hypertension in Type 2 Diabetes. , 2008, , 251-263.		0
5030	Diabetische Nephropathie. , 2008, , 385-416.		0
5032	Controlling blood pressure in type-2 diabetes. Independent Nurse, 2008, 2008, .	0.0	0
5033	Intensive Glucose Control and Cardiovascular Outcomes: Focused on Recent Clinical Trials. Journal of Korean Endocrine Society, 2008, 23, 289.	0.1	1
5035	Clinical Management of the Metabolic Syndrome. , 2008, , 154-223.		2
5036	ç³-ã°¿ç—...æ,£è€...ã«ãšãã,è¡€ãœ\$ç®¡ç†. Okayama Igakkai Zasshi, 2008, 119, 311-313.	0.0	0
5038	Quality of care for the woman with diabetes in pregnancy. Series in Maternal-fetal Medicine, 2008, , 399-408.	0.1	0

#	ARTICLE	IF	CITATIONS
5039	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy: a randomized controlled trial (FIELD). Arterial Hypertension (Russian Federation), 2008, 14, 245-256.	0.1	0
5040	Results of ADVANCE study - an advance in the treatment of hypertension and diabetes mellitus. Arterial Hypertension (Russian Federation), 2008, 14, 288-293.	0.1	0
5041	Preventing visual loss in people with diabetes. Independent Nurse, 2008, 2008, .	0.0	0
5042	Rationale for Fixed-Dose Combination Therapy to Reach Lower Blood Pressure Goals. Southern Medical Journal, 2008, 101, 918-924.	0.3	2
5044	Prise en charge des diabétiques. , 2009, , 105-117.		0
5045	4 Hypertensie. , 2009, , 61-72.		0
5046	Diabetic Nephropathy in Childhood and Adolescence (I) : Clinical Features. Journal of the Korean Society of Pediatric Nephrology, 2009, 13, 1.	0.1	3
5048	Wat is de eerste keus bij behandeling van hypertensie bij type 2 diabetes?. , 2009, , 57-62.		0
5049	Complications of diabetes. , 2009, , 41-57.		0
5051	Malattie cerebrovascolari dell'encefalo. , 2009, , 3-39.		0
5052	Change of Selection to Antihypertensive Drugs in Hypertensive Patients with Diabetes Mellitus: In Pohang - Gyeongju Primary Care Research Network. Korean Journal of Family Medicine, 2009, 30, 197.	0.4	3
5053	Chapter 24 Hypertension in diabetic patients. , 2009, , .		0
5054	Modern therapeutic approach to hypertension management in patients with diabetes mellitus: facts and view points. Arterial Hypertension (Russian Federation), 2009, 15, 42-45.	0.1	0
5055	Why It Is Important To Know The Diabetes Type?. Kansas Journal of Medicine, 2009, 2, 41-42.	0.1	0
5056	Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. Arterial Hypertension (Russian Federation), 2009, 15, 31-41.	0.1	0
5057	AP control of as the most efficacious tool for the prevention of cardiovascular complications in patients with type 2 diabetes mellitus. Diabetes Mellitus, 2009, 12, 10-13.	0.5	0
5058	Reducing CVD risk. Independent Nurse, 2009, 2009, .	0.0	0
5060	First steps in hypertension care. Independent Nurse, 2009, 2009, .	0.0	0

#	ARTICLE	IF	CITATIONS
5061	Modeling the Value for Money of Changing Clinical Practice Change. Medical Care, 2009, 47, 1053-1061.	1.1	6
5062	Formes cliniques " Cas particuliers. , 2010, , 91-110.		0
5063	Épidémiologie de la rétinopathie diabétique. , 2010, , 1-6.		0
5064	Traitement de la rétinopathie diabétique. , 2010, , 111-141.		0
5066	Diabetic Eye Disease. , 2010, , 971-983.		0
5067	Diabetic Macular Ischemia. , 2010, , 203-225.		1
5068	Bewegungstherapie bei koronarer Herzkrankheit. , 2010, , 115-142.		1
5071	Microvascular Complications of Diabetes. , 2010, , 355-357.e2.		0
5072	Classification et aspects cliniques. , 2010, , 51-74.		0
5073	Épidémiologie des états diabétiques. , 2010, , 3-10.		0
5074	Artériopathie des membres inférieurs et diabète. , 2010, , 263-271.		0
5075	Rétinopathie diabétique. , 2010, , 193-206.		0
5076	Désordres cliniques et biologiques associés. , 2010, , 77-98.		0
5077	Clinical Examples in Managing Diabetic Retinopathy. , 2010, , 403-439.		0
5078	Wat is de eerste keus bij behandeling van hypertensie bij type 2 diabetes?. , 2010, , 42-47.		0
5079	Diabetes Mellitus: Is the Presence of Nephropathy Important as a Cardiovascular Risk Factor for Cardioneral Syndrome?. , 2010, , 145-157.		0
5081	Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. , 2010, , 250-262.		0
5082	Systemic and Ocular Factors Influencing Diabetic Retinopathy. , 2010, , 77-103.		0

#	ARTICLE	IF	CITATIONS
5083	Interaction Between Patients With Type 2 Diabetes And Diabetes Nurse Specialists During Annual Check-Ups: A Study Using Video Recordings. Internet Journal of Advanced Nursing Practice, 2010, 11, .	0.0	2
5084	Defining Diabetic Retinopathy Severity. , 2010, , 105-120.		3
5090	Point: Metabolic Surgery Plays a Key Role in Endocrinology Practiceâ€”The Case for Incorporating RYGB in the Standard Clinical Algorithm to Treat Obesity and Diabetes. Endocrine Practice, 2010, 16, 39-42.	1.1	0
5092	Diabetes in Special Populations. , 2011, , 317-355.		0
5093	Hypertension in Diabetics. , 2011, , 239-265.		0
5095	Diabetes and Cardiovascular Disease. , 2010, , 173-194.		0
5096	Diabetes and Vision. , 2010, , 111-134.		0
5097	Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 387.	1.1	1
5098	What are the optimal values of systolic blood pressure in patients with diabetes? The ACCORD Blood Pressure study completed. Cor Et Vasa, 2010, 52, 700-705.	0.1	0
5099	Major Clinical Trials on Treatment for Diabetic Retinopathy. , 2010, , 201-209.		0
5101	Primary Prevention of Stroke. , 2011, , 242-251.		0
5108	Female Preponderance in the Discordant Association between Retinopathy and Nephropathy in Patients with Type 2 Diabetes Mellitus. International Journal of Clinical Medicine, 2011, 02, 13-17.	0.1	1
5110	Treatment of Refractory Diffuse Diabetic Macular Edema with Intravitreal Bevacizumab. Qatar Medical Journal, 2011, 2011, .	0.2	1
5111	Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 22-27.	0.4	0
5113	Creating Secondary Learning Resources from Web Based Conversational Learning Around â€”Rational Usage of Medicinesâ€™ in Diabetes. International Journal of User-Driven Healthcare, 2011, 1, 77-84.	0.1	0
5116	Ocular Diseases and Hypertension. Korean Journal of Medicine, 2012, 83, 591.	0.1	3
5117	References, Bibliography & Further Reading. , 2012, , 287-306.		0
5119	Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. , 2012, , 249-266.		0

#	ARTICLE	IF	CITATIONS
5120	Pathologie, Klinik und Behandlung von diabetischen retinalen Gefäß-erkrankungen. , 2012, , 99-162.		0
5121	Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population. International Journal of Basic and Clinical Pharmacology, 2012, 1, 160.	0.0	1
5123	Polarization Sensitivity. Biological and Medical Physics Series, 2012, , 175-207.	0.3	0
5124	Severity of carbohydrate metabolism disturbances, arterial hypertension stage, and lipid profile in patients with metabolic syndrome. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 13-18.	0.4	1
5125	SECTION III Special Considerations Overview. , 2012, , 173-174.		0
5126	Benefits of vasodilating beta-adrenoblockers for arterial hypertension treatment. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 87-92.	0.4	0
5128	Retinal and Choroidal Manifestations of Systemic Hypertension. , 2013, , 417-423.		0
5130	RELATIONSHIPS BETWEEN METABOLIC PARAMETERS AND PLAQUE VULNERABILITY IN THE CAROTID ARTERIES IN PATIENTS WITH DIABETES MELLITUS TYPE 2. Acta Medica Medianae, 2012, , 29-37.	0.0	0
5131	POVEZANOST METABOLIČEKIH PARAMETARA I VULNERABILNOSTI PLAKOVA NA KAROTIDNIM ARTERIJAMA KOD OSOBA OBOLELIH OD DIJABTES MELITUSA TIP 2. Acta Medica Medianae, 2012, , 29-37.	0.0	0
5132	Diabetic cardiomyopathy – What do we know about it?. World Journal of Cardiovascular Diseases, 2013, 03, 26-32.		
5134	Diabetic cardiomyopathy – What do we know about it?. World Journal of Cardiovascular Diseases, 2013, 03, 26-32.	0.0	2
5135	Diabetes mellitus bij volwassenen. , 2013, , 307-344.		0
5136	Vascular Complications in Diabetes. , 2013, , 313-337.		0
5137	Impact of Hypertension on Type 2 Diabetes in Mysore Population of South India. International Journal of Clinical Medicine, 2013, 04, 561-570.	0.1	1
5138	Target Blood Pressure in Diabetes. Journal of Korean Diabetes, 2013, 14, 1.	0.1	1
5141	Systemic Diseases and Glaucoma. , 2014, , 479-507.		0
5143	Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. , 2014, , 265-286.		0
5144	Editorial: Sailing across the sea of guidelines. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2013, 20, 361-367.	0.3	0

#	ARTICLE	IF	CITATIONS
5145	Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. , 2014, , 265-275.		0
5146	Diabetes and Chronic Kidney Disease. , 2014, , 43-55.		0
5147	Fettstoffwechsel und Hypertonie bei Diabetes. , 2014, , 217-237.		0
5148	Diabetologie für die Pflege. , 2014, , 7-103.		0
5149	Risk factors associated with stroke recurrence and death in patients with ischemic stroke of Yamagata prefecture in Japan. Nosotchu, 2014, 36, 425-431.	0.0	1
5150	Impacto sanitario y social de las enfermedades endocrinas metabólicas. Diabetes. , 2014, , 81-100.		0
5151	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
5152	Determination of Prothrombotic Gene Polymorphisms and Stroke Risk Factors in Young Ischemic Stroke Patients. Sakarya Tıp Dergisi, 2014, 4, 119-124.	0.0	1
5153	Diabetische Folgeerkrankungen. , 2014, , 239-296.		0
5154	Preventing the Progression of Diabetic Kidney Disease. American Journal of Internal Medicine, 2014, 2, 26.	0.1	0
5155	Prevention and management of diabetic retinopathy. Journal of the Korean Medical Association, 2014, 57, 525.	0.1	0
5156	Artériopathie des membres inférieurs et diabète. , 2014, , 277-284.		0
5157	Épidémiologie des états diabétiques. , 2014, , 3-9.		0
5158	Rétinopathie diabétique. , 2014, , 215-227.		0
5159	Diabetes and the Kidney. , 2014, , 345-357.		0
5161	DIABETO PRIEĖROS KLINIKINIS AUDITAS VILNIAUS UNIVERSITETO LIGONINĖS SANTARIĖKĖ KLINIKĖS ĄEIMOS MEDICINOS CENTRE. Medicinos Teorija Ir Praktika, 2014, 20, 387-394.	0.0	0
5163	Excess cardiovascular risk in patients with type 2 diabetes: do we need to look beyond LDL cholesterol?. British Journal of Diabetes and Vascular Disease, 2014, 14, 10.	0.6	0
5165	The management of erectile dysfunction associated with diabetes. Sexual Dysfunction, 1998, 1, 113-118.	0.0	0

#	ARTICLE	IF	CITATIONS
5166	Treatment of Type 2 Diabetes Mellitus: Which Treatment Options are Best Suited for our Patients?. Endocrine Practice, 1998, 4, 425-426.	1.1	0
5167	UKPDS: A Faltering Success. Endocrine Practice, 1998, 4, 428-429.	1.1	0
5169	Diabetes und koronare Herzkrankheit. , 1999, , 345-418.		0
5170	Treating type 2 diabetes. BMJ: British Medical Journal, 1999, 318, 666-666.	2.4	0
5171	Diabetes mellitus and anaesthesia. Current Opinion in Anaesthesiology, 1999, 12, 343-347.	0.9	4
5172	Diabetes and hypertension: an update. Current Opinion in Endocrinology, Diabetes and Obesity, 1999, 6, 245.	0.6	0
5174	ACE inhibition in Chronic Renal Failure and in the Treatment of Diabetic Nephropathy: Focus on Spirapril. Journal of Cardiovascular Pharmacology, 1999, 34, S31-S34.	0.8	0
5175	Yonder: Grandparenthood, rural health, diabetes, & perinatal psychiatry. British Journal of General Practice, 2014, 64, 299-299.	0.7	0
5176	Magnitude of Obesity, Abdominal Adiposity and their Association with Hypertension and Diabetes- A Cross Sectional Study. Journal of Metabolic Syndrome, 2014, 03, .	0.1	0
5177	Authorsâ€™ reply. Singapore Medical Journal, 2014, 55, 554-554.	0.3	1
5178	The role of glucose-lowering drugs in blood pressure control in patients with type 2 diabetes mellitus. Arterial Hypertension (Russian Federation), 2015, 21, 334-348.	0.1	0
5179	Diabetes Mellitus: Alterations in Vessel Wall Properties. , 2015, , 221-236.		0
5180	Treatment of DME with Steroids. , 2015, , 55-67.		0
5181	Improving the Undiagnosed Rate of Diabetes Mellitus Using a Point-of-Care A1C Device. Journal of Diabetes, Metabolic Disorders & Control, 2015, 2, .	0.2	0
5183	Improved management and 10-year outcomes in diabetic kidney disease in routine clinical care. British Journal of Diabetes and Vascular Disease, 2015, 15, 27.	0.6	0
5184	High Fiber Caribbean Diets with Low-Intermediate GI Improve Glycemic Control, Cardiovascular and Inflammatory Indicators in Overweight Persons with Type 2 Diabetes: A Randomized Control Study. Current Research in Nutrition and Food Science, 2015, 3, 36-45.	0.3	5
5186	Stroke of Diabetic Subject: Experience of The Neurology Service of Cocody Teaching Hospital at Abidjan (Ivory Coast). Journal of Neurological Disorders, 2016, 04, .	0.1	1
5188	Knowledge Attitude and Practice of General Physicians for Early Detection of Diabetic Nephropathy in Cotonou. Open Journal of Nephrology, 2016, 06, 122-131.	0.0	2

#	ARTICLE	IF	CITATIONS
5193	The management of diabetic retinopathy in the public sector of eThekweni district of KwaZulu-Natal. African Vision and Eye Health, 2016, 75, .	0.1	2
5194	Testing of risk perception survey - Diabetes mellitus in Korea. Journal of the Korean Data and Information Science Society, 2016, 27, 477-486.	0.0	0
5195	Effect of 8 Weeks Aerobic Interval Training on Glycosylated Hemoglobin and Insulin Resistance Index in Diabetic Mellitus Type 2 Women. Ufuq-i DÄnish, 2016, 22, 137-143.	0.3	1
5196	Treatment of Peripheral Arteriopathy in Women. , 2017, , 219-227.		0
5197	A STUDY ON THE IMPACT OF HYPERTENSION IN PATIENTS WITH DIABETIC RETINOPATHY. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 4210-4214.	0.0	0
5198	Safe and effective antihypertensive therapy in obesity. PraktickÄ© LÄ©kÄ½renstvÄ½; 2016, 12, 176-181.	0.0	0
5199	Effective Treatment Matters: Revitalizing Pharmacovigilance. , 2017, , 121-130.		0
5200	Current Treatment Recommendations. , 2017, , 163-186.		1
5201	Diabetes in Older Adults. , 2017, , 1-18.		0
5202	Hypertension in Older Adolescents and Young Adults. , 2017, , 1-12.		0
5203	Stakeholdersâ€™ perspectives on the management of diabetic retinopathy for a district health system â€œ South Africa. African Vision and Eye Health, 2017, 76, .	0.1	2
5205	Five Years Trends in Antihypertensive Monotherapy and Blood Pressure Control in Patients Referred to Tertiary Care Centre. SSRN Electronic Journal, 0, , .	0.4	0
5209	Hypertension - Updated. , 2017, , .		0
5210	DIABETIC RETINOPATHY- AN OVERVIEW. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 4660-4665.	0.1	0
5211	CORRELATION OF HBA1C WITH SIGHT-THREATENING DIABETIC RETINOPATHY (STDR) IN TYPE 2 DIABETES MELLITUS. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 4451-4455.	0.0	1
5213	Hypertension in Older Adolescents and Young Adults. , 2018, , 651-662.		0
5214	Fall 54: PrÄ½vention â€œ 55 Jahre, â™€, DM Typ 2, Aufnahme mit Herzinfarkt. , 2018, , 217-219.		0
5215	Diabetes Mellitus and Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 695-704.	0.1	1

#	ARTICLE	IF	CITATIONS
5216	Interaction of renin-angiotensin system gene polymorphisms with hypertension in Chinese patients with type 1 diabetes and retinopathy. <i>Oncotarget</i> , 2018, 9, 7582-7589.	0.8	1
5218	Diabetes and the Eye. <i>Endocrinology</i> , 2018, , 231-273.	0.1	0
5219	Hypertension and Diabetes. <i>Endocrinology</i> , 2018, , 109-130.	0.1	0
5220	Arterielle Hypertonie. , 2018, , 23-54.		0
5223	Nonproliferative Diabetic Retinopathy. , 2019, , 21-95.		0
5224	An mHealth Diabetes Intervention for Glucose Control: Health Care Utilization Analysis. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10776.	1.8	9
5225	Microvascular Structural Alterations and Tissue Perfusion in Hypertension/Diabetes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 183-196.	0.1	0
5226	Hypertension and Diabetes. <i>Endocrinology</i> , 2019, , 1-22.	0.1	0
5227	Artériopathie des membres inférieurs et diabète. , 2019, , 391-398.		1
5228	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. , 2019, , 377-390.		0
5229	Relationships between the diabetes awareness and clinical indices/nutrient intakes in Korean adults: Based on the 2012–2013 Korea National Health and Nutrition Examination Survey Data. <i>Nutrition Research and Practice</i> , 2019, 13, 240.	0.7	1
5230	Diabetes and the Eye. <i>Endocrinology</i> , 2019, , 1-43.	0.1	0
5231	Prise en charge de la maladie rénale diabétique. , 2019, , 313-343.		0
5232	Thérapeutique des dysordres associés. , 2019, , 253-267.		0
5233	Dysordres cliniques et biologiques associés. , 2019, , 91-110.		0
5234	Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. <i>Meditinskiy Sovet</i> , 2019, , 138-145.	0.1	1
5235	Rétinopathie diabétique. , 2019, , 297-312.		0
5236	Diabetic Retinopathy: Surgical Aspects. <i>Retina Atlas</i> , 2019, , 55-65.	0.0	0

#	ARTICLE	IF	CITATIONS
5238	Pharmacologic Renal Protection. , 2019, , 101-112.		0
5241	CLINICAL STUDY OF ASSOCIATION OF BMI WITH RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2222-2226.	0.0	0
5242	CLINICAL STUDY OF ASSOCIATION OF BMI WITH NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2323-2327.	0.0	0
5244	Correlation Between Glycaemic Indices and Central Foveal Thickness in Diabetic Retinopathy. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2778-2781.	0.0	0
5245	Magnitude of Diabetic Retinopathy in Outpatients Presenting with Cataract in a Tertiary Care Hospital. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 3937-3940.	0.1	0
5246	Observations of the Exercise-Induced Interarm Blood Pressure Difference. Translational Journal of the American College of Sports Medicine, 2020, 5, 1-6.	0.3	0
5248	Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks. Current Diabetes Reviews, 2020, 16, 189-199.	0.6	1
5249	Novel Treatments for Diabetic Macular Edema and Proliferative Diabetic Retinopathy. Current Diabetes Reports, 2021, 21, 43.	1.7	14
5250	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. Journal of the American Heart Association, 2021, 10, e021230.	1.6	2
5252	Primary Hypertension. , 2020, , 125-133.		0
5255	Cocoa olein glycerolysis with lipase >Candida antarctica; in a solvent free system. Grasas Y Aceites, 2020, 71, 383.	0.3	1
5256	Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	23
5257	Diabetes mellitus and the kidney. , 2020, , 4975-4987.		0
5259	Dental Implant Treatment for Diabetic Patients. , 2020, , 103-127.		0
5260	Diabetes and the Eye. Endocrinology, 2020, , 231-273.	0.1	0
5261	REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. Journal of Lipid and Atherosclerosis, 2020, 9, 406.	1.1	4
5262	Epidemiology and Genetics of Diabetic Retinopathy. , 2020, , 1-20.		0
5263	Correlation of Risk Factors with Severity of Diabetic Retinopathy - A Retrospective Study. Journal of Evolution of Medical and Dental Sciences, 2020, 09, 101-104.	0.1	1

#	ARTICLE	IF	CITATIONS
5264	Hypertension and Diabetes. <i>Endocrinology</i> , 2020, , 109-130.	0.1	0
5265	Diabetes in Older Adults. , 2020, , 211-228.		0
5266	Efficacy of Alzer^{gt;®} and Diamel, Nutritional Supplements, in the Prevention of Severe Diabetic Macular Edema. <i>Open Journal of Ophthalmology</i> , 2020, 10, 307-322.	0.1	0
5267	Sympathetic overdrive in patients with impaired carbohydrate metabolism. <i>LÄ~ki UkraÄ~ni</i> , 2020, .	0.0	0
5269	The Functional State of the Myocardium in Patients with Ischemic Heart Disease, Diabetes Mellitus Type 2 and Cardiac Insufficiency. <i>Lviv Clinical Bulletin</i> , 2020, 1, 52-60.	0.1	0
5270	Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020999.	1.6	3
5271	Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry. <i>PLoS ONE</i> , 2021, 16, e0259157.	1.1	6
5273	The Development of Atherosclerosis in Patients with Diabetes Mellitus. <i>UkraÄ~nsË¼urnal Medicini BA~ologÄ~Ä Ta Sportu</i> , 2020, 5, 145-149.	0.0	0
5274	Creating Secondary Learning Resources from Web Based Conversational Learning Around â€Rational Usage of Medicinesâ€™ in Diabetes. , 0, , 130-137.		0
5276	Treatment of Diabetes. , 2003, , 681-694.		1
5277	COMMENTARY: CANCER IN THE ELDERLY: PREVENTION AND BETTER CARE NEEDED. , 2006, , 153-158.		0
5279	Parakrine Faktoren bei der diabetischen Retinopathie. , 2006, , 445-458.		0
5282	Hypertonie. , 2005, , 377-396.		0
5283	Arterielle Hypertonie bei Diabetes mellitus. , 2005, , 26-39.		0
5284	Stoffwechsel des Herzens bei Diabetes. , 2005, , 101-121.		0
5285	Clinical Trials With Calcium Antagonists in Older Patients With Hypertension. , 2005, , 369-380.		0
5286	Combination Drug Therapy in the Elderly. , 2005, , 399-425.		0
5287	Obesity, Diabetes, and Hypertension. , 2006, , 169-192.		1

#	ARTICLE	IF	CITATIONS
5288	Medical Therapy for Carotid Artery Stenosis. , 2007, , 11-31.		0
5289	An Evidence-Based Approach to Type 2 Diabetes. , 2006, , 303-321.		0
5290	Supporting Evidence-Based Endocrine Practice. , 2006, , 87-100.		0
5291	Introduction to Diabetes. , 2006, , 1-37.		2
5292	Management of Hypertension. , 2006, , 93-112.		0
5293	Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. , 2006, , 113-143.		0
5294	Epidemiology and Prevention of Cardiovascular Disease in Diabetes. , 2009, , 19-33.		0
5295	Screening and Treatment of Early Diabetic Renal Disease in Type 1 and Type 2 Diabetes. , 2006, , 403-417.		0
5296	Management of Diabetic End-Stage Renal Disease With Dialysis. , 2006, , 453-469.		0
5298	Beta-Blockers. , 2007, , 1-35.		0
5302	Hemodiyaliz Tedavisi GÄ¶ren Diyabetik Hastalarda Å–IÅ¶Å¼len HbA1c DeÄ¶yerlerindeki DeÄ¶yiÅ¶kenliÄ¶yin SaÄ¶ykalÄ¶m ile Å°liÅ¶kisi. UludaÄ¶ Üœniversitesi TÄ±p FakÅ¼ltesi Dergisi, 0, , .	0.2	0
5303	Impact of Endocrine Disorders on Blood Pressure. Endocrinology, 2021, , 29-58.	0.1	2
5304	The Patient with Hypertension and Type II Diabetes mellitus in General Practice: Modern Aspects of Therapy. Family Medicine, 2020, .	0.1	0
5306	Improving Current Glycated Hemoglobin Prediction in Adults: Use of Machine Learning Algorithms With Electronic Health Records. JMIR Medical Informatics, 2021, 9, e25237.	1.3	4
5307	Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus. International Journal of Ophthalmology, 2013, 6, 141-5.	0.5	11
5308	Hypertension and diabetes mellitus: a collision of two heavyweight non-communicable diseases. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2022, 27, 57-69.	0.4	2
5309	Effects of continuous subcutaneous insulin infusion on clinical parameters in patients with different sociodemographic and clinical characteristics. International Journal of Diabetes in Developing Countries, 0, , 1.	0.3	0
5311	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. Antioxidants, 2021, 10, 1849.	2.2	3

#	ARTICLE	IF	CITATIONS
5313	Association of Acute Kidney Injury During Diabetic Ketoacidosis With Risk of Microalbuminuria in Children With Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2022, 176, 169.	3.3	16
5314	Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004â€“2016. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 579.	0.7	3
5315	Standards of Medical Care in Diabetesâ€“2006. <i>Diabetes Care</i> , 2006, 29, s4-s42.	4.3	702
5316	Diabetic Nephropathy and Diabetic Kidney Disease. <i>Journal of Diabetes Mellitus</i> , 2021, 11, 359-377.	0.1	3
5318	Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. <i>European Endocrinology</i> , 2021, 17, 92.	0.8	1
5320	PREVALENCE, PATHOGENESIS, CLASSIFICATION, IMAGING, SCREENING AND MANAGE-MENT OF DIABETIC RETINOPATHY- A CRITICAL REVIEW. <i>International Ayurvedic Medical Journal</i> , 2021, 9, 1433-1442.	0.0	0
5321	Epidemiology and risk factors for development of diabetic retinopathy. , 2021, 1, 128-137.		0
5322	Estimation of the Level of Glycosylated Hemoglobin as a Predictor Factor to Bevacizumab Injection in Diabetic Macular Edema in a Sample of Iraqi Patients. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 9, 1480-1483.	0.1	0
5323	Cardiovascular Risk Factors Drive Impaired Fasting Glucose to Type 2 Diabetes: Findings After a 9-Year Follow-Up in the PURE Study in Poland. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 1.	0.8	0
5324	Screening for primary aldosteronism in the diabetic population: a cohort study. <i>Internal Medicine Journal</i> , 2023, 53, 709-716.	0.5	3
5325	Current Management of Diabetic Macular Edema. , 0, , .		1
5327	Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1102-1111.	1.5	8
5328	Hypertension and Diabetes. , 2022, , 263-291.		2
5330	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. <i>BMC Nephrology</i> , 2022, 23, 9.	0.8	32
5332	Prevalence and associated factors of hypertension complications among hypertensive patients at University of Gondar Comprehensive Specialized Referral Hospital. <i>Clinical Epidemiology and Global Health</i> , 2022, 13, 100951.	0.9	1
5333	Development of a diabetic retinopathy screening model for a district health system in Limpopo Province, South Africa. <i>African Vision and Eye Health</i> , 2022, 81, .	0.1	1
5334	The cultural beliefs and practices of diabetes self-management in Javanese diabetic patients: An ethnographic study. <i>Heliyon</i> , 2022, 8, e08873.	1.4	10
5335	Uncontrolled Blood Pressure and Associated Factors Among Persons With Diabetes: A Community Based Study From Kerala, India. <i>Frontiers in Public Health</i> , 2021, 9, 778235.	1.3	3

#	ARTICLE	IF	CITATIONS
5336	Understanding the interrelationships of type 2 diabetes and hypertension with brain and cognitive health: A UK Biobank study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 938-947.	2.2	7
5337	Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 112-119.	5.5	37
5338	Joint modeling of time to diabetic retinopathy and change in fasting blood sugar among type 2 diabetic patients, Northwest Ethiopia. <i>Scientific Reports</i> , 2022, 12, 2236.	1.6	0
5339	Blood Pressure Monitoring as a Digital Health Tool for Improving Diabetes Clinical Outcomes: Retrospective Real-world Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32923.	2.1	2
5340	Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. <i>Advances in Therapy</i> , 2021, 39, 923.	1.3	4
5341	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S175-S184.	4.3	168
5342	Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. <i>Diabetes Care</i> , 2006, 29, 142-4.	4.3	39
5343	Current Situation and New Progress of the Prevention and Treatment of Diabetic Macular Oedema. <i>Medical Diagnosis</i> , 2022, 12, 72-83.	0.0	0
5344	High prevalence of undiagnosed impaired glucose tolerance in patients with rheumatoid arthritis. <i>SAGE Open Medicine</i> , 2022, 10, 205031212210880.	0.7	1
5347	Correlation between diabetic retinopathy and glycaemic variability, assessed with continuous glucose monitoring in patients with type 2 diabetes mellitus—a review. <i>Scripta Scientifica Medica</i> , 2021, 53, 9.	0.1	0
5348	Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2397.	1.8	32
5349	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, 593-604.	0.8	1
5351	Hypertensive eye disease. <i>Nature Reviews Disease Primers</i> , 2022, 8, 14.	18.1	25
5352	Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. <i>Scientific Reports</i> , 2022, 12, 3525.	1.6	7
5353	Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database. <i>Hypertension Research</i> , 2022, , .	1.5	2
5354	The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature. <i>Nutrients</i> , 2022, 14, 1252.	1.7	24
5355	Diabetic retinopathy for the non-ophthalmologist. <i>Clinical Medicine</i> , 2022, 22, 112-116.	0.8	24
5356	Evaluation of drug utilization pattern of antidiabetic drugs and 10-year cardiovascular risk in new and recently diagnosed type 2 diabetes mellitus patients: a prospective, longitudinal, observational, hospital-based study. <i>International Journal of Diabetes in Developing Countries</i> , 0, , 1.	0.3	0

#	ARTICLE	IF	CITATIONS
5357	Toll-Like Receptor Signalling Pathways and the Pathogenesis of Retinal Diseases. <i>Frontiers in Ophthalmology</i> , 2022, 2, .	0.2	1
5358	Intensive Blood Pressure Treatment Goals: evidence for cardiovascular protection from observational studies and clinical trials. <i>American Journal of Hypertension</i> , 2022, , .	1.0	0
5359	Association Between Cardiovascular Disease Risk Factors and Mortality in Adults With Diabetes: A Stratified Analysis by Sex, Race, and Ethnicity. <i>International Journal of Public Health</i> , 2022, 67, 1604472.	1.0	1
5360	Prediction of Diabetes Mellitus using Machine Learning. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 0, , 17-20.	0.0	0
5361	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. <i>European Journal of Internal Medicine</i> , 2022, 101, 49-55.	1.0	9
5362	Establishing target systolic and diastolic blood pressure in diabetic patients with hypertension: what do we need to consider?. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 993-1003.	0.6	0
5363	Printed educational materials directed at Ontario family physicians do not improve adherence to guideline recommendations for diabetes management: a pragmatic, factorial, cluster randomized controlled trial [ISRCTN72772651]. <i>BMC Family Practice</i> , 2021, 22, 243.	2.9	0
5364	Nephropathy and chronic renal insufficiency. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 262-264.	0.2	0
5365	Obstructive Sleep Apnoea, Other Sleep Parameters and Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2021, 21, 58.	1.7	3
5366	A Promising Combination: PACAP and PARP Inhibitor Have Therapeutic Potential in Models of Diabetic and Hypertensive Retinopathies. <i>Cells</i> , 2021, 10, 3470.	1.8	6
5367	Prevalence of uncontrolled hypertension in people with comorbidities in sub-Saharan Africa: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e045880.	0.8	8
5368	Arterial stiffness, hemodynamics, and microvascular complications in conditions characterized by low arterial pulsatility. , 2022, , 771-779.		0
5369	The prevalence of retinopathy in prediabetes: A systematic review. <i>Survey of Ophthalmology</i> , 2022, 67, 1332-1345.	1.7	14
5370	Improving Diabetes Care: A Fijian Diabetes Service Improvement Study. <i>International Journal of Chronic Diseases</i> , 2022, 2022, 1-9.	1.9	0
5371	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e227705.	2.8	15
5375	Management of Insulin Resistance and Associated Conditions. , 0, , 119-177.		0
5377	Intensive blood pressure treatment: beneficial for all but the smoking hypertensives?. <i>Journal of Hypertension</i> , 2003, 21, 697-700.	0.3	3
5378	Influencing factors for dietary behaviors of patients with diabetic nephropathy. <i>Acta Medica Okayama</i> , 2010, 64, 39-47.	0.1	1

#	ARTICLE	IF	CITATIONS
5381	Epidemiology and Genetics of Diabetic Retinopathy. , 2022, , 2935-2953.		0
5382	The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review. SN Comprehensive Clinical Medicine, 2022, 4, 1.	0.3	2
5383	<scp>HbA1c</scp> , blood pressure and cholesterol control in adults with diabetes: A report card for Kuwait. Journal of Diabetes Investigation, 2022, , .	1.1	2
5384	Effects of Hypertension on Two-Year Outcomes According to Glycemic Status in Patients With Acute Myocardial Infarction Receiving Newer-Generation Drug-Eluting Stents. Angiology, 2022, , 000331972210982.	0.8	0
5385	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine, 2022, 28, 982-988.	15.2	48
5386	The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Advances in Therapy, 2022, 39, 3180-3198.	1.3	2
5387	INFLUENCE OF CONTROL GLYCEMIA ON PARAMETERS OF HEART RHYTHM VARIABILITY, QTAND JT-INTERVALS IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES. Eurasian Heart Journal, 2013, , 67-72.	0.2	0
5389	Long-term prediction models for vision-threatening diabetic retinopathy using medical features from data warehouse. Scientific Reports, 2022, 12, 8476.	1.6	4
5390	Impact of Pharmacist-Led Interventions to Improve Clinical Outcomes for Adults With Type 2 Diabetes at Risk of Developing Cardiovascular Disease: A Systematic Review and Meta-analysis. Journal of Pharmacy Practice, 2023, 36, 888-899.	0.5	3
5392	Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells. Yonsei Medical Journal, 2022, 63, 530.	0.9	0
5393	The effects of vitamin E on non-proliferative diabetic retinopathy in type 2 diabetes mellitus: Are they sustainable with 12â€™months of therapy. SAGE Open Medicine, 2022, 10, 205031212210953.	0.7	5
5395	Prevalence of diabetic retinopathy and self-reported barriers to eye care among patients with diabetes in the emergency department: the diabetic retinopathy screening in the emergency department (DRS-ED) study. BMC Ophthalmology, 2022, 22, .	0.6	3
5397	Biochemical mechanism underlying the pathogenesis of diabetic retinopathy and other diabetic complications in humans: the methanol-formaldehyde-formic acid hypothesis. Acta Biochimica Et Biophysica Sinica, 2022, 54, 415-451.	0.9	0
5398	Controversies in Hypertension II: The Optimal Target Blood Pressure. American Journal of Medicine, 2022, 135, 1168-1177.e3.	0.6	2
5399	Hypertension and the kidneys. British Journal of Hospital Medicine (London, England: 2005), 2022, 83, 1-11.	0.2	8
5401	<scp>EndoBarrier</scp> treatment for longstanding type 2 diabetes and obesity: outcomes one year after <scp>EndoBarrier</scp> in 90 consecutively treated patients. Practical Diabetes, 2022, 39, 13.	0.1	1
5402	Improving the screening of risk factors in diabetic retinopathy. Expert Review of Endocrinology and Metabolism, 2022, 17, 235-243.	1.2	7
5403	Timeâ€™limited diets and the gut microbiota in cardiometabolic disease. Journal of Diabetes, 0, , .	0.8	12

#	ARTICLE	IF	CITATIONS
5404	Status and Trends of the Association Between Diabetic Nephropathy and Diabetic Retinopathy From 2000 to 2021: Bibliometric and Visual Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
5405	The Causal Effect of Systolic Blood Pressure Lowering on Vascular Outcomes in Diabetes: A Mendelian Randomization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2616-2625.	1.8	7
5406	Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7005.	1.8	4
5407	Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6500.	1.8	13
5409	Diabetic nephropathy: Clinical presentation, course, and novel treatment possibilities. <i>OpÅta Medicina</i> , 2022, , 1-1.	0.3	0
5410	Retinal Thickness and Morphology Changes on OCT in Youth with Type 2 Diabetes. <i>Ophthalmology Science</i> , 2022, 2, 100191.	1.0	3
5411	Evaluation of the Effect of Garlic Tablet as a Complementary Treatment for Patients with Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-7.	1.0	6
5414	The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 877-886.	1.3	5
5415	ÐÑ-Ð°ÑfÐ²Ð°Ð½Ð½Ð°ÑÑ, ÐµÑÑ-Ð°Ñ»ÑCED½Ð¾Ñ- Ð¾Ñ-ÐµÑÑ, ÐµÐ½Ð½Ñ-Ñ- Ð½Ð°ÑÑÑÐ½Ð½Ð¾Ð½Ð½Ð½Ñf ÐµÑ, Ð		
5416	Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre. <i>Canadian Journal of Diabetes</i> , 2023, 47, 31-37.e2.	0.4	1
5417	Unconventional avenues to decelerate diabetic retinopathy. <i>Survey of Ophthalmology</i> , 2022, 67, 1574-1592.	1.7	6
5419	Diabetic Eye Disease. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2000, 30, 332-343.	0.2	0
5420	Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 645-654.	5.5	33
5421	Incidence, progression and regression of diabetic retinopathy in a northeastern Chinese population. <i>British Journal of Ophthalmology</i> , 2023, 107, 1509-1515.	2.1	3
5422	Investigation of the correlation between diabetic retinopathy and prevalent and incident migraine in a national cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
5423	Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study. <i>Diabetes Care</i> , 2022, 45, 2144-2151.	4.3	5
5424	Prediction of complications of type 2 Diabetes: A Machine learning approach. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 110013.	1.1	15
5425	Trends in glycemic control, cardiovascular risk factors and chronic complications of type 2 diabetes, 2012â€“2016, in a healthcare area of Barcelona. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 110014.	1.1	2

#	ARTICLE	IF	CITATIONS
5428	New Insights into Treating Early and Advanced Stage Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8513.	1.8	11
5429	The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy. <i>Journal of Personalized Medicine</i> , 2022, 12, 1253.	1.1	0
5430	Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S49-S79.	0.6	1
5431	Quality of care and prescription patterns among patients with diabetic kidney disease—a large-scale cohort study from Taiwanese clinics. <i>PeerJ</i> , 0, 10, e13636.	0.9	2
5432	Glycemic status and the association of change in blood pressure with incident cardiovascular disease. <i>American Heart Journal</i> , 2022, 254, 48-56.	1.2	2
5433	Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology. <i>Ophthalmology and Therapy</i> , 2022, 11, 1937-1950.	1.0	6
5434	The association between advanced glycation end products (AGEs) and ABC (hemoglobin A1C, blood Tj ETQq0 0 0 rgBT /Overlock 10 Tf diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	7
5435	The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature. <i>BMC Medicine</i> , 2022, 20, .	2.3	21
5436	Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study. , 2022, 23, .		0
5437	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
5438	Predictors Associated with Type 2 Diabetes Mellitus Complications over Time: A Literature Review. , 2022, 1, 13-23.		3
5440	A PRACTICAL APPROACH TO TYPE 2 DIABETES. <i>Nursing Clinics of North America</i> , 2001, 36, 193-202.	0.7	3
5441	THE TREATMENT OF HYPERTENSION IN PATIENTS WITH DIABETES. <i>Nursing Clinics of North America</i> , 2001, 36, 273-289.	0.7	1
5442	Epidemiological Aspects of Diabetic Retinopathy at the Center of the Application of the Diploma of Specialised Studies in Ophthalmology (Cadeso)/Donka-Conakry. <i>Advances in Infectious Diseases</i> , 2022, 12, 533-546.	0.0	0
5443	Pharmacotherapy of diabetic retinopathy. , 2022, , 343-356.		0
5444	Range of Risk Factor Levels, Risk Control, and Temporal Trends for Nephropathy and End-stage Kidney Disease in Patients With Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 2326-2335.	4.3	10
5445	Blood Pressure Target in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 667-674.	1.8	8
5446	Considerations for Optimal Blood Pressure Target of Hypertension. , 0, Publish Ahead of Print, .		1

#	ARTICLE	IF	CITATIONS
5447	The long-term cost-effectiveness of once-weekly semaglutide 1Âmg vs. dulaglutide 3Âmg and 4.5Âmg in the UK. <i>European Journal of Health Economics</i> , 0, , .	1.4	2
5449	ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2022, 23, 872-902.	1.2	36
5450	DASH diet vs. DASH diet plus physical activity in older patients with type 2 diabetes and high blood pressure: A randomized clinical trial. <i>Nutrition and Health</i> , 0, , 026010602211242.	0.6	0
5451	Presence and development of diabetic retinopathy in 153â€%238 patients with type 2 diabetes in the Danish Registry of Diabetic Retinopathy. <i>Acta Ophthalmologica</i> , 2023, 101, 207-214.	0.6	6
5452	Effects of Camellia tea and herbal tea on cardiometabolic risk in patients with type 2 diabetes mellitus: A systematic review and metaâ€analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2022, 36, 4051-4062.	2.8	14
5453	Cystic Fibrosis-Related Diabetes: Clinical Approach and Knowledge gaps. <i>Paediatric Respiratory Reviews</i> , 2022, , .	1.2	1
5454	Blood pressureâ€independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes. <i>British Journal of Pharmacology</i> , 2023, 180, 80-93.	2.7	4
5455	Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. <i>Cells</i> , 2022, 11, 3362.	1.8	45
5456	Suboptimal blood pressure control and its associated factors among people living with diabetes mellitus in sub-Saharan Africa: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2022, 11, .	2.5	3
5457	Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. <i>Nature Medicine</i> , 2022, 28, 2056-2065.	15.2	29
5458	New strategies to improve clinical outcomes for diabetic kidney disease. <i>BMC Medicine</i> , 2022, 20, .	2.3	20
5459	Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitusâ€”results from the TRIUMPH randomised controlled trial. <i>Hypertension Research</i> , 0, , .	1.5	2
5460	Role of glycosylated hemoglobin in microvascular complications in type 2 diabetes mellitus: cross sectional study. <i>MÃ–Ã¼narodnij EndokrinologÃ–Anij Å½urnal</i> , 2022, 18, 319-323.	0.1	3
5461	Onceâ€weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the <sc>UK</sc>: A longâ€term costâ€effectiveness analysis based on <sc>SUSTAIN</sc> 11. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 491-500.	2.2	4
5464	Editorâ€™s Pick: Addressing Hypertension in the Patient with Type 2 Diabetes Mellitus: Pathogenesis, Goals, and Therapeutic Approach. <i>European Medical Journal Diabetes</i> , 0, , 84-92.	4.0	1
5465	Randomized controlled trials of biomarker targets. <i>Clinical Trials</i> , 0, , 174077452211318.	0.7	0
5466	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	3
5468	The effect of green tea on blood pressure in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Journal of Herbal Medicine</i> , 2023, 37, 100622.	1.0	0

#	ARTICLE	IF	CITATIONS
5469	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. <i>Frontiers in Cardiovascular Drug Discovery</i> , 2022, , 191-229.	0.0	0
5470	Analysis of the impact of a diabetes education program on glycemic control and prevalence of chronic complications. <i>Archives of Endocrinology and Metabolism</i> , 2022, , .	0.3	0
5471	Perspectives of diabetic retinopathyâ€™ challenges and opportunities. <i>Eye</i> , 2023, 37, 2183-2191.	1.1	4
5472	Quantification of risk factors for diabetic retinopathy progression. <i>Acta Diabetologica</i> , 2023, 60, 363-369.	1.2	7
5473	ANDA-Evaluating Facilitated Feedback Enhancement - a Cluster randomised Trial (ANDA-EFFECT): protocol for a cluster randomised trial of audit feedback augmented with education and support, compared to feedback alone, on acceptability, utility and health outcomes in diabetes centres in Australia. <i>Trials</i> , 2022, 23, .	0.7	0
5474	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. <i>Presse Medicale</i> , 2023, 52, 104160.	0.8	1
5475	Caring for Patients With Diabetes in Stroke Neurology. <i>Stroke</i> , 2023, 54, 894-904.	1.0	5
5476	11. Chronic Kidney Disease and Risk Management: <i>Standards of Care in Diabetesâ€™2023</i>. <i>Diabetes Care</i> , 2023, 46, S191-S202.	4.3	97
5477	Blood Pressure-Lowering Treatment and Macrovascular Events. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 305-326.	0.1	0
5478	Controlling Blood Pressure in 50% of All Hypertensive Patients: An Achievable Goal in the Healthy People 2010 Report?. <i>Journal of Investigative Medicine</i> , 2003, 51, 373-385.	0.7	0
5479	Blood Pressure Control in Patients with Diabetic Kidney Disease. <i>Electrolyte and Blood Pressure</i> , 2022, 20, 39.	0.6	0
5480	Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study. <i>Hypertension Research</i> , 2023, 46, 565-574.	1.5	4
5481	Diabetes and Microcirculation. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 167-177.	0.1	0
5482	Blood Pressure Lowering and Microvascular Complications of Diabetes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 327-335.	0.1	0
5483	Blood Pressure Thresholds for Initiation of Drug Treatment: Blood Pressure Targets in Diabetes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 377-387.	0.1	0
5485	Optic Nerve Regeneration in Diabetic Retinopathy: Potentials and Challenges Ahead. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1447.	1.8	2
5486	Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. <i>Swiss Medical Weekly</i> , 2023, 153, 40004.	0.8	4
5487	Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 389-403.	0.1	0

#	ARTICLE	IF	CITATIONS
5489	Hypertension the "Missed Modifiable Risk Factor"™ for Diabetic Neuropathy: a Systematic Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101581.	1.1	2
5491	Risk Amplifiers for Vascular Disease and CKD in South Asians. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 681-688.	2.2	0
5492	Impact of metabolic control on all-cause mortality in a nationwide cohort of patients with diabetes from Colombia. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
5493	Machine Learning Approach to Drug Treatment Strategy for Diabetes Care. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 325-332.	1.8	3
5494	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	6
5496	Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. <i>Lancet, The</i> , 2023, 401, 1302-1312.	6.3	30
5497	Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis. <i>Progress in Retinal and Eye Research</i> , 2023, 94, 101151.	7.3	2
5498	Diabetic retinopathy in the pediatric population: Pathophysiology, screening, current and future treatments. <i>Pharmacological Research</i> , 2023, 188, 106670.	3.1	3
5499	Continuity of Medication Use by US Adults With Diabetes, 2005-2019. <i>JAMA Network Open</i> , 2023, 6, e2253562.	2.8	3
5500	Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus. <i>Endocrinology, Diabetes and Metabolism</i> , 2023, 6, .	1.0	1
5501	Body Position and Orthostatic Hypotension in Hypertensive Adults: Results from the Syst-Eur Trial. <i>Hypertension</i> , 2023, 80, 820-827.	1.3	3
5502	Diabetic Macular Oedema Guidelines: An Australian Perspective. <i>Journal of Ophthalmology</i> , 2023, 2023, 1-22.	0.6	1
5503	Treating the Diabetic Hypertensive: Consensus and Differences. , 0, , 98-104.		0
5505	CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 97-109.	0.7	0
5506	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	15
5507	The Relationship between Vascular Aging Phenotypes and Renal Damage among Individuals with Type 2 Diabetes. <i>CardioRenal Medicine</i> , 2023, , 91-100.	0.7	0
5508	Measuring the Quality of Care of Diabetic Patients at the Specialist Outpatient Clinics in Public Hospitals in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2007, 36, 980-986.	0.2	8
5509	Intensive blood pressure control in older patients with hypertension" a STEP in the right direction?. <i>Postgraduate Medical Journal</i> , 2023, 99, 47-49.	0.9	0

#	ARTICLE	IF	CITATIONS
5510	To the assessment of the use of sugar-reducing drugs from the position of safety. , 2023, 1, 41-48.		0
5511	Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression. International Journal of Molecular Sciences, 2023, 24, 4785.	1.8	1
5512	The renin-angiotensin system in the eye. , 2023, , 419-447.		0
5513	Genome-Wide Associations and Confirmatory Meta-Analyses in Diabetic Retinopathy. Genes, 2023, 14, 653.	1.0	5
5514	Global Prevalence of Diabetic Retinopathy in Pediatric Type 2 Diabetes. JAMA Network Open, 2023, 6, e231887.	2.8	7
5515	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane Library, 2023, 2023, .	1.5	3
5516	Update on Medical Management of Diabetes. Orthopedic Clinics of North America, 2023, , .	0.5	0
5517	Common retinal disorders. , 2018, , 413-435.		0
5518	Fasting Glucose, Glycated Hemoglobin, and 2h Post-load Blood Glucose Are Independently Associated With Arterial Stiffness in Diabetes: The ELSA-Brasil Study. Angiology, 0, , 000331972311661.	0.8	1
5519	Association of blood pressure with incident diabetic microvascular complications among diabetic patients: Longitudinal findings from the UK Biobank. Journal of Global Health, 0, 13, .	1.2	1
5520	Prospective, Observational, Multicenter, Real-World Study of the Efficacy, Safety, and Pattern of Use of the Dexamethasone Intravitreal Implant in Diabetic Macular Edema in France: Short-Term Outcomes of LOUVRE 3. Ophthalmology and Therapy, 2023, 12, 1671-1692.	1.0	1
5521	Blood Pressure in CKD. , 2023, , 115-129.		0
5522	Introduction of Diabetic retinopathy and principles of treatment. , 2024, , 1-26.		0
5523	HbA1C, proliferative and non-proliferative retinopathy in diabetic patients. Medicina Clinica Practica, 2023, 6, 100371.	0.2	0
5524	Effect of Diabetes Mellitus on the Progress of Osteoarthritis. Advances in Clinical Medicine, 2023, 13, 5434-5443.	0.0	0
5525	Impact of presentation at conference with timed release of academic publication. Internal and Emergency Medicine, 0, , .	1.0	0
5527	Risk Factors for Recurrent Vitreous Hemorrhage in Type 2 Diabetes Mellitus Patients after Posterior Vitrectomy. Journal of Clinical Medicine, 2023, 12, 2989.	1.0	2
5528	Nanoparticles as drug delivery agents for managing diabetic retinopathy. , 2023, , 329-364.		0

#	ARTICLE	IF	CITATIONS
5529	Reduced incidence of cardiovascular disease in patients with type 2 diabetes through the integrated improvement of diabetes care by comparing two prospective observational cohorts in real-world clinical practice (JDDM 72). Diabetes Research and Clinical Practice, 2023, , 110674.	1.1	0
5542	Lasers in Diabetic Retinopathy. , 2023, , 61-116.		0
5543	Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?. Hypertension Research, 2023, 46, 1892-1899.	1.5	4
5546	Preface: A New Disease?. , 2023, , 1-12.		0
5547	The "Old" Oral Antidiabetics. , 2023, , 551-563.		0
5549	More Than Retinopathy. Has the Time Come to Recognize Diabetic Retinopathy as Neuro-vasculopathy? Would This Change Your Practice?. , 2023, , 393-433.		0
5559	Diabetes and Hypertension. Contemporary Cardiology, 2023, , 399-424.	0.0	0
5560	Renin-Angiotensin-Aldosterone System in Diabetic Cardiovascular Complications. Contemporary Cardiology, 2023, , 863-894.	0.0	0
5581	Hypertension in diabetes. Pediatric Nephrology, 0, , .	0.9	0
5583	Cardio-Cerebro-Vascular Disease. , 2023, , 883-895.		0
5587	Diabetes Mellitus:. , 2024, , 439-455.		0
5605	Diabetic Kidney Disease: Increasing Hope with Transformative Therapies. , 2023, , 41-53.		0